

(12) STANDARD PATENT

(11) Application No. AU 2003217606 C1

(19) AUSTRALIAN PATENT OFFICE

20 Sep 2004

2003217606

WO 2003/100029 A3

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
4 December 2003 (04.12.2003)

PCT

(10) International Publication Number
WO 2003/100029 A3

(51) International Patent Classification⁷: C12N 5/20 (74) Agent: LAUDER, Leona, L.; Suite 450, 465 California Street, San Francisco, CA 94104-1840 (US).

(21) International Application Number: PCT/US2003/005136 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TI, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 22 February 2003 (22.02.2003) (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English (30) Priority Data: 60/383,068 23 May 2002 (23.05.2002) US 60/431,499 5 December 2002 (05.12.2002) US (71) Applicant (for AM, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG only): BAYER HEALTH-CARE [US/US]; Diagnostic Business Group, 511 Benedict Avenue, Tarrytown, NY 10591-5097 (US).

(71) Applicant (for all designated States except US): INSTITUTE OF VIROLOGY [SK/SK]; Slovak Academy of sciences, Dubravská Cesta 9, 84246 Bratislava (SK).

(72) Inventors; and (75) Inventors/Applicants (for US only): PASTOREK, Jaromir [SK/SK]; Novoveska 18, 84 107 Bratislava (SK). PASTOREKOVA, Silvia [SK/SK]; Novoveska 18, 84 107 Bratislava (SK). ZATOVICOVA, Miriam [SK/SK]; Martinengova 22, 81 102 Bratislava (SK). ZAVADA, Jan [CZ/CZ]; Na pekne vyhlidce 1, 16200 Prague (CZ). ORTOVA GUT, Marta [CZ/CZ]; Opatovicka 22, 11001 Prague (CZ).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
3 June 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MN/CA IX-SPECIFIC MONOCLONAL ANTIBODIES GENERATED FROM MN/CA IX-DEFICIENT MICE AND METHODS OF USE

(57) Abstract: Disclosed herein among other MN/CA IX-related inventions are new MN/CA IX-specific antibodies generated from MN/CA IX-deficient mice, preferably monoclonal antibodies and immunoreactive fragments and engineered variants thereof. Subsets of the new antibodies are to either the proteoglycan-like (PG) domain or to the carbonic anhydrase (CA) domain of MN/CA IX, and methods are provided by which antibodies can be prepared to the other MN/CA IX domains. Such new MN/CA IX-specific antibodies, fragments and variants are useful diagnostically/prognostically and therapeutically for cancer and precancer. Particularly preferred are the new monoclonal antibodies, fragments and variants that are specific for the non-immunodominant epitopes of MN/CA IX, which antibodies are, among other uses, useful to detect soluble MN/CA IX (s-CA IX) in body fluids, alone but preferably in combination with antibodies specific to the immunodominant epitopes of MN/CA IX, for example, in a sandwich assay.

2003217606 19 Nov 2004

SOLUBLE FORM OF CARBONIC ANHYDRASE IX (s-CA IX), ASSAYS TO DETECT s-CA IX, CA IX's COEXPRESSION WITH HER-2/neu/c-erbB-2, and CA IX-SPECIFIC MONOCLONAL ANTIBODIES TO NON-IMMUNODOMINANT EPITOPE

FIELD OF THE INVENTION

5 The present invention is in the general area of medical genetics and in the fields of biochemical engineering, immunochemistry and oncology. More specifically, it relates to the MN gene -- a cellular gene considered to be an oncogene, known alternatively as *MN/CA9*, *CA9*, or carbonic anhydrase 9, which 10 gene encodes the oncoprotein now known alternatively as the MN protein, the *MN/CA IX* isoenzyme, *MN/CA IX*, carbonic anhydrase IX, CA IX or the *MN/G250* protein.

15 More specifically, the instant invention is directed to new *MN/CA IX*-specific antibodies prepared in *MN/CA IX*-deficient mice (knock out mice) and to uses of those new antibodies. Significantly, some of the new *MN/CA IX*-specific 20 antibodies, preferably monoclonal antibodies and immunoreactive fragments thereof are directed to non-immunodominant epitopes on CA IX proteins and polypeptides, rendering such antibodies and immunoreactive fragments, among many diagnostic/prognostic and therapeutic uses, useful in highly specific double antibody sandwich assays to detect *MN/CA IX* antigen, particularly soluble *MN/CA IX* antigen (s-CA IX) found in body fluids.

25 This invention is also directed to the soluble *MN/CA IX* antigen (s-CA IX) itself, and assays to detect or to detect and quantify it. Further this invention concerns the coexpression of CA IX and HER-2/neu/c-erbB-2 ("HER-2"), and diagnostic/prognostic and therapeutic methods in parallel with and/or alternative to 30 those targeting HER-2. Particularly preferred are assays to detect both the HER-2 ectodomain ("p100") and the CA IX extracellular domain (50/54 kilodaltons) in the same body fluid sample from a cancer patient. Backup therapeutic methods targeting CA IX can be used for patients not responding to HER-2 therapy. Such integrated diagnostic/prognostic and therapeutic methods with HER-2 and CA IX as targets can provide clinicians with more comprehensive resources to help cancer patients, such as, metastatic breast cancer patients.

BACKGROUND OF THE INVENTION

As indicated above, the MN gene and protein are known by a number of alternative names, which names are used herein interchangeably. The MN protein was found to bind zinc and have carbonic anhydrase (CA) activity and is now considered to be the ninth carbonic anhydrase isoenzyme – MN/CA IX or CA IX [Opavsky et al. 1996]. According to the carbonic anhydrase nomenclature, human CA isoenzymes are written in capital roman letters and numbers, while their genes are written in italic letters and arabic numbers. Alternatively, "MN" is used herein to refer either to carbonic anhydrase isoenzyme IX (CA IX) proteins/polypeptides, or carbonic anhydrase isoenzyme 9 (CA9) gene, nucleic acids, cDNA, mRNA etc. as indicated by the context.

The MN protein has also been identified with the G250 antigen.

Uemura et al., "Expression of Tumor-Associated Antigen MN/G250 in Urologic Carcinoma: Potential Therapeutic Target," J. Urol., 154 (4 Suppl.): 377 (Abstract 1475; 1997) states: "Sequence analysis and database searching revealed that G250 antigen is identical to MN, a human tumor-associated antigen identified in cervical carcinoma (Pastorek et al., 1994)."

CA IX is a cancer-related carbonic anhydrase identified by Zavada, Pastorekova, Pastorek (U.S. Patent 5,387,676) using the M75 monoclonal antibody first described by Pastorekova et al. [Virology 187: 620-626 (1992)]. That antibody was employed in cloning of cDNA encoding CA IX [Pastorek et al., Oncogene, 9: 2788-2888 (1994)], in assessment of CA IX expression in tumors and normal tissues [Zavada et al., Int J Cancer, 54: 268-274, (1993) and many other references], in study of CA IX regulation by cell density [Lieskovska et al., Neoplasma, 46: 17-24, (1999), Kaluz et al., Cancer Research, 62: 4469-4477, (2002)] as well in demonstration of CA IX induction by hypoxia [Wykoff et al., Cancer Research, 60: 7075-7083 (2000), and many other references]. All these studies supported the assumption made in the original U.S Patent 5,387,676 that CA IX can be used diagnostically and/or prognostically as a preneoplastic/neoplastic tumor marker and therapeutically as a target, and showed that the M75 monoclonal antibody is a valuable CA IX-specific reagent useful for different immunodetection methods and immunotargeting approaches.

Zavada et al., International Publication Number WO 93/18152 (published 16 September 1993) and U.S. Patent No. 5,387,676 (issued February 7, 1995), describe the discovery and biological and molecular nature of the MN gene and protein. The MN gene was found to be present in the chromosomal DNA of all 5 vertebrates tested, and its expression to be strongly correlated with tumorigenicity.

The MN protein was first identified in HeLa cells, derived from a human carcinoma of cervix uteri. It is found in many types of human carcinomas (notably uterine cervical, ovarian, endometrial, renal, bladder, breast, colorectal, lung, esophageal, and prostate, among others). Very few normal tissues have been found 10 to express MN protein to any significant degree. Those MN-expressing normal tissues include the human gastric mucosa and gallbladder epithelium, and some other normal tissues of the alimentary tract. Paradoxically, MN gene expression has been found to be lost or reduced in carcinomas and other preneoplastic/neoplastic diseases in some tissues that normally express MN, e.g., gastric mucosa.

15 In general, oncogenesis may be signified by the abnormal expression of MN protein. For example, oncogenesis may be signified: (1) when MN protein is present in a tissue which normally does not express MN protein to any significant degree; (2) when MN protein is absent from a tissue that normally expresses it; (3) when MN gene expression is at a significantly increased level, or at a significantly 20 reduced level from that normally expressed in a tissue; or (4) when MN protein is expressed in an abnormal location within a cell.

Zavada et al., WO 93/18152 and Zavada et al., WO 95/34650 (published 21 December 1995) disclose how the discovery of the MN gene and protein and the strong association of MN gene expression and tumorigenicity led to 25 the creation of methods that are both diagnostic/prognostic and therapeutic for cancer and precancerous conditions. Methods and compositions were provided therein for identifying the onset and presence of neoplastic disease by detecting or detecting and quantitating abnormal MN gene expression in vertebrates. Abnormal MN gene expression can be detected or detected and quantitated by a variety of 30 conventional assays in vertebrate samples, for example, by immunoassays using MN-specific antibodies to detect or detect and quantitate MN antigen, by hybridization assays or by PCR assays, such as RT-PCR, using MN nucleic acids, such as, MN cDNA, to detect or detect and quantitate MN nucleic acids, such as, MN mRNA.

MN/CA IX was first identified in HeLa cells, derived from human carcinoma of cervix uteri, as both a plasma membrane and nuclear protein with an apparent molecular weight of 58 and 54 kilodaltons (kDa) as estimated by Western blotting. It is N-glycosylated with a single 3kDa carbohydrate chain and under non-reducing conditions forms S-S-linked oligomers [Pastorekova et al., *Virology*, 187: 620-626 (1992); Pastorek et al., *Oncogene*, 9: 2788-2888 (1994)]. MN/CA IX is a transmembrane protein located at the cell surface, although in some cases it has been detected in the nucleus [Zavada et al., *Int. J. Cancer*, 54: 268-274 (1993); Pastorekova et al., *supra*].

10 MN is manifested in HeLa cells by a twin protein, p54/58N. Immunoblots using a monoclonal antibody reactive with p54/58N (MAb M75) revealed two bands at 54 kd and 58 kd. Those two bands may correspond to one type of protein that most probably differs by post-translational processing.

15 Zavada et al., WO 93/18152 and/or WO 95/34650 disclose the MN cDNA sequence (SEQ ID NO: 1) shown herein in Figure 1A-1C, the MN amino acid sequence (SEQ ID NO: 2) also shown in Figure 1A-1C, and the MN genomic sequence (SEQ ID NO: 3) shown herein in Figure 2A-2F. The MN gene is organized into 11 exons and 10 introns. The human MN cDNA sequence of SEQ ID NO: 1 contains 1522 base pairs (bp). The MN cDNA sequence of SEQ ID NO: 70 contains 20 1552 bp [EMBL Acc. No. X66839; Pastorek et al. (1994)].

25 The first thirty seven amino acids of the MN protein shown in Figure 1A-1C (SEQ ID NO: 2) is the putative MN signal peptide [SEQ ID NO: 4]. The MN protein has an extracellular (EC) domain [amino acids (aa) 38-414 of Figure 1A-1C (SEQ ID NO: 5)], a transmembrane (TM) domain [aa 415-434 (SEQ ID NO: 6)] and an intracellular (IC) domain [aa 435-459 (SEQ ID NO: 7)]. The extracellular domain contains the proteoglycan-like (PG) domain at about amino acids (aa) 53-111 (SEQ ID NO. 8) or preferably at about aa 52-125 (SEQ ID NO: 98), and the carbonic anhydrase (CA) domain at about aa 135-391 (SEQ ID NO: 9) or preferably, at about aa 121-397 (SEQ ID NO: 101).

30 Zavada et al., WO 93/18152 and WO 95/34650 describe the production of MN-specific antibodies. A representative and preferred MN-specific antibody, the monoclonal antibody M75 (Mab M75), was deposited at the American Type Culture Collection (ATCC) in Manassas, VA (USA) under ATCC Number HB 11128. The M75 antibody was used to discover and identify the MN protein and can be used to

identify readily MN antigen in Western blots, in radioimmunoassays and immunohistochemically, for example, in tissue samples that are fresh, frozen, or formalin-, alcohol-, acetone- or otherwise fixed and/or paraffin-embedded and deparaffinized. Another representative and preferred MN-specific antibody, Mab 5 MN12, is secreted by the hybridoma MN 12.2.2, which was deposited at the ATCC under the designation HB 11647. Example 1 of Zavada et al., WO 95/34650 provides representative results from immunohistochemical staining of tissues using MAb M75, which results support the designation of the MN gene as an oncogene.

10 Immunodominant epitopes are considered to be essentially those that are within the PG domain of MN/CA IX, including the repetitive epitopes for the M75 mab, particularly the amino acid sequence PGEEDLP (SEQ ID NO: 11), which is 4X identically repeated in the N-terminal PG region (Zavada et al. 2000). The epitope for the MN12 mab is also immunodominant.

15 The M75 mab was first reported in Pastorekova et al., Virology, 187: 620-626 (1992) and is claimed specifically, as well as generically with all MN/CA IX-specific antibodies, polyclonal and monoclonal as well as fragments thereof, in a number of U.S. and foreign patents, including, for example, Zavada et al., U.S. Patent No. 5,981,711 and EP 0 637 336 B1. [See also, Zavada et al., U.S. Patent Nos. 5,387,676; 5,955,075; 5,972,353; 5,989,838; 6,004,535; 6,051,226; 6,069,242; 20 6,093,548; 6,204,370; 6,204,887; 6,297,041; and 6,297,051; and Zavada et al., AU 669694; CA 2,131,826; DE 69325577.3; and KR 282284.] Those Zavada et al. U.S. and foreign patents are herein incorporated by reference.

25 CA IX is a highly active member of α carbonic anhydrase family of zinc metalloenzymes that catalyze the reversible conversion between carbon dioxide and bicarbonate [Pastorek et al. (1994); Opavsky et al. (1996); Chegwidden et al. (2000); Wingo et al, (2001)]. It is one of 14 isoforms that exist in mammals and occupy different subcellular positions, including cytoplasm (CA I, II, III, VII), mitochondrion (CA VA, VB), secretory vesicles (CA VI) and plasma membrane (CA IV, IX, XII, XIV). Some of the isozymes are distributed over broad range of tissues (CA I, II, CA IV), 30 others are more restricted to particular organs (CA VI in salivary glands) and two isoforms have been linked to cancer tissues (CA IX, XII) [reviewed in Chegwidden (2000), Pastorek and Pastorekova (2003)]. Enzyme activity and kinetic properties, as well as sensitivity to sulfonamide inhibitors vary from high (CA II, CA IX, CA XII, CA

IV) to low (CA III) [Supuran and Scozzafava (2000)]. Several isoforms designated as CA-related proteins (CA-RP VIII, X, XI) are acatalytic due to incompletely conserved active site. This extraordinary variability among the genetically related members of the same family of proteins creates a basis for their employment in diverse

5 physiological and pathological processes. The catalytic activity is of fundamental relevance for the maintenance of acid-base balance and exchange of ions and water in metabolically active tissues. Via this activity, CAs substantially contribute to respiration, production of body fluids (vitreous humor, gastric juice, cerebrospinal fluid), bone resorption, renal acidification etc. (Chegwidden 2000).

10 CA IX isozyme integrates several properties that make it an important subject of basic as well as clinical research. First of all, expression of CA IX is very tightly associated with a broad variety of human tumors, while it is generally absent from the corresponding normal tissues [Zavada et al. (1993); Liao et al. (1994); Turner et al., 1997; Liao et al., 1997; Saarnio et al., 1998; Vermeylen et al., 1999; 15 Ivanov et al. (2001); Bartosova et al. (2002)]. This is principally related to tumor hypoxia that strongly activates transcription of CA9 gene via a hypoxia-inducible transcription factor binding to a hypoxia-response element localized just upstream of transcription initiation site in CA9 promoter [Wykoff et al. (2000)]. Since tumor hypoxia is an important phenomenon with dramatic implications for cancer 20 development and therapy [Hockel and Vaupel (2001)], CA IX bears a significant potential as an intrinsic hypoxic marker with a prognostic/predictive value and as a promising therapeutic target [Wykoff et al. (2000); Wykoff et al. (2001); Beasley et al. (2001); Giatromanolaki et al. (2001); Koukourakis et al. (2001)]. In favor of the proposed clinical applications, CA IX is an integral plasma membrane protein with a 25 large extracellular part exposed at the surface of cancer cells and is thus accessible by the targeting tools, including the specific monoclonal antibodies. Furthermore, CA IX differs from the other CA isozymes by the presence of a unique proteoglycan-related region (PG) that forms an N-terminal extension of the extracellular CA domain and allows for elimination of cross-recognition with other isozymes [Opavsky 30 et al. (1996)]. Moreover, CA IX has been functionally implicated in cell adhesion and due to high catalytic activity it has been proposed to contribute to acidification of extracellular microenvironment [Zavada et al. (2000); Ivanov et al.,(1998)]. Therefore, targeting the CA IX protein for abrogation of its function is expected to have therapeutic effects. In addition to potential clinical exploitation of CA IX, there

is an increasing interest to resolve many basic molecular and functional aspects of CA IX, because the knowledge on its precise role in cancer cells, on the contribution of different domains/sequence motifs, and concerning its regulation is still fragmentary.

5 So far, most of the basic CA IX-related studies were performed using a single mouse monoclonal antibody M75 that recognizes the N-terminal PG region of CA IX [Pastorekova (1992), Zavada (2000)]. This antibody proved to be highly specific and perfectly suitable for certain purposes including immunohistochemical analyzes of cancer tissue sections [Liao et al. (1994); Ivanov et al. (2001) and 10 references therein], targeting hypoxic tumor cells in animal models [Chrastina et al. (2003)], CA IX immunodetection *in vitro*, and molecular characterization [Pastorek et al. (1994); Lieskovska et al. (1999); Kaluz et al. (1999); Kaluz et al. (2002), Olive et al. (2001)]. On the other hand, CA IX-specific monoclonal antibodies with epitope 15 specificity different from that of M75 have not heretofore been available for approaches that are based on capture-detection principle or for study of mutated variants of CA IX. There had been many significant obstacles to producing such antibodies previously. The instant invention solves the problems involved in producing antibodies to the non-immunodominant epitopes of CA IX and discloses a variety of clinical and experimental uses for such antibodies.

20

SUMMARY OF THE INVENTION

In one aspect, the instant invention concerns new CA IX-specific 25 antibodies generated in CA IX-deficient mice, particularly to monoclonal antibodies and immunoreactive fragments thereof, that are directed to non-immunodominant epitopes on the CA IX extracellular domain. A representative CA IX-specific antibody generated in CA IX-deficient mice as described in Example 2 is the V/10 mab, produced by the V/10-VU, which hybridoma was deposited on February 19, 30 2003 under the Budapest Treaty at the Belgian Coordinated Collections of Microorganisms (BCCM) at the Laboratorium Voor Moleculaire Biologie-Plasmidencollectie (LMBP) in Gent, Belgium.

In view of the protocols specifically detailed herein, the CA IX-specific antibodies generated in the CA IX-deficient mice are directed to the PG or CA domains, ones of skill in the art realize that the analogous methods to those detailed

herein alone or in combination with conventional methods known in the art can be used to produce CA IX-specific antibodies or immunoreactive antibody fragments to other domains of CA IX as shown in Figure 4, for example, the TM or IC domains.

In another aspect, the new CA IX-specific antibodies generated in CA IX-deficient mice and particularly monoclonal antibodies and immunoreactive fragments thereof not directed to immunodominant epitopes of CA IX can be used clinically – diagnostically and/or prognostically to detect precancer and cancer (preneoplastic/neoplastic disease) and therapeutically to treat precancer and cancer (prenoplastic/neoplastic disease). The new CA IX-specific antibodies generated in CA IX-deficient mice to non-immunodominant epitopes can be used diagnostically/prognostically or therapeutically alone or in combination with CA IX-specific antibodies not generated in CA IX-deficient mice, such as the M75 monoclonal antibody. The antibodies of this invention directed to other than the PG domain of CA IX are particularly useful to detect the soluble form of the CA IX antigen (s-CA IX) found in body fluids with CA IX-specific antibodies directed to the PG domain. Preferably such assays include CA IX-specific antibodies directed to the PG and CA domains, but such antibodies directed to other domains, as for example, the IC or TM, in combination with such antibodies to any of the other domains, or as long as such antibodies do not have the same, overlapping and/or closely neighboring epitopes that would cause steric hindrance or blocking of each other's binding could be suitable for such assays. Optimizing assays for different MN target antigens would be within the skill of the art. Double-antibody sandwich assays using the CA-IX-specific antibodies of this invention are particularly preferred for diagnostic/prognostic assays to detect or detect and quantify the soluble form of CA IX (s-Ca IX) in body fluids.

The CA IX-specific antibodies generated in CA IX-deficient mice, particularly those not directed to immunodominant epitopes CA IX, alone or in combination with other such CA IX-specific antibodies or with CA IX-specific antibodies directed to immunodominant epitopes, such as the M75 monoclonal antibody, can also be used to detect or detect and quantitate different deletion variants of CA IX protein.

The CA IX-specific antibodies of this invention generated in CA IX-deficient mice, particularly those directed to non-immunodominant epitopes, can be used individually or in combination with other such CA IX-specific antibodies in

cancer research, diagnostics/prognostics for precancer/cancer, in making cancer treatment decisions, in the developing new forms of cancer treatment, and in anti-tumor vaccines. For example, the CA IX-specific antibodies generated in CA IX-deficient mice directed to various domains of CA IX, for example, to the CA, TM or IC

5 domains, can be used also to detect and/or identify deletion variants of CA IX. More particularly, for example, the CA IX-specific antibodies generated in CA IX-deficient mice, particularly those not directed to immunodominant epitopes, can be used alone or in combination with CA IX-specific antibodies for many uses, among which are the following.

10 a) In basic and pre-clinical research

- Study of the structure-function relationship in CA IX molecule;
- Study of the mechanism of release of soluble CA IX from cancer cells, determination of its biological activity and exploring its possible pathophysiological aspects;
- 15 • Study of the signal transduction pathways upstream and downstream of CA IX;
- Study of CA IX role in tumor growth and metabolism;
- Study of CA IX role in response to treatment by drugs, radiation, inhibitors etc.;

b) In cancer screening, detection, diagnosis and prognosis

20

- Detection of CA IX (and its putative variants) in tumor specimens for tumor diagnosis, prediction of treatment outcome and prognosis of disease development;
- Development of sensitive test(s) for detection of soluble CA IX in body fluids;
- Development of screening approaches based on CA IX detection and monitoring 25 of cancer relapse or metastasis after treatment;
- Imaging of tumor and metastases;

c) In tumor therapy

30

- Preparation of humanized antibodies, single-chain fragments, diabodies, minibodies, bispecific antibodies and other form of antibodies for therapeutic purposes;

- Unconjugated antibody-based therapy to hinder cancer expansion and/or progression either by blocking CA IX activity, or by antibody-dependent cell cytotoxicity, or by complement-mediated cytotoxicity;
- Bispecific antibody-based therapy directed to tumor lysis by cytotoxic T cells;
- 5 • Therapy by antibody coupled with enzyme converting prodrug to active anticancer drug;
- Radioimmunotherapy by antibody conjugated with radioisotope;
- Therapy by antibody coupled with toxin;
- Therapy by antibody coupled with chemotherapeutic drugs;
- 10 • Therapy by antibody combined with conventional therapeutic drugs (or different inhibitors of cancer-related pathways), bioreductive drugs, or radiotherapy to increase treatment efficacy;
- Combined therapy with antibodies to other cancer-related antigens, or with cytokines;
- Gene therapy with plasmid/vector-coupled antibody for targeted delivery; and

15

d) For anti-tumor vaccination

- Production of anti-idiotypic antibodies with internal image of CA IX for use as a vaccine.

In one aspect, there is provided an isolated soluble form of MN/CA IX antigen,
20 wherein said MN/CA IX antigen comprises at least one immunodominant epitope of
MN/CA IX protein.

The soluble CA IX (s-CA IX) found in vertebrate body fluids, preferably
mammalian body fluids, more preferably human body fluids, has a molecular weight of
from about 10 kilodaltons (kd) to about 65 kd, preferably from about 15 kd to about 54
25 kd, more preferably from about 20 kd to about 54 kd; still more preferably said s-CA IX
has a molecular weight of either from about 15 kd to about 35 kd or from about 45 kd to
about 54 kd, more preferably either from about 20 kd to about 30 kd or from about 50 kd
to about 54 kd, and most preferably said s-CA IX has a molecular weight predominantly
as a twin protein having a molecular weight of about 50/54 kd as approximated from
30 Western blotting.

The s-CA IX found in body fluids and in the culture medium of tumor cell lines,
e.g., HT29, is primarily seen on Western blots as a twin band of 50/54 kd. The other
major form of CA IX is the cell associated, transmembrane protein seen on Western blot
as a twin band of 54/58 kd. The s-CA IX found in body fluids and tissue culture (TC)
35 media is considered to be the CA IX extracellular portion released by

proteolytic cleavage from the transmembrane (TM) and intracellular (IC) domains. The s-CA IX is predominantly a twin band of 50/54 kd on Western blot, is considered to represent only the extracellular part of CA IX, comprising the proteoglycan-like (PG) domain and the carbonic anhydrase (CA domain (see Figure 4). The complete 5 cell-associated CA IX, predominantly a twin band of 54/58 kd on Western blot, further comprises a transmembrane (TM) region and an intracellular (IC) anchor.

The s-CA IX also exists in other smaller forms, preferably 20-30 kd, which is considered to comprise the CA domain or parts thereof. Higher molecular weight species of the s-CA IX of about 62 kd have been seen in the body fluids of 10 cancer patients, but such species are considered to be rare and perhaps aberrant, as conjoined with other molecular species, in view of the theoretical molecular weight of the CA IX extracellular (EC) domain being about 50/54 kd.

The s-CA IX is considered to be a diagnostic/prognostic marker of many different cancers. A preferred diagnostic/prognostic use for s-CA IX is 15 considered to be to monitor patients after surgical removal of a tumor, and to make decisions about the optimal method for therapy. The CA IX-specific antibodies that are directed to the non-immunodominant epitopes of this invention alone or in combination with CA IX-specific antibodies to the immunodominant epitopes, such as that of the M75 mab or V/18 mab, are considered important to detect all forms of 20 s-CA IX, which are at low concentrations in body fluids.

Preferred samples in which to assay MN antigen by, for example, Western blotting or radioimmunoassay, are tissue and/or cell extracts. However, MN antigen, particularly in a soluble form, as the extracellular domain, can be detected in body fluids, which can include among other fluids: blood, serum, plasma, semen, 25 breast exudate, gastric secretions, fecal suspensions, bile, saliva, tears, sputum, mucous, urine, lymph, cytosols, ascites, pleural effusions, amniotic fluid, bladder washes, bronchioalveolar lavages and cerebrospinal fluid. It is preferred that the MN antigen be concentrated from a larger volume of body fluid before testing. Preferred body fluids to assay would depend on the type of cancer for which one was testing, 30 but in general preferred body fluids would be urine, serum, fecal suspensions, mucous, gastric secretions, bile, breast exudate, pleural effusions and ascites.

A preferred immunoassay format to detect s-CA IX in vertebrate, preferably mammalian, and more preferably human body fluids is a double antibody sandwich assay, using CA IX-specific antibodies directed to different regions of CA

IX. A preferred combination of CA IX-specific antibodies would be, for example, the M75 mab to the PG domain and the V/10 mab to the CA domain.

The s-CA IX that can be detected or detected and quantitated can be bound by CA IX-specific antibodies to the EC domain of CA IX, preferably to the PG or CA domains, such as the M75 mab or the V/10 mab, respectively. The smaller form of the s-CA IX with a molecular weight of about 20 to about 30 kd, is considered to lack the PG domain, so that form would preferably be detected and quantitated by CA IX-specific antibodies directed to CA domain, preferably to epitopes that are substantially separated on that domain, which separation may well depend on the conformational nature of the epitopes and the protein/polypeptide 3-D structure, that may differ from that of the full-length CA IX or EC domain thereof.

One method of detecting or detecting and quantifying s-Ca IX protein/polypeptide in a vertebrate body fluid comprise the steps of

(a) contacting said sample with one or more antibodies which specifically bind to CA IX protein or to CA IX polypeptide which comprises at least 16 amino acids; and

(b) detecting or detecting and quantifying binding of said antibody in said sample. In such a method, one or more of said CA IX-specific antibodies is or are labeled. Such methods can be in standard formats, as for example, Western blots, enzyme-linked immunosorbent assays, radioimmunoassays, competition immunoassays, dual antibody sandwich assays, immunohistochemical staining assays, agglutination assays, and fluorescent immunoassays. Such method can be diagnostic and/or prognostic for cancerous or precancerous diseases, wherein said disease is associated with abnormal expression of CA IX protein, selected from the group consisting of mammary, urinary tract, kidney, ovarian, uterine, bladder cervical, endometrial, vaginal, vulvar, prostate, liver, lung, skin, thyroid, pancreatic, testicular, brain, head and neck, gastrointestinal, and mesodermal precancerous and cancerous diseases.

Such methods might be particularly directed to precancerous and cancerous diseases of breast, colon, rectum and of the urinary tract, as of the kidney, bladder, urethra. Renal cell carcinoma (RCC) and metastatic breast cancer, and precancer leading thereto, are considered particular targets for the diagnostic/prognostic assay methods that detect or detect and quantify s-CA IX in body fluids.

Another aspect of this invention concerns the coexpression of CA IX and HER-2/neu/c-erbB-2 ("HER-2") in precancers and cancers. As reported in Example 11, below, a significant correlation of expression of the two genes has been observed. Trastuzumab or herceptin is a humanized mab to HER-2 used to treat HER-2-positive cancers, particularly breast cancers, more particularly metastatic breast cancer [Horton, M.B., Cancer Control, 9(6): 499-507 (2002)]. Herceptin can be given alone to a patient but can enhance the effectiveness of several chemotherapeutic agents. However, a significant proportion of HER-2-positive cancers do not respond to herceptin [Kuter, I. (2001)]. It would be advantageous to test cancer patients for both HER-2 and MN/CA IX expression to enlarge the clinical perspective, therapeutic resources and diagnostic/prognostic parameters to pick the optimal therapeutic combinations for the most promising treatment outcomes.

As explained herein, CA IX is considered to be a hypoxia marker, and hypoxia indicates radiation resistance, and indicates how chemotherapy might progress. For example, drugs like bleomycin have an obligate requirement for oxygen in order to be toxic. When a clinician selects a chemotherapeutic drug or is deciding whether to use radiation with another modality, such as herceptin, whether the tumor cells are expressing CA IX indicating hypoxic conditions, should be a factor in the therapeutic decision.

Also disclosed herein are therapeutic methods for targeting CA IX expressing cells. Antibodies, preferably mabs, and often preferably immunoreactive antibody fragments, are well as bispecific, chimeric, humanized variants, intrabodies, among other variants, alone or conjugated to toxic agents, can be used. Further CA inhibitors provide another option to the clinician.

Particularly significant are assays for s-CA IX which are analogous to those for HER-2, which sheds its ectodomain ("p100") into body fluids (See, for example, Carney et al., U.S. Patent No. 5,401,638). Such tests could be performed on even the same patient body fluid sample with labeling that could be selected for detection by the same automated system.

So, in one aspect, this invention concerns methods of sequentially or simultaneously detecting or detecting and quantitating s-CA IX and the HER-2 ectodomain in patient body fluids, particularly from breast cancer patients. In another aspect, the invention concerns testing the body fluids of a cancer patient particularly a breast cancer patient, that are HER-2 positive but nonresponders to

2003217606 27 Aug 2007

herceptin, and treating the subset that are CA IX-positive with CA IX-specific antibodies, preferably mabs or fragments thereof or appropriate antibody variants, preferably fully humanized, alone or conjugated to a toxin, or alternatively with CA inhibitors, or with such CA IX-specific antibodies and/or CA inhibitors with rationally selected conventional therapies, including, for example, appropriate chemotherapeutic agents and in some cases radiation.

Thus, there is provided an isolated soluble form of MN/CA IX antigen, wherein said isolated soluble form of MN/CA IX antigen comprises at least one non-immunodominant epitope of MN/CA IX protein, which is released from precancerous and/or cancerous cells of a vertebrate into a body fluid.

In one embodiment, the soluble form of the MN/CA IX antigen has a molecular weight of about 50 to 54 kd. In this embodiment, the soluble form of the MN/CA IX antigen may comprise the proteoglycan-like (PG) and carbonic anhydrase (CA) domains of the MN/CA IX antigen.

In another embodiment, the soluble form of the MN/CA IX antigen has a molecular weight of about 20 to 30 kd. In this embodiment, the soluble form of the MN/CA IX antigen may comprise the carbonic anhydrase (CA) domain of the MN/CA IX antigen or parts of said CA domain.

In one embodiment, the soluble form of the MN/CA IX antigen is specifically bound by the M75 monoclonal antibody that is secreted from the hybridoma VU-M75, which was deposited at the American Type Culture Collection under ATCC No. HB 11128.

In certain embodiments the precancerous and/or cancerous cells of a vertebrate are human cells.

In certain embodiments, the body fluid is selected from the group consisting of blood, serum, plasma, semen, breast exudate, saliva, tears, sputum, mucous, urine, gastric secretions, fecal suspensions, bile, lymph, cytosols, ascites, pleural effusions, amniotic fluid, bladder washes, bronchioalveolar lavages and cerebrospinal fluid.

Also provided is a method of detecting or detecting and quantifying in a vertebrate body fluid soluble MN/CA IX antigen, wherein said soluble MN/CA IX antigen comprises at least one non-immunodominant epitope of MN/CA IX protein, comprising the steps of:

(a) contacting a sample of said body fluid with one or more MN/CA IX-specific antibodies and/or with one or more MN/CA IX-specific antigen

27 Aug 2007

2003217606

binding antibody fragments, wherein at least one of said MN/CA IX-specific antibodies or antibody fragments, specifically binds to a non-immunodominant epitope of MN/CA IX protein; and

(b) detecting or detecting and quantifying binding of said one or more antibodies and/or said one or more antibody fragments in said sample.

In one embodiment of this method, the one or more of said antibodies and/or antibody fragments are labeled.

The method may be in a format that is selected from the group consisting of Western blots, enzyme-linked immunosorbent assays, radioimmunoassays, competition immunoassays, dual antibody sandwich assays, immunohistochemical staining assays, agglutination assays, and fluorescent immunoassays.

In certain embodiments, the one or more antibodies and/or said one or more antibody fragments specifically bind to a soluble form of MN/CA IX antigen, which soluble MN/CA IX antigen is released from precancerous and/or cancerous cells of a vertebrate into a body fluid.

The one or more antibodies may be monoclonal. The one or more monoclonal antibodies may be selected from the group consisting of the monoclonal antibodies designated M75, which are secreted by the hybridoma VU-M75, which is deposited at the American Type Culture Collection under Accession No. HB 11128, and monoclonal antibodies that are not directed to the M75 epitope.

In another embodiment, the method is diagnostic and/or prognostic for precancerous and/or cancerous disease, wherein said disease is associated with abnormal expression of MN/CA IX antigen, selected from the group consisting of mammary, urinary tract, kidney, ovarian, uterine, bladder, cervical, endometrial, vaginal, vulvar, prostate, liver, lung, skin, thyroid, pancreatic, testicular, brain, head and neck, gastrointestinal, colorectal and mesodermal precancerous and cancerous diseases.

The method may be diagnostic, or diagnostic and prognostic for precancerous and/or cancerous disease selected from the group consisting of renal cell carcinoma, urinary tract precancerous and cancerous diseases, breast cancer, breast precancer, colorectal cancer and colorectal precancer.

In certain embodiments of the method a sandwich immunoassay is used to detect, or detect and quantify said soluble MN/CA IX antigen. In these embodiments the antibodies may be monoclonal, and wherein one monoclonal antibody of said

27 Aug 2007
2003217606

sandwich is specific for the carbonic anhydrase (CA) domain of the MN/CA IX antigen, and wherein the other monoclonal antibody of said sandwich assay is directed to the proteoglycan-like (PG) domain of the MN/CA IX antigen. In a particular embodiment, the antibody directed to the CA domain is the V/10 monoclonal antibody, which is secreted from the hybridoma cell line V/10-VU, which is deposited under the Budapest Treaty at the International Depository Authority of the Belgian Coordinated Collection of Microorganisms (BCCM) at the Laboratorium voor Moleculaire Biologie-Plasmidencollectie (LMBP) at the Universiteit Gent in Gent, Belgium, under Accession No. LMBP 6009CB, and wherein the antibody directed to the PG domain is the M75 monoclonal antibody, which is secreted from the hybridoma cell line VU-M75, which is deposited under the Budapest Treaty at the American Type Culture Collection under Accession No. HB 11128.

In certain embodiments of the method, the one or more antibodies and/or antibody fragments are selected from the group comprising MN/CA IX- specific monoclonal antibodies generated from MN/CA IX-deficient mice, fragments of MN/CA IX-specific antibodies generated from MN/CA IX-deficient mice, antibodies and antibody fragments specific to the MN/CA IX carbonic anhydrase (CA) domain, antibodies and antibody fragments specific to MN/CA IX non-immunodominant epitopes, and antibodies and antibody fragments specific to the proteoglycan-like (PG) domain of the MN/CA IX antigen.

In certain embodiments, the method further comprises using antibodies and/or antibody fragments specific to the HER-2 ectodomain to detect, or to detect and quantify HER-2 ectodomain having a molecular weight of from about 97 to about 115 kilodaltons in said body fluid.

In certain embodiments, the body fluid is from a cancer patient, whose response to treatment comprising the use of a monoclonal antibody or antibody fragment specific to a HER-2 protein/polypeptide is considered unsatisfactory.

In particular embodiments wherein the body fluid is from a cancer patient, the method further comprises basing treatment modalities upon whether both soluble MN/CA IX antigen and HER-2 ectodomain are present in said body fluid.

Also provided is a monoclonal antibody generated from a MN/CA IX-deficient mammal wherein said antibody binds specifically to a non-immunodominant epitope of MN/CA IX antigen.

2003217606
27 Aug 2007

In one embodiment, the MN/CA IX- deficient mammal is a mouse that has a null mutation in *Car9*.

In another embodiment, the domain is selected from the group consisting of the carbonic anhydrase (CA) domain, the proteoglycan-like (PG) domain, the transmembrane (TM) domain, and the intracellular (IC) domain.

In one embodiment, the domain is selected from the group consisting of the carbonic anhydrase (CA) domain and the proteoglycan-like (PG) domain.

In a particular embodiment, the monoclonal antibody specifically binds the carbonic anhydrase (CA) domain of the MN/CA IX antigen.

In certain embodiments, the epitope for said monoclonal antibody is within the amino acid sequence of SEQ ID NO: 9, which has the amino acid sequence from amino acid 135 to amino acid 391 of Figure 1, is within the amino acid sequence of SEQ ID NO: 101, which has the amino acid sequence from amino acid 121 to amino acid 397 of Figure 1, or is within amino acid sequences substantially homologous to the amino acid sequences of SEQ ID NOS: 9 and 101.

In certain embodiments, the epitope for said monoclonal antibody is closely associated with the amino acid sequence of SEQ ID NO: 67, which has the amino acid sequence from amino acid 279 to amino acid 291 of Figure 1, or which monoclonal antibody specifically binds to an epitope within SEQ ID NO: 69, which has the amino acid sequence from amino acid 166 to amino acid 397 of Figure 1, or to an epitope within an amino acid sequence substantially homologous to SEQ ID NO: 69.

In one embodiment, the monoclonal antibody specifically binds to the proteoglycan-like (PG) domain of the MN/CA IX antigen.

In another embodiment, the epitope for the monoclonal antibody is within an amino acid sequence selected from the group consisting of SEQ ID NO: 8, which has an amino acid sequence from amino acid 53 to amino acid 111 of Figure 1, SEQ ID NO: 98, which has an amino acid sequence from amino acid 52 to amino acid 125 of Figure 1, and amino acid sequences substantially homologous to SEQ ID NO: 8 and SEQ ID NO: 98.

In certain embodiments of the monoclonal antibody which specifically binds the transmembrane domain of the MN/CA IX antigen, the transmembrane domain has the amino acid sequence of SEQ ID NO: 6, which has the amino acid sequence from amino acid 415 to amino acid 434 of Figure 1, or has an amino acid sequence substantially homologous to SEQ ID NO: 6.

2003217606 27 Aug 2007

In certain embodiments of the monoclonal antibody which specifically binds the transmembrane domain of the MN/CA IX antigen, the intracellular domain has the amino acid sequence of SEQ ID NO: 7, which has the amino acid sequence from amino acid 435 to amino acid 459 of Figure 1, or has an amino acid sequence that is substantially homologous to SEQ ID NO: 7. In a particular embodiment, the monoclonal antibody binds the epitope represented by SEQ ID NO: 68 which has the amino acid sequence from amino acid 435 to amino acid 450 of Figure 1.

In certain embodiments, the monoclonal antibody is produced by the hybridoma VU-V10, deposited at BCCMTM/LMBP under Accession No. LMBP 6009CB.

In one embodiment, the monoclonal antibody is selected from the group consisting of antigen-binding fragments comprising MN/CA IX antigen binding regions. The fragments may be single chain molecules, comprising peptide-linked V_H and V_L domains, which may be dimerized.

Also provided is the hybridoma VU-V10 which produces the monoclonal antibody V/10 and which has been deposited at BCCMTM/LMBP under Accession No. LMBP 6009CB.

Also provided is a monoclonal antibody or antibody fragment that is specific to MN/CA IX antigen that is not directed to an immunodominant epitope of the MN/CA IX antigen.

The monoclonal antibodies or antibody fragments described above may be humanized.

The monoclonal antibodies or antibody fragments described above may be coupled with a radioisotope, a chemotherapeutic drug, a toxin or a carbonic anhydrase inhibitor.

Also provided is a method of therapy for precancerous and/or cancerous disease, wherein said disease is associated with abnormal expression of MN/CA IX antigen, comprising the use of one or more monoclonal antibodies or antibody fragments described above.

Also provided is method of therapy for precancerous and/or cancerous disease, comprising the use of a monoclonal antibody generated from a MN/CA IX-deficient mammal wherein said antibody binds specifically to a non-immunodominant epitope of MN/CA IX antigen, administered in conjunction with one or more chemotherapeutic drugs, carbonic anhydrase inhibitors, cytokines, antibodies directed

2003217606 27 Aug 2007

to immunodominant epitopes of MN/CA IX antigen, antibodies to cancer-related antigens other than MN/CA IX antigen, and/or radiotherapy.

In particular embodiments of the method of detecting and quantifying in a vertebrate body fluid soluble MN/CA IX antigen, wherein said soluble MN/CA IX antigen comprises at least one non-immunodominant epitope of MN/CA IX protein, comprising the steps of:

(a) contacting a sample of said body fluid with one or more MN/CA IX-specific antibodies and/or with one or more MN/CA IX-specific antigen binding antibody fragments, wherein at least one of said MN/CA IX-specific antibodies or antibody fragments, specifically binds to a non-immunodominant epitope of MN/CA IX protein; and

(b) detecting or detecting and quantifying binding of said one or more antibodies and/or said one or more antibody fragments in said sample,

wherein the body fluid is from a cancer patient,

the method further comprises basing treatment modalities upon whether both soluble MN/CA IX antigen and HER-2 ectodomain are present in said body fluid, whose body fluids contain both detectable soluble MN/CA IX antigen and HER-2 ectodomain, comprising the use of a monoclonal antibody, wherein said antibody binds specifically to MN/CA IX antigen.

In one embodiment, the method of detecting or detecting and quantifying in a vertebrate body fluid soluble MN/CA IX antigen, wherein said soluble MN/CA IX antigen comprises at least one non-immunodominant epitope of MN/CA IX protein, comprises the steps of:

(a) contacting a sample of said body fluid with one or more MN/CA IX-specific antibodies and/or with one or more MN/CA IX-specific antigen binding antibody fragments, wherein at least one of said MN/CA IX-specific antibodies or antibody fragments, specifically binds to a non-immunodominant epitope of MN/CA IX protein; and

(b) detecting or detecting and quantifying binding of said one or more antibodies and/or said one or more antibody fragments in said sample,

and wherein the method further comprises using antibodies and/or antibody fragments specific to the HER-2 ectodomain to detect, or to detect and quantify HER-2 ectodomain having a molecular weight of from about 97 to about 115 kilodaltons in said body fluid, and wherein the body fluid is from a cancer patient,

2003217606 27 Aug 2007

the method further comprises basing treatment modalities upon whether both soluble MN/CA IX antigen and HER-2 ectodomain are present in said body fluid, comprising the use of a carbonic anhydrase inhibitor.

Also provided is a method of gene therapy for a precancerous and/or cancerous disease, wherein said disease is associated with abnormal expression of MN/CA IX antigen, comprising the use of the monoclonal antibody generated from a MN/CA IX-deficient mammal wherein said antibody binds specifically to the carbonic anhydrase (CA) domain of MN/CA IX antigen, the antibody coupled to a plasmid/vector for targeted delivery to a cell expressing MN/CA IX antigen.

Also provided is an anti-idiotype antibody to an idioype of a monoclonal antibody generated from a MN/CA IX-deficient mammal, wherein said antibody binds specifically to a non-immunodominant epitope of MN/CA IX antigen, or an anti-idiotype antibody to an idioype of a monoclonal antibody or antibody fragment that is specific to MN/CA IX antigen that is not directed to an immunodominant epitope of the MN/CA IX antigen. Also provided is a method of therapy for precancerous and/or cancerous disease, comprising the administration of such an anti-idiotype antibody as a vaccine.

Further provided is a method of detecting deletion variants of MN/CA IX antigen, comprising the use of a monoclonal antibody or monoclonal antibodies generated from a MN/CA IX-deficient mammal, wherein said antibody binds specifically to a non-immunodominant epitope of MN/CA IX antigen, or a monoclonal antibody or antibody fragment that is specific to MN/CA IX antigen that is not directed to an immunodominant epitope of the MN/CA IX antigen, and optionally a monoclonal antibody or monoclonal antibodies directed to an immunodominant epitope of MN/CA IX antigen.

Also provided is a hybridoma that secretes any one of the above described monoclonal antibodies.

Also provided is the use of one or more MN/CA IX-specific antibodies and/or one or more MN/CA IX-specific antigen binding antibody fragments in the preparation of a diagnostic or medicament for use in the diagnosis and/or prognosis for precancerous and/or cancerous disease associated with abnormal expression of MN/CA IX antigen, wherein at least one of said MN/CA IX-specific antibodies or antibody fragments specifically binds to a non-immunodominant epitope of MN/CA IX protein. In certain embodiments, the disease is selected from the group consisting

2003217606 27 Aug 2007

of mammary, urinary tract, kidney, ovarian, uterine, bladder, cervical, endometrial, vaginal, vulvar, prostate, liver, lung, skin, thyroid, pancreatic, testicular, brain, head and neck, gastrointestinal, colorectal and mesodermal precancerous and cancerous diseases.

Also provided is a use of a monoclonal antibody generated from a MN/CA IX-deficient mammal in the preparation of a medicament for use in the treatment of precancerous and/or cancerous diseases associated with abnormal expression of MN/CA IX antigen, wherein said MN/CA IX-specific antibody specifically binds to a non-immunodominant epitope of MN/CA IX protein. In certain embodiments, the monoclonal antibody specifically binds the carbonic anhydrase (CA) domain of MN/CA IX.

Also provided is a use of a monoclonal antibody generated from a MN/CA IX-deficient mammal which specifically binds to a non-immunodominant epitope of the carbonic anhydrase (CA) domain of MN/CA IX protein, coupled to a plasmid/vector in the preparation of a medicament for targeted delivery of gene therapy for a precancerous and/or cancerous disease associated with abnormal expression of MN/CA IX antigen.

Also provided is a use of an anti-idiotype antibody directed to an idiotype of an antibody which specifically binds to a non-immunodominant epitope of MN/CA IX protein in the preparation of a vaccine for the therapy of a precancerous and/or cancerous disease associated with the expression of MN/CA IX antigen.

Abbreviations

The following abbreviations are used herein:

5-FC	-	5-fluorocytosine
5-FC	-	5-fluorouracil
^a	-	predicted target domain
aa	-	amino acid
ATCC	-	American Type Culture Collection
bp	-	base pairs
BLV	-	bovine leukemia virus
BSA	-	bovine serum albumin
BRL	-	Bethesda Research Laboratories

ΔCA	-	deletion variant of MN/CA IX protein lacking the CA domain expressed in transfected MDCK cells
CA	-	carbonic anhydrase
CAM	-	cell adhesion molecule
CARP	-	carbonic anhydrase related protein
CAT	-	Chloramphenicol acetyltransferase
Ci	-	curie
CIS	-	carcinoma in situ
cm	-	centimetre
CMV	-	cytomegalovirus
cpm	-	counts per minute
C-terminus-	carboxyl-terminus	
CTL	-	cytotoxic T lymphocytes
°C	-	degrees centigrade
DEAE	-	diethylaminoethyl
DMEM	-	Dulbecco modified Eagle medium

	ds	-	double-stranded
	EDTA	-	ethylenediaminetetraacetate
	EGF	-	epidermal growth factor
	EIA	-	enzyme immunoassay
5	ELISA	-	enzyme-linked immunosorbent assay
	EMSA	-	electrophoretic mobility shift assay
	EPO	-	erythropoietin
	ER	-	estrogen receptor
	ex	-	antigen in cellular extract
10	F	-	fibroblasts
	FACS	-	cytofluorometric study
	FCS	-	fetal calf serum
	FITC	-	fluorescein isothiocyanate
	fl	-	full length MN/CA IX expressed in MDCK (madin Darby Canine Kidney) canine renal epithelial cells stably transfected with the wild type cDNA
15	FTP	-	DNase 1 footprinting analysis
	GST-MN	-	fusion protein MN glutathione S-transferase
	GVC	-	ganciclovir
20	H	-	HeLa cells
	HBS	-	HIF-binding site
	H-E	-	haematoxylin-eosin
	HEF	-	human embryo fibroblasts
	HeLa K	-	standard type of HeLa cells
25	HeLa S	-	Stanbridge's mutant HeLa D98/AH.2
	H/F-T	-	hybrid HeLa fibroblast cells that are tumorigenic; derived from HeLa D98/AH.2
	H/F-N	-	hybrid HeLa fibroblast cells that are nontumorigenic; derived from HeLa D98/AH.2
30	HIF	-	hypoxia-inducible factor
	HPV	-	Human papilloma virus
	HRE	-	hypoxia response element
	HRP	-	horseradish peroxidase
	HSV	-	Herpes simplex virus

	IC	-	intracytoplasmic or intracellular
	IF	-	immunofluorescence
	IFN	-	interferon
	IHC	-	immunohistochemistry
5	IL-2	-	interleukin-2
	Inr	-	initiator
	IP	-	immunoprecipitation with the Protein A Sepharose
	IPTG	-	isopropyl-beta-D-thiogalacto-pyranoside
	kb	-	kilobase
10	kbp	-	kilobase pairs
	kd or kDa	-	kilodaltons
	KS	-	keratan sulphate
	KLH	-	keyhole limpet hemacyanin
	LCMV	-	lymphocytic choriomeningitis virus
15	LTR	-	long terminal repeat
	M	-	molar
	mA	-	milliampere
	Mab or mab	-	monoclonal antibody
	MCSF	-	macrophage colony stimulating factor
20	ME	-	mercaptoethanol
	MEM	-	minimal essential medium
	min.	-	minute(s)
	mg	-	milligram
	ml	-	milliliter
25	mM	-	millimolar
	MMC	-	mitomycin C
	mmol	-	millimole
	MLV	-	murine leukemia virus
	N	-	normal concentration
30	ND	-	not done
	NEG	-	negative
	ng	-	nanogram
	nm	-	nanometer
	nt	-	nucleotide

	N-terminus	-	amino-terminus
	ODN	-	oligodeoxynucleotide
	ORF	-	open reading frame
	PA	-	Protein A
5	PBS	-	phosphate buffered saline
	PCR	-	polymerase chain reaction
	PEST	-	combination of one-letter abbreviations for proline, glutamic acid, serine, threonine
	PG	-	proteoglycan-like region
10	PGK	-	phosphoglycerate kinase
	pl	-	isoelectric point
	PMA	-	phorbol 12-myristate 13-acetate
	POS	-	positive
	Py	-	pyrimidine
15	RACE	-	rapid amplification of cDNA ends
	RCC	-	renal cell carcinoma
	RIA	-	radioimmunoassay
	RIP	-	radioimmunoprecipitation
	RIPA	-	radioimmunoprecipitation assay
20	RNP	-	RNA protection assay
	RT-PCR	-	reverse transcriptase polymerase chain reaction
	SAC	-	<u>Staphylococcus aureus</u> cells
	<u>S. aureus</u>	-	<u>Staphylococcus aureus</u>
	sc	-	subcutaneous
25	SDRE	-	serum dose response element
	SDS	-	sodium dodecyl sulfate
	SDS-PAGE	-	sodium dodecyl sulfate-polyacrylamide gel electrophoresis
	SINE	-	short interspersed repeated sequence
	SP	-	signal peptide
30	SP-RIA	-	solid-phase radioimmunoassay
	SSDS	-	synthetic splice donor site
	SSH	-	subtractive suppressive PCR
	SSPE	-	NaCl (0.18 M), sodium phosphate (0.01 M), EDTA (0.001 M)
	SV40	-	simian virus 40

	TBE	-	Tris-borate/EDTA electrophoresis buffer
	TC	-	tissue culture
	TCA	-	trichloroacetic acid
	TC media	-	tissue culture media
5	TC	-	tissue culture
	tk	-	thymidine kinase
	TM	-	transmembrane
	TMB	-	tetramethylbenzidine
	Tris	-	tris (hydroxymethyl) aminomethane
10	μ Ci	-	microcurie
	μ g	-	microgram
	μ l	-	microliter
	μ M	-	micromolar
	VEGF	-	vascular endothelial growth factor
15	VSV	-	vesicular stomatitis virus
	VV	-	vaccinia virus
	WB	-	Western blotting
	WHO	-	World Health Organization
	X-MLV	-	xenotropic murine leukemia virus
20			

Cell Lines

	AGS	--	cell line derived from a primary adenogastric carcinoma [Barranco and Townsend, <u>Cancer Res.</u> , 43: 1703 (1983) and <u>Invest. New Drugs</u> , 1: 117 (1983)]; available from the ATCC under CRL-1739;
	A498	--	RCC cell line (ATCC HTB-44)
30	BL-3	--	bovine B lymphocytes [ATCC CRL-8037; leukemia cell suspension; <u>J. Natl. Cancer Inst.</u> (Bethesda) 40: 737 (1968)];

2003217606 21 Feb 2003

WO 03/100029

PCT/US03/05136

	C33	--	a cell line derived from a human cervical carcinoma biopsy [Auersperg, N., <u>J. Nat'l. Cancer Inst.</u> (Bethesda), 32: 135-148 (1964)]; available from the ATCC under HTB-31;
5	C33A	--	human cervical carcinoma cells [ATCC HTB-31; <u>J. Natl. Cancer Inst.</u> (Bethesda) 32: 135 (1964)];
10	C4.5	--	CHO wild-type, parental to Ka13, the same cell line as that described in Wood et al., <u>J. Biol. Chem.</u> , 273: 8360-8368 (1998);
15	COS	--	simian cell line [Gluzman, Y., <u>Cell</u> , 23: 175 (1981)];
20	HeLa	--	from American Type Culture Collection (ATCC)
25	HeLa K	--	standard type of HeLa cells; aneuploid, epithelial-like cell line isolated from a human cervical adenocarcinoma [Gey et al., <u>Cancer Res.</u> , 12: 264 (1952); Jones et al., <u>Obstet. Gynecol.</u> , 38: 945-949 (1971)] obtained from Professor B. Korych, [Institute of Medical Microbiology and Immunology, Charles University; Prague, Czech Republic];
30	HeLa D98/AH.2 (also HeLa s)	--	Mutant HeLa clone that is hypoxanthine guanine phosphoribosyl transferase-deficient (HGPRT ⁻) kindly provided by Eric J. Stanbridge [Department of Microbiology, College of Medicine, University of California, Irvine, CA (USA)] and reported in Stanbridge et al., <u>Science</u> , 215: 252-259 (15 Jan. 1982); parent of hybrid cells H/F-N and H/F-T, also obtained from E.J. Stanbridge; HT29
			A cell line derived from colorectal carcinoma. (ATCC No. HBT-38; DSMZ ACC299);

2003217606 21 Feb 2003

WO 03/100029

PCT/US03/05136

	Ka13	-	CHO mutant cell functionally defective for the HIF-1 α subunit, the same cell line as that described in Wood et al. (1998), <u>supra</u> ;
5	KATO III	--	cell line prepared from a metastatic form of a gastric carcinoma [Sekiguichi et al., <u>Japan J. Exp. Med.</u> , 48: 61 (1978)]; available from the ATCC under HTB-103;
10	MDCK	--	The MDCK cell line was derived from a kidney from an apparently normal adult female cocker spaniel by S.H. Madin and N.B. Barby in 1958. (ATCC CCL-34);
15	NIH-3T3	--	murine fibroblast cell line reported in Aaronson, <u>Science</u> , 237: 178 (1987);
20	QT35	--	quail fibrosarcoma cells [ECACC: 93120832; <u>Cell</u> , 11: 95 (1977)];
25	Raj	--	human Burkitt's lymphoma cell line [ATCC CCL-86; <u>Lancet</u> , 1: 238 (1964)];
	Rat2TK ⁻	--	cell line (rat embryo, thymidine kinase mutant) was derived from a subclone of a 5'-bromo-deoxyuridine resistant strain of the Fischer rat fibroblast 3T3-like cell line Rat1; the cells lack appreciable levels of nuclear thymidine kinase [Ahrens, B., <u>Virology</u> , 113: 408 (1981)];
30	SiHa	--	human cervical squamous carcinoma cell line [ATCC HTB-35; Friedl et al., <u>Proc. Soc. Exp. Biol. Med.</u> , 135: 543 (1990)];
	XC	--	cells derived from a rat rhabdomyosarcoma induced with Rous sarcoma virus-induced rat sarcoma [Svoboda, J., <u>Natl. Cancer Center Institute Monograph No. 17</u> , IN: "International

Conference on Avian Tumor Viruses" (J.W. Beard ed.), pp. 277-298 (1964)], kindly provided by Jan Svoboda [Institute of Molecular Genetics, Czechoslovak Academy of Sciences; Prague, Czech Republic]; and

5

CGL1 -- H/F-N hybrid cells (HeLa D98/AH.2 derivative);

CGL2 -- H/F-N hybrid cells (HeLa D98/AH.2 derivative):

CGL3 -- H/F-T hybrid cells (HeLa D98/AH.2 derivative);

10

CGL4 -- H/F-T hybrid cells (HeLa D98/Ah.2 derivative).

Nucleotide and Amino Acid Sequence Symbols

The following symbols are used to represent nucleotides herein:

15

Base

<u>Symbol</u>	<u>Meaning</u>
A	adenine
C	cytosine
G	guanine
T	thymine
U	uracil
I	inosine
M	A or C
R	A or G
W	A or T/U
S	C or G
Y	C or T/U
K	G or T/U
V	A or C or G
H	A or C or T/U
D	A or G or T/U
B	C or G or T/U
N/X	A or C or G or T/U

There are twenty main amino acids, each of which is specified by a different arrangement of three adjacent nucleotides (triplet code or codon), and which are linked together in a specific order to form a characteristic protein. A three-letter or one-letter convention is used herein to identify said amino acids, as, for example, in Figure 1 as follows:

		3 Ltr.	1 Ltr.
	<u>Amino acid name</u>	<u>Abbrev.</u>	<u>Abbrev.</u>
	Alanine	Ala	A
	Arginine	Arg	R
10	Asparagine	Asn	N
	Aspartic Acid	Asp	D
	Cysteine	Cys	C
	Glutamic Acid	Glu	E
	Glutamine	Gln	Q
15	Glycine	Gly	G
	Histidine	His	H
	Isoleucine	Ile	I
	Leucine	Leu	L
	Lysine	Lys	K
20	Methionine	Met	M
	Phenylalanine	Phe	F
	Proline	Pro	P
	Serine	Ser	S
	Threonine	Thr	T
25	Tryptophan	Trp	W
	Tyrosine	Tyr	Y
	Valine	Val	V
	Unknown or other		X

30 BRIEF DESCRIPTION OF THE FIGURES

Figure 1A-C provides the nucleotide sequence for a MN cDNA [SEQ ID NO: 1] clone isolated as described herein. Figure 1 A-C also sets forth the predicted amino acid sequence [SEQ ID NO: 2] encoded by the cDNA.

Figure 2A-F provides a 10,898 bp complete genomic sequence of MN [SEQ ID NO: 3]. The base count is as follows: 2654 A; 2739 C; 2645 G; and 2859 T. The 11 exons are in general shown in capital letters, but exon 1 is considered to begin at position 3507 as determined by RNase protection assay.

5 Figure 3 provides an exon-intron map of the human MN/CA IX gene. The positions and sizes of the exons (numbered, cross-hatched boxes), Alu repeat elements (open boxes) and an LTR-related sequence (first unnumbered stippled box) are adjusted to the indicated scale. The exons corresponding to individual MN/CA IX protein domains are enclosed in dashed frames designated PG
10 (proteoglycan-like domain), CA (carbonic anhydrase domain), TM (transmembrane anchor) and IC (intracytoplasmic tail). Below the map, the alignment of amino acid sequences illustrates the extent of homology between the MN/CA IX protein PG region (aa 53-111) [SEQ ID NO: 8] and the human aggrecan (aa 781-839) [SEQ ID NO: 10].

15 Figure 4 schematically represents the MN protein structure. The abbreviations are the same as used in Figure 3. The scale indicates the number of amino acids.

Figure 5(A) shows the alignment of amino acid sequences of the human CA IX (HCA IX) and the mouse CA IX (MCA IX) proteins deduced from the corresponding cDNAs [Pastorek et al. (1994), EMBL Accession No. X66839; Ortova Gut et al. (2002), EMBL Accession No. AJ245857]. Homologous amino acids are written on a grey background. Figure 5(B) is a schematic illustration of CA IX variants used for immunization and/or immunodetection purposes as described herein. The positions of the amino acids related to CA IX domain composition and to regions involved in variants are indicated below. Arrangement of antigenic sites for the antibodies (Y), assumed from the competitive assay, is shown above the scheme. The percentage of amino acid homology between human and mouse CA IX proteins is written inside the linear model of the full-length human CA IX protein, that is composed of signal peptide (SP), proteoglycan-like region (PG), carbonic anhydrase domain (CA), transmembrane anchor (TM) and intracytoplasmic tail (IC).

Figure 6 provides a checker board map of antigenic sites delineated on the basis of the competitive binding ELISA. Antigen-coated plates were incubated with fixed amount of biotin-labeled antibody and increasing amount of non-labeled

competitor antibody. Results are expressed as a percentage of absorbance measured in the absence of the competitor antibody.

Figure 7 shows the relationship between CA9 and other breast tumour markers in malignant breast specimens as evaluated by chi-square and Mann-Whitney tests. Figure 7(A) illustrates the percentage of breast marker-positive tumours in subgroups of CA9-positive versus CA9-negative specimens. The significance of the association between expression of CA9 and individual markers is given above the appropriate columns. Concordance of data corresponds to the percentage of specimens showing equal positivity/negativity for both CA9 and the particular other marker. Figure 7(B) illustrates the range of 5% to 95% quantile and median of expression of marker-specific PCR products detected in marker-positive tumours from CA9-positive and CA9-negative subgroups, respectively, with values of significance above the relevant columns.

Figure 8 shows the strategy for the targeted disruption of the mouse *Car9* gene. Figure 8A -- Targeting strategy: *top*, genomic structure of *Car9* locus showing exons 1-9; *middle*, pCar9-neo targeting vector of 6.8 kb with pgk-neo cassette replacing 14 bp in exon 1, *bottom*, structure of the gene after homologous recombination. The 4.0 kb *Xba*I (X) and 6.5 kb *Eco*RI (E) fragments present in the wild type allele are shown above, and the 2.0 kb *Xba*I and 8.3 kb *Eco*RI fragments present in the mutated allele are shown below. Positions of the restriction sites for *Bam*HI (B), *Hind*III (H) and the probes used to distinguish between the wild type and the mutant alleles after digestion with *Eco*RI are indicated. Figure 8B --The position of the primers on the *Car9* genomic locus is schematically illustrated.

Figure 9 provides a statistical analysis of the numbers of cells in stomachs of *Car9*^{+/+} versus *Car9*^{-/-} mice. As quantified by the Mann-Whitney rank test, the mutant mouse stomachs showed significantly increased total numbers of cells on one hand (A) and decreased numbers of H⁺/K⁺-ATPase positive parietal cells (B) and pepsinogen-positive chief cells (C) on the other hand. Regression analysis revealed significant correlation between total cells numbers and numbers of parietal cells in gastric units (D) and significant difference between the slopes of regression lines corresponding to gastric units of *Car9*^{+/+} and *Car9*^{-/-} mice, respectively.

Figure 10 shows the results of ELISAs for CA IX antigen. HT29 cells were grown in 5 cm Petri dish, supplied with 5 ml of media, and exchanged 2 days

before harvest. The extract from cell monolayer in this culture contained 5 mg of total protein. Extracts from the tumours were prepared directly from the excisions, without previous cultivation in vitro. Media from the cultures of tumour fragments were harvested after 2 days. A = purified CA IX protein (described in Závada *et al*, 2000); 5 B = TC media; C = extracts from cells and tumours; O = purified CA IX; ● = A498 cells; ■ = HT29 cells; patients No. ▲ = 38; ▼ = 50; ♦ = 59.

DETAILED DESCRIPTION

The following references are cited herein or provide updated information concerning the *MN/CA9* gene and the *MN/CA IX* protein. All the listed references as well as other references cited herein are specifically incorporated by reference.

- 15 • Aboagye *et al.*, Anticancer Drug Des., 13(6): 703-730 (Sep. 1998)
- Airley *et al.*, Clin. Cancer Res., 7: 928-934 (2001)
- Airley *et al.*, Brit. J. Cancer, 86 (Suppl. 1): S13-S33 (2002)
- Arteaga, C.L., Breast Cancer Res., 5(2): 96-100 (2003)
- Bartosova *et al.*, J. Pathol., 197: 1-8 (2002)
- 20 • Beasley *et al.*, Cancer Research, 61: 5262-5267 (2001)
- Bergstein, I., Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics, Bowcock AM (ed.), Humana Press: Totowa, pp. 143-169 (1999)
- Brizel *et al.*, Cancer Res., 56: 941-943 (1996)
- Brizel *et al.*, Int. J. Radiat. Oncol. Biol. Phys., 38: 285-289 (1997)
- 25 • Carney *et al.*, U.S. Patent No. 5,401,638
- Chapman, J.D., Radiother. Oncol., 20(Suppl. 1): 18-19 (1991)
- Chegwidden *et al.* (eds.), "The Carbonic Anhydrase Inhibitors – New Horizons," EXS (Basel) Vol. 90 (2000)
- Christianson and Cox, Annu. Rev. Biochem., 68: 33-57 (1999)
- 30 • EXS (Experientia Supplementa) (Basel) Vol. 90 [Birkhauser; Boston, MA (USA): 2000]
- Chia *et al.*, J. Clin. Oncol., 19: 3660-3668 (2001)
- Chrastina *et al.*, "Biodistribution and Pharmacokinetics of ¹²⁵I-labeled Monoclonal Antibody M75 Specific for Carbonic Anhydrase IX, an Intrinsic Marker of Hypoxia, in Nude Mice Xenografted with Human Colorectal Carcinoma," International Journal of Cancer, 106(6): 873-881 (July 20, 2003)

15

20

25

30

- Clark M., Immunol. Today, 21(8): 397-402 (Aug. 2000)
- Dachs et al., Nature Medicine, 3: 515-520 (1997)
- Dalbadie-McFarland et al., PNAS (USA), 79: 6409 (1982)
- Davis et al., Cancer Metastasis Rev., 18(4): 421-425 (1999)
- Ebert et al., J. Biol. Chem., 270(49): 29083-29089 (1995)
- Evans et al., Cancer Res., 56: 405-411 (1996)
- Ey et al., Biochemistry, 15: 429-436 (1978)
- Fleming et al., J. Clin. Invest., 96: 2907-2913 (1995)
- Forsythe et al., Mol. Cell. Biol., 16: 4604-4613 (1996)
- Fyles et al., Radiother. Oncol., 45: 149-156 (1998)
- Gavilondo and Lerrick, Biotechniques, 29(1): 128-132, 134-136 and 183 passim (July 2000)
- Gibadulinova et al., Acta Virol., 42: 369-374 (1999)
- Giatromanolaki et al., Cancer Res., 61(21): 7992-7998 (2001)
- Glennie et al., Nature, 295: 712 (1982)
- Goldyne et al., Adv. Exp. Med. Biol., 314: 317-327 (1991)
- Gray et al., Br. J. Radiol., 26: 638-648 (1953)
- Gumbiner, B., Cell, 84: 345-357 (1996)
- Gura, T., Nature, 417(6889): 584-586 (June 6, 2002)
- Jain and Baxter, Cancer Res., 48: 7022-7032 (1988)
- Jain et al., Nature Med., 6(2): 131-132 (2000)
- Hall, E.J., Radiobiology for the Radiologist, 5th ed., Philadelphia (PA): Lippincott (1998)
- Harris, A.L., Nature Reviews Cancer, 2: 38-47 (2002)
- Heber et al., Adv. Exp. Med. Biol., 399: 41-51 (1996)
- Hockel and Vaupel, Journal of National Cancer Institute, 93(4): 266-276 (Feb. 21, 2001)
- Hockel and Vaupel., CME J. Gyn. Oncol., 6/2: 216-225 (2001)
- Hockel and Vaupel, Seminars in Oncol., 28 (Supp.. 2): 36-41 (April 2001)
- Hockel et al., Radiother. Oncol., 26: 45-50 (1993)
- Hocker et al., Am. J. Physiol., 270: G619-633 (1996)
- Hodgkiss et al., Adv. Exp. Med. Biol., 428: 61-67 (1997)

- Holliger and Bohlen, Cancer Metastasis Rev., 18(4): 411-419 (1999)
- Hoogenboom and Chames, Immunol. Today, 21(8): 371-378 (Aug. 2000)
- Hui et al., Clinical Cancer Research, 8: 2595-2604 (2002)
- Hunter, W.M., "Radioimmunoassay," In: Handbook of Experimental Immunology, 5 pp. 14.1-14.40 (D.W. Weir ed.; Blackwell, Oxford/London/Edinburgh/Melbourne; 1978)
- Ishikawa et al., J. Exp. Med., 186: 999-1014 (1997)
- Ivanov et al., PNAS (USA), 95: 12596-12601 (1998)
- Ivanov et al., American Journal of Pathology, 158: 905-919 (2001)
- Kaestner et al., Genes Dev., 11: 1583-1595 (1997)
- Kallinowski et al., Int. J. Radiat. Oncol. Biol. Phys., 19: 953-961 (1990)
- Kaluz et al., Journal of Biological Chemistry, 274: 32588-32595 (1999)
- Kaluz et al., Cancer Research, 62: 4469-4477 (2002)
- Karam et al., Am. J. Physiol., 272: G1209-1220 (1997)
- Kaufmann et al., Lancet, 345: 615-619 (1995)
- Kennedy et al., Int. J. Radiat. Oncol. Biol. Phys., 37: 897-905 (1997)
- Knowlden et al., Oncogene, 17: 1949-1957 (1998)
- Koch et al., Br. J. Cancer, 72: 869-874 (1995)
- Korinek et al., Nature Genetics, 19: 379-383 (1998)
- Koukarakis et al., Clin. Cancer Res. 7(11): 3399-3403 (2001)
- Kuter, I., The Oncologist, 6: 338-346 (2001)
- Lane et al., Meth. Enzymol., 121: 183-192 (1986)
- Laughner et al., Mol. Cell Biol., 21: 3995 (2001)
- Lee et al., J. Clin. Invest., 106: 1447-1445 (2000)
- Lefebvre et al., Science, 274: 259-262 (1996)
- Lewis et al., PNAS (USA) 85: 1962-1966 (1988)
- Li et al., Mol Cell Biol., 20: 697-701 (2000)
- Liao and Stanbridge, Cancer Epidemiol. Biomar. Prev., 5: 549-557 (1996)
- Liao and Stanbridge, Cancer, 88: 1108-1121 (2000)
- Liao et al., Am. J. Pathol., 145: 598-609 (1994)
- Liao et al., Cancer Res., 57: 2827-2831 (1997)
- Lieskovska et al., Neoplasma, 46: 17-24 (1999)

- Lindmo et al., J. Immunol. Methods, 72: 77-89 (1984)
- Lancaster et al., Cancer Res., 61: 6394-6399 (2001)
- Mandriota et al., Cancer Cell, 1: 459-468 (2002)
- Marks et al., BioTechnology, 10: 779 (1992)
- 5 • Maren, T.H., J. Glaucoma, 4(1): 49-62 (1995)
- Maxwell et al., PNAS (USA), 90: 2423-2427 (1993)
- McKiernan et al., Cancer Res., 57: 2362-2365 (1997)
- McKiernan et al., Cancer, 86: 492-497 (1999)
- Murakami et al., BJU Int., 83: 743-747 (1999)
- 10 • Moinfar et al., Cancer Res., 60: 2562-2566 (2000)
- Nordsmark et al., Int. J. Radiat. Oncol. Biol. Phys., 49(2): 581-586 (2001)
- Nordsmark et al., Radiother. Oncol., 41: 31-39 (1996)
- Olive et al., Cancer Research, 61: 8924-8929 (2001)
- Opavsky et al., Genomics, 33: 480-487 (1996)
- 15 • Ortova-Gut et al., Gastroenterology, 123: 1889-1903 (2002)
- Osborne et al., Science Med: 32-41 (1996)
- Owens and Young, J. Immunol. Methods, 168(2): 149-165 (Feb. 10, 1994)
- Parkkila and Parkkila, Scand. J. Gastroenterol., 31: 305-317 (1996)
- Parkkila et al., PNAS (USA), 97: 2220-2224 (2000)
- 20 • Pastorek et al., Oncogene, 9: 2877-2888 (1994)
- Pastorekova et al., Virology, 187: 620-626 (1992)
- Pastorekova et al., Gastroenterology, 112: 398-408 (1997)
- Peles et al., Cell, 82: 251-260 (1995)
- Petit et al., Am. J. Pathol., 151: 1523-1530 (1997)
- 25 • Powell et al., Radiother. Oncol., 50(2): 167-171 (Feb 1999)
- Raleigh et al., Cancer Res., 58(17): 3765-3768 (Sep. 1, 1998)
- Ramalho-Santos et al., Development, 127: 2763-2772 (2000)
- Revillion et al., Euro J. Cancer, 34: 791-808 (1998)
- Saarnio et al., Gut, 41(3): 186 (1997)
- 30 • Saarnio et al., Am. J. Pathol., 153: 279-285 (1998)
- Saarnio et al., J. Histochem Cytochem, 46: 497-504 (1998)
- Saarnio et al., J. Histochem. Cytochem., 47: 517-524 (1999)

- Saarnio et al., Journal of Hepatology, 35: 643-649 (2001)
- Sandhu, J.S., Crit. Rev. Biotechnol., 12(5-6): 437-462 (1992)
- Scarff et al., Gastronenterology, 117: 605-618 (1999)
- Seibert and Chenchik, Nucleic Acids Res., 21: 2019-2020 (1993)
- 5 • Sharp et al., Development, 121: 149-151 (1995)
- Spicer et al., J. Biol. Chem., 275: 21555-21565 (2000)
- Stratford and Workman, Anti Cancer Drug Design, 13: 519-528 (1998)
- Sundfor et al., Br. J. Cancer, 78: 88822-88827 (1998)
- Sundfor et al., Radiother. Oncol., 54: 101-107 (2000)
- 10 • Supuran and Scozzafava, Expert Opin. Ther. Patents, 12(2): 217-242 (2002)
- Supuran et al., Bioorg. Med. Chem., 9: 703-714 (2001)
- Swinson et al., Br. J. Cancer, 86 (Supp. 1): S13 (2002)
- Swinson et al., J. Clin. Oncol., 21(3): 473-482 (Feb. 1, 2003)
- Teicher et al., Anticancer Res., 13(5A): 1549-1556 (1993)
- 15 • Trikha et al., Current Opinion in Biotechnology, 13(6): 609-614 (2002)
- Turner et al., Hum. Pathol., 28: 740-744 (1997)
- Turner et al., Brit. J. Cancer, 86: 1276-1282 (2002)
- Uemura et al., B. J. Cancer, 81: 741-746 (1999)
- Varia et al., Gynecol. Oncol., 71: 270-277 (1998)
- 20 • Vaughan et al., Nat. Biotechnol., 16(6): 535-539 (June 1998)
- Vaupel and Hoeckel, Intl. J. Oncol., 17(5): 869-879 (Nov. 2000)
- Vaupel and Hoeckel, Adv. Exp. Med. Biol., 471: 533-539 (2000)
- Vermeylen et al., Eur. Resp. J., 14: 806-811 (1999)
- Von Mehren et al., Annu. Rev. Med., 54: 343-369 (2003)
- 25 • Wiesener et al., Blood, 92: 2260-2268 (1998)
- Wingo et al., Biochem. Biophys. Res. Comm., 288: 666-669 (2001)
- World Health Organization. Histological typing of breast tumours. 2nd ed. In: International Histological Classification of Tumours, Geneva: World Health Organization, 1981
- 30 • Wright, N.A., Int. J. Exp. Pathol., 81: 117-143 (2000)
- Wykoff et al., Cancer Res., 60: 7075-7083 (2000)
- Wykoff et al., Am. J. Pathol., 158(3): 1011-1019 (March 2001)

- Young et al., PNAS (USA), 85: 9533-9537 (1988)
- Zavada et al., Int. J. Cancer, 54: 268-274 (1993)
- Zavada et al., Brit. J. Cancer, 82: 1808-1813 (2000)
- Zou and Rajewsky, Science, 262(5137): 1271-1274 (Nov. 19, 1993)

5

Previous attempts to produce CA IX-specific antibodies with specificity different from the M75 monoclonal antibody had been unsuccessful apparently due to the fact that human CA IX differs from the mouse homologue predominantly in the N-terminal amino acid sequence containing the M75 epitope. This sequence appears 10 to be strongly immunogenic possibly because the immunized mice recognize it as non-self, while they do not direct a humoral response to the other, more conserved parts of the human CA IX molecule.

Disclosed herein are detailed methods in Examples 1 and 2 on how to generate from CA IX-deficient mice, hybridoma cell lines producing monoclonal 15 antibodies specific for different extracellular regions of human CA IX protein. Provided herein is detailed characterization of those monoclonal antibodies, assessment of their reactivity in various immunodetection methods, and the relative position of the epitopes. Further provided are various clinical, diagnostic/prognostic, therapeutic and experimental utilities for those monoclonal antibodies.

20

Preparation of CA IX Deficient Mice and New CAIX-Specific
Antibodies Generated from Said CA IX-Deficient Mice

Example 1 details how the MN/CA IX-deficient mice were generated. 25 The knock out mice were used to generate new CA IX-specific monoclonal antibodies (mabs), some of which were directed to other than the CA IX immunodominant epitopes.

It was one object of the inventors to generate monoclonal antibodies (mabs) directed to epitopes different than that to which the M75 mab is directed 30 and/or to generate antibodies with the same epitope specificity as the M75 mab, but with different biological properties. To generate such mabs, the inventors used the knock out mice with the targeted disruption of *Car9* gene (coding for mouse MN/CA IX protein), as described herein and in Ortova-Gut et al. (2002) because the knock

out mice recognize the entire human MN/CA IX protein as a foreign molecule and may potentially develop humoral responses to epitopes localized in various regions of the human MN/CA IX protein.

5 In contrast, the wild type mice (wt mice) that express mouse MN/CA IX protein direct the immune response to the N-terminal part of human MN/CA IX because the N-terminal part of the human MN/CA IX protein differs more from the mouse protein than other domains of the human MN/CA IX protein. The wt mice preferentially produce antibodies to epitopes close to or overlapping the epitope to which the M75 mab is directed.

10 Initial experiments immunizing the MN/CA IX-deficient mice with mouse cells transfected with human MN/CA IX cDNA were not successful, as all the mabs produced were directed to the N-terminal domain of the human MN/CA IX protein, as is the M75 mab. If mabs to epitopes in other regions of the MN/CA IX protein were to be produced, a different immunization protocol was determined to be necessary
15 at about amino acids (aa) 53-111 (SEQ ID NO. 8) or preferably at about aa 52-125 (SEQ ID NO: 98).

20 There were a number of challenges to overcome. During hybridoma generation, there were several technical problems that required specific solution. First, it was a suitable immunization procedure that had to be invented to assure
25 production of required antibodies. For that purpose, we used different types of immunogens including the recombinant variant of CA IX protein containing the central carbonic anhydrase domain, but lacking N-terminal PG domain (see Example 2 below that shows, which immunization scheme led to production of MN/CA IX-specific antibodies). The other technical problem was development of appropriate screening system that would allow for selection MN/CA IX-specific antibodies and elimination of the non-specific ones, as explained in Example 1.

30 The inventors produced a recombinant variant of human MN/CA IX protein containing only the central carbonic anhydrase domain of MN/CA IX (the CA IX domain), but lacking the N-terminal PG domain as well as the transmembrane and intracytoplasmic regions. The cDNA coding for the CA IX domain was fused to glutathione-S-transferase (GST), expressed in bacteria and purified by affinity chromatography using glutathione S-Sepharose (Pharmacia). The GST-CA IX protein was inoculated as a third immunization dose either bound to the sepharose or eluted from the matrix. The improved immunization protocols, new fusions, yields

of hybridomas and numbers of MN/CA IX specific clones are summarized in the tables of Example 2.

Ten new fusions were made and more than 8000 clones were grown and screened. All MN/CA IX-specific hybridomas were subjected to the freezing-refreezing procedure and consequent subcloning (at least 100 subclones for each clone) in order to select the hybridomas of optimum viability and stable antibody production. That very significant effort resulted in the generation of 11 hybridomas synthesizing MN/CA-IX-specific monoclonal antibodies.

The new MN/CA IX-specific mabs were analyzed to determine their isotype and extensively tested for their reactivity by different immunodetection methods as described in Example 2. Knowledge of the mab isotype is important because the constant region of IgG is closely associated with its biological activity. Various isotypes carry out different effector functions, including complement activation and antibody-dependent cell mediated cytotoxicity. Most of the new antibodies were of IgG2a isotype. Those were able to recognize and bind to the full-length MN/CA IX protein in all tested methods, i.e. ELISA, Western blotting, immunoprecipitation and immunofluorescence. There were also two IgM and two IgG1 antibodies that did not react in immunoprecipitation because of their inability or decreased capacity to bind via Fc fragments to Protein A Sepharose. However, those antibodies showed MN/CA IX-specific reactivity in ELISA, Western blotting and immunofluorescence. The results indicate that the new antibodies recognize both native and denatured MN/CA IX protein and are potentially useful for different immunodetection approaches.

To determine the domain specificity of the new antibodies, the inventors used the full-length MN/CA IX antigen as well as the antigen lacking the CA domain to test the Mab reactivity in both immunoprecipitation and immunofluorescence. Monoclonal antibodies VII/20, VII/28, VII/32, VII/38, V/10 and V/12 immunoprecipitated the full-length MN/CA IX protein, but failed to react with the ΔCA deletion variant. Similar reactivity was observed in the immunofluorescence experiments, indicating that those antibodies are specific for the CA domain of MN/CA IX.

Mab VII/13 with predicted anti-CA specificity reacted well with the full-length MN/CA IX upon Western blotting. On the other hand, it did not show any reactivity in immunoprecipitation or immunofluorescence. The inventors consider

that that mab may be directed to a cryptotope that can be exposed only after the full denaturation of the antigen, whereas it remains hidden in the native or only partially denatured protein.

Among four of the new mabs with the proposed specificity to the N-terminal PG domain of MN/CA IX, three (IV/6, IV/14, IV/11) were of isotypes that are not applicable for immunoprecipitation, because they do not bind to protein A. Antibody IV/18 was able to immunoprecipitate the full-length MN/CA IX protein but not the Δ CA deletion variant. On the other hand, it reacted well with both types of antigen in immunofluorescence. Surprisingly, Mab IV/11 exhibited cytoplasmic reactivity with FL and Δ CA in immunofluorescence experiments. That result might be explained by its specificity to an immature intracytoplasmic form of the protein.

Predicted domain specificity of the new monoclonal antibodies corresponds to their capacity to compete with the M75 mab for binding to MN/CA IX as determined in competitive ELISA using biotinylated M75 mab and individual mabs in samples of hybridoma medium. Preliminary data indicates that the inventors have successfully generated seven new monoclonal antibodies whose epitopes are different from that of the M75 mabs. Another four new mabs seem to be directed to epitopes overlapping the M75 mab's epitope, but have a different isotype than the M75 mab does.

20

Study of in vitro biological activities of the new monolonal antibodies

The most intriguing and significant feature of the monoclonal antibodies is their ability to interfere with tumor cell growth, which ability can be exploited in anti-tumor therapy. Biological activity of the monoclonal antibodies may be related either to their isotype or to their capacity to engage the receptor molecule and block the signal transduction pathway. Isotype determines the Fc-receptor-dependent mechanisms that contribute substantially to the action of cytotoxic antibodies against tumors (e.g., antibody-dependent cell-mediated cytotoxicity, ADCC and complement-mediated cell lysis). Several mouse monoclonal antibodies of IgG1 and IgG2a isotypes and specificity against different antigens (including HER2/neu, CD20, PSCA) have been shown to stimulate ADCC. Some antibodies may have also a "direct" activity due to receptor-ligand blockade or triggering the pro-apoptotic

response (e.g. trastuzumab, a humanized IgG1 antibody to HER2/neu, and its "parent" mouse antibody).

As a first step to evaluation of the therapeutic potential of the new monoclonal antibodies specific for MN/CA IX, the inventors are analyzing the effects 5 of the mabs on tumor cell growth and invasion *in vitro*. The cells are being cultivated in different conditions (including normoxia, hypoxia, serum-starvation, low glucose) and treated with various concentrations of the purified mabs. Proliferation of the treated cells will be measured by MTS assay, and the extent of apoptosis will be determined by TdT labeling and FACS analysis. In addition, the capacity of the new 10 mabs to influence *in vitro* invasion of the tumor cells through the matrigel membranes will be analysed. The mabs may be combined therapeutically with chemotherapeutic agents. Such a combination has been shown to be effective for trastuzumab that was also developed from a typical mouse monoclonal antibody. Therefore, the additive effect of the drugs and MN/CA IX-specific antibody treatment 15 to select mabs with the potential therapeutic efficacy is being investigated.

Humanized, partially or completely, versions of such mabs can be prepared.

Those monoclonal antibodies that react with the CA domain of MN/CA IX will be subjected to additional analysis to evaluate their potential capacity to inhibit the enzyme activity of MN/CA IX. The enzyme activity is thought to be highly relevant 20 for the biological role of MN/CA IX. Therefore, the "anti-catalytic" antibodies may become useful tools to elucidate the real significance of CA activity of MN/CA IX in tumor biology and may possibly act in the modulation of tumor growth.

Also, the inventors are evaluating the capacity of the MN/CA IX-specific 25 antibodies to induce ADCC *in vitro*. Most of the new antibodies are of IgG2a isotype and two of them are IgG1 isotype – both isotypes have been shown to be effective in complement and cell-mediated lysis.

Generation of monoclonal antibodies to mouse MN/CA IX protein

The inventors perceive that investigators involved in the pre-clinical 30 research of tumor hypoxia and anti-hypoxic therapeutic approaches would like to use specific antibodies for detection of the mouse MN/CA IX as a marker of hypoxia in experimentally induced mouse tumors. The M75 mab is not suitable for that purpose. The M75 mab recognizes the rat and pig proteins, but not the mouse

homolog, because its epitope is not preserved in the primary structure of the mouse MN/CA IX.

Availability of the cDNA encoding the mouse MN/CA IX protein allows production of a sufficient amount of a recombinant antigen that can be used for the immunization of the MN/CA IX-deficient mice and generation of corresponding monoclonal antibodies. Such mabs to the mouse MN/CA IX protein may be very useful for future studies of tumor progression utilizing animal models. In addition, the anti-mouse mabs may represent useful tools for pre-clinical examinations of therapeutic targeting of MN/CA IX-positive tumors without the need for immunodeficient animals xenografted with the human tumor cells.

Whether some of the new mabs against human MN/CA IX cross-react with the mouse protein is being investigated. Especially those directed to the CA domain are good candidates because the mouse and human MN/CA IX proteins differ mostly in the N-terminal PG-like regions, but show high sequence homology in the CA domain. Therefore, the reactivity of anti-human mabs to the mouse antigen (both recombinant and extracted from the cells transfected with the mouse cDNA) is being tested.

Example 1 provides the details on how the CA IX-deficient mice (mice with null mutation of *Car9*) were prepared by targeted gene disruption. Example 1 also reports on the identification of a *Car9* cDNA and gene encoding the mouse CA IX, phenotypic consequences of a targeted disruption of *Car9* gene and their impact on understanding the physiological significance of CA IX.

CA IX is a highly active enzyme with adhesion, functionally implicated in acid-base balance and intercellular communication. It is normally present in the basolateral membranes of gastrointestinal epithelium and ectopically expressed in many carcinomas. The CA IX deficient mice revealed much about its physiological relevance.

Mice homozygous for the mutation developed gastric hyperplasia of the glandular epithelium with numerous cysts. The first changes were observed in the newborn animals, indicating involvement of CA IX in the development. The hyperplasia of the stomach corpus became prominent at the end of gastric morphogenesis in four-weeks-old mice. Loss of CA IX led to overproduction of mucus-secreting pit cells and reduction of both pepsinogen-positive chief cells and H⁺/K⁺-ATPase-positive parietal cells. It was concluded that phenotypic

consequences of the *Car9* null mutation demonstrate important and non-redundant role of CA IX in morphogenesis and homeostasis of the glandular gastric epithelium via the control of cell proliferation and differentiation. More detail concerning those points can be found in Example 1 and in Ortova-Gut et al., *Gastroenterology*, 123:

5 1889-1903 (2002), the latter showing captioned photographs.

One of skill in the art with the instant disclosure enabling the production of CA IX specific antibodies to the CA domain, could analogously make CA IX-specific antibodies to the other CA IX domains. For example, instead of using the recombinant CA domain of CA IX fused to GST as the booster in the protocols of 10 Example 2 below, one of skill in the art would know that using a recombinant TM (SEQ ID NO: 6) domain or a recombinant IC (SEQ ID NO: 7) domain of CA IX would produce antibodies primarily directed to the respective domain used as the booster. Conventional variations of such methods, for example, using synthetic proteins/polypeptides of the selected domain are within the skill of the art.

15 One of skill in the art could also make antibodies to other regions of CA IX by conventional methods known in the art. For example, peptides from a CA IX region could be conjugated to a carrier, for example, to keyhole limpet hemocyanin (KLH), to prepare antibodies, either polyclonal or monoclonal, to the selected peptide. Such antibodies could be screened by conventional means to determine 20 whether the resulting antibodies are specific to the selected domain. Anti-peptide production services are commercially available, for example, from Aves Labs, Inc. in Tigard, Oregon (USA).

25 Immunodominant Epitopes in PG Domain and
In Neighboring Regions

Figure 4 schematically shows the basic structure of the full-length CA IX. As indicated above, the extracellular domain comprises the PG and CA domains as well as some spacer or perhaps hinge regions. The CA IX immunodominant 30 epitopes are primarily in the PG region at about aa 53-111 (SEQ ID NO: 8) or at about aa 52-125 (SEQ ID NO: 98), preferably now considered to be at about aa 52-125 (SEQ ID NO: 98). The immunodominant epitopes of CA IX may be located in regions neighboring the PG region. For example, the epitope for aa 36-51 (SEQ ID NO: 21) would be considered an immunodominant epitope.

The main CA IX immunodominant epitope is that for the M75 mab.

The M75 monoclonal antibody is considered to be directed to an immunodominant epitope in the N-terminal, proteoglycan-like (PG) region of CA IX. The epitope of M75 has been identified as amino acid sequence PGEEDLP (SEQ ID NO: 11), which is 4x identically repeated in the N-terminal PG region of CA IX [Zavada et al. (2000)]. Closely related epitopes to which the M75 mab may also bind, which are also exemplary of immunodominant epitopes include, for example, the immunodominant 6X tandem repeat that can be found at amino acids (aa) 61-96 (SEQ ID NO. 12) of Figure 1A-1C, showing the predicted CA IX amino acid sequence. Variations of the immunodominant tandem repeat epitopes within the PG domain include GEEDLP (SEQ ID NO: 13) (aa 61-66, aa 79-84, aa 85-90 and aa 91-96), EEDL (SEQ ID NO: 14) (aa 62-65, aa 80-83, aa 86-89, aa 92-95), EEDLP (SEQ ID NO: 15) (aa 62-66, aa 80-84, aa 86-90, aa 92-96), EDLPSE (SEQ ID NO: 16) (aa 63-68), EEDLPSE (SEQ ID NO: 17) (aa 62-68), DLPGEE (SEQ ID NO: 18) (aa 82-87, aa 88-93), EEDLPS (SEQ ID NO: 19) (aa 62-67) and GEDDPL (SEQ ID NO: 20) (aa 55-60). Other immunodominant epitopes could include, for example, aa 68-91 (SEQ ID NO: 22).

The monoclonal antibodies MN9 and MN12 are considered to be

20 directed to immunodominant epitopes within the N-terminal PG region SEQ ID NOS: 19-20, respectively. The MN7 monoclonal antibody could be directed to an immunodominant epitope neighboring the PG region at aa 127-147 (SEQ ID NO: 23) of Figure 1A-1C.

An epitope considered to be preferred within the CA domain (SEQ ID

25 NO: 9) is from about aa 279-291 (SEQ ID NO: 67). An epitope considered to be preferred within the intracellular domain (IC domain) (SEQ ID NO: 7) is from about aa 435-450 (SEQ ID NO: 68).

SEQ ID NO: 69 (aa 166-397 of Figure 1A-1C) is considered to be an important antigenic component of the CA domain. There are several antigenic sites 30 within the CA domain. As can be seen in Figure 6, there are four groups of the CA IX-specific monoclonal antibodies prepared in CA IX-deficient mice such that they are directed to the CA domain; three of those groups are within SEQ ID NO: 69.

S-CA IX

Examples herein show that in addition to its previously described cell-associated form of CA IX (p54/58), there is a soluble form of CA IX. As described below in Examples 3-9 s-CA IX has been observed in tissue culture media from tumor cell lines, such as HT29. Furthermore, we have found s-CA IX in the blood serum and urine of cancer patients.

Preferred soluble forms of CA IX proteins/polypeptides according to this invention are those proteins and/or polypeptides that have substantial homology with the CA IX protein having the deduced amino acid sequence as shown in Figure 1 [SEQ ID NO: 2]. For example, such substantially homologous soluble CA IX proteins/ polypeptides are those that are reactive with the CA IX-specific antibodies of this invention, preferably the Mabs M75, V-10 or their equivalents.

It can also be appreciated that a protein or polypeptide produced by a neoplastic cell *in vivo* could be altered in sequence from that produced by a tumor cell in cell culture or by a transformed cell. Thus, CA IX proteins and/or polypeptides which have varying amino acid sequences including without limitation, amino acid substitutions, extensions, deletions, truncations and combinations thereof, fall within the scope of this invention. It can also be appreciated that a protein extant within body fluids is subject to degradative processes, such as, proteolytic processes; thus, soluble CA IX proteins that are significantly truncated and CA IX polypeptides may be found in body fluids, such as, sera. The phrase "CA IX antigen" is used herein to encompass CA IX proteins and/or polypeptides.

Assays

Assays according to this invention are provided to detect and/or quantitate soluble forms of CA IX antigen in vertebrate samples, preferably mammalian samples, more preferably human samples. Soluble forms of CA IX antigen may be detected by immunoassay, for example, Western blotting or radioimmunoassay, among other techniques.

Preferred samples in which to assay soluble forms of CA IX antigen, as the extracellular domain, are body fluids, which can include among other fluids: blood, serum, plasma, semen, breast exudate, gastric secretions, fecal suspensions, bile, saliva, tears, sputum, mucous, urine, lymph, cytosols, ascites, pleural effusions, amniotic fluid, bladder washes, bronchioalveolar lavages and cerebrospinal fluid. It

is preferred that the soluble CA IX antigen be concentrated from a larger volume of body fluid before testing. (Examples 3-11 below are representative.) Preferred body fluids to assay would depend on the type of cancer for which one was testing, but in general preferred body fluids would be urine, serum, mucous, gastric secretions,

5 bile, breast exudate, pleural effusions and ascites.

The assays of this invention are both diagnostic and/or prognostic, i.e., diagnostic/prognostic. The term "diagnostic/ prognostic" is herein defined to encompass the following processes either individually or cumulatively depending upon the clinical context: determining the presence of disease, determining the

10 nature of a disease, distinguishing one disease from another, forecasting as to the probable outcome of a disease state, determining the prospect as to recovery from a disease as indicated by the nature and symptoms of a case, monitoring the disease status of a patient, monitoring a patient for recurrence of disease, and/or determining the preferred therapeutic regimen for a patient. The diagnostic/prognostic methods

15 of this invention are useful, for example, for screening populations for the presence of neoplastic or pre-neoplastic disease, determining the risk of developing neoplastic disease, diagnosing the presence of neoplastic and/or pre-neoplastic disease, monitoring the disease status of patients with neoplastic disease, and/or determining the prognosis for the course of neoplastic disease.

20 The present invention is useful for screening for the presence of a wide variety of neoplastic diseases as indicated above. The invention provides methods and compositions for evaluating the probability of the presence of malignant or pre-malignant cells, for example, in a group of cells freshly removed from a host. Such an assay can be used to detect tumors, and help in the diagnosis and prognosis of 25 disease. The assays can also be used to confirm the absence or removal of all tumor tissue following surgery, cancer chemotherapy and/or radiation therapy. It can further be used to monitor cancer chemotherapy and tumor reappearance.

We have used the method of Western blot in experiments reported in the examples below to confirm the presence of soluble CA IX protein in human urine 30 and serum. This method is time-consuming and laborious. However, the presence of soluble forms of CA IX antigen can be detected and/or quantitated using a number of well-defined diagnostic assays. Those in the art can adapt any of the conventional immunoassay formats to detect and/or quantitate soluble CA IX antigen. A preferred diagnostic format for the method of this invention is the dual

antibody sandwich assay. Many other formats for detection of CA IX antigen and CA IX-specific antibodies are, of course available. Those can be Western blots, ELISAs (enzyme-linked immunosorbent assays), RIAs (radioimmunoassay), competitive EIA or dual antibody sandwich assays, among other assays all commonly used in the 5 diagnostic industry. In such immunoassays, the interpretation of the results is based on the assumption that the antibody or antibody combination will not cross-react with other proteins and protein fragments present in the sample that are unrelated to CA IX.

Suitable detection means include the use of labels such as 10 radionuclides, enzymes, coenzymes, fluorescers, chemiluminescers, chromogens, enzyme substrates or co-factors, enzyme inhibitors, free radicals, particles, dyes and the like. Such labeled reagents may be used in a variety of well known assays, such as radioimmunoassays, enzyme immunoassays, e.g., ELISA, fluorescent immunoassays, and the like. See for example, U.S. Patent Nos. 3,766,162; 15 3,791,932; 3,817,837; and 4,233,402.

Methods to prepare antibodies useful in the assays of the invention are described below. The examples below detail representative assays according to this invention.

Representative of one type of dual antibody sandwich ELISA assay for 20 soluble CA IX antigen is a format wherein a microtiter plate is coated with antibodies made to the extracellular domain of CA IX proteins/polypeptides or antibodies made to whole cells expressing CA IX proteins, and to this is added a patient body fluid sample, for example, serum or urine. After a period of incubation permitting any antigen to bind to the antibodies, the plate is washed and another set of anti-CA IX 25 antibodies which are linked to an enzyme, is added, incubated to allow reaction to take place, and the plate is then rewashed. Thereafter, enzyme substrate is added to the microtiter plate and incubated for a period of time to allow the enzyme to work on the substrate, and the adsorbance of the final preparation is measured. A large change in absorbance indicates a positive result. In a preferred embodiment of the 30 invention, the first monoclonal antibody of a dual antibody sandwich assay is selected from the group consisting of the monoclonal antibodies designated M75 which are secreted by the hybridoma VU-M75, and a second enzyme-linked monoclonal antibody is selected from the group consisting of monoclonal antibodies

directed to an epitope other than that to which the M75 monoclonal antibody is directed, more preferably to an epitope other than the proteoglycan domain.

It is also apparent to one skilled in the art of immunoassays that CA IX proteins and/or polypeptides can be used to detect and/or quantitate the presence of 5 soluble CA IX antigen in the body fluids of patients. In one such embodiment, a competition immunoassay is used, wherein the CA IX protein/polypeptide is labeled and a body fluid sample is added to compete with the binding of the labeled CA IX protein/polypeptide to antibodies specific to CA IX protein/polypeptide.

In another embodiment, an immunometric assay may be used wherein 10 a labeled antibody made to a CA IX protein or polypeptide comprising the extracellular domain is used. In such an assay, the amount of labeled antibody which complexes with the antigen-bound antibody is directly proportional to the amount of soluble CA IX antigen in the sample.

An exemplary immunoassay method of this invention to detect and/or 15 quantitate soluble CA IX antigen in a vertebrate sample comprises the steps of:

20 a) incubating said vertebrate sample with one or more sets of antibodies (an antibody or antibodies) that bind to soluble CA IX antigen wherein one set is labeled or otherwise detectable;
b) examining the incubated sample for the presence of immune complexes comprising soluble CA IX antigen and said antibodies.

Another exemplary immunoassay method according to this invention is that wherein a competition immunoassay is used to detect and/or quantitate soluble CA IX antigen in a vertebrate sample and wherein said method comprises the steps of:

25 a) incubating a vertebrate sample with one or more sets of CA IX-specific antibodies and a certain amount of a labeled or otherwise detectable CA IX protein/polypeptide wherein said CA IX protein/ polypeptide competes for binding to said antibodies with soluble CA IX antigen present in the sample;
b) examining the incubated sample to determine the amount of 30 labeled/detectable CA IX protein/polypeptide bound to said antibodies; and
c) determining from the results of the examination in step b) whether soluble CA IX antigen is present in said sample and/or the amount of soluble CA IX antigen present in said sample.

Once antibodies (including biologically active antibody fragments) having suitable specificity have been prepared, a wide variety of immunological assay methods are available for determining the formation of specific antibody-antigen complexes. Numerous competitive and non-competitive protein binding assays have been described in the scientific and patent literature, and a large number of such assays are commercially available. Exemplary immunoassays which are suitable for detecting a serum antigen include those described in U.S. Patent Nos. 3,984,533; 3,996,345; 4,034,074; and 4,098,876.

A hybridoma that produces a representative CA IX-specific antibody, 10 the monoclonal antibody M75 (Mab M75), was deposited at the ATCC under Number HB 11128 as indicated above. The M75 antibody was used to discover and identify the CA IX protein and can be used to identify readily CA IX antigen in Western blots, in radioimmunoassays and immunohistochemically, for example, in tissue samples that are fresh, frozen, or formalin-, alcohol-, acetone- or otherwise fixed and/or 15 paraffin-embedded and deparaffinized.

Immunoassay Test Kits

The above outlined assays can be embodied in test kits to detect 20 and/or quantitate soluble CA IX antigen. Kits to detect and/or quantitate soluble CA IX antigen can comprise CA IX protein(s)/polypeptides(s). Such diagnostic/prognostic test kits can comprise one or more sets of antibodies, polyclonal and/or monoclonal, for a sandwich format wherein antibodies recognize epitopes on the soluble CA IX antigen, and one set is appropriately labeled or is 25 otherwise detectable.

Test kits for an assay format wherein there is competition between a labeled (or otherwise detectable) CA IX protein/polypeptide and CA IX antigen in the sample, for binding to an antibody, can comprise the combination of the labeled protein/polypeptide and the antibody in amounts which provide for optimum 30 sensitivity and accuracy.

A kit for use in an enzyme-immunoassay typically includes an enzyme-labelled reagent and a substrate for the enzyme. The enzyme can, for example, bind either a CA IX-specific antibody of this invention or to an antibody to such an CA IX-specific antibody. Test kits may comprise other components as necessary, for

example, to perform a preferred assay as outlined in Example 8 below. Such test kits can have other appropriate formats for conventional assays.

Preparation of CA IX-Specific Antibodies

5 The term "antibodies" is defined herein to include not only whole antibodies but also biologically active fragments of antibodies, preferably fragments containing the antigen binding regions. Descriptions of preparing CA IX-specific antibodies such as M75 suitable for use in immunoassays according to this invention have been described (Zavada et al. US Patent No. 5,387,676). Such antibodies may 10 be prepared by conventional methodology and/or by genetic engineering. Antibody fragments may be genetically engineered, preferably from the variable regions of the light and/or heavy chains (V_H and V_L), including the hypervariable regions, and still more preferably from both the V_H and V_L regions. For example, the term "antibodies" 15 as used herein comprehends polyclonal and monoclonal antibodies and biologically active fragments thereof including among other possibilities "univalent" antibodies [Glennie et al., Nature, 295: 712 (1982)]; Fab proteins including Fab' and $F(ab')_2$ fragments whether covalently or non-covalently aggregated; light or heavy chains alone, preferably variable heavy and light chain regions (V_H and V_L regions), and more preferably including the hypervariable regions [otherwise known as the 20 complementarity determining regions (CDRs) of said V_H and V_L regions]; F_c proteins; "hybrid" antibodies capable of binding more than one antigen; constant-variable region chimeras; "composite" immunoglobulins with heavy and light chains of different origins; "altered" antibodies with improved specificity and other characteristics as prepared by standard recombinant techniques and also by 25 oligonucleotide-directed mutagenesis techniques [Dalbadie-McFarland et al., PNAS (USA), 79: 6409 (1982)].

30 There are conventional techniques for making polyclonal and monoclonal antibodies well-known in the immunoassay art. Immunogens to prepare CA IX-specific antibodies include CA IX proteins and/or polypeptides, preferably purified, among others.

Anti-peptide antibodies are also made by conventional methods in the art as described in European Patent Publication No. 44,710 (published Jan. 27, 1982). Briefly, such anti-peptide antibodies are prepared by selecting a peptide from an CA IX amino acid sequence as from Figure 1, chemically synthesizing it,

conjugating it to an appropriate immunogenic protein and injecting it into an appropriate animal, usually a rabbit or a mouse; then, either polyclonal or monoclonal antibodies are made, the latter by the Kohler-Milstein procedure.

Besides conventional hybridoma technology, newer technologies can

5 be used to produce antibodies according to this invention. For example, the use of the polymerase chain reaction (PCR) to clone and express antibody V-genes and phage display technology to select antibody genes encoding fragments with binding activities has resulted in the isolation of antibody fragments from repertoires of PCR amplified V-genes using immunized mice or humans. [Marks et al., BioTechnology,

10 10: 779 (1992)]. Descriptions of preparing antibodies by recombinant techniques can be found, for example, in U.S. Patent No. 4,816,567 (issued March 28, 1989).

Preparation of Monoclonal Antibodies

Monoclonal antibodies for use in the assays of this invention may be

15 obtained by methods well known in the art. The production of hybridoma VU-M75 which secretes MAb M75 is exemplary and described below. MAb M75 serves to identify CA IX proteins/polypeptides in various laboratory diagnostic tests, for example, in tumor cell cultures or in clinical samples.

Monoclonal antibodies specific for this invention can be prepared by

20 immunizing appropriate mammals, preferably rodents, more preferably rabbits or mice, with an appropriate immunogen, for example, CA IX proteins/polypeptides attached to a carrier protein if necessary.

One obstacle to overcome in detecting s-CA IX antigen in body fluids was the extremely low concentration of s-CA IX in blood serum and in urine, of the

25 order of 10–100 pg/ml. To detect such an antigen, it is necessary to use two different monoclonal antibodies, directed to non-overlapping epitopes of CA IX. However, until now only one suitable monoclonal antibody, M75, was available for use to detect the CA IX protein. Recently, the inventors overcame this obstacle by using knockout mice with the targeted disruption of *Car9* gene to generate a series

30 of monoclonal antibodies specific for various antigenic sites of CA IX protein as described in Example 2. While Mab M75 is specific for the proteoglycan (PG) domain of the CA IX protein, MAb V-10 (one Mab generated by the knockout of *Car9*) is specific for the carbonic anhydrase (CA) domain. By optimizing

combinations and dilutions of two monoclonal antibodies, the inventors were able to obtain extremely sensitive and specific reactions.

MAb M75. Monoclonal antibody M75 (MAb M75) is produced by mouse lymphocytic hybridoma VU-M75, which was initially deposited in the

5 Collection of Hybridomas at the Institute of Virology, Slovak Academy of Sciences (Bratislava, Czechoslovakia) and was deposited under ATCC Designation HB 11128 on September 17, 1992 at the American Type Culture Collection (ATCC). The production of hybridoma VU-M75 is described in Zavada et al., WO 93/18152.

Mab M75 recognizes both the nonglycosylated GST-CA IX fusion 10 protein and native CA IX protein as expressed in CGL3 cells equally well. The M75 MAb recognizes both native and denatured forms of CA IX protein [Pastorekova et al. (1992)].

The monoclonal antibodies useful according to this invention to identify 15 soluble CA IX proteins/polypeptides can be labeled in any conventional manner, for example, with enzymes such as horseradish peroxidase (HRP), fluorescent compounds, or with radioactive isotopes such as, ¹²⁵I, among other labels. A preferred label, according to this invention is ¹²⁵I, and a preferred method of labeling the antibodies is by using chloramine-T [Hunter, W.M., "Radioimmunoassay," In: Handbook of Experimental Immunology, pp. 14.1-14.40 (D.W. Weir ed.; Blackwell, 20 Oxford/London/Edinburgh/Melbourne; 1978)]. Also preferred is the method of labeling the antibodies using peroxidase.

Described herein is the soluble form of CA IX protein (s-CA IX) shed by tumor cells in tissue culture, and detected in the urine and serum of cancer patients. The s-CA IX shed from tumor cells into culture medium is somewhat shortened. In 25 one embodiment of the invention, the s-CA IX protein is shortened to 50 and 54 kDa, compared with the cell-associated CA IX protein (p54/58). This size corresponds to extracellular part of CA IX molecule, which is composed of PG (proteoglycan-like) and CA (carbonic anhydrase) domains which have been cleaved off from the remainder of the molecule, the TM (transmembrane segment) and IC (intracellular 30 tail) of CA IX (see Figure 4). The p50/54 form of s-CA IX contains both PG and CA domains, since it reacts with both MAb M75, specific for PG and with MAb V-10, specific for the CA domain.

The high frequency and marked enhancement of CA IX expression in superficial bladder cancer, combined with the relative absence in normal transitional

epithelium, and the fact that CA IX is a transmembrane protein found in tumor patient urine, suggests that measurement of shed protein in the urine could be a potential marker of recurrence.

The s-CA IX could be recombinantly, synthetically or otherwise

5 biologically produced, as for example, by proteolytic cleavage or purification from tissue culture medium of an appropriate cell line that expresses MN/CA IX, and could be used therapeutically and/or diagnostically/prognostically. One theory would be that such s-CA IX could be used to sequester the unknown ligand to CA IX, which is considered to activate the signal transduction that results in oncogenic effects.

10 Another therapeutic use for the s-CA IX would be as a vaccine.

The s-CA IX could be used diagnostically/prognostically, for example, to detect MN/CA-IX-specific antibodies in body fluids, or as a calibrator or control in assays to detect comparably sized forms of the naturally occurring s-CA IX in a patient's body fluids. For each of the identified uses, preferably the prepared form of

15 s-CA IX is substantially the CA IX extracellular domain (SEQ ID NO: 5) having a molecular weight of about 50/54 kd.

Since CA IX is known to be expressed on the luminal surface of the bladder when bladder cancer is present [Turner et al., *Br. J. Cancer*, 86: 1276-1282 (2002], and since CA IX is a transmembrane protein, it could be hypothesized that

20 measurement of shed protein in the urine could be a marker of recurrence. Such "shed protein" is now known to be s-CA IX, predominantly as the extracellular domain of CA IX (SEQ ID NO: 5).

Coexpression of C-erbB-2 and CA IX

25 Example 11 discloses how CA IX was distributed in normal, benign and malignant breast tissues and compared with expression of breast tumour markers including oestrogen receptor (ER), c-erbB2, c-erbB3 and CD44. Tissue specimens were analysed using immunohistochemistry and/or reverse transcriptase-polymerase chain reaction (RT-PCR). CA IX was detected by IHC in 12/26 (46%) malignant

30 tissues, 4/36 (11%) benign lesions, but not in 10 normal breasts. Staining was mostly confined to plasma membranes of abnormal epithelial cells, but in five cases was found in adjacent stroma. Semiquantitative RT-PCR detected CA9 mRNA in 25/39 (64%) malignant tumours, 11/33 (33%) benign lesions, but in none of three normal breasts. Comparative RT-PCR analysis of malignant tissues revealed a

relationship between CA9 positivity and *c-erbB2* overexpression ($p=0.05$). Moreover, CA9-positive specimens displayed significantly higher median level of *c-erbB2* than CA9-negative ones ($p=0.02$). No significant association was found with the other markers. The results of this study support possible importance of CA IX for 5 breast carcinogenesis and indicate its usefulness as a breast tumour marker and therapeutic target.

Disclosed herein is the significant association of the ectopic expression of CA IX and the overexpression of HER-2/neu/c-erbB-2. Some of the features associated with high HER-2/neu/c-erbB-2 expression, such as invasion and 10 metastatic capability, may also be mediated by coexpression of CA IX.

A significant proportion of Her-2/neu/c-erbB-2-positive cancers do not respond to treatment by herceptin, a humanized monoclonal antibody against Her-2/neu/c-erbB-2 [Kuter, I. 2001]. Inhibitors of the coexpressed CA IX could provide 15 alternative therapeutic approaches. Such inhibitors include, for example, polyclonal and/or monoclonal antibodies, including immunoreactive fragments, and mono- or bi-specific variants, and related anti-anti-idiotype antibodies. Each of those antibody variants and fragments thereof can be used alone and/or conjugated to cytotoxic agents. [See, for example, Zavada et al., U.S. Patent Nos. 5,955,075 (Sept. 21, 1999) and 6,051,226 (April 18, 2000), and Zavada et al. EP 0 637 836 B1 (July 7, 20 1999).]

Another class of CA IX inhibitors are the carbonic anhydrase (CA) inhibitors. [See, for example, Chegwidden et al. (2000); Hockel and Vaupel (2001) (April 2001) (Feb. 21, 2001); Supuran and Scozzfava (2002); Teicher et al. (1993) and Maren, T.H. (1995).] Inhibition of CA activity has been shown to reduce invasion 25 of some tumor cell lines [Parkkila et al. (2000)], and CA inhibitor treatment may be beneficial as an adjunct to cancer chemotherapy, synergizing with chremotherapeutic agents in animal models. [Teicher (1993); Parkkila (2000)]. CA inhibitors, e.g., acetazolamide or sulfonamides, have been shown to reduce tumor invasiveness or block tumor growth, respectively [Parkkila et al. (2000); Supuran et 30 al., (2001)]. Further, CA isoenzyme antagonism has been observed to augment the cytotoxic effects of various chemotherapeutic agents, including platinum based drugs [Teicher et al. (1993)].

The classic, clinically important CA inhibitors are aromatic/heterocyclic sulfonamides. Exemplary are acetazolamide, methazolamide, ethoxzolamide,

dichlorophenamide, dorzolamide and brinzolamide. A large number of derivatives to enhance desired pharmacological/physicochemical prospective such as water solubility are new being developed [Supuran and Scozzafava (2002)].

Hypoxia and Therapy

Tumor hypoxia occurs as a consequence of an inadequate supply of blood borne oxygen due to the disorganized and chaotic vascular network that develops in tumors [Hockel and Vaupel (2001)]. Tumor hypoxia has been considered to present a therapeutic problem since hypoxic cells are radiation resistant [Gray et al. (1953); Hall, E.J. (1988)], and recent measurements of tumor oxygenation in the clinic have shown clear correlations with outcome of radiotherapy [Höckel et al. (1993); Nordmark et al. (1996); Brizel et al. (1997); Fyles et al. (1998); Sundfor et al. (2000)]. The role of tumor hypoxia for the outcome of chemotherapy is less clear, but there are a number of reasons why hypoxia may be important. For example, drugs like bleomycin have an obligate requirement for oxygen in order to be toxic. Chronically hypoxic cells tend to be out of cycle and resistant to cell cycle phase specific drugs. Finally, since hypoxic cells lie far from a functional vascular capillary, many chemotherapeutic drugs find it extremely difficult to diffuse that distance in sufficient concentrations to be toxic [Jain et al. (2000)].

20 Clinical observations have suggested hypoxia can cause cellular changes that result in a more aggressive phenotype [Höckel and Vaupel (2001)]. Such hypoxia-related malignant progression may result in increased potential for local invasiveness and metastatic spread [Brizel et al. (1996), Höckel et al. (1996) Sundfor et al. (1998)]. Results from experimental systems support the notion that 25 these changes are indeed hypoxia-mediated [Young et al. (1988), Graeber et al. (1996)].

30 There is a need to identify those patients most likely to respond to adjuvant therapy directed towards hypoxic cells. Such therapeutic approaches could include methods to improve tumour oxygenation such as Carbogen [Powell et al. (1997)], the use of bioreductive drugs [Stratford and Workman (1998)] or hypoxia-mediated gene therapy approaches [Dachs et al. (1997)]. Currently, the method that has received most widespread use to measure tumour oxygenation is the Eppendorf polarographic oxygen electrode [Kallinowski et al. (1990)]. However, it has limited use in that it is invasive and can only be used on relatively superficial tumours.

Nevertheless, this method of pO₂ measurement has generated many clinical therapeutic correlations and any subsequent methods of hypoxia measurement must be compared to it.

Bioreductive drug markers provide an alternative approach for 5 assessing the level and extent of tumor hypoxia. This was first articulated by Chapman and colleagues [see Chapman (1991) for review] who used the 2-nitroimidazole, misonidazole. Related compounds such as pimonidazole [Raleigh et al. (1998)], EF-5 [Koch et al. (1995)], NITP [Hodgkiss et al. (1997)] and SR4554 [Aboagye et al. (1998)] have subsequently been developed. They are all structurally 10 similar and will identify intracellular levels of oxygenation at which it is known that cells will be resistant to radiation [see e.g., Evans et al. (1996)]. Pimonidazole is at the most advanced stage of clinical evaluation [Kennedy et al. (1997); Varia et al. (1998)] and recently a clinical comparative study has been made between Eppendorf 15 measurements of pO₂ and the extent of pimonidazole adduct formation in carcinoma of the cervix [Nordström et al. (2001)]. In this latter study, there was a trend for tumors with relatively high pO₂ readings to show lower pimonidazole binding, however, there was no significant correlation seen between these two assays of hypoxia.

Another method to assess the presence of hypoxia in human tumors is to take 20 advantage of the phenomenon of hypoxia-mediated gene expression. Up regulation of a variety of genes in hypoxia is mediated by activation of the transcription factor HIF-1 (hypoxia-inducible factor-1). The HIF-1 protein is stabilized under hypoxic conditions and binds to genetic enhancer sequences (HREs, hypoxia responsive elements) that exist in the promoter regions of genes including erythropoietin 25 [Maxwell et al. (1993)], VEGF [Forsythe et al. (1996)], GLUT-1 [Ebert et al. (1995)] and CA IX [Wycoff et al. (2000)]. The expression of these genes in human tumours could potentially be determined at the time of tumour biopsy and thus provide an inexpensive, minimally invasive means of measuring tumour hypoxia. If validated, this approach could facilitate the rational selection of patients into various treatment 30 arms of clinical trials and allow appropriate application of therapeutic strategies directed towards hypoxic cells.

Recently the expression of GLUT-1 (glucose transporter-1) and CA IX (carbonic anhydrase IX) has been measured in carcinoma of the cervix and correlated with Eppendorf measurements of pO₂ and these immunohistochemical

measurements have in turn also been related to therapeutic outcome [Airley et al. (2001); Loncster et al. (2001)]. A study was done as reported in Airley et al. (2002) to relate the expression of the hypoxia-regulated genes GLUT-1 and CA9 to the presence of bound pimondazole adducts in carcinoma of the cervix.

CA IX, which, along with CA XII, was initially characterised as a hypoxia-inducible gene due to its overexpression in VHL defective cell lines, catalyses the reversible hydration of carbon dioxide to carbonic acid, providing a means of regulating pH in tumours [Wykoff et al. (2000)]. CA IX may therefore work to help counteract the intracellular acidic conditions found in oxygen deprived regions of tumours. These acidic conditions being promoted, to some extent, by the hypoxia-mediated over-expression of Glut-1, in turn allows increased anaerobic glycolysis. The initial validation of CA IX as a marker of hypoxia in advanced carcinoma of the cervix [Loncaster et al. (2001)] has been accompanied by a range of studies which relate the presence of this enzyme to poor outcome in breast [Chia et al. (2001)], non-small cell lung [Giatromanolaki et al. (2001) and head and neck cancers [Koukourakis et al. (2001)].

The Airley et al. (2002) study concluded that further evidence was provided that hypoxia-regulated membrane proteins such as Glut-1 and CA IX may be used clinically to infer the presence of hypoxia in tumors, which allow the rational use of new modalities, such as bioreductive chemotherapy and/or hypoxia-regulated gene therapy.

Airley et al., Brit. J. Cancer, 86 (Suppl. 1): S13-S33 (2002) states: "Hypoxic cells are known to be radioresistant and chemoresistant, thus, a reliable surrogate marker of hypoxia is desirable to ensure that treatment with radiotherapy or hypoxia-directed therapies, such as the use of bioreductive drugs, may be rationally applied. Recently, the HIF-1-regulated proteins Glut-1 and CA IX were validated as intrinsic markers of hypoxia by comparison with pO_2 measured using the Eppendorf oxygen electrode, which is believed to measure both acute and chronic hypoxia."

Swinson et al., Br. J. Cancer, 86 (Supp. 1): S13 (2002) states: "The presence of activated epidermal growth factor receptor (EGFR) and HER2 reception has been postulated to augment the cellular hypoxic response by increasing synthesis and enhancing the transcriptional activity of HIF-1 . . . [citing to Laughner et al. (2001)]." The HIF-1 transcription factor upregulates CA IX and other enzymes

2003217606
21 Feb 2003

involved in cellular pH homeostasis, as well as vascular endothelial growth factor (VEGF) and enzymes involved in anaerobic metabolism such as glucose transporter-1.

5 Swinson et al., J. Clin. Oncol., 21(3): 473-82 (Feb. 1, 2003) evaluated CA IX as a hypoxia marker and its prognostic significance in non-small cell lung cancer (NSCLC). Standard immunohistochemical (IHC) techniques with the M75 mab were used to study tumor sections from 175 resected NSCLC cases. Membranous (m) CA IX ($P=0.005$), cytoplasmic (c) ($p = 0.018$) and stromal CA IX ($p < 0.001$) expression correlated with the extent of tumor necrosis (TN). Perinuclear (p)

10 CA IX ($p = 0.035$) was associated with poor prognosis. Swinson et al. concluded that mCA IX is a marker of tumor cell hypoxia, and that pCA IX is representative of an aggressive phenotype. The absence of CA IX staining close to microvessels indicates that the tissues are relatively well oxygenated.

15 Vaupel and Hoeckel, "Predictive power of the tumor oxygenation status," Advances in Experimental Medicine and Biology, 471: 533-539 (2000) point out that tumor hypoxia not only indicates decreased radiosensitivity but is generally associated with malignant progression of disease. So far data indicate that tumor hypoxia and clinical aggressiveness in terms of resistance to therapy and tumor dissemination are interrelated.

20

Anticancer Drugs and Antibodies that Block
Interaction of MN Protein and Receptor Molecules

25 MN protein is considered to be a uniquely suitable target for cancer therapy for a number of reasons including the following. (1) It is localized on the cell surface, rendering it accessible. (2) It is expressed in a high percentage of human carcinomas (e.g., uterine cervical, renal, colon, breast, esophageal, lung, head and neck carcinomas, among others), but is not normally expressed to any significant extent in the normal tissues from which such carcinomas originate.

30 (3) It is normally expressed only in the stomach mucosa and in some epithelia of the digestive tract (epithelium of gallbladder and small intestine). An anatomic barrier thereby exists between the MN-expressing preneoplastic/neoplastic and MN-expressing normal tissues. Drugs, including antibodies, can thus be

administered which can reach tumors without interfering with MN-expressing normal tissues.

(4) MAbs M75 has a high affinity and specificity to MN protein. (5) MN cDNA and MN genomic clones which encompass the protein-coding and gene regulatory sequences have been isolated. (6) MN-specific antibodies have been shown to have among the highest tumor uptakes reported in clinical studies with antitumor antibodies in solid tumors, as shown for the MN-specific chimeric antibody G250 in animal studies and in phase I clinical trials with renal carcinoma patients. [Steffens et al., *J. Clin. Oncol.*, 15: 1529 (1997).] Also, MN-specific antibodies have low uptake in normal tissues.

Data as presented in Zavada et al., WO 00/24913 are consistent with the following theory concerning how MN protein acts in normal tissues and in preneoplastic/neoplastic tissues. In normal tissues (e.g., in stomach mucosa), MN protein is considered to be a differentiation factor. It binds with its normal receptor S (for stomach). Stomach carcinomas have been shown not to contain MN protein.

Ectopic expression of MN protein in other tissues causes malignant conversion of cells. Such ectopic expression is considered to be caused by the binding of MN protein with an alternative receptor H (for HeLa cells), coupled to a signal transduction pathway leading to malignancy. Drugs or antibodies which block the binding site of MN protein for receptor H would be expected to cause reversion of preneoplastic/neoplastic cells to normal or induce their death.

Design and Development of MN-Blocking Drugs or Antibodies

A process to design and develop MN-blocking drugs, e.g., peptides with high affinity to MN protein, or antibodies, has several steps. First, is to test for the binding of MN protein to receptors based on the cell adhesion assay as described in Zavada et al., WO 00/24913. That same procedure would also be used to assay for drugs blocking the MN protein binding site. In view of the alternative receptors S and H, stomach epithelial cells or revertants (containing preferentially S receptors), HeLa cells (containing the H receptor and lacking the S receptor) would be used in the cell adhesion assay.

To identify the receptor binding site of MN protein, deletion variants of MN protein lacking different domains can be used to identify region(s) responsible for interaction of MN protein with a receptor. A preferred MN binding site is considered

to be closely related or identical to the epitope for MAb M75, as the amino acid sequence PGEEDLP (SEQ ID NO: 11) which is 4X identically repeated in the N-terminal PG region of CA IX, or at least closely related copies within the 6-fold tandem repeat of 6 amino acids (aa) of aa 61-96 (SEQ ID NO: 12) as shown in

5 Figue 1A-1C in the proteoglycan-like domain of the MN protein. Smaller deletion variants can be prepared within that relevant domain, e.g., fusion proteins with only small segments of MN protein can be prepared. Also, controlled digestion of MN protein with specific proteases followed by separation of the products can be performed.

10 Further, peptides comprising the expected binding site can be synthesized. All of those products can be tested in cell adhesion assays, as exemplified below. [See, e.g., Pierschbacher and Ruoslahti, PNAS, 81:5985 (1984); Ruoslahti and Pierschbacher, Science, 238: 491.]

Molecules can be constructed to block the MN receptor binding site.

15 For example, use of a phage display peptide library kit [as Ph.D®-7 Peptide 7-Mer Library Kit from New England Biolabs; Beverly, MA (USA)] as exemplified in Examples 2 and 3 of Zavada et al. WO 00/24913, can be used to find peptides with high affinity to the target molecules. Biologic activity of the identified peptides will be tested in vitro by inhibition of cell adhesion to MN protein, by effects on cell 20 morphology and growth characteristics of MN-related tumor cells (HeLa) and of control cells. [Symington, J. Biol. Chem., 267: 25744 (1992).] In vivo screening will be carried out in nude mice that have been injected with HeLa cells.

Peptides containing the binding site of the MN protein will be prepared [e.g. MAPs (multiple antigen peptides); Tam, J.P., PNAS (USA) 85: 5409 (1988); 25 Butz et al., Peptide Res., 7: 20 (1994)]. The MAPs will be used to immunize animals to obtain antibodies (polyclonal and/or monoclonal) that recognize and block the binding site. [See, e.g., Brooks et al., Cell, 79: 1157 (1994).] "Vaccination" would then be used to test for protection in animals. Antibodies to the MN binding site could potentially be used to block MN protein's interaction(s) with other 30 molecules.

Computer modeling can also be used to design molecules with specific affinity to MN protein that would mediate steric inhibition between MN protein and its receptor. A computer model of the MN binding site for the receptor will contain spatial, electrostatic, hydrophobic and other characteristics of this structure.

Organic molecules complementary to the structure, that best fit into the binding site, will be designed. Inorganic molecules can also be similarly tested that could block the MN binding site.

The use of oncoproteins as targets for developing new cancer therapeutics is considered conventional by those of skill in the art. [See, e.g., Mendelsohn and Lippman, "Growth Factors," pp. 114-133, IN: DeVita et al. (eds.), Cancer: Principles and Practice of Oncology (4th Ed.; Lippincott; Philadelphia, 1993).] In its broadest sense, the design of blocking drugs can be based in competitive inhibition experiments. Such experiments have been used to invent drugs since the discovery of sulfonamides (competitive inhibitors of para-aminobenzoic acid, a precursor of folic acid). Also, some cytostatics are competitive inhibitors (e.g., halogenated pyrimidines, among others).

However, the application of such approaches to MN is new. In comparison to other tumor-related molecules (e.g. growth factors and their receptors), MN has the unique property of being differentially expressed in preneoplastic/neoplastic and normal tissues, which are separated by an anatomic barrier.

Other CA IX Detection Methods

Diagnostic nucleic acid can be labelled, directly or indirectly, by methods known in the art, and can be used in conventional Southern or Northern hybridization assays. Such assays can be employed in identifying transformants or for in vitro diagnosis, such as to detect MN mRNA in tissues as a measure of oncogenic activity. The presence of MN mRNA or precursors thereto for most tissues being indicative of oncogenic activity, whereas the absence or a reduced level of MN mRNA in stomach and gallbladder tissues in comparison to the levels of mRNA found in the counterpart normal tissues is considered indicative of oncogenic activity. DNA which encodes MN proteins can be obtained by chemical synthesis, by screening reverse transcripts of mRNA from placental or other cells, or by screening genomic libraries from eukaryotic cells, among other methods.

MN-specific antibodies can be bound by serologically active MN proteins/polypeptides in samples of such body fluids as blood, plasma, serum, lymph, mucous, tears, urine, spinal fluid and saliva; however, such antibodies are found most usually in blood, plasma and serum, preferably in serum. Correlation of

the results from the assays to detect and/or quantitate MN antigen and MN-specific antibodies reactive therewith, provides a preferred profile of the disease condition of a patient.

5 The presence of MN antigen or antibodies can be detected and/or quantitated using a number of well-defined diagnostic assays. Those in the art can adapt any of the conventional immunoassay formats to detect and/or quantitate MN antigen and/or antibodies.

10 Many formats for detection of MN antigen and MN-specific antibodies are, of course available. Those can be Western blots, ELISAs, RIAs, competitive EIA or dual antibody sandwich assays, immunohistochemical staining, among other assays all commonly used in the diagnostic industry. In such immunoassays, the interpretation of the results is based on the assumption that the antibody or antibody combination will not cross-react with other proteins and protein fragments present in the sample that are unrelated to MN.

15 Representative of one type of ELISA test for MN antigen is a format wherein a microtiter plate is coated with antibodies made to MN proteins/polypeptides or antibodies made to whole cells expressing MN proteins, and to this is added a patient sample, for example, a tissue or cell extract. After a period of incubation permitting any antigen to bind to the antibodies, the plate is washed 20 and another set of anti-MN antibodies which are linked to an enzyme is added, incubated to allow reaction to take place, and the plate is then rewashed. Thereafter, enzyme substrate is added to the microtiter plate and incubated for a period of time to allow the enzyme to work on the substrate, and the adsorbance of the final preparation is measured. A large change in absorbance indicates a positive 25 result.

It is also apparent to one skilled in the art of immunoassays that MN proteins and/or polypeptides can be used to detect and/or quantitate the presence of MN antigen in the body fluids, tissues and/or cells of patients. In one such embodiment, a competition immunoassay is used, wherein the MN 30 protein/polypeptide is labeled and a body fluid is added to compete the binding of the labeled MN protein/polypeptide to antibodies specific to MN protein/polypeptide.

In another embodiment, an immunometric assay may be used wherein a labeled antibody made to a MN protein or polypeptide is used. In such an assay,

the amount of labeled antibody which complexes with the antigen-bound antibody is directly proportional to the amount of MN antigen in the sample.

A representative assay to detect MN-specific antibodies is a competition assay in which labeled MN protein/polypeptide is precipitated by antibodies in a sample, for example, in combination with monoclonal antibodies recognizing MN proteins/polypeptides. One skilled in the art could adapt any of the conventional immunoassay formats to detect and/or quantitate MN-specific antibodies. Detection of the binding of said antibodies to said MN protein/polypeptide could be by many ways known to those in the art, e.g., in humans with the use of anti-human labeled IgG.

An exemplary immunoassay method of this invention to detect and/or quantitate MN antigen in a vertebrate sample comprises the steps of:

- a) incubating said vertebrate sample with one or more sets of antibodies (an antibody or antibodies) that bind to MN antigen wherein one set is labeled or otherwise detectable;
- b) examining the incubated sample for the presence of immune complexes comprising MN antigen and said antibodies.

Another exemplary immunoassay method according to this invention is that wherein a competition immunoassay is used to detect and/or quantitate MN antigen in a vertebrate sample and wherein said method comprises the steps of:

- a) incubating a vertebrate sample with one or more sets of MN-specific antibodies and a certain amount of a labeled or otherwise detectable MN protein/polypeptide wherein said MN protein/ polypeptide competes for binding to said antibodies with MN antigen present in the sample;
- b) examining the incubated sample to determine the amount of labeled/detectable MN protein/polypeptide bound to said antibodies; and
- c) determining from the results of the examination in step b) whether MN antigen is present in said sample and/or the amount of MN antigen present in said sample.

Once antibodies (including biologically active antibody fragments) having suitable specificity have been prepared, a wide variety of immunological assay methods are available for determining the formation of specific antibody-antigen complexes. Numerous competitive and non-competitive protein binding assays have been described in the scientific and patent literature, and a

large number of such assays are commercially available. Exemplary immunoassays which are suitable for detecting a serum antigen include those described in U.S. Patent Nos. 3,984,533; 3,996,345; 4,034,074; and 4,098,876.

Antibodies employed in assays may be labeled or unlabeled.

5 Unlabeled antibodies may be employed in agglutination; labeled antibodies may be employed in a wide variety of assays, employing a wide variety of labels.

Suitable detection means include the use of labels such as radionuclides, enzymes, coenzymes, fluorescers, chemiluminescers, chromogens, enzyme substrates or co-factors, enzyme inhibitors, free radicals, particles, dyes and 10 the like. Such labeled reagents may be used in a variety of well known assays, such as radioimmunoassays, enzyme immunoassays, e.g., ELISA, fluorescent immunoassays, and the like. See for example, U.S. Patent Nos. 3,766,162; 3,791,932; 3,817,837; and 4,233,402.

15 Immunoassay Test Kits

The above outlined assays can be embodied in test kits to detect and/or quantitate MN antigen and/or MN-specific antibodies (including biologically active antibody fragments). Kits to detect and/or quantitate MN antigen can comprise MN protein(s)/polypeptides(s) and/or MN-specific antibodies, polyclonal 20 and/or monoclonal. Such diagnostic/prognostic test kits can comprise one or more sets of antibodies, polyclonal and/or monoclonal, for a sandwich format wherein antibodies recognize epitopes on the MN antigen, and one set is appropriately labeled or is otherwise detectable.

Test kits for an assay format wherein there is competition between a 25 labeled (or otherwise detectable) MN protein/polypeptide and MN antigen in the sample, for binding to an antibody, can comprise the combination of the labeled protein/polypeptide and the antibody in amounts which provide for optimum sensitivity and accuracy.

Test kits for MN-specific antibodies preferably comprise 30 labeled/detectable MN proteins(s) and/or polypeptides(s), and may comprise other components as necessary, such as, controls, buffers, diluents and detergents. Such test kits can have other appropriate formats for conventional assays.

A kit for use in an enzyme-immunoassay typically includes an enzyme-labelled reagent and a substrate for the enzyme. The enzyme can, for example,

bind either an MN-specific antibody of this invention or to an antibody to such an MN-specific antibody.

Preparation of MN-Specific Antibodies

5 The term "antibodies" is defined herein to include not only whole antibodies but also biologically active fragments of antibodies, preferably fragments containing the antigen binding regions. Further included in the definition of antibodies are bispecific antibodies that are specific for MN protein and to another tissue-specific antigen.

10 Antibodies of the invention may be prepared by conventional methodology and/or by genetic engineering. Chimeric antibodies that are humanized to reduce antigenicity are preferred for in vivo use. Antibody fragments may be genetically engineered, preferably from the variable regions of the light and/or heavy chains (V_H and V_L), including the hypervariable regions, and still more preferably from both the V_H and V_L regions. For example, the term "antibodies" as used herein comprehends polyclonal and monoclonal antibodies and biologically active fragments thereof including among other possibilities "univalent" antibodies [Glennie et al., Nature, 295: 712 (1982)]; Fab proteins including Fab' and $F(ab')_2$ fragments whether covalently or non-covalently aggregated; light or heavy chains alone, preferably variable heavy and light chain regions (V_H and V_L regions), and more preferably including the hypervariable regions [otherwise known as the complementarity determining regions (CDRs) of said V_H and V_L regions]; F_c proteins; "hybrid" antibodies capable of binding more than one antigen; constant-variable region chimeras; "composite" immunoglobulins with heavy and light chains of different origins; "altered" antibodies with improved specificity and other characteristics as prepared by standard recombinant techniques and also by oligonucleotide-directed mutagenesis techniques [Dalbadie-McFarland et al., PNAS (USA), 79: 6409 (1982)].

15 20 25

Bispecific Antibodies. Bispecific antibodies can be produced by chemically coupling two antibodies of the desired specificity. Bispecific MAbs can preferably be developed by somatic hybridization of 2 hybridomas. Bispecific MAbs for targeting MN protein and another antigen can be produced by fusing a hybridoma that produces MN-specific MAbs with a hybridoma producing MAbs specific to another antigen. For example, a cell (a quadroma), formed by fusion of a hybridoma

producing a MN-specific MAb and a hybridoma producing an anti-cytotoxic cell antibody, will produce hybrid antibody having specificity of the parent antibodies. [See, e.g., *Immunol. Rev.* (1979); *Cold Spring Harbor Symposium Quant. Biol.*, 41: 793 (1977); van Dijk et al., *Int. J. Cancer*, 43: 344-349 (1989).] Thus, a hybridoma

5 producing a MN-specific MAb can be fused with a hybridoma producing, for example, an anti-T3 antibody to yield a cell line which produces a MN/T3 bispecific antibody which can target cytotoxic T cells to MN-expressing tumor cells.

It may be preferred for therapeutic and/or imaging uses that the antibodies be biologically active antibody fragments, preferably genetically

10 engineered fragments, more preferably genetically engineered fragments from the V_H and/or V_L regions, and still more preferably comprising the hypervariable regions thereof. However, for some therapeutic uses bispecific antibodies targeting MN protein and cytotoxic cells would be preferred.

15 There are conventional techniques for making polyclonal and monoclonal antibodies well-known in the immunoassay art. Immunogens to prepare MN-specific antibodies include MN proteins and/or polypeptides, preferably purified, and MX-infected tumor line cells, for example, MX-infected HeLa cells, among other immunogens.

20 Anti-peptide antibodies are also made by conventional methods in the art as described in European Patent Publication No. 44,710 (published Jan. 27, 1982). Briefly, such anti-peptide antibodies are prepared by selecting a peptide from an MN amino acid sequence as from Figure 1, chemically synthesizing it, conjugating it to an appropriate immunogenic protein and injecting it into an appropriate animal, usually a rabbit or a mouse; then, either polyclonal or 25 monoclonal antibodies are made, the latter by a Kohler-Milstein procedure, for example.

30 Besides conventional hybridoma technology, newer technologies can be used to produce antibodies according to this invention. For example, the use of the PCR to clone and express antibody V-genes and phage display technology to select antibody genes encoding fragments with binding activities has resulted in the isolation of antibody fragments from repertoires of PCR amplified V-genes using immunized mice or humans. [Marks et al., *BioTechnology*, 10: 779 (July 1992) for references; Chiang et al., *BioTechniques*, 7(4): 360 (1989); Ward et al., *Nature*, 341: 544 (Oct. 12, 1989); Marks et al., *J. Mol. Biol.*, 222: 581 (1991); Clackson et al.,

Nature, 352: (15 August 1991); and Mullinax et al., PNAS (USA), 87: 8095 (Oct. 1990).]

Descriptions of preparing antibodies, which term is herein defined to include biologically active antibody fragments, by recombinant techniques can be found in U.S. Patent No. 4,816,567 (issued March 28, 1989); European Patent Application Publication Number (EP) 338,745 (published Oct. 25, 1989); EP 368,684 (published June 16, 1990); EP 239,400 (published September 30, 1987); WO 90/14424 (published Nov. 29, 1990); WO 90/14430 (published May 16, 1990); Huse et al., Science, 246: 1275 (Dec. 8, 1989); Marks et al., BioTechnology, 10: 779 (July 1992); La Sastry et al., PNAS (USA), 86: 5728 (August 1989); Chiang et al., BioTechniques, 7(40): 360 (1989); Orlandi et al., PNAS (USA), 86: 3833 (May 1989); Ward et al. Nature, 341: 544 (October 12, 1989); Marks et al., J. Mol. Biol., 222: 581 (1991); and Hoogenboom et al., Nucleic Acids Res., 19(15): 4133 (1991).

15 Representative Mabs

Monoclonal antibodies for use in the assays of this invention may be obtained by methods well known in the art for example, Galfre and Milstein, "Preparation of Monoclonal Antibodies: Strategies and Procedures," in Methods in Enzymology: Immunochemical Techniques, 73: 1-46 [Langone and Vanatis (eds); Academic Press (1981)]; and in the classic reference, Milstein and Kohler, Nature, 256: 495-497 (1975).]

Although representative hybridomas of this invention are formed by the fusion of murine cell lines, human/human hybridomas [Olsson et al., PNAS (USA), 77: 5429 (1980)] and human/murine hybridomas [Schlom et al., PNAS (USA), 77: 6841 (1980); Shearman et al. J. Immunol., 146: 928-935 (1991); and Gorman et al., PNAS (USA), 88: 4181-4185 (1991)] can also be prepared among other possibilities. Such humanized monoclonal antibodies would be preferred monoclonal antibodies for therapeutic and imaging uses.

Monoclonal antibodies specific for this invention can be prepared by 30 immunizing appropriate mammals, preferably rodents, more preferably rabbits or mice, with an appropriate immunogen, for example, MaTu-infected HeLa cells, MN fusion proteins, or MN proteins/polypeptides attached to a carrier protein if necessary. Exemplary methods of producing antibodies of this invention are described below.

The monoclonal antibodies useful according to this invention to identify MN proteins/polypeptides can be labeled in any conventional manner, for example, with enzymes such as horseradish peroxidase (HRP), fluorescent compounds, or with radioactive isotopes such as, ¹²⁵I, among other labels. A preferred label, 5 according to this invention is ¹²⁵I, and a preferred method of labeling the antibodies is by using chloramine-T [Hunter, W.M., "Radioimmunoassay," In: Handbook of Experimental Immunology, pp. 14.1-14.40 (D.W. Weir ed.; Blackwell, Oxford/London/Edinburgh/ Melbourne; 1978)].

Representative mabs of this invention include Mabs M75, MN9, MN12 10 and MN7 described below. Monoclonal antibodies of this invention serve to identify MN proteins/polypeptides in various laboratory diagnostic tests, for example, in tumor cell cultures or in clinical samples.

Epitopes

15 The affinity of a MAb to peptides containing an epitope depends on the context, e.g. on whether the peptide is a short sequence (4-6 aa), or whether such a short peptide is flanked by longer aa sequences on one or both sides, or whether in testing for an epitope, the peptides are in solution or immobilized on a surface. Therefore, it would be expected by ones of skill in the art that the representative 20 epitopes described herein for the MN-specific MAbs would vary in the context of the use of those MAbs.

Epitope Mapping

Epitope mapping was performed by the Novatope system, a kit for 25 which is commercially available from Novagen, Inc. [See, for analogous example, Li et al., Nature, 363: 85-88 (6 May 1993).] In brief, the MN cDNA was cut into overlapping short fragments of approximately 60 base pairs. The fragments were expressed in E. coli, and the E. coli colonies were transferred onto nitrocellulose paper, lysed and probed with the mab of interest. The MN cDNA of clones reactive 30 with the mab of interest was sequenced, and the epitopes of the mabs were deduced from the overlapping polypeptides found to be reactive with each mab.

Therapeutic Use of MN-Specific Antibodies

The MN-specific antibodies of this invention, monoclonal and/or polyclonal, preferably monoclonal, and as outlined above, may be used therapeutically in the treatment of neoplastic and/or pre-neoplastic disease, either alone or in combination with chemotherapeutic drugs or toxic agents, such as ricin A. Further preferred for therapeutic use would be biologically active antibody fragments as described herein. Also preferred MN-specific antibodies for such therapeutic uses would be humanized monoclonal antibodies and/or bispecific antibodies.

MN-specific antibodies can be administered in a therapeutically effective amount, preferably dispersed in a physiologically acceptable, nontoxic liquid vehicle, to patients afflicted with preneoplastic/neoplastic disease. The MN-specific antibody can be given alone or as a carrier of an anti-tumor drug. Among the various antiproliferative, antineoplastic or cytotoxic agents that may be linked to the MN-specific antibodies are antimetabolites, such as the antifolate, methotrexate, or the purine or pyrimidine analogs mercaptopurine and fluorouracil. Others include antibiotics, lectins such as ricin and abrin, toxins such as the subunit of diphtheria toxin, radionuclides such as ²¹¹Astatine and ¹³¹Iodine, radiosensitizers such as misanidazole or neutron sensitizers such as boron containing organics. Such agents may be attached to the antibody by conventional techniques such as glutaraldehyde cross-linking.

MN-specific antibodies can be used to target cytotoxic cells (e.g. human T cells, monocytes or NK cells). Cytotoxic cells can be attached to MN-expressing tumor cells through Fc receptors on the cytotoxic cells, which bind the Fc portion of a MN-specific antibody, or via a bridging antibody of dual specificity, that is, a bispecific antibody specific for MN protein and for the cytotoxic cell.

The cytotoxic cell can be targeted by allowing the bispecific antibody to bind the cell. After targeting, the cells can be administered to the patient. Therapy with targeted cells can be used as an adjunct to surgical therapy, radiation therapy, or chemotherapy.

30

Anti-Idiotype MN-Specific Antibodies as Tumor Vaccines and Anti-Anti-Idiotype Antibody Sera as Immunotherapeutic

MN-specific anti-idiotype antibodies have therapeutic utility as a vaccine for neoplastic disease associated with abnormal MN expression. MN-

specific anti-anti-idiotype sera also have therapeutic anti-tumor efficacy. Those therapeutic utilities are demonstrated by research done with the MN-specific G250 MAb, and anti-idiotype antibodies thereto (Ab2), and further anti-anti-idiotype sera (Ab3) as demonstrated by the studies described below.

5 Uemura et al., Biotherapy (Japan) 10(3): 241-244 (1996) (English summary) define an anti-idiotype antibody (Ab2) as "an antibody directed against an antigenic determinant located within a variable region of the immunoglobulin molecule. Ab2 mimicking the normal antigen (so-called internal image Ab2) may be used as a surrogate antigen for vaccination to trigger the host's immune system 10 specifically against the nominal antigen."

Uemura et al., id., having previously isolated six internal image murine Ab2s directed against the G250 MAb -- NUH31, 51, 71, 82 (IgG1) and NUH44 (IgG2a), explores the application of monoclonal Ab2 as tumor vaccines. Uemura et al. investigated in view of "previous results that RCC tumor-associated-antigen-related idotype vaccination induced antigen-specific humoral as well as cellular responses, the antitumor efficacy of anti-anti-idiotype antibody (Ab3) sera obtained from mice immunized with different internal image Ab2 that . . . mimic the RCC-associated antigen . . . G250 [MN] . . . Nu/nu BALB/c mice carrying small established NU12 human RCC xenografts (G250+, 20 mm³) rr receiving an s.c. 15 injection of 2×10^5 SK-RC-52 (G250+) RCC cells were treated by i.p. injection of 0.2 ml Ab3 sera. This treatment resulted in complete tumor rejection and significant tumor growth inhibition as compared to control groups (p<0.01)." Uemura et al. concluded that "immunization with Ab2s elicits powerful anti-tumor effects in 20 immunocompetent animals."

25 Uemura et al., J. Urol., 159(5)(Suppl.): Abstract 724 (May 1998), describe MN as an immunotherapeutic target for renal cell carcinoma (RCC). The therapeutic potential of the MN-specific MAb G250 was evaluated in combination with IFN/IL-2/MCSF (interferon, interleukin-2, macrophage colony stimulating factor) and Ab2 (NUH82)-induced mouse serum (Ab3-82). Ab2s are monoclonal anti-30 idiotype antibodies raised against MAbG250 which have been shown to be useful as tumor vaccines for RCC.

Uemura et al., id. reported that mice with NUR-2 RCC xenografts were treated by peri-tumor injection of MAbG250 and/or cytokines or 0.2 ml of Ab3 sera with/without MCSF. The tumor volume in MAbG250 treated animals was

significantly lower than in the controls. IFN or IL-2 treatments was similarly effective, but MCSF resulted in no significant tumor inhibition. The IFN/IL-2/MAbG250 therapy increased significantly the anti-tumor effects as compared to MAbG250 or cytokine monotherapy. Further, Ab3-based (Ab2-induced) immunotherapy resulted in

5 tremendous tumor monotherapy growth inhibition as compared to MAbG250 or the other cytokine combination therapies.

10 MN-Specific Intrabodies -- Targeted Tumor Killing Via Intracellular Expression of MN-Specific Antibodies to Block Transport of MN Protein to Cell Surface

The gene encoding antibodies can be manipulated so that the antigen-binding domain can be expressed intracellularly. Such "intrabodies" that are targeted to the lumen of the endoplasmic reticulum provide a simple and effective mechanism for inhibiting the transport of plasma membrane proteins to the cell surface. [Marasco, W.A., "Review -- Intrabodies: turning the humoral immune system outside in or intracellular immunization," Gene Therapy, 4: 11-15 (1997); Chen et al., "Intracellular antibodies as a new class of therapeutic molecules for gene therapy," Hum. Gene Ther., 5(5): 595-601 (1994); Mhashilkar et al., EMBO J., 14: 1542-1551 (1995); Mhashilkar et al., J. Virol., 71: 6486-6494 (1997); Marasco (Ed.), Intrabodies: Basic Research and Clinical Gene Therapy Applications, (Springer Life Sciences 1998; ISBN 3-540-64151-3) (summarizes preclinical studies from laboratories worldwide that have used intrabodies); Zanetti and Capra (Eds.), "Intrabodies: From Antibody Genes to Intracellular Communication," The Antibodies: Volume 4, 15 (Harwood Academic Publishers; ISBN 90-5702-559-0 (Dec. 1997)]; Jones and Marasco, Advanced Drug Delivery Reviews, 31 (1-2): 153-170 (1998); Pumphrey and Marasco, Biodrugs, 9(3): 179-185 (1998); Dachs et al., Oncology Res., 9(6-7): 313-325 (1997); Rondon and Marasco, Ann. Rev. Microbiol., 51: 257-283 (1997); Marasco, W.A., Immunotechnology, 1(1): 1-19 (1995); and Richardson and Marasco, Trends in Biotechnology, 13(8): 306-310 (1995).]

MN-specific intrabodies may prevent the maturation and transport of MN protein to the cell surface and thereby prevent the MN protein from functioning in an oncogenic process. Antibodies directed to MN's EC, TM or IC domains may be useful in this regard. MN protein is considered to mediate signal transduction by

transferring signals from the EC domain to the IC tail and then by associating with other intracellular proteins within the cell's interior. MN-specific intrabodies could disrupt that association and perturb that MN function.

5 Inactivating the function of the MN protein could result in reversion of tumor cells to a non-transformed phenotype. [Marasco et al. (1997), supra.]

10 Antisense expression of MN cDNA in cervical carcinoma cells, as demonstrated herein, has shown that loss of MN protein has led to growth suppression of the transfected cells. It is similarly expected that inhibition of MN protein transport to the cell surface would have similar effects. Cloning and intracellular expression of the M75 MAb's variable region is to be studied to confirm that expectation.

15 Preferably, the intracellularly produced MN-specific antibodies are single-chain antibodies, specifically single-chain variable region fragments or sFv, in which the heavy- and light-chain variable domains are synthesized as a single polypeptide and are separated by a flexible linker peptide, preferably (Gly₄-Ser)₃ [SEQ ID NO: 116].

20 MN-specific intracellularly produced antibodies can be used therapeutically to treat preneoplastic/neoplastic disease by transfecting preneoplastic/neoplastic cells that are abnormally expressing MN protein with a vector comprising a nucleic acid encoding MN-specific antibody variable region fragments, operatively linked to an expression control sequence. Preferably said expression control sequence would comprise the MN gene promoter.

Antibody-Mediated Gene Transfer Using MN-Specific
Antibodies or Peptides for Targeting MN-Expressing Tumor Cells

25 An MN-specific antibody or peptide covalently linked to polylysine, a polycation able to compact DNA and neutralize its negative charges, would be expected to deliver efficiently biologically active DNA into an MN-expressing tumor cell. If the packed DNA contains the HSVtk gene under control of the MN promoter, the system would have double specificity for recognition and expression only in MN-expressing tumor cells. The packed DNA could also code for cytokines to induce 30 CTL activity, or for other biologically active molecules.

The M75 MAb (or, for example, as a single chain antibody, or as its variable region) is exemplary of such a MN-specific antibody. Example 5 discloses heptapeptides (SEQ ID NOS: 107-109) that bind to the enzymatic center of the CA

domain of the MN protein and, selected peptides or proteins comprising such heptapeptides would also be expected to bind to a binding site on the extracellular domain of the MN protein.

5 Imaging Use of Antibodies

Further, the MN-specific antibodies of this invention when linked to an imaging agent, such as a radionuclide, can be used for imaging. Biologically active antibody fragments or humanized monoclonal antibodies, may be preferred for imaging use.

10 A patient's neoplastic tissue can be identified as, for example, sites of transformed stem cells, of tumors and locations of any metastases. Antibodies, appropriately labeled or linked to an imaging agent, can be injected in a physiologically acceptable carrier into a patient, and the binding of the antibodies can be detected by a method appropriate to the label or imaging agent, for example, by 15 scintigraphy. Exemplary are studies with the G250 Mab.

Steffens et al., J. Urol., 159(5)(Suppl.): Abstract 562 (May 1998), describe a Phase I/II study with ^{131}I -cG250 MAb in patients with metastasized RCC. MAb cG250 is a chimeric MAb in which constant regions of the mouse immunoglobulin have been exchanged for human immunoglobulin regions.

20 [Oosterwijk and Debruyne, World J. Urol., 13: 186 (1995).] Uptake of the cG250 MAb in primary RCC was shown to be as high as 0.52 percent of the injected dose per gram of tumor tissue (%ID/g). The study concluded that ^{131}I -cG250 is a promising candidate for radioimmunotherapy and a phase I/II activity dose escalation study was initiated to determine the safety, maximum tolerable dose (MTD) and 25 therapeutic potential of ^{131}I -cG250."

30 Bander et al., Proceedings Am. Urol. Assoc., 155(Suppl.): 583A (Abstract 1088) (May 1996), describes renal cancer imaging with the MN-specific MAb G250, which detects MN present in 85-90% of renal cancers but does not detect MN on normal kidney cells. Bander et al. reports that 48 patients were entered in clinical trials with ^{131}I -G250 MAb.

MN Gene -- Cloning and Sequencing

Figure 1A-C provides the nucleotide sequence for a full-length MN cDNA clone [SEQ ID NO: 1]. Figure 2A-F provides a complete MN genomic

sequence [SEQ ID NO: 3]. The nucleotide sequence for a proposed MN promoter is shown in Figure 2A-F at nts 3001 to 3540 [SEQ ID NO: 24].

It is understood that because of the degeneracy of the genetic code, that is, that more than one codon will code for one amino acid [for example, the 5 codons TTA, TTG, CTT, CTC, CTA and CTG each code for the amino acid leucine (leu)], that variations of the nucleotide sequences in, for example, SEQ ID NOS: 1 and 3 wherein one codon is substituted for another, would produce a substantially equivalent protein or polypeptide according to this invention. All such variations in the nucleotide sequences of the MN cDNA and complementary nucleic acid 10 sequences are included within the scope of this invention.

It is further understood that the nucleotide sequences herein described and shown in Figures 1 and 2 represent only the precise structures of the cDNA, genomic and promoter nucleotide sequences isolated and described herein. It is expected that slightly modified nucleotide sequences will be found or can be 15 modified by techniques known in the art to code for substantially similar or homologous MN proteins and polypeptides, for example, those having similar epitopes, and such nucleotide sequences and proteins/ polypeptides are considered to be equivalents for the purpose of this invention. DNA or RNA having equivalent codons is considered within the scope of the invention, as are synthetic nucleic acid 20 sequences that encode proteins/polypeptides homologous or substantially homologous to MN proteins/polypeptides, as well as those nucleic acid sequences that would hybridize to said exemplary sequences [SEQ. ID. NOS. 1, 3 and 24] under stringent conditions, or that, but for the degeneracy of the genetic code would hybridize to said cDNA nucleotide sequences under stringent hybridization 25 conditions. Modifications and variations of nucleic acid sequences as indicated herein are considered to result in sequences that are substantially the same as the exemplary MN sequences and fragments thereof.

Stringent hybridization conditions are considered herein to conform to standard hybridization conditions understood in the art to be stringent. For example, 30 it is generally understood that stringent conditions encompass relatively low salt and/or high temperature conditions, such as provided by 0.02 M to 0.15 M NaCl at temperatures of 50°C to 70°C. Less stringent conditions, such as, 0.15 M to 0.9 M salt at temperatures ranging from 20°C to 55°C can be made more stringent by

adding increasing amounts of formamide, which serves to destabilize hybrid duplexes as does increased temperature.

Exemplary stringent hybridization conditions are described in Sambrook et al., Molecular Cloning: A Laboratory Manual, pages 1.91 and 9.47-9.51 (Second Edition, Cold Spring Harbor Laboratory Press; Cold Spring Harbor, NY; 1989); Maniatis et al., Molecular Cloning: A Laboratory Manual, pages 387-389 (Cold Spring Harbor Laboratory; Cold Spring Harbor, NY; 1982); Tsuchiya et al., Oral Surgery, Oral Medicine, Oral Pathology, 71(6): 721-725 (June 1991).

Plasmids containing the MN genomic sequence (SEQ ID NO: 3) -- the A4a clone and the XE1 and XE3 subclones -- were deposited at the American Type Culture Collection (ATCC) on June 6, 1995, respectively under ATCC Deposit Nos. 97199, 97200, and 97198.

Exon-Intron Structure of Complete MN Genomic Region

The complete sequence of the overlapping clones contains 10,898 bp (SEQ ID NO: 3). Figure 3 depicts the organization of the human MN gene, showing the location of all 11 exons as well as the 2 upstream and 6 intronic Alu repeat elements. All the exons are small, ranging from 27 to 191 bp, with the exception of the first exon which is 445 bp. The intron sizes range from 89 to 1400 bp. The CA domain is encoded by exons 2-8, while the exons 1, 10 and 11 correspond respectively to the proteoglycan-like domain, the transmembrane anchor and cytoplasmic tail of the MN/CA IX protein. Table 1 below lists the splice donor and acceptor sequences that conform to consensus splice sequences including the AG-GT motif [Mount, Nucleic Acids Res. 10: 459-472 (1982)].

TABLE 1
Exon-Intron Structure of the Human MN Gene

Exon	Size	Genomic Position**	SEQ ID NO	5'splice donor	SEQ ID NO
1	445	*3507-3951	25	AGAAC gtaagt	46
2	30	5126-5155	26	TGGAG gtgaga	47
3	171	5349-5519	27	CAGTC gtgagg	48
4	143	5651-5793	28	CCGAG gtgagc	49
5	93	5883-5975	29	TGGAG gtacca	50
6	67	7376-7442	30	GGAAG gtcagt	51
7	158	8777-8934	31	AGCAG gtgggc	52
8	145	9447-9591	32	GCCAG gtacag	53
9	27	9706-9732	33	TGCTG gtgagt	54
10	82	10350-10431	34	CACAG gtatta	55
11	191	10562-10752	35	ATAAT end	

Intron	Size	Genomic Position **	SEQ ID NO	3'splice acceptor	SEQ ID NO
1	1174	3952-5125	36	atacag GGGAT	56
2	193	5156-5348	37	cccccag GCGAC	57
3	131	5520-5650	38	acgcag TGCAA	58
4	89	5794-5882	39	tttcag ATCCA	59
5	1400	5976-7375	40	cccccag GAGGG	60
6	1334	7443-8776	41	tcacag GCTCA	61
7	512	8935-9446	42	cccttag CTCCA	62
8	114	9592-9705	43	ctccag TCCAG	63
9	617	9733-10349	44	tgcgcag GTGACA	64
10	130	10432-10561	45	acacag AAGGG	65

** positions are related to nt numbering in whole genomic sequence including the 5' flanking region [Figure 2A-F]

5 * number corresponds to transcription initiation site determined below by RNase protection assay

Mapping of MN Gene Transcription Initiation and Termination Sites

Zavada et al., WO 95/34650 describes the process of mapping the MN gene transcription initiation and termination sites. A RNase protection assay was

used for fine mapping of the 5' end of the MN gene. The probe was a uniformly labeled 470 nucleotide copy RNA (nt -205 to +265) [SEQ ID NO: 66], which was hybridized to total RNA from MN-expressing HeLa and CGL3 cells and analyzed on a sequencing gel. That analysis has shown that the MN gene transcription initiates 5 at multiple sites, the 5' end of the longest MN transcript being 30 nt longer than that previously characterized by RACE.

MN Proteins and/or Polypeptides

The phrase "MN proteins and/or polypeptides" (MN 10 proteins/polypeptides) is herein defined to mean proteins and/or polypeptides encoded by an MN gene or fragments thereof. An exemplary and preferred MN protein according to this invention has the deduced amino acid sequence shown in Figure 1. Preferred MN proteins/polypeptides are those proteins and/or polypeptides that have substantial homology with the MN protein shown in Figure 1. For example, 15 such substantially homologous MN proteins/ polypeptides are those that are reactive with the MN-specific antibodies of this invention, preferably the Mabs M75, V/10, MN12, MN9 and MN7 or their equivalents.

A "polypeptide" or "peptide" is a chain of amino acids covalently bound by peptide linkages and is herein considered to be composed of 50 or less amino 20 acids. A "protein" is herein defined to be a polypeptide composed of more than 50 amino acids. The term polypeptide encompasses the terms peptide and oligopeptide.

MN proteins exhibit several interesting features: cell membrane localization, cell density dependent expression in HeLa cells, correlation with the 25 tumorigenic phenotype of HeLa x fibroblast somatic cell hybrids, and expression in many human carcinomas among other tissues. MN protein can be found directly in tumor tissue sections but not in general in counterpart normal tissues (exceptions noted above as in normal gastric mucosa and gallbladder tissues). MN is also expressed sometimes in morphologically normal appearing areas of tissue 30 specimens exhibiting dysplasia and/or malignancy. Taken together, these features suggest a possible involvement of MN in the regulation of cell proliferation, differentiation and/or transformation.

It can be appreciated that a protein or polypeptide produced by a neoplastic cell in vivo could be altered in sequence from that produced by a tumor

cell in cell culture or by a transformed cell. Thus, MN proteins and/or polypeptides which have varying amino acid sequences including without limitation, amino acid substitutions, extensions, deletions, truncations and combinations thereof, fall within the scope of this invention. It can also be appreciated that a protein extant within

5 body fluids is subject to degradative processes, such as, proteolytic processes; thus, MN proteins that are significantly truncated and MN polypeptides may be found in body fluids, such as, sera. The phrase "MN antigen" is used herein to encompass MN proteins and/or polypeptides.

It will further be appreciated that the amino acid sequence of MN
10 proteins and polypeptides can be modified by genetic techniques. One or more amino acids can be deleted or substituted. Such amino acid changes may not cause any measurable change in the biological activity of the protein or polypeptide and result in proteins or polypeptides which are within the scope of this invention, as well as, MN muteins.

15 The MN proteins and polypeptides of this invention can be prepared in a variety of ways according to this invention, for example, recombinantly, synthetically or otherwise biologically, that is, by cleaving longer proteins and polypeptides enzymatically and/or chemically. A preferred method to prepare MN proteins is by a recombinant means.

20

Recombinant Production of MN Proteins and Polypeptides

A representative method to prepare the MN proteins shown in Figure 1 or fragments thereof would be to insert the full-length or an appropriate fragment of MN cDNA into an appropriate expression vector. In Zavada et al., WO 93/18152,
25 supra, production of a fusion protein GEX-3X-MN (now termed GST-MN) using a partial cDNA in the vector pGEX-3X (Pharmacia) is described. Nonglycosylated GST-MN (the MN fusion protein MN glutathione S-transferase) from XL1-Blue cells.

Zavada et al., WO 95/34650 describes the recombinant production of both a glycosylated MN protein expressed from insect cells and a nonglycosylated
30 MN protein expressed from E. coli using the expression plasmid pEt-22b [Novagen Inc.; Madison, WI (USA)]. Recombinant baculovirus express vectors were used to infect insect cells. The glycosylated MN 20-19 protein was recombinantly produced in baculovirus-infected sf9 cells [Clontech; Palo Alto, CA (USA)].

Preparation of MN-Specific Antibodies

The term "antibodies" is defined herein to include not only whole antibodies but also biologically active fragments of antibodies, preferably fragments containing the antigen binding regions. Monoclonal and polyclonal antibodies use

5 encompassed by that term as the context indicates. Further included in the definition of antibodies are bispecific antibodies that are specific for MN protein and to another tissue-specific antigen. Von Mehren et al., *Annu. Rev. Med.*, 54: 343-369 (2003) explains the use of mabs for cancer therapy and clearly delineates preferred fragments thereof.

10 Size is critical to the design of antibody fragments used for tumor therapy; smaller fragments often have diminished affinity and antigen specificity. A class of molecules of about 25 kDa, single-chain FV (scFv) molecules, composed of peptide-linked V_H and V_L domains, are large enough to be effective targeting vehicles while providing the basis for the construction of larger antibody-based reagents.

15 However, the scFv molecules are small enough to allow their rapid renal elimination, and therefore are attractive candidates for radiolabelling. They can also be dimerized into larger molecules for slower systemic clearance and greater avidity for target cells, making them potentially useful in tumor therapy.

Zavada et al., WO 93/18152 and WO 95/34650 describe in detail 20 methods to produce MN-specific antibodies, and detail steps of preparing representative MN-specific antibodies as the M75, MN7, MN9, and MN12 monoclonal antibodies. Bispecific Antibodies. Bispecific antibodies can be produced by chemically coupling two antibodies of the desired specificity. Bispecific MAbs can preferably be developed by somatic hybridization of 2 hybridomas.

25 Bispecific MAbs for targeting MN protein and another antigen can be produced by fusing a hybridoma that produces MN-specific MAbs with a hybridoma producing MAbs specific to another antigen. For example, a cell (a quadroma), formed by fusion of a hybridoma producing a MN-specific MAb and a hybridoma producing an anti-cytotoxic cell antibody, will produce hybrid antibody having specificity of the

30 parent antibodies. [See, e.g., *Immunol. Rev.* (1979); *Cold Spring Harbor Symposium Quant. Biol.*, 41: 793 (1977); van Dijk et al., *Int. J. Cancer*, 43: 344-349 (1989).] Thus, a hybridoma producing a MN-specific MAb can be fused with a hybridoma producing, for example, an anti-T3 antibody to yield a cell line which produces a

MN/T3 bispecific antibody which can target cytotoxic T cells to MN-expressing tumor cells.

It may be preferred for therapeutic and/or imaging uses that the antibodies be biologically active antibody fragments, preferably genetically engineered fragments, more preferably genetically engineered fragments from the V_H and/or V_L regions, and still more preferably comprising the hypervariable regions thereof. However, for some therapeutic uses bispecific antibodies targeting MN protein and cytotoxic cells would be preferred.

10 Humanized or Fully Human Antibodies to Various CA IX Domains

For clinical use, whether diagnostic/prognostic or therapeutic, but preferably for therapeutic use, it is preferable to use humanized or more preferably fully human CA IX specific antibodies. Such antibodies could be made to any of the CA IX domains, the extracellular domain, including the PG and CA regions, the TM and/or IC domains. It may be preferred to downregulate CA IX abnormally expressing cells by contacting them with CA IX-specific antibodies directed to the extracellular domain, and more specifically to either the PG and/or CA regions. One might also interfere with the signal transduction of CA IX by contacting the IC domain with antibodies specific thereto.

20 References that are representative of those explaining how one of skill in the art can prepare humanized and fully human antibodies by antibody engineering, including the use of transgenic mice include the following: Clark M., Immunol. Today, 21(8): 397-402 (Aug. 2000); Davis et al., Cancer Metastasis Rev., 18(4): 421-425 (1999); Gavilondo and Larrick, Biotechniques, 29(1): 128-132 and 134-136, 138 *passim* (July 2000); Zou and Rajewsky, Science, 262(5137): 1271-1274 (Nov. 19, 1993); Sandhu, J.S., Crit. Rev. Biotechnol., 12(5-6): 437-462 (1992); Vaughan et al., Nat. Biotechnol., 16(6): 535-539 (June 1998); Hoogenboom and Chames, Immunol. Today, 21(8): 371-378 (Aug. 2000); Holliger and Bohlen, Cancer Metastasis Rev., 18(4): 411-419 (1999); Owens and Young, J. Immunol. Methods, 168(2): 149-165 (Feb. 10, 1994); and Gura, T., Nature, 417(6889): 584-586 (June 6, 2002).

Epitopes

The affinity of a MAb to peptides containing an epitope depends on the context, e.g. on whether the peptide is a short sequence (4-6 aa), or whether such a short peptide is flanked by longer aa sequences on one or both sides, or whether in 5 testing for an epitope, the peptides are in solution or immobilized on a surface.

Therefore, it would be expected by ones of skill in the art that the representative epitopes described herein for the MN-specific MAbs would vary in the context of the use of those MAbs.

The term "corresponding to an epitope of an MN protein/polypeptide" 10 will be understood to include the practical possibility that, in some instances, amino acid sequence variations of a naturally occurring protein or polypeptide may be antigenic and confer protective immunity against neoplastic disease and/or anti-tumorigenic effects. Possible sequence variations include, without limitation, amino acid substitutions, extensions, deletions, truncations, interpolations and 15 combinations thereof. Such variations fall within the contemplated scope of the invention provided the protein or polypeptide containing them is immunogenic and antibodies elicited by such a polypeptide or protein cross-react with naturally occurring MN proteins and polypeptides to a sufficient extent to provide protective immunity and/or anti-tumorigenic activity when administered as a vaccine.

20

MN-Specific Intrabodies -- Targeted Tumor Killing Via Intracellular
Expression of MN-Specific Antibodies to
Block Transport of MN Protein to Cell Surface

25 The gene encoding antibodies can be manipulated so that the antigen-binding domain can be expressed intracellularly. Such "intrabodies" that are targeted to the lumen of the endoplasmic reticulum provide a simple and effective mechanism for inhibiting the transport of plasma membrane proteins to the cell surface. [Marasco, W.A., "Review -- Intrabodies: turning the humoral immune system outside in or intracellular immunization," Gene Therapy, 4: 11-15 (1997); Chen et al., 30 "Intracellular antibodies as a new class of therapeutic molecules for gene therapy," Hum. Gene Ther., 5(5): 595-601 (1994); Mhashilkar et al., EMBO J., 14: 1542-1551 (1995); Mhashilkar et al., J. Virol., 71: 6486-6494 (1997); Marasco (Ed.), Intrabodies: Basic Research and Clinical Gene Therapy Applications, (Springer Life Sciences

1998; ISBN 3-540-64151-3) (summarizes preclinical studies from laboratories worldwide that have used intrabodies); Zanetti and Capra (Eds.), "Intrabodies: From Antibody Genes to Intracellular Communication," The Antibodies: Volume 4,

5 [Harwood Academic Publishers; ISBN 90-5702-559-0 (Dec. 1997)]; Jones and Marasco, Advanced Drug Delivery Reviews, 31 (1-2): 153-170 (1998); Pumphrey and Marasco, Biodrugs, 9(3): 179-185 (1998); Dachs et al., Oncology Res., 9(6-7): 313-325 (1997); Rondon and Marasco, Ann. Rev. Microbiol., 51: 257-283 (1997)]; Marasco, W.A., Immunotechnology, 1(1): 1-19 (1995); and Richardson and Marasco, Trends in Biotechnology, 13(8): 306-310 (1995).]

10 MN-specific intrabodies may prevent the maturation and transport of MN protein to the cell surface and thereby prevent the MN protein from functioning in an oncogenic process. Antibodies directed to MN's EC, TM or IC domains may be useful in this regard. MN protein is considered to mediate signal transduction by transferring signals from the EC domain to the IC tail and then by associating with other intracellular proteins within the cell's interior. MN-specific intrabodies could disrupt that association and perturb that MN function.

15 Inactivating the function of the MN protein could result in reversion of tumor cells to a non-transformed phenotype. [Marasco et al. (1997), supra.]

20 Antisense expression of MN cDNA in cervical carcinoma cells has shown that loss of MN protein has led to growth suppression of the transfected cells. It is similarly expected that inhibition of MN protein transport to the cell surface would have similar effects. Cloning and intracellular expression of the M75 MAB's variable region is to be studied to confirm that expectation.

25 Preferably, the intracellularly produced MN-specific antibodies are single-chain antibodies, specifically single-chain variable region fragments or scFv, in which the heavy- and light-chain variable domains are synthesized as a single polypeptide and are separated by a flexible linker peptide, preferably (Gly₄-Ser)₃.

30 MN-specific intracellularly produced antibodies can be used therapeutically to treat preneoplastic/neoplastic disease by transfecting preneoplastic/neoplastic cells that are abnormally expressing MN protein with a vector comprising a nucleic acid encoding MN-specific antibody variable region fragments, operatively linked to an expression control sequence. Preferably said expression control sequence would comprise the MN gene promoter.

Antibody-Mediated Gene Transfer Using MN-Specific
Antibodies or Peptides for Targeting MN-Expressing Tumor Cells

An MN-specific antibody or peptide covalently linked to polylysine, a
5 polycation able to compact DNA and neutralize its negative charges, would be
expected to deliver efficiently biologically active DNA into an MN-expressing tumor
cell. If the packed DNA contains the HSVtk gene under control of the MN promoter,
the system would have double specificity for recognition and expression only in MN-
expressing tumor cells. The packed DNA could also code for cytokines to induce
10 CTL activity, or for other biologically active molecules. The M75 MAb (or, for
example, as a single chain antibody, or as its variable region) is exemplary of such a
MN-specific antibody.

The following examples are for purposes of illustration only and are not
meant to limit the invention in any way.

15

EXAMPLE 1
Preparation of CA IX-Deficient Mice

MATERIALS AND METHODS

20 Cloning of mouse *Car9* cDNA

Mouse cDNA was obtained by RT PCR using primers derived from a
human *Car9* cDNA (EMBL Accession No. X66839; SEQ ID NO: 70). The template
total RNA was prepared from C57BL/6J mouse stomach by acid guanidium
thiocyanate-phenol/chloroform isolation [Siebert et al. (1993)]. First strand synthesis
25 was carried out under standard conditions using SuperScript II reverse transcriptase
(Life Technologies, Germany). The set of the human primers was as follows: *sense*
ATC CAC GTG GTT CAC CTC AG (SEQ ID NO: 71) and *antisense* CTT TGG TTC
CCC TTC TGT GC (SEQ ID NO: 72); corresponding to the human cDNA fragment
760-1345 [SEQ ID NO: 73] of Figure 1A-1C. PCR reactions were carried out in 30
30 cycles (94°C, 30 sec, 55°C, 40 sec, and 72°C, 60 sec). Entire cDNA including open
reading frame, 3'- and 5'-untranslated regions, was obtained by the 3' and 5' RACE
(rapid amplification of cDNA ends). The 3' and 5' RACE kits (Life Technologies) were
used as recommended by the manufacturer. Two gene-specific primers were used in
3' RACE: *sense* S1 - CAG GAG AGC CCA GAA GAA AA (SEQ ID NO: 74); *sense*

S2 - TGA AGG GTC TCT GAC CAC AC (SEQ ID NO: 75). Three gene-specific primers were used in 5' RACE: *antisense* A1 - AGC TGT AGG AGG AAG GCG AT (SEQ ID NO: 76); *antisense* A2 - TGA CAG CAA AGA GAA GGC CA (SEQ ID NO: 77); *antisense* A3 - CAG GGA AGG AAG CCT CAA TC (SEQ ID NO: 78). All resulting amplicons were cloned with the TA Cloning® KIT (Invitrogen, Netherlands) and sequenced on Applied Biosystems automatic sequencer. The cDNA sequence was deposited in EMBL (Accession No. AJ245857; SEQ ID NO: 79).

Cloning of mouse *Car9* gene

A mouse embryonic stem (ES) cell 129/Sv BAC library (Genome Systems, USA) was screened with the full size *Car9* cDNA. BAC DNA was analyzed with various restriction endonucleases and hybridized with the murine *Car9* cDNA. Selected positive clones resulting from *EcoRI* (6.5kb) and *KpnI* (1.4kb) digestion were subcloned into pBluescript KS and analyzed by automatic sequencing. The 15 genomic sequence was deposited in the GenBank (Accession No. AY049077; SEQ ID NO: 80).

Generation of *Car9* deficient mouse

The *EcoRI-HindIII* fragment (5.9 kb) derived from the subcloned 20 genomic *EcoRI* fragment and encompassing the first 6 exons of the *Car9* gene was used for the construction of the p*Car9*-neo targeting vector. The p*Car9*-neo vector was constructed by standard recombinant techniques in a pBluescript KS lacking *BamHI* restriction site. *EcoRI-BamHI* restriction fragment (1.5kb) was used as a 5' genomic arm containing the promoter and a part of the first exon. *BamHI-HindIII* 25 restriction fragment (4.5kb) was used as a 3' genomic arm extending from the end of the first exon to the exon 6. Using this approach, the sequence of 14bp region situated between the two *BamHI* sites was deleted from the first exon and replaced by the phosphoglycerate kinase-neomycin phosphotransferase (pgk-neo) cassette. Linearized targeting vector was introduced into E14 ES 129/Ola cell line by 30 electroporation. Targeted ES cell clones were enriched by selection with G418 (400 µg/ml) and identified by Southern blot analysis using *EcoRI-XbaI* fragment as an external 5' probe and *HindIII-EcoRI* fragment as an external 3' probe (see Fig.8). Cloned ES cell lines were injected into C57BL/6J blastocysts to produce C57BL/6J-129/Ola chimeric mice. Chimeras were created from two different ES clones

possessing the *pCar9*-neo inserted by homologous recombination. The *r29/Ola* contribution in adult chimeric offspring was determined by coat color. Southern blotting with the above-described probes was used to recognize those mice that carried the targeted allele. Animal experiments were approved by the government 5 office LAGETSI, Berlin, under the license number G 0224/00.

Analysis of the *Car9* mRNA expressed from the targeted gene

Isolation of RNA from *Car9*^{+/+} and *Car9*^{-/-} mouse stomach, RT PCR and 5' RACE were performed and analyzed as described above using the following 10 primers: (i) primers for the 5'RACE: 900A *antisense* - GAT ACA TCC AAA CCT GGG ATC TCA A (SEQ ID NO: 81); 800A *antisense* - TCC TGC AGA AAG GCA GCC AAA ACT G (SEQ ID NO: 82); 700A *antisense* - CAG GGA AAC GGT GAC CAT TGA CTG T (SEQ ID NO: 83); (ii) primers for RT PCR: A (*MNG sense*) - GAC ACC CCA GTC AGC TGC ATG GCC T (SEQ ID NO: 84); B (*NeoV*) - CAT TCT CAG TAT 15 TGT TTT GCC AAG TT (SEQ ID NO: 85); C (*Neo sense*) - CGA AGG AGC AAA GCT GCT ATT GGC C (SEQ ID NO: 86); D (*MNA antisense*) - TGT GCT CAG GAG CCT CGG GAG TCG A (SEQ ID NO: 87); E (*EXS1 sense*) - AGT CAA GGT TCC CAC GGG GAT GAA (SEQ ID NO: 88); F (*1403A antisense*) - AAG GAG GCT GTA 20 TAA CAG GCA GGA C (SEQ ID NO: 89).

Preparation of the rabbit anti-mouse CA IX polyclonal antibody

Full length *Car9* cDNA was subcloned into the bacterial expression vector pGEX-4T-1. GST-mCAIX bacterial recombinant protein was produced in transformed *E. coli* strain DH5[[alpha]] cells following induction with 1 mM IPTG for 5 25 hrs and isolated from the bacterial cell lysate by affinity chromatography using Glutathione Sepharose 4B (Amersham Pharmacia, Sweden). Rabbits were inoculated intramuscularly with 1 mg of the GST-mCAIX fusion protein and complete Freund's adjuvant. The next three injections at monthly intervals were given with 0.25 mg of the protein and incomplete adjuvant. To remove GST-specific antibodies, 30 immune sera were purified using Glutathione Sepharose-bound GST protein and tested for the reactivity to mouse CA IX. Selected serum was employed in 1:500 dilution in immunohistochemical analysis described below and in immunoblotting. Briefly, protein extracts were prepared from the stomach mucosa of *Car9*^{+/+} and *Car9*^{-/-} mice as well as from the mock-transfected and *Car9* cDNA-transfected

NIH3T3 cells using lipofectamine (Life Technologies). Total protein concentrations were determined using BCA kit (Pierce, USA) in all samples and aliquots containing equal amount of total proteins were analyzed as described elsewhere [Pastorekova et al. (1997)].

5

Analysis of blood gases, electrolytes and serum gastrin

Awakened mice were gently warmed for 10 min under a red light lamp to increase peripheral blood circulation. Blood (1.5-5.5 ml) from the tail vein was collected from several animals in heparin-, EDTA-treated tubes or non-treated tubes and analyzed for gases, electrolytes and pH using automated laboratory analyzers (Boehringer Mannheim, Germany) according to manufacturer's recommendations. The gastrin levels were measured using a specific antibody raised against human gastrin 17 as described [Hocker et al. (1996)].

15

Histochemical and immunohistochemical analyses

Tissue specimens from *Car9*^{+/+} and *Car9*^{-/-} mice were cut from stomach, duodenum, jejunum, ileum, colon, liver, pancreas, kidney and lung. The specimens were fixed in Carnoy's fluid (absolute ethanol + chloroform + glacial acetic acid in 6:3:1 ratio) for 24 hr at 4°C or in 4% neutral-buffered formaldehyde for 24-48 hr at room temperature. The samples were then dehydrated, embedded in paraffin wax in a vacuum oven at 58°C, and sections of 5 µm were placed on gelatin-coated microscope slides. For the histochemical analysis, the sections were stained with hematoxylin/eosin and with diastase-resistant periodic acid Schiff (PAS). The immunohistochemical analysis was carried out using the following primary antibodies: anti-CA IX rabbit polyclonal serum (described above, diluted 1:500), anti-PCNA rabbit polyclonal antibody, anti-E-cadherin rabbit polyclonal antibody, anti- α catenin rabbit polyclonal antibody and anti- β catenin rabbit polyclonal antibody (all from Santa Cruz Biotechnology, Santa Cruz, CA, final concentration 5 µg/100 µl), polyclonal sheep anti-human pepsinogen II antibody (Binding Site, UK, diluted 1:2000), and polyclonal rabbit anti- α subunit of porcine gastric H⁺/K⁺-ATPase (Calbiochem-Novabiochem, Germany, diluted 1:50). The immunostaining of tissue sections was performed by the biotin-streptavidin complex method, employing the following steps: (1) Pre-treatment of the sections with undiluted cow colostral whey for 40 min and rinsing in phosphate-buffered saline (PBS). (2) Incubation for 1 hr

with the first antibody (except overnight incubation with anti-H⁺/K⁺-ATPase antibody) in PBS containing 1% bovine serum albumin (BSA). (3) Treatment with cow colostral whey for 40 min and rinsing in PBS. (4) Incubation for 1 hr with biotinylated swine anti-rabbit IgG (Dakopatts, Copenhagen, Denmark) or donkey anti-sheep/goat IgG (Binding Site) diluted 1:300 in 1% BSA-PBS. (5) Incubation for 30 min with peroxidase-conjugated streptavidin (Dakopatts) diluted 1:500 in PBS. (6) Incubation for 2 min in DAB solution containing 9 mg 3,3'-diaminobenzidine tetrahydrochloride (Fluka, Buchs, Switzerland) in 15 ml PBS + 5µ 30% H₂O₂. The sections were washed three times for 10 min in PBS after incubation steps 2, 4, and 5. All the incubations and washings were carried out at room temperature and the sections were finally mounted in Permount (Fisher Scientific, Fair Lawn, NJ). The stained sections were examined and photographed with Nikon Eclipse E600 (Tokyo, Japan) microscope.

15

Morphometric analysis and statistical evaluation of data

Stomach specimens from 10 wild type and 10 CA IX-deficient mice at the age of 26 and 35 weeks were stained for pepsinogen C and α subunit of H⁺/K⁺-ATPase. Both total and immunostained cells were counted in 50 longitudinally cut glands per mouse. Mann-Whitney rank test was applied to compare the numbers of 20 cells in the *Car9*^{+/+} versus *Car9*^{-/-} mice. Relationship between the total numbers of cells and the numbers of parietal cells within the gastric units was analyzed in both groups of animals by regression analysis and the strength of the linear relationship was estimated by the Pearson's correlation coefficient R. Slopes of regression lines were compared by T test. P values of <0.05 and <0.01 were considered as 25 significant and highly significant, respectively, for each of two tests.

RESULTS

Identification of *Car9* cDNA

Cloning and characterization of the cDNA and gene encoding the 30 mouse CA IX was the first step towards generation of CA IX-deficient mice. Mouse *Car9* cDNA fragment was isolated by RT PCR using primers derived from the human cDNA [Pastorek et al. (1994)] and the template RNA isolated from the stomach of C57 BL/6J mouse. The full-length cDNA was obtained by rapid amplification of cDNA ends in both 5'/3' directions. It encompasses 1965 bp composed of 32 bp 5'

untranslated region, 1311 bp open reading frame and 622 bp 3' untranslated sequence (deposited in EMBL database under the Accession No. AJ245857; SEQ ID NO: 79).

The *Car9* cDNA has a coding capacity for a 437 amino acid protein (deposited in EMBL database under the Accession No. CAC80975 (Q8VDE4); SEQ ID NO: 90) with a theoretical molecular mass of 47.3 kDa. The mouse protein shows 69.5% sequence identity with its human homologue and has a similar predicted domain arrangement [Opavsky et al. (1996)]. Amino acids (aa) 1-31 (SEQ ID NO: 91) correspond to a signal peptide. The N-terminal extracellular region of the mature protein (aa 32-389) (SEQ ID NO: 92) is composed of a proteoglycan-like region (aa 48-107) (SEQ ID NO: 93), and a carbonic anhydrase domain (aa 112-369) (SEQ ID NO: 94). The C-terminal region (aa 390-437) (SEQ ID NO: 95) consists of the transmembrane anchor (aa 390-411) (SEQ ID NO: 96) and a short cytoplasmic tail (aa 412-437) (SEQ ID NO: 97). Most of the sequence differences between the mouse and human CA IX were found within the proteoglycan-like (PG) region, while the CA domain revealed the highest conservation. However, out of the five key amino acids involved in the enzyme active site (His⁹⁴, His⁹⁶, Glu¹⁰⁶, His¹¹⁹, Thr¹⁹⁹) [Christianson and Cox (1999)] all are preserved in human CA IX, but one is altered in the mouse isoenzyme (Thr¹⁹⁹→Ser). Despite this substitution, the mouse CA IX bound to a sulfonamide agarose suggesting that it may possess an enzyme activity.

Availability of *Car9* cDNA allowed the analysis of the expression pattern of *Car9* mRNA in mouse tissues. A ribonuclease protection assay (RNP) was carried out with a riboprobe of 170 bp designed to detect the 3' part of the region encoding the CA domain. As expected on the basis of the distribution in human and rat tissues, the highest level of *Car9* mRNA was detected in the mouse stomach. Medium level of *Car9* mRNA was found in the small intestine and colon, while the kidney and brain showed very weak expression. The liver and spleen were negative. Noteworthy, the RNP signal was also present in the mouse embryo at the age of embryonic day E18.5, but not in embryonic stem cells and in the E10.5 embryo. This may suggest a role for CA IX in the development of the mouse gastrointestinal tract.

Organization of *Car9* gene

In order to isolate the *Car9* gene and determine its organization, the full-length *Car9* cDNA was used for screening of a mouse embryonic stem cell 129/Ola genomic library in pBAC108L. Obtained was one BACM-355(G13) clone that contained complete *Car9* genomic sequence as confirmed by restriction mapping and Southern blot analysis of a mouse wild type genomic DNA. Three overlapping genomic fragments derived from this clone were subcloned into pBluescript II KS.

Analysis of the genomic sequence (GenBank Accession No. AY049077; SEQ ID NO: 80) revealed that the *Car9* gene covers 8.7 kb of the mouse genome and consists of 11 exons and 10 introns. Distribution of introns and exon-to-protein domain relationships are similar to the human counterpart [Opavsky et al. (1996)]. The Southern hybridization pattern indicated that *Car9* is a single copy 15 gene. The *EcoRI-HindIII* fragment encompassing 5.9 kb and spanning the promoter region and exons 1-6 was used for a construction of the targeting vector.

Targeting of the *Car9* gene and generation of *Car9*^{-/-} mice

To disrupt the *Car9* gene in the mouse embryonic stem cells, a p*Car9*-neo targeting vector was constructed using the above-described genomic fragment. The first exon was interrupted by a replacement of a 14 bp region (at position 268-282) with a pgk-neo cassette in a reverse orientation (Fig.8A). Since the deleted region corresponded to a part of the PG domain of CA IX, insertion of a pgk-neo cassette caused a disruption of this domain and a separation of the sequence 25 encoding the signal peptide from the rest of the protein. Moreover, deletion of the 14 bp was designed to cause a shift of the reading frame in the murine *Car9* mRNA and prevent its correct translation.

After electroporation and selection of E14 embryonic stem cells by G418, eight clones that had undergone homologous recombination were identified. 30 Two of them were chosen for further manipulations. As confirmed by the Southern blotting with the 3' and 5' external probes, both targeted clones were shown to be without unintended rearrangements at the *Car9* locus. Using these two lines of mutant ES cells, chimeric and *Car9*⁺⁻ mice that were healthy and fertile were generated. The intercrossing of the heterozygous mice resulted in all three

genotypes with Mendelian distribution among the offspring, as demonstrated by Southern blot analysis from the tail genomic DNA samples. [Southern blot showed the genotyping of the offspring from a heterozygous mating. DNA from tails of 3-weeks old mice was digested with *Eco*RI and hybridized with the 3' probe. The 5 bands corresponded to wild type (6.5 kb) and mutated (8.3 kb) allele, respectively.]

RT PCR analysis with the gene specific primers revealed that homozygous *Car9*^{-/-} mice expressed mRNA that was lacking exon 1. In contrast, both mutated and wild type transcripts contained exons 2-11. Furthermore, pgk-neo-derived primers in combination with exon 1-specific primers allowed for PCR 10 amplification of the genomic DNA from *Car9*^{-/-} mice confirming that the cassette was successfully introduced into the *Car9* locus. Corresponding RT PCR amplicons from mutated RNA were absent, bringing additional evidence that the 5' end of *Car9* mRNA is missing. It was deduced from the 5' mRNA sequence obtained by RACE analysis that this was due to unexpected splicing of mutated *Car9* transcript leading 15 to deletion of the 5' untranslated region as well as the sequences coding for signal peptide, large part of PG-like domain and majority of pgk-neo cassette. Thus, the *Car9*^{-/-} mice expressed chimeric mRNA that contained 77 nucleotides derived from the pgk-neo cassette linked via the 3' part of PG domain-related sequence (starting from nt 283) to the rest of *Car9* cDNA. There were two potential translation initiation 20 codons. The first AUG codon was out of frame. The second one would potentially lead to translation of the truncated protein that could not be properly processed due to the lack of signal peptide. Absence of this putative translation product in the mutant stomach was demonstrated by Western blotting analysis performed with the rabbit polyclonal antiserum raised against the full-length recombinant mouse CA IX 25 protein. [Western blot analysis of the protein extracts from the wild type *Car9*^{+/+} and mutant *Car9*^{-/-} mouse stomach epithelium were performed. Extracts from NIH3T3 cells transfected with the full length *Car9* cDNA and from mock-transfected NIH3T3 cells served as controls. The blot was processed with anti-CA IX rabbit antiserum raised against a full-length recombinant GST-mCA IX protein.]

30 The CA IX-deficient mice showed no deviations from their wild type litter mates in growth, behavior, reproductive potential, health and life span. No morphological and histological abnormalities were observed in their lung, spleen, liver, kidney, jejunum, ileum and colon.

Gastric phenotype of CA IX mutant mice

Histopathological examination of stomach specimens from *Car9*^{-/-} mice regularly revealed remarkable hyperplastic changes when compared to stomachs of their heterozygous and wild type litter mates. While no changes were visible in mutant mice during embryonic development, an increase in mucosal thickness was seen at postnatal day P0.5. The hyperplasia became prominent in 4 weeks-old animals, but it did not progress with the age and remained similar in 1.5 years old mice.

In adult *Car9*^{-/-} mice, the hyperplastic changes affected only the glandular stomach epithelium, while the squamous epithelium of the non-glandular forestomach remained normal. The most pronounced hyperplasia concerned the corpus region. Mucosal folds were more prominent in the homozygous mutant mice than in their wild type littermates, and the pit-to-gland ratio increased to 1:3 or even 1:2 from the usual 1:4 in the wild type and heterozygous animals. These hyperplastic changes in the *Car9*^{-/-} mouse mucosa were accompanied with numerous pathological cysts lined with a single layer of low cuboidal epithelial cells. No morphological signs of dysplasia were observed in any of the stomach sections from 2 to 3 mice checked at monthly intervals up till 1.5 years of age and normal structure of the subepithelial lamina propria was seen at all age points.

Presence of hyperplasia in *Car9*^{-/-} mouse mucosa was confirmed by the morphometric analysis of stomach sections that revealed a highly significant ($P=0.0007$) difference between the total numbers of cells counted per 50 gastric units in 10 *Car9*^{+/+} mice compared to 10 *Car9*^{-/-} mice (see Fig. 9A). Based on median values, the mucosa of CA IX deficient mouse contained approximately by 30% more cells than the control epithelium.

Interestingly, small duodenal adenomas with slight to moderate dysplasia were observed in three of 15 *Car9*^{-/-} mice. It cannot be excluded that their appearance was also associated with loss of CA IX, which is normally expressed in the proximal small intestine.

Cell proliferation, death and adhesion in hyperplastic mucosa

To explore possible mechanisms that underlie gastric hyperplasia in *Car9*^{-/-} mice, performed were immunohistochemical analyses of the stomach sections obtained from both mutant and wild type mice. First, an antibody raised

against the mouse CA IX to analyze its distribution in the wild type stomach was employed. Strong CA IX-specific staining occurred in the corpus but not in the forestomach of adult *Car9^{+/+}* mice, consistent with the reversible presence of phenotypic changes only in the corpus, but not in the forestomach of the *Car9^{-/-}* mice. Positive staining of the *Car9^{+/+}* stomach corpus was distributed in all epithelial cells, but its intensity was strongest at the basolateral surfaces of mature glandular and superficial pit cells. Noteworthy, immunohistochemical staining revealed lack of CA IX in stomachs of E15.5 and E17.5 embryos, but showed that it is weakly expressed in the stomach of the newborn mice.

Because hyperplasia may involve an increase in cellular proliferation and/or decrease in apoptosis, the determination of whether one of these two processes, or both were responsible for the observed gastric phenotype was considered important. Studied was the expression of PCNA, a marker of proliferating cells and observed characteristic staining pattern restricted to the proliferative zone in the *Car9^{+/+}* mouse mucosa. In contrast, the proliferative compartment was considerably expanded in *Car9^{-/-}* mice as suggested by the widely spread staining signal. Total number of PCNA-positive cells in mutant epithelium was markedly increased. On the other hand, annexin V staining and TUNEL DNA fragmentation analysis performed to assess the extent of apoptosis did not reveal any differences between the *Car9^{-/-}* and *Car9^{+/+}* mouse stomachs in proportion of apoptotic cells, thus indicating that hyperplasia could not be attributed to an impaired cell death.

Further immunohistochemical stainings were carried out to analyze possible relationship between gastric epithelial hyperplasia and expression of adhesion-related molecules, including E-cadherin, β -catenin and α -catenin. These analyses were based on the importance of cadherin/catenin-mediated pathways for proper development and organization of epithelial tissues [Gumbiner, B. (1996)] and on the observations supporting possible role of CA IX in cell adhesion and communication [Zavada et al. (2000), Pastorekova et al. (1997)]. We found that gastric mucosa of the wild type animals expressed E-cadherin predominantly at the basolateral surfaces of mature epithelial cells located in the deep glands and surface pits, in a fashion reminiscent of normal CA IX distribution. In contrast, E-cadherin-positive staining of *Car9^{-/-}* mouse stomach was slightly weaker throughout the mucosa and its regional arrangement was less apparent. However, total E-cadherin

level determined by Western blotting in mutant stomach did not differ from the wild type control. Expression of α - and β -catenins showed similar pattern: both catenins were mostly present in mature epithelial cells of $Car9^{+/+}$ mice, while their staining signal in $Car9^{-/-}$ mice was weaker and disorganized. The data indicate that loss of CA IX may result in perturbation of normal cell-cell adhesion albeit without pronounced effect on the expression level of the studied adhesion molecules.

Aberrant cell lineage distribution in the corpus of $Car9^{-/-}$ mouse stomach

The above observations led us to examine the spatial distribution and proportion of the major cell types in the stomach epithelium of the $Car9^{-/-}$ mice in comparison with the $Car9^{+/+}$ controls. To detect the mucus-producing pit cells, sections of the glandular stomachs were stained with a diastase-resistant periodic acid of Schiff (PAS). PAS staining of the wild type stomach corpus was strongly positive in the surface pit region. In contrast, $Car9^{-/-}$ mice showed a markedly different staining pattern, with the intense PAS signal mostly expanded from the surface to the base of the corpus mucosa, although there was some inter-individual variation in the extent of the PAS positive area. This could probably occur as a result of abundant production and aberrant migration of the mucous cells that consequently populated inappropriate areas of the gastric epithelium.

Numbers of parietal cells were assessed by the morphometric analysis following immunohistochemical detection of α subunit of H^+/K^+ -ATPase that served as a parietal cell lineage marker. As it is shown on Fig. 9B, stomachs of $Car9^{-/-}$ mice contained significantly reduced proportion of parietal cells when compared to the wild type controls ($P=0.0051$). Regression analysis revealed significant positive correlation between the numbers of parietal cells and the total numbers of cells in gastric units from both wild type and CA IX-deficient mouse stomachs (Pearson's correlation coefficients $R^2=0.68$ and $R^2=0.61$, respectively). Slopes of the regression lines of gastric units from $Car9^{-/-}$ and $Car9^{+/+}$ mice, respectively, were significantly different ($P<0.0005$) and CA IX-deficient gastric units showed clear tendency toward diminished production of parietal cells with increasing hyperplasia (Fig. 9D). Altogether, these data support the view that loss of CA IX resulted in the perturbed differentiation of parietal cells.

To determine the position and number of functional chief cells, we performed an immunohistochemical staining for a pepsinogen C, a chief cell lineage-

specific marker [Karam et al. (1997)]. Cells containing pepsinogen granules were confined to the basal area in both normal and CA IX-deficient mouse gastric epithelia. However, morphometric analysis has revealed a marked depletion of chief cells in corpus mucosa of *Car9*^{-/-} mice. As demonstrated on Fig. 9C, decrease in percentage of chief cells was highly significant (P=0.0001).

Abnormal composition of the *Car9*^{-/-} mouse gastric epithelium suggests that loss of CA IX has affected a cell-lineage allocation by redirecting the differentiation program towards the formation of pit cells at the expense of parietal and chief cells.

Systemic acid-base and electrolyte status

Based on the abundant expression in normal gastric mucosa and relationship to other carbonic anhydrases acting in alimentary tract, CA IX has been proposed to participate in maintenance of acid-base balance. Its basolateral localization indicated that it could be involved in electrolyte exchange within the mucosa and/or with the submucosal region rather than in production of gastric acid that is directly linked to the catalytic properties of highly active CA II isoenzyme [Parkkila et al. (1996)]. Therefore, systemic acid/base and electrolyte status of the *Car9*^{-/-} mice were examined. Blood samples taken from the adult mutant mice were compared to the samples from the age-matched wild type controls with respect to blood pH and content of plasma electrolytes. We have also measured the serum level of gastrin, as it may predict changes in gastric acid secretion. However, no statistically significant differences were found in any of the examined parameters (Table 2), suggesting that elimination of CA IX resulting in gastric hyperplasia did not lead to any gross physiological defects.

TABLE 2

Plasma electrolytes, blood pH and serum gastrin were measured in two separate measurements from the blood of *Car9*^{+/+} and *Car9*^{-/-} animals.

30	Genotype	pH	HCO ₃ ⁻ (mM)	Cl ⁻ (mM)	K ⁺ (mM)	Na ⁺ (mM)	Serum gastrin (pg/ml)
	<i>Car9</i> ^{+/+}	7.30 ± 0.035	24.35 ± 1.95	119 ± 2	3.8 ± 0.6	139.5 ± 4.5	60 ± 4
35	<i>Car9</i> ^{-/-}	7.32 ± 0.015	24.15 ± 0.55	118 ± 6	4.9 ± 0.4	141.5 ± 3.5	59 ± 12

DISCUSSION

Morphogenesis of gastric mucosa in mouse is a complex process initiated during late gestation by a series of events. These include formation of primordial buds around embryonic day E18, precursor cell differentiation from postnatal day P1 to P7, elongation of buds due to increase in number of precursors and their progeny from P7 to P15 and finally, assembly of gastric units and compartmentalization of cellular migration-differentiation programs between P15 and P21 [Karam et al. (1997)]. Accomplishment of this complex process results in self-renewing epithelium in which cell proliferation is confined to the stem and precursor cells in the middle portion of the unit. Their progenitors bi-directionally migrate and simultaneously differentiate to supply the surface and the base of the unit by functional mature cells [Wright, N.A. (2000)]. Maintenance of a dynamic equilibrium between cell differentiation and proliferation ensures the proper mucosal functioning and integrity.

Expression of CA IX is firstly detectable at low level in mouse newborn stomach at day P0.5, during the early phase of gastric unit morphogenesis, and its abundance increases towards the adult age. The protein occupies membranes of epithelial cells throughout the adult mucosa of gastric body, but its level is higher in mature superficial pit cells and deep glandular cells.

Consistently with expression pattern and coincidentally with the course of gastric unit morphogenesis, targeted disruption of a *Car9* gene encoding CA IX leads to manifestation of the gastric hyperplasia. First mild changes in the thickness of the gastric mucosa appear in the newborn *Car9*^{-/-} mice as early as at day P0.5. This is the time when expression of CA IX initiates in the wild type stomach. Absence of CA IX results in partial elongation of buds probably as a consequence of excessive cell proliferation, while the normal bud elongation occurs later, between days P7 and P15. Hyperplastic changes are clearly visible in the 4-weeks' mutant mouse mucosa, when the unit morphogenesis is finished, but do not progress with the age. Deregulated proliferation affects the mucosa without any evident morphological alterations of the cells and without any significant changes in the cell death.

Interestingly, no additional phenotypic changes were observed in other tissues that normally do express CA IX, except the rare cases of duodenal adenoma.

This could be due to redundancy provided by related carbonic anhydrase isozymes [Parkkila et al. [1996]] similarly as it has been suggested for disruption of *Tcf-7/2* gene resulting in changes only in the small intestine but not in the colon, where this gene is highly expressed [Korinek et al. (1998)].

5 The hyperplasia of *Car9*^{-/-} gastric corpus mucosa is accompanied with increased pit-to-gland ratio and aberrant distribution of mucus-producing pit cells as well as significant reduction of parietal and chief cells. These alterations indicate that loss of CA IX may directly affect lineage repertoire and partially disturb positional instructions that normally direct upward migration of pit cell precursors and their 10 descendants. Alternatively, elimination of CA IX may affect differentiation of parietal cells that are the important source of instructions affecting other cells lineages [Karam et al. (1997)]. Hence, disbalance in production of pit and chief cells may be secondary to changes in parietal cell population.

Phenotype of mice with the targeted disruption of *Car9* gene is 15 reminiscent of other genetically modified models, including the mice lacking α/β subunits of H^+/K^+ -ATPase [Spicer et al. (2000), Scarff et al. (1999)], *Kvlq1* voltage-gated potassium channel [Lee et al. (2000)], and the mice overexpressing $TGF\alpha$ [(Sharp et al. (1995)]. These models show some similarities, but differ from *Car9*^{-/-} model in specific aspects. Mice lacking either of two subunits of H^+/K^+ -ATPase are 20 hypergastrinemic and achlorhydric, consistently with the established role of H^+/K^+ -ATPase in production of gastric acid. Both models contain normal numbers of parietal cells but these have aberrant secretory membranes. Number of chief cells is reduced in mice deficient in β subunit but not in α subunit. The *Kvlq1*-deficient mice 25 display mucous neck cell hyperplasia and production of vacuolated, nonfunctional parietal cells leading to hypergastrinemia and hypochlorhydria.

In contrast, there are no significant changes in serum gastrin levels in mice overexpressing $TGF\alpha$ despite expanded mucous pit cell population and depletion of mature parietal and chief cells. These findings are in accord with our 30 observations. Because changes in levels of serum gastrin usually reflect perturbed gastric acid secretion, both studies indicate that CA IX and $TGF\alpha$ may not be directly involved in the production of gastric acid but may have other important functions within the gastric mucosa.

Based on all available facts, CA IX appears to contribute to balance between differentiation and proliferation in gastric mucosa via negative control of cell

2003217606
21 Feb 2003

proliferation and as a possible regulatory component of migration-associated differentiation program. Loss of CA IX therefore leads to uncoupling of proliferation control from differentiation and migration signals and, consequently, to disruption of normal mucosal integrity and architecture.

5 Molecular pathways underlying the proposed CA IX function are not known. As a cell surface molecule, CA IX may be involved in reception and/or processing of maturation signals impeding the proliferation. In addition, it may serve as an acceptor of instructions that direct differentiation, spatial assignment and allocation of cell lineages. Taking into account phenotypic similarities with additional 10 transgenic models, list of possible candidates acting in the CA IX-related putative signal transduction pathway may involve mesenchymal transcription factor Fkh6 [Kaestner et al. (1997)], Shh protein expressed in the epithelium of glandular stomach [Ramalho-Samos et al. (2000)], pS2 trefoil protein [Lefebvre et al. (1996)], NF- κ B2 transcription factor [Ishikawa et al. (1997)], and/or modulator of cadherin 15 function IQGAP1 [Li et al. (2000)]. However, genetic modifications of these genes lead to phenotypic changes beyond that observed with CA IX, involving more distinct alterations in differentiation program and/or physiological defects, such as development of dysplasia, or systemic changes in electrolyte status. Therefore, it is possible that they act upstream of CA IX or occupy independent signaling traits.

20 In fact, CA IX possesses several features predisposing it to function in a signal transduction. The PG-like region located at the N-terminus of human CA IX homologue was shown to possess the cell adhesion capacity *in vitro* [Zavada et al. (2000)]. Via this region, CA IX located at the basolateral membranes may influence 25 transmission of adhesion signals between mucosal cells and/or between mucosal and mesenchymal cells. In support of this view, stomach mucosa of mice lacking CA IX shows disorganized distribution of critical adhesion-related molecules E-cadherin, α -catenin and β -catenin, although their levels are not markedly altered. Moreover, assuming from the homology with other carbonic anhydrases, large enzyme core of CA IX forms wide and deep pocket that may potentially serve as a receptor site. This 30 idea is quite plausible given the capability of CA domain present in RPTP β and γ to bind contactin, a neural cell-specific regulator of adhesion and differentiation [Peles et al. (1995)].

Functional involvement of the carbonic anhydrase activity of mouse CA IX in stomach mucosa is unclear, first due to lack of precise knowledge concerning

its efficiency in catalyzing reversible conversion between carbon dioxide and carbonic acid and second because of absence of any systemic acid-base and gastrin imbalance in *Car9*^{-/-} mice. The latter may be also related to the presence of other CA isoenzymes whose activity may compensate for deficiency of CA IX. A highly active cytosolic CA II is present in surface epithelial cells where it produces bicarbonate and in parietal cells where it provides protons for secretion of gastric acid [Parkkila et al. (2000)]. Another isoenzyme, salivary CA VI, is swallowed into the stomach in order to buffer mucosal surface by removal of excessive acid in the form of carbon dioxide [*Id.*]. In addition, CA IV is expressed in the endothelial cells of the submucosal capillaries and mitochondrial CA V in parietal cells and G cells [Fleming et al (1995), Saarnio et al, (1999)]. However, significance of individual isoenzymes and their interplay in gastric morphogenesis and physiology is largely unknown also because the corresponding animal models are not available. The only exception is heritable CA II deficiency induced in mouse by chemical mutagenesis. Those mutant mice suffer from renal acidification, growth retardation and calcification of blood vessels, but no gastric phenotype has been reported [Lewis et al. (1998)].

Thus, *Car9*^{-/-} mice represent the first animal model of carbonic anhydrase deficiency constructed by the gene targeting. Moreover, phenotypic consequences of the targeted disruption of *Car9* gene demonstrate important and nonredundant role of CA IX in control of cell proliferation/differentiation and protection of integrity of the stomach mucosa. CA IX is clearly required for the normal gastric morphogenesis and coordination of the dynamic homeostasis within the gastric epithelium. These conclusions are in accord with the high level of CA IX in normal human stomach mucosa and its diminished expression observed in gastric tumor cell lines and tumors *in vivo* [Pastorekova et al. (1997)].

In summary, the analysis of CA IX null-mutation in mice revealed the biological importance of this protein and provided a useful model for clarifying its role in the morphogenesis of stomach mucosa. As can be seen in Example 2, the CA IX-deficient mice were also integral to the aspects of the invention herein concerning a new series of monoclonal antibodies.

EXAMPLE 2

CA IX-Specific Monoclonal Antibodies Generated from CA IX – Deficient Mice

MATERIALS AND METHODS

Cell culture

5 Hybridoma cell lines were grown in DMEM medium supplemented with 10% FCS (BioWhittaker, Verviers, Belgium), 2 mM glutamine and 40 µg/ml gentamicin (Lek, Slovenia) at 37°C in 5% CO₂ in air. The same cultivation conditions were applied to following cell lines that were used either as a source of CA IX antigen or as negative controls: mouse NIH 3T3 fibroblasts permanently transfected
10 with the full-length human CA9 cDNA (NIH 3T3-fICA IX) and corresponding mock transfected NIH 3T3-neo controls [Pastorek et al. (1994)], MDCK cells transfected with the full-length CA9 cDNA (MDCK-fICA IX) and corresponding MDCK-neo controls, human HT 29 colon carcinoma cells as well as human HeLa cervical carcinoma cells naturally expressing CA IX, and C33a cervical carcinoma cells
15 negative for CA IX.

For the immunization purposes, the cells grown for 24-48 h were washed twice in PBS, scraped, collected by centrifugation and re-suspended in appropriate volume of PBS. For the final booster, NIH 3T3-fICA IX cells were extracted with OCG extraction buffer composed of 0.5M NaCl, 0.5% octyl-beta-D-glucopyranoside (Chemical Institute SAV, Bratislava, Slovakia), 0.1mM PMSF for 30
20 min at 4°C, scraped, centrifuged for 5 min at 13 000 rpm and dialyzed against PBS for 48 h at 4°C.

Cloning and preparation of recombinant GST-CA IX proteins

25 The cDNA fragments encoding PG and CA extracellular domains of CA IX (see Figure 5) were either individually or together amplified by specific primers using a full-length CA9 cDNA as a template. The fragment coding for PG domain (aa 52-125) (SEQ ID NO: 98) was obtained with PG3 (sense) 5'-TAG AAT TCG GCT CTT CTG GGG AAG AT-3' (SEQ ID NO: 99) and PG4 (antisense) 5'- ATA CTC
30 GAG GGG TTC TTG AGG ATC TCC-3' (SEQ ID NO: 100) primers, and the fragment coding for CA domain (aa 121-397) (SEQ ID NO: 101) was obtained with CA5 (sense) 5'-TAG AAT TCG ATC CTC AAG AAC CCC AG -3' (SEQ ID NO: 102) and CA6 (antisense) 5'- AAT CTC GAG ACT GCT GTC CAC TCC AGC -3' (SEQ ID

NO: 103) primers. The combination of primers PG3 and CA6 was employed to produce cDNA fragment encoding PG+CA domains (aa 52-397) (SEQ ID NO: 104).

The resulting PCR products were cloned into pGEX 4T-1 bacterial plasmid via *Eco*RI and *Xba*I restriction sites inserted in the primer sequences.

5 Fusion proteins GST-PG, GST-CA, GST-PG+CA were expressed in *E. coli* strain DH5 α using the standard procedure [Gibadulinova et al. (1999)]. The full-length fusion GST-fICA IX protein generated earlier was produced in parallel. The proteins were purified by affinity chromatography using Glutathion-S Sepharose (Amersham Pharmacia) and eluted with 10 mM GSH (reduced glutathion). Obtained proteins 10) were utilized either as antigens for MAb testing or as immunogen (GST-CA) for immunization.

Immunization

For immunization, CA IX-deficient mice generated and characterized 15 by Ortova Gut et al. (2002) were used at the age of eight to ten weeks. The mice were injected intraperitoneally (i.p.) with 5×10^6 NIH 3T3-fICA IX cells in 0.5 ml PBS. Three weeks later, the mice received either the same i.p. injection of NIH 3T3-fICA 20 IX cells or i.p. injection of 5×10^6 HT-29 cells in 0.5 ml PBS. After another three weeks, mice were boosted alternatively as follows: (i) i.p. with 100 μ g of GST-CA protein bound to Glutathion-S Sepharose in 0.5 ml PBS, (ii) intravenously (i.v.) with 100 μ g of eluted GST-CA protein in 200 μ l PBS, (iii) i.p. with 5×10^6 NIH 3T3-fICA IX cells in 0.5 ml PBS, (iv) i.v. with 200 μ l OCG extract of NIH 3T3-CA IX cells. Splenocytes were harvested three days later and fused with the Sp2/0 myeloma 25 cells.

Production of Mabs

The fusion of splenocytes from immunized mice with Sp2/0 cells was carried out according to Lane et al. (1986). Hybridomas were selected in DMEM-HAT medium. The supernatants were screened for the specific reactivity towards CA 30 IX by ELISA as described below. Positive hybridoma cultures were cloned by limiting dilution using Terasaki microplates. Clonal hybridoma cells lines were expanded, subjected to freezing-refreezing and repeatedly tested for reactivity to CA IX. Large quantities of antibodies were purified from hybridoma culture medium

using affinity chromatography on Protein A Sepharose Cl-4B (Amersham Biosciences AB, Upsala, Sweden) as described by Ey et al. (1978).

ELISA screening

5 Screening of positive hybridomas was performed by a sandwich ELISA. Microplate wells were coated overnight at 37°C with RIPA extract (specified below) of NIH 3T3-fICA IX cells, diluted 1:10 in PBS, and in parallel with analogous extract of NIH 3T3-neo cells as a negative control. Then the coated wells were incubated with undiluted culture media from individual hybridomas. Peroxidase-
10 labeled pig anti-mouse IgG (Sevapharma, Praha, Czech Republic) was used as detector. M75 MAb was employed as positive control.

For the differential ELISA screening, the wells were coated with the following antigens: 10 ng/well of GST-fICA IX, 10 ng/well of GST-CA IX, RIPA extract of HeLa cells diluted 1:10 in PBS, RIPA extract of HT-29 cells diluted 1:10 in
15 PBS, and then assayed as above.

Determination of isotypes

MAb isotypes were determined by ELISA using affinity purified rabbit anti-mouse IgG1, IgG2a, IgG2b, IgG3, IgM and IgA antibodies (Mouse Monoclonal Antibody Isotyping Reagents, Sigma, St. Louis, USA) according to instructions of the manufacturer.

Immunofluorescence

Cells grown on glass coverslips were fixed in ice-cold methanol at –20
25 °C for 5 min. Non-specific binding was blocked by incubation with PBS containing 1% BSA for 30 min at 37°C. Then, the cells were sequentially incubated with primary antibodies diluted in PBS with 0.5 % BSA (PBS-BSA) for 1 h at 37°C, washed three times with PBS-BSA for 10 min, incubated with anti-mouse FITC-conjugated horse antibody (Vector Laboratories, Burlingame, USA.) diluted 1:300 in
30 PBS-BSA for 1 h at 37°C and washed as before. Finally, the cells were mounted onto slides in mounting medium with Citifluor (Agar), analyzed by a Nikon E400 epifluorescence microscope equipped with objectives PlanFluor 20x, 40x and photographed. Images were acquired by Nikon Coolpix 990.

Immunoblotting

Cells grown in confluent monolayer were rinsed twice with cold PBS and solubilized in ice-cold RIPA buffer (1% Triton X-100, 1% deoxycholate, 0.15 M NaCl, pH 7.2) containing COMPLETE cocktail of protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany) for 30 min on ice. The extracts were collected, cleared by centrifugation at 15 000 rpm for 10 min at 4°C and stored at -80°C. Protein concentration in extracts was quantified by BCA protein assay reagent (Pierce, Rockford, Illinois, USA).

10 Total cellular extracts (50 µg of proteins/lane) were resolved in 10 % SDS-PAGE gel. The proteins were then transferred onto PVDF membrane (Amersham Pharmacia Biotech, Little Chalfont Buckinghamshire, England). After blocking in 5% nonfat dry milk with 0.2% Nonidet P40 in PBS, the membrane was probed with MAbs (undiluted hybridoma medium), washed and treated with secondary anti-mouse HRP-conjugated swine antibody diluted 1:5000 (SEVAPHARMA, Prague, Czech Republic). The protein bands were visualized by enhanced chemiluminescence using ECL kit (Amersham Pharmacia Biotech).

Cell biotinylation

20 Cells in monolayer of 70%-80% confluence grown in a 10 cm dish were washed with ice-cold buffer A (20 mM sodium hydrogen carbonate, 0.15 M NaCl, pH 8.0). Immediately before use, 1 mg of NHS-LC-Biotin (Pierce) was dissolved in 50 µl DMSO, mixed with 4 ml buffer A, added to cells and incubated for 60 minutes at 4°C. After the biotinylation, the cells were washed 5 times with buffer A and extracted as 25 described above.

Immunoprecipitation.

Tested MAb in a volume of 1 ml culture medium was bound to 25 µl 50% suspension of protein-A Sepharose (Pharmacia, Uppsala, Sweden) in RIPA buffer for 2 hrs at RT. Biotinylated cell extract (200 µl) was pre-cleared with 20 µl of 30 50% suspension of protein-A Sepharose and then added to bound MAb. Immunocomplexes collected on protein-A Sepharose were washed according to Williams et al. (1985), boiled 5 minutes in Laemmli loading buffer and separated by SDS-PAGE gel (10%) electrophoresis. Afterwards, the proteins were transferred

onto PVDF membrane and revealed with peroxidase-conjugated streptavidin (1:1000, Pierce) followed by ECL.

Biotinylation of MAbs

5 Purified MAbs were labeled with NHS-LC-Biotin (Pierce) according to the instructions of the manufacturer. Briefly, 2 mg purified IgG dissolved in PBS, pH 8.0 were incubated with 100 µg NHS-LC-Biotin for 2 h on ice. Free biotin was removed using microconcentrator (PALL Gelman Lab., Wien, Austria) or gel filtration.

10 *Competitive antibody-binding ELISA*

Extract of NIH 3T3-fICA IX cells was adsorbed on microplate wells at a concentration corresponding to 50% of maximal binding of labeled MAbs. Coated plates were washed and saturated with 10% FCS in PBS. Serial tenfold dilutions of purified MAbs in 30 µl and a constant amount of biotinylated MAb in 30 µl were added and incubated overnight at 4°C. The plates were washed and peroxidase-labeled streptavidin (Pierce) was used as a detector.

RESULTS

20 *Generation and basic characterization of monoclonal antibodies to CA IX*

To avoid an epitope preference caused by the significant difference in the N-terminal sequences of the mouse and human CA IX proteins and produce monoclonal antibodies directed also to other protein regions (Fig.5), we prepared the new CA IX-specific monoclonal antibodies with the CA IX-deficient mice constructed 25 in Example 1 [Ortova Gut (2002)]. It was hypothesized that those mice that do not express their own CA IX protein would recognize the entire human CA IX molecule as non-self and direct their humoral response to different portions of the protein.

We examined five immunization protocols based on different combinations of human cells that naturally express high level of CA IX (HT 29, 30 mouse cells with ectopic overexpression of CA IX (NIH 3T3-fICA IX) and finally, recombinant protein composed of glutathion-S transferase fused to CA domain of CA IX (GST-CA). Three protocols led to successful production of CA IX-specific MAbs (Table 3).

TABLE 3

Overview of immunization protocols, fusions
and yields of CA IX-specific hybridomas.

Fusion No.	Immunization Scheme ^a	Total No. Of clones	Non-Specific ^b	MN-specific hybridomas		
				Initial No. ^c	Subclone ^d	Stable
I	1.NIH 3T3-fICA IX i.p.	50	0	1	0	0
	2.NIH 3T3-fICA IX i.p.					
	3.NIH 3T3-fICA IX i.p.					
II, III	1.NIH 3T3-fICA IX i.p.	1700	50	60	6	0
	2.NIH 3T3-fICA IX i.p.					
	3.HT-29 i.p.					
IV	1.NIH 3T3-fICA IX i.p.	800	40	5	5	4
	2.NIH 3T3-fICA IX i.p.					
	3.OCGexNIH-CA IX i.v.					
V, VI	1.NIH 3T3-fICA IX i.p.	1220	17	9	6	2
	2.NIH 3T3-fICA IX i.p.					
	3.GST-CA IX i.p.					
VII, VIII, IX, X	1.NIH 3T3-fICA IX i.p.	4400	16	83	12	5
	2.HT-29 i.p.					
	3.GST-CA IX i.p.					
Altogether		8170	123	158	29	11

5 ^a Brief description of the immunization scheme including order of injections, type of immunogen and route of administration (i.p. – intraperitoneal, i.v. – intravenous)
 Immunogens:
 NIH 3T3-fICA IX – mouse NIH3T3 fibroblasts stably transfected with the wild type CA9 cDNA

OCGexNIH-CA IX – extract from NIH 3T3-fICA IX cells obtained using OCG detergent

HT-29 – human colorectal carcinoma cells naturally expressing MN/CA IX

GST-CA IX – recombinant bacterial CA domain of MN/CA IX fused to GST

5 ^b Non-specific hybridomas producing the MAbs against non-CA IX mouse or human cellular proteins of unknown identity

^c MN-specific hybridomas that were successfully subcloned

^d Hybridomas with optimum viability and stable productivity of MN-specific Mabs

Altogether, we performed 10 fusions and screened 8170 hybridomas. Initially selected 158 hybridomas producing CA-IX reactive antibodies in ELISA screening were reduced to 29 hybridomas after subcloning and finally to 11 viable and stable clones after freezing-refreezing. Seven of these antibodies were of IgG2a isotype, two antibodies were IgG1 and two were of IgM isotype (Table 4).

15

TABLE 4

Summary of the isotypes and reactivity of the new CA IX-specific monoclonal antibodies in comparison with M75

Antigen		N, HT, G	HT, HL, M	HT, HL, M?	M, HT
Mab	Isotype	ELISA	Blotting	Precipitation	Fluorescence
M75	IgG2b	+	+	+	+
IV/6	IgM	+	+	nd	+
IV/18	IgG2a	+	+	+	+
IV/14	IgM	+	-	nd	nd
IV/11	IgG1	+	-	-	+
V/10	IgG2a	+	-	+	+
V/12	IgG2a	+	-	+	+
VII/13	IgG1	+	-	-	-
VII/20	IgG2a	+	-	+	+
VII/28	IgG2a	+	-	+	+
VII/32	IgG2a	+	-	+	+
VII/38	IgG2a	+	-	+	+

20

Reactivity of the new Mabs including M75 for comparison was examined using the following antigens:

N - extract from transfected mouse NIH 3T3-fICA IX cells expressing human CA IX protein in parallel with corresponding NIH 3T3-neo as negative control
 HT - extract from human HT-29 cells naturally expressing high level of CA IX
 HL - extract from human HeLa cells naturally expressing CA IX in dense culture
 G - recombinant GST-fICA IX fusion protein
 M - transfected MDCK-fICA IX cells compared to MDCK-neo controls

The antibodies were first tested in ELISA against the full-length CA IX antigen expressed in mouse and human cell lines. All antibodies bound to extracts of NIH 3T3-CA IX cells and HT-29 cells, but not to control NIH 3T3-neo cells and C33a 15 CA IX-negative human cervical carcinoma cells. They also recognized GST-CA IX protein, but not the GST only, supporting their specificity for CA IX (Table 5).

TABLE 5

Target domains of the CA IX-specific monoclonal antibodies based 20 on the reactivity to truncated forms of CA IX

Antigen	PGCA (G)	PG (G)	ΔCA (M)	ΔCA (M)	ΔPG (M)	Target domain
Mab	ELISA		Precipitation	Fluorescence		Target domain
M75	+	+	Nd	+	-	PG
IV/18	+	+	Nd	+	-	PG
V/10	+	-	-	-	+	CA
V/12	+	-	-	-	+	CA
VII/20	+	-	-	-	+	CA
VII/28	+	-	-	-	+	CA
VII/32	+	-	-	-	+	CA
VII/38	+	-	-	-	+	CA

Domain-specificity of the monoclonal antibodies was determined with the following antigens:

PGCA (G) – N-terminal portion of CA IX molecule containing both PG and CA domains expressed as GST-PGCA fusion protein

5 PG (G) – PG domain expressed as GST-PG fusion protein

CA (G) – CA domain expressed as GST-CA fusion protein

ΔCA (M) – truncated variant of CA IX protein expressed in MDCK cells from transfected cDNA with deletion in a region encoding CA domain

ΔPG (M) – truncated variant of CA IX protein expressed in MDCK cells from

10 transfected cDNA with deletion in a region encoding PG domain

Indirect immunofluorescence demonstrated that all the examined antibodies bound to an antigen localized at the cell surface of transfected polarized epithelial cells MDCK as well as of HT-29 human colon carcinoma cells that naturally express CA IX. [The cells were grown to confluence, fixed by methanol and incubated with representative monoclonal antibodies followed by FITC-conjugated anti-mouse antibodies. All the antibodies revealed plasma membrane CA IX-specific staining in both cell lines used. Cells with omitted primary antibody and treated only by the secondary antibody served as a negative control.] Distribution of the staining signal was identical to distribution of CA IX visualized by M75.

Noteworthy, only two of the new Mabs, namely IV/6 and IV/18, and the old Mab M75 reacted in immunoblotting with naturally expressed CA IX derived from HT-29 and HeLa cells, respectively, and with CA IX ectopically expressed in MDCK cells. The antibodies of IgG2 isotype were all able to immunoprecipitate CA IX from the extract of both HT-29 and HeLa human cells labeled by biotinylation. [The cells were grown to confluence, labeled by biotin, and extracted with RIPA buffer. CA IX was immunoprecipitated from the cell extracts as described in Materials and Methods, separated by SDS-PAGE, and blotted. Blots were incubated with peroxidase-conjugated streptavidin and developed by ECL.] They also immunoprecipitated the CA IX protein ectopically expressed in MDCK cells.

Determination of target domains by antibody binding to recombinant variants of CA IX

The initial tests proved the reactivity of the new monoclonal antibodies towards human CA IX. To reveal the target protein domains, we selected the antibodies with the best properties and performed additional series of analyses using recombinant variants of CA IX protein produced in bacteria and variants of CA IX protein expressed from truncated cDNAs transfected to NIH 3T3 and MDCK cells, respectively. [Immunofluorescence detection of CA IX and its deletion variants Δ PG and Δ CA expressed in transfected MDCK cells was used. The cells were grown to confluence, fixed by methanol and incubated with new monoclonal antibodies followed by FITC-conjugated anti-mouse antibodies. The antibodies revealed plasma membrane CA IX-specific staining only in the cells expressing CA IX variant containing their target domain.] The results summarized in Table 5 indicate that one of the newly produced antibodies, namely IV/18, is directed to PG domain, similar to M75.

The other six antibodies (i.e. V/10, V/12, VII/20, VII/28, VII/32 and VII/38) target the CA domain, as also confirmed by their capacity to immunoprecipitate the full-length CA IX protein, but not its deletion variant lacking a large portion of CA domain. [CA IX was immunoprecipitated from extracts of MDCK cells expressing the full length CA IX protein and its Δ CA variant, respectively. The cells were grown to confluence, labeled by biotin, and extracted with RIPA buffer. CA IX was immunoprecipitated from the cell extracts as described in Materials and Methods, separated by SDS-PAGE, and blotted. Blots were incubated with peroxidase-conjugated streptavidin and developed by ECL.] In fact, these reagents represent a proof-of-concept that CA IX-deficient mice are suitable for generation of monoclonal antibodies that recognize the regions outside the immunodominant PG domain.

Mapping of antigenic sites by competitive binding

In order to determine relative positions of the antigenic sites, recognized by the monoclonal antibodies within their target domains, we performed a competitive-binding assay. Biotin-labeled purified antibodies were allowed to bind in the concurrent presence of increasing amount of the non-labeled competitive antibodies. Extent of binding of the labeled antibody in the presence of the non-labeled competitor was expressed as per cent of the binding in the absence of the

competitor. Examination of all different pairs of the MAbs including the homologous ones and their classification according to the extent of competition allowed for elaboration of a basic map indicating principal relationships between the antibodies, their clustering and relationships between the clusters (Fig. 6). The map shows that

5 the M75 and IV/18 antibodies recognize overlapping antigenic sites in a separate region, consistent with their proven specificity for the PG domain of CA IX protein. The antibodies targeting CA domain form three clusters. Two pairs of the MAbs, namely V/12 versus VII/20 and V/10 versus VII/32, respectively, showed significant mutual competitions indicating their overlapping epitopes within two separable
10 antigenic sites. However, strong one-sided competition between one member of each of two antigenic site-related clusters, i.e. V/10 (label) and V/12 (competitor), indicated that the two sites partially extend over each other via the epitopes corresponding to V/10 and V/12 MAbs. MAb VII/38 belongs to a distinct site within a CA domain of CA IX.

15 The map of antigenic sites provides important information that can be further utilized to propose non-competing pairs of antibodies that would be suitable for sensitive immunodetection of CA IX antigen using capture-detection approaches.

DISCUSSION

20 Due to a strong association with cancer tissues and proposed functional involvement in tumor progression, carbonic anhydrase IX has become an interesting object for both basic and clinical research, as evidenced by the growing number of CA IX-related papers [summarized in Pastorek and Pastorekova (2003)]. Most of these papers were based on the utilization of a CA IX-specific monoclonal
25 antibody M75 [Pastorekova et al. (1992)]. The M75 MAb has facilitated acquisition of many important data, but certain aspects of CA IX could not be touched without additional detection tools, including the monoclonal antibodies directed to M75-independent antigenic sites.

30 We describe herein the generation of such antibodies using a mice deficient for CA IX as donors of immune splenocytes for fusion and hybridoma production. This strategy has been chosen in order to eliminate the epitope preference possibly related to a high regional homology between the mouse and human proteins particularly in the sequences outside the M75 target domain [Ortova Gut et al. (2002)]. Our assumption that the mice lacking CA IX would recognise also

these regions as a non-self has been approved by the production of six monoclonal antibodies directed to CA domain of CA IX. Interestingly, the immunization protocol that led to successful generation of the anti-CA antibodies involved the injection of a recombinant CA IX variant containing only the CA domain as a key third dose 5 component. Instead, injection with the full-length CA IX antigen extracted from the transfected NIH 3T3 cells resulted in production of antibodies out of which MAb IV/18 competes with M75, and two other antibodies (IV/6 and IV/14) also appear to bind to the PG region, similar to M75. This experience suggests that even in the absence of endogenous mouse CA IX protein that would normally compromise the immune 10 recognition of highly homologous regions of human CA IX (including the CA domain) by the immunized mice, the M75 MAb-binding PG domain behaves as strongly immunodominant. The reason for the apparent immunodominance could reside in both N-terminal exposition and the amino acid sequence of the PG domain that is highly acidic and composed of four perfect and two imperfect hexameric repeats 15 [Opavsky et al. (1996)]. These repetitions potentially offer multiple binding sites (and may influence also relative affinity of MAbs) and the very N-terminal position of this region may allow for its spatial protrusion from the presumably globular CA domain in the extracellular portion of CA IX [Pastorek et al. (1994)].

These attributes of PG domain may also explain the finding that anti- 20 PG MAbs recognize denatured CA IX protein in immunoblotting, while anti-CA MAbs fail to do so. It is possible to speculate, that relatively short PG domain with repetitive motifs constitutes a linear antigenic region that does not suffer from denaturing, while a presumably globular structure of the large CA domain carrying putative conformational epitopes can be completely disrupted. This idea is 25 consistent with the finding that both anti-PG and anti-CA are able to immunoprecipitate native CA IX antigen extracted with mild detergents as well as the antigen on the surface of transfected MDCK cells that were fixed by methanol. Such antigen apparently possesses intact epitopes irrespective of whether they are linear or conformational.

30 As delineated by the competitive immunoassay performed with the repertoire of the new MAbs, CA domain contains three distinct antigenic sites, two of which partially overlap. While it is possible to propose relative mutual positions of these sites, it is difficult to predict their localization on CA domain. Based on the extent of the deletion that was associated with the loss of binding of these MAbs we

21 Feb 2003
2003217606

can at least conclude that the CA antigenic region spans the amino acids 166-397 (SEQ ID NO: 105) of CA IX. However, it cannot be excluded, that the deletion lead to disconnection of the antigenic site(s) partly located also on the amino acids 135-166 (SEQ ID NO: 106) that remained preserved in the ΔCA deletion variant.

5 Characteristics of the new CA IX-specific monoclonal antibodies allow us to foresee their clinical applications. In the basic research, these antibodies represent important specific reagents for study of functional contribution of PG and CA domains, respectively. Each of these two extracellular domains of CA IX has been associated with different aspects of tumor progression: enzymatically active
10 CA domain is thought to contribute to acidification of tumor microenvironment and PG domain (absent from other CA isoforms) is believed to determine its participation in adhesion-related processes. Using the MAbs generated as disclosed herein in CA IX-deficient mice, it will be possible to differentiate between biological effects exerted by these domains expressed separately in the form of deletion variants or mutants of
15 CA IX.

Nevertheless, the main potential of the new MAbs is in their clinical applications. Many clinical studies of different tumor tissues have recently demonstrated predictive and prognostic value of CA IX, especially related to its tight connection with tumor hypoxia [Loncaster et al. (2001); Chia et al. (2001);
20 Giatromanolaki et al. (2001); Koukourakis et al. (2001); Hui et al. (2002)]. In this respect, it is obvious that the new MAbs can be utilized for detection and/or targeting of CA IX-expressing cancer cells in different settings (as reviewed in von Mehren et al, 2003). Future experiments designed to examine the biological activity of these MAbs will also show, whether they could be of any significance for antibody-
25 mediated anti-cancer therapy, analogously to well-known MAbs directed to HER-2/neu/c-erbB2 and EGFR oncoproteins. Also importantly, the availability of non-competing antibodies specific for distinct antigenic sites on two separate extracellular domains offers an opportunity to elaborate a sensitive assay that could be particularly important for detection of CA IX in body fluids of cancer patients. As
30 disclosed herein and detailed in Example 3 below the extracellular portion of CA IX is shed from tumor cell surfaces and can be detected in body fluids, particularly blood and urine of cancer carriers by immunoprecipitation. Development of a fast and reliable micro-assay based on combination of the antibodies described in this work could potentially allow for non-invasive monitoring of cancer patients.

In summary, the anti-human CA IX monoclonal antibodies generated using CA IX-deficient mice and characterized in this paper, represent important tools for improvement of our knowledge on structure-function relationship in CA IX molecule, for better understanding of CA IX role in cancer development, for elucidating its clinical implications and for clinically relevant detection of CA IX in biological materials.

EXAMPLES 3 – 10

The following materials and methods were used in the Examples 3-10 below.

MATERIALS AND METHODS

15 Cell and tumor cultures and media

The cell line HT29 (DSMZ ACC299), derived from colorectal carcinoma, and A498 (ATCC No. HTB-44) from renal clear cell carcinoma, were grown in D-MEM supplied with 10% FCS (Gibco), unless otherwise stated. In Example 8, the HT29 cells were cultivated in Dulbecco's MEM medium (BioWhittaker, Verviers, Belgium) supplemented with 10% FCS (BioWhittaker) and 160g/ml gentamicin (Lek, Slovenia). The A549 lung carcinoma cells were grown in DMEM (Sigma) supplemented with 10% FCS (Globepharm), L-glutamine (2 μ M), penicillin (50 IU/ml), and streptomycin sulphate (50 μ g/ml). Cell cultures were maintained in a humidified atmosphere with 5% CO₂ at 37°C. For short-term cultures of tumors, fresh tumor excisions were cut in 1 mm pieces, rinsed with PBS, suspended in D-MEM with 10% FCS (about 50 -100 mg of fresh weight of tumor fragments in 5 ml of the medium) and incubated in 5 cm Petri dishes at 37°C in a 5% CO₂ incubator. Cell lysis buffer: PBS with 1% Igepal CA-630 (Sigma), 0.25 % deoxicholate and proteinase inhibitors [Zavada et al. (2000)].

30

Effect of reoxygenation of hypoxically induced CA IX protein tissue culture

Studies of gene expression were performed on A549 lung carcinoma cells approaching confluence in normal growth medium. Parallel incubations were performed on aliquots of cells in normoxia (humidified air with 5% CO₂) and hypoxia.

Hypoxic conditions were generated in a Napco 7001 incubator (Precision Scientific) with 0.1% O₂, 5% CO₂, and balance N₂. Reoxygenation experiments were performed by exposure of cells to hypoxia for 16 h followed by a return to normoxia for the indicated time.

5

Patient serum and urine

All patients routinely underwent ultrasound and CT before surgery to obtain information for the standard staging protocol. Serum and urine from these patients were obtained before surgery and 5 days after it. In some patients a sample of tumour tissue after nephrectomy was used for short-term RCC cultures. In all these patients the diagnosis was confirmed by the histological finding of RCC. 18 patients acted as controls, these had been admitted to the hospital for other urological conditions than RCC (infectious disease, urinary stones, other urological tumours, etc.). The study was approved by the Departmental Ethics Committee.

15 Sera of healthy blood donors were kindly provided by Dr. Eva Hamšíková, Institute of Haematology and Blood Transfusion, Prague.

Blood plasma from nude mice with xenograft of HT29 cells

20 Male nude mice CD-1 nu/nu (Charles River, Germany) were injected subcutaneously in the flank with 5x10⁵ HT29 cells at 6-8 weeks of age. Approximately 2-3 weeks after injection, heparinized plasma samples were prepared; blood was drawn from either the eye or by heart puncture prior to mouse dissection and xenograft removal.

25

Immunological reagents and methods

Monoclonal antibodies: M75 specific for PG region of CA IX has been produced by Pastorekova et al. (1992); V-10 specific for CA domain generated as described in Example 2. The isotype of MAb M75 is IgG 2b and of V-10 is IgG 2a.

30 The IgG was purified from hybridoma TC fluid by affinity chromatography as before protein A Sepharose CL-4B column (Amersham Pharmacia Biotech, Uppsala, Sweden). Purity of the M75 was checked by SDS-PAGE [(Zavada et al. (2000)].

M75 was labeled by ¹²⁵I using chloramines T method as described by Hunter (1978). Free ¹²⁵I was removed by the size exclusion chromatography on

Sephadex G50 column (Amersham Pharmacia Biotech). Specific activity of the radiolabeled antibody was determined after the precipitation of the antibody together with BSA carrier protein by trichloroacetic acid.

To determine the immunoreactive fraction, 10^4 cpm of ^{125}I -M75 in 100 µl of PBS containing 3% BSA and 0.05% Tween-20 were added to wells of 96-well plates coated with increasing amounts of antigen extracted from HT29 cells and incubated for 2 hours at 37°C. The bound radioactivity was measured after washings and lysis with 2M NaOH, using the Clinigamma counter from Pharmacia LKB (Uppsala, Sweden). Nonspecific binding was determined in the presence of 100-fold molar excess of unlabeled M75 and subtracted from the total binding. The results were analyzed as described by Lindmo et al. (1984).

For the concentration of immune complexes formed by the MAbs with CA IX antigen from TC media or cell extracts Protein A-Sepharose (Sigma # P-9424) was used; the MAb-CA IX complexes from human sera or urine were adsorbed to anti-mouse IgG-Agarose (Sigma #A-6531). Alternatively, we used Magnetic beads anti-mouse IgG (Immunotech-Coulter # 1181). The immunoperoxidase conjugate M75-Px was prepared using the Peroxidase labeling kit (Roche Diagnostics #1829696, GmBH, Mannheim, Germany.)

Immunoprecipitation of s-CA IX from mouse blood plasma and cell culture medium was performed as follows: A confluent monolayer of HT29 cells was washed with PBS and fresh medium was applied (15ml per 10 cm dish). After 18 h incubation, the medium was harvested and filtered through a 0.22 µm-pore-size filter. Samples of cell culture medium and heparinized plasma were preincubated with protein A-Sepharose CL-4B (Pharmacia Biotech) to remove potentially competing calf and mouse IgG prior to immunoprecipitation with M75. Immunoprecipitation was performed from 1ml of heparinized plasma (diluted 1:2 with PBS) and from 3 ml of cell culture media by incubation with 50 µl of suspension of protein A-Sepharose with bound M75 Mab for 2 h at room temperature with gentle rotation.

Immunoprecipitation of s-CA IX from human sera and urine was carried out as follows: to 0.75 ml of serum or 10 ml of urine (both clarified by centrifugation) was added 2 µg of M75 IgG for 60 min. at room temperature. Following this, each sample was supplied with 50 µl of 50% pre-washed anti-mouse IgG Agarose beads and the suspension was agitated on a rotator for 4 hours or overnight at + 4 °C. Then the beads with bound mouse IgG and immune complexes were centrifuged

(1200 rpm/2 min.), the pellet was resuspended in 1 ml PBS-T (phosphate buffered saline with 0.05% Tween 20, Sigma) centrifuged as above and the beads were heated in 60 µl of Laemmli sample buffer at 100 ° C for 5 min. blood sera. The precipitates, when analysed by Western blots developed with M75-peroxidase conjugate and ECL, in addition to s-CA IX p50/54 were showing strong non-specific bands of 92 and 125 kDa. These cross-reactive proteins were present also in control human sera.

We were able to eliminate the non-specific bands by using two different monoclonal antibodies. For immunoprecipitation MAb V-10 specific for the CA 10 domain was employed, while M75-peroxidase conjugate, specific for PG domain, was used for developing the blots. Only the lanes loaded with precipitate obtained with M75 show, in addition to CA IX bands at 50 and 54 kD, also the cross-reaction with human serum proteins of 92 and 128 kDa. The lanes employing new non-M75 MAbs for immunoprecipitation showed no cross-reaction visible on the scan or the 15 film.

A second problem encountered with CA IX immunoprecipitated from human sera was that Western blots looked dirty or obscured by smears and clouds. We suspected that this was due to a partial denaturation of M75-IgG during 20 conjugation with peroxidase, using HPLC we found that M75 IgG which had been conjugated with activated peroxidase under conditions recommended by the manufacturer formed oligomers several times larger than corresponding to 5 Px molecules for 1 IgG. Therefore, we reduced the Px:IgG ratio 3x and obtained the conjugate yielding a clear background on Western blots with immunoprecipitate from human sera.

25

Immunohistochemistry

CA IX immunostaining using monoclonal antibody M75 in Example 9 was as described [for example in Wykoff et al. (2000)]. Slides were viewed by two 30 observers. The CA IX score was derived from the product of (i) the percentage of tumor cells staining for CA IX and (ii) the average intensity of that staining on a scale of 1 (least intense) to 3.

ELISA

The "sandwich" was composed of these layers in MaxiSorp strips or plates (NUNC, Denmark): (1) immobilized phase: MAb V-10 IgG, 5 μ g/ml in 50 mM carbonate buffer pH 9.6, was adsorbed 3 h at room temperature; (2) test antigen 5 dilutions in PBS with 1% FCS were adsorbed overnight at +4 °C; (3) M75-Px conjugate 1:5000 in PBS with 1% FCS, was allowed to bind for 2 hr. at room temperature; (4) orthophenylenediamine (OPD, Sigma) 1 mg/ml in 100 mM phosphate/citrate buffer pH 5.0 + 1 μ l/ml of 30% H₂O₂ (Sigma), was allowed to react 30 min. in the dark at room temperature. After each step the strips or plates were 0 washed 4x with PBS-T.

Immunoblots

SDS-PAGE and Western blotting were as described before [Zavada et al. (2000)]. Whole cell protein extracts were prepared from tissue culture cells by 10 s homogenization in denaturing conditions [Wiesener et al. (1998)]. Aliquots were 15 separated by SDS-polyacrylamide gel electrophoresis and transferred to Immobilon-P membranes (Immobilon™-P, Millipore, Bedford, UK). CA IX was detected using the mouse monoclonal anti-human CA IX antibody M75 (1:50) as described [(Pastorekova et al. (1992)]. For Examples 3-7 and 10, HRP-conjugated goat-anti- 20 mouse immunoglobulin (DAKO) (1:2000) was applied for 1 h at room temperature (RT). ECL Plus (Amersham Pharmacia) was used for visualization. For Example 8, the cells (cell monolayer and sediment of tumor homogenates, respectively) were extracted by RIPA buffer (1% Triton X-100, 0.1% sodium deoxycholate, 1mM PMSF, 25 20 μ g/ml trypsin inhibitor, 1mM ethylenediaminetetraacetic acid in PBS) for 30 min at room temperature. The extracts were then centrifuged (15 min at 13,000 rpm) and concentration of proteins was determined by BCA assay (Pierce) according to the manufacturer's instruction. The extracts (aliquots containing 30g of proteins) were directly analyzed. Culture medium and plasma were first concentrated by 30 immunoprecipitation with M75 Mab as described above. Samples were separated by electrophoresis on a 10% SDS-PAGE gel, blotted onto the membrane as described above. The membrane was incubated with ¹²⁵I-labeled M75 Mab and then exposed to X-ray film.

EXAMPLE 3Cell-associated and soluble CA IX in cell cultures

Western blot analysis was performed to determine CA IX in culture media (soluble CA IX) or in cell extracts (cell-associated CA IX), as described above.

5 As previously described, various human tumor cell lines, when grown to a high density, produce CA IX seen on Western blots as a "twin" protein p54/58 [Pastorekova et al. (1992); Zavada et al., (1993)]. Present results are consistent with these reports: cell extracts from the colorectal carcinoma cell line HT29 show 54 and 10 58 kDa bands of CA IX on the Western blot. Media from these cell cultures also contain CA IX, but the soluble form is somewhat shorter, with 2 bands of 50 and 54 kDa. The total content of CA IX in cell extracts is about 10x higher than in the medium, as determined by ELISA (Fig. 10).

EXAMPLE 4CA IX in tumor extracts and in media of short-term cultures of RCC

15 The study included 50 patients (28 men and 22 women, mean age 63.2, range 36-79) with newly diagnosed RCC. Western blots of the extracts from RCC tumors resemble blots of tumor cell cultures. They also contain two bands of 54 and 58 kDa, and the proportion of CA IX per total protein is somewhat lower than 20 in HT29 cells (Fig. 10). All of the 6 RCC tumor extracts were strongly CA IX positive. Control kidneys and a non-RCC tumor, an angiomyoma, do not contain any CA IX.

Shedding of s-CA IX was examined in short-term cultures: fresh tumor excisions from the patients were cut in 1mm pieces and grown in short-term cultures in DMEM with 10% FCS, as described above. The medium from a suspension 25 culture of tumor fragments was harvested after 2 days and analysed by Western blotting and ELISA (Fig. 10). Again, both the concentration and M_r of s-CA IX were comparable (two bands of 50 and 54 kDa) with cultures of the tumor cell line HT29.

EXAMPLE 5Recovery of CA IX 50 and 58 kDa bands from dilutedHT29 cell extract or TC medium

The concentration of CA IX in blood serum and in urine of RCC patients is too low to be detected without previous concentration. Therefore, we first

21 Feb 2003
2003217606

tested how efficiently CA IX can be immunoprecipitated from cell extracts or TC media of HT29 cells.

Immunoprecipitation was performed as described above. The result was somewhat puzzling. Original HT29 cell extract or TC medium contained 2 bands of CA IX. However, after addition of M75 antibody followed by PA-Sepharose beads and a low speed centrifugation, no CA IX was detected in the supernatant and all of the CA IX antigen was present in the pellet. Surprisingly, it was seen only as a single band of 54 kDa, no matter whether it was from cell extract (cell-associated CA IX) or from the medium (soluble CA IX). The other band disappeared. When the pellets were mixed with corresponding supernatants, the lost bands appeared again in their original intensity. For the re-appearance of the lost band, it was sufficient to add FCS to a final concentration of 1-2%. This observation suggests that FCS (or various other proteins) is providing some sort of steric support for CA IX on Western blots. In this experiment, the p54 band did not disappear after adding the MAb and Protein A – Sepharose and centrifugation, most likely because on migration in PAGE it overlaps with denatured heavy chain of M75 IgG. Since this observation, we have added 1.5% FCS to Laemmli sample buffer for extracting of CA IX from the immunoprecipitates and for diluting the samples before gel electrophoresis and Western blotting. We conclude that the sensitive detection of CA IX antigens on Western blots requires the presence of other "contaminating" proteins which do not cross-react with CA IX.

EXAMPLE 6

CA IX in blood serum of RCC patients

As described in Examples 3-5, there were no problems with detection and quantitation of CA IX protein in extracts from cells or tumors and in culture media. The concentration of CA IX was sufficient for direct analysis by Western blotting or by ELISA. Control cell extracts or media showed no false positivity or non-specific bands.

The difficulties emerged when we started to test human blood sera. The concentration of CA IX was too low and the concentration of normal blood serum proteins was too high to allow direct gel separation. Therefore, we prepared immunoprecipitates from control and patients' sera using M75, followed by anti-mouse IgG agarose beads. The precipitates, when analysed by Western blots

developed with M75-peroxidase conjugate and ECL, in addition to the s-CA IX p50/54 bands showed strong non-specific bands of 92 and 125 kDa. These cross-reactive proteins were present also in control human sera.

Fortunately, we were able to eliminate the non-specific bands by using 5 two different monoclonal antibodies, as described above. For immunoprecipitation MAb V-10 specific for the CA domain was employed, while M75-peroxidase conjugate, specific for PG domain, was used for developing the blots.

We tested 30 samples of sera from RCC patients, 14 sera of patients 10 with tumors other than RCC, 6 sera of non-tumor patients suffering from various urological diseases and 42 sera of healthy blood donors. Sera evaluated as positive were found mainly in the RCC group. Out of total 30 RCC sera, 12 scored as "positive" (40%). The RCC group included 1 sarcomatous RCC, which was CA IX positive. Among 14 non-RCC tumor patients, 1 was positive (papillary carcinoma).

There does not seem to be a clear correlation between tumor size and 15 the presence or concentration of CA IX in the serum. All sera evaluated as "negative," including sera of healthy blood donors, did in fact show an extremely weak 50 kDa band of s-CA IX, which became well visible only after prolonged exposure of the blots.

For Western blot analysis of soluble CA IX protein in blood sera of 20 RCC patients and of control individuals, each lane was loaded with immunoprecipitate corresponding to the original 0.6 ml of the serum. Sera samples were from three healthy blood donors: a patient (100) who had stones in the urether; patients with non-RCC tumors: (39) papillary carcinoma from renal cells, (103) urothelial tumor of renal pelvis, (121) sarcomatoid renal carcinoma; all other 25 samples, RCC (the largest are No. 68, 2350 cm³; No. 36, 1466 cm³; No. 50, 725 cm³; and the smallest, No. 102, 9 cm³; No. 112, 14 cm³).

To obtain more support for presumed origin of blood s-CA IX from the tumors, we tested several paired sera from RCC patients before and after 30 nephrectomy. Indeed, in 3 cases the sera after operation contained much less of s-CA IX than corresponding pre-operation sera. One exception was patient No. 68, showing an increase of s-CA IX level – but this patient underwent only a palliative operation. Only a moderate decrease of s-CA IX was seen in the patient No. 104; in his case the post-operative sample was taken only 1 day after nephrectomy,

whereas in all other patients the post-operative samples were obtained 7 days after operation.

EXAMPLE 7

5

CA IX in urine of RCC patients

The RCC patients (see Example 6 above) excrete s-CA IX protein in urine. For obvious reasons, we could afford to concentrate the antigen from 10 ml of urine (or from larger volumes if needed), and load 1 lane on the gel with an aliquot corresponding to 8 ml. For the Western blot analysis, the non-tumor patients Nos.

10

45 and 48 had stones in the urether; non-RCC tumor patients No. 28 and 57 had angiolioma and No. 39 had a papillary carcinoma. All other samples were from patients with RCC (largest tumors were No. 36, 1466 cm³; No. 50, 725 cm³; the smallest, No. 44, 1 cm³; No. 60, 12 cm³; and No. 38, 14 cm³).

15

Our results show that a relatively high percentage (19/27 = 70%) of the patients excrete CA IX in urine. The M_r of the s-CA IX protein is about the same as in blood (see Example 6). In some of the urine samples, there is an additional band of intermediate size. In two strongly positive samples (No. 50 and 54) there is an additional band of 62 kDa. Control specimens of urine from 25 healthy persons, 2 non-tumor and from 3 non-RCC tumor urology patients were all CA IX negative.

20

As shown in Examples 3 and 4, shedding of CA IX is moderately efficient. Two days after media exchange, the medium contains about 10% of the total amount of CA IX compared with the cell monolayer (Fig. 10). On the other hand, the concentration of s-CA IX in the blood of RCC patients, even if they carry very large tumors, is approximately 1000 x lower than in TC media (Table 6). This

25

shows that s-CA IX is rapidly cleared from the blood. There may be several mechanisms of clearance. We have demonstrated one of them: excretion in the urine without any major degradation. Concentration of the s-CA IX in urine corresponds approximately to the antigen in blood. Possibly, some of CA IX could be degraded to smaller fragments; we are aware of the existence of CA IX-related

30

polypeptides of 20-30 kDa lacking the PG domain. But their sensitive detection and quantification will require optimizing the conditions of assays, probably double antibody sandwich assays using CA IX-specific mabs to the CA domain. Two urine samples – Nos. 50 and 54 contain a larger protein of 62 kDa, reacting with MAb

M75. Significance of this larger protein is not clear; it was not found in the blood or in tumor extract from the same patient.

The data on CA IX concentration in biological materials tested in Examples 3-7 are summarized in Table 6 below.

TABLE 6
Concentration of CA IX in biological materials

	HT29 cell extract *	4 mg/g total protein
	Fresh RCC extract	0.5 – 2 mg/g total protein
	Normal kidney extract	not detectable
	HT29 TC medium *	100 ng/ml
	RCC TC media	100 ng/ml
	Sera of RCC patients	20 pg – 3.6 ng/ml
15	Control sera	5 – 25 pg/ml
	Urine of RCC patients	20 pg – 3 ng/ml
	Control urine	0 – 2 pg/ml

* 5 cm Petri dish corresponds to 5 ml of medium or to 0.5 mg total protein extracted
20 from cell monolayer.

There is a wide range of concentrations observed. The results for cell and tumor extracts and for TC media are based on ELISA. The CA IX concentration in blood sera and in urine was determined by densitometric reading of films exposed with Western blots and calculated by a comparison with included calibration with
25 HT29 medium, titrated in ELISA. All the blots must be taken only as approximate, due to high biological variability (density-dependent expression of CA IX in cell cultures, volume of fluids consumed by the patients before providing the urine for CA IX determination). Western blots are only a semi-quantitative method and there exists no clear-cut borderline between "normal" and "elevated" concentrations of the
30 antigen.

EXAMPLE 8

Soluble Form of CA IX in medium of HT29 culture and in
serum of nude mice with a xenograft of HT29 cells

21 Feb 2003
2003217606

The appearance of soluble CA IX in the medium of HT29 culture and in the serum of nude mice with a xenograft of HT29 cells were compared [Chrastina et al. *in press* (2003)]. In this experiment, we used athymic nude mice xenografted with 5 HT29 human colorectal carcinoma, as described above. Western blotting using ¹²⁵I-M75 mab showed the level of CA IX in xenograft and in HT29 culture *in vitro*. Soluble CA IX shedded to culture medium and to blood plasma was first concentrated by immunoprecipitation and then subjected to Western blotting analysis.

10 Western blot analysis showed that *in vivo* expression of CA IX in the HT29 xenograft was lower than in culture, possibly due to presence of CA IX-negative stroma surrounding the tumor parenchyma as well as to *in situ* heterogeneity of expression in the tumor cells as mentioned above. In addition, a 15 subpopulation of CA IX molecules with the size corresponding to the extracellular portion of the protein (s-CA IX) was detectable in both culture medium and blood circulation as a result of antigen shedding from the cell membrane.

EXAMPLE 9

Expression of CA IX in bladder cancer sections

20 The expression pattern of CA IX in superficial and invasive bladder cancers has been compared by immunohistochemical methods [Turner et al., *Br. J. Cancer*, 86:1276-1282(2002)]. The expression of CA IX was enhanced in bladder cancer specimens, greater in superficial than invasive tumors, confirming CA IX as a possible marker to detect urinary tract tumors.

25 Formalin-fixed, paraffin-embedded tissue specimens collected by standard surgical oncology procedures were obtained from the Pathology Department, John Radcliffe Hospital, Oxford, UK. Samples of normal bladder were taken from cadaveric organ donors at the time of nephroureterectomy.

30 CA IX expression was evaluated by immunochemistry in 22 cases on serial sections (Table 7), as described above. These 22 cases were selected to represent the range of stage and grade in human bladder tumors, and in two samples of normal bladder. In 17 cases, CA IX was expressed maximally on the luminal surface of tumors and around regions of necrosis in invasive tumors. In addition, while both superficial and invasive tumors showed luminal enhancement,

this was much more marked in superficial tumors. CA IX was not detected in normal bladder specimens, nor was it detected in samples from the patient with isolated CIS.

The high frequency and marked enhancement of CA IX expression in
5 superficial bladder cancer in this experiment, combined with the relative absence in normal transitional epithelium, and the fact that CA IX is a transmembrane protein, suggests that measurement of shed protein in the urine could be a potential marker of recurrence.

TABLE 7
Expression of CA IX protein in human bladder cancer

	Patient	Tumor stage/grade	CA IX immunostaining
5	1	CIS	-ve
	2	Ta G1	luminal
	3	Ta G1	luminal
	4	Ta G2	luminal
10	5	T1 G1	luminal
	6	T1 G2	luminal
	7	T1 G2	luminal
	8	T1 G2	luminal
	9	T1 G2	luminal
15	10	T2 G2	luminal and perinecrotic
	11	T2 G2	luminal and invasive tumor
	12	T2 G3	luminal
	13	T2 G3	luminal
	14	T2 G3	luminal but sparse
20	15	T2 G2, CIS in separate biopsy	perinecrotic CIS-ve
	16	T2 G2, CIS in separate biopsy	perinecrotic CIS weakly positive
	17	T2 G2	luminal and perinecrotic
25	18	T2 G3	luminal and perinecrotic
	19	T2 G3	invasive tumor
	20	T2 G3, CIS in separate biopsy	luminal and perinecrotic CIS -ve
30	21	T3 G3	-ve
	22	T4 G3, CIS in separate biopsy	luminal, CIS weakly positive

- In serial sections expression of CA IX was assessed by immunochemistry using monoclonal antibody M75.

EXAMPLE 10

Temporal relationship of CA IX expression to hypoxia and reoxygenation

Hypoxically-induced CA IX protein was shown to be present in tissue culture for 72 hours, even after reoxygenation, further supporting its potential usefulness as a biomarker [Turner et al., (2002)]. Previously hypoxic induction of CA IX in invasive bladder cancer cell lines had not been detected [Wykoff et al. (2000)], which is consistent with the observation of the low level of CA IX expression in invasive tumors. There appears to be no currently available cell lines derived from superficial human bladder tumors. For those reasons, the A549 lung carcinoma cell line, which shows marked hypoxic induction of the CA9 gene, was chosen for this experiment. Western blot analysis of expression of CA IX protein in A549 lung carcinoma cells was performed after growth under hypoxic conditions and then subsequent reoxygenation. Levels of CA IX protein detected remained constant for at least 72 h, indicating that the protein may persist in tissues for a relatively long period of time.

Example 11

Comparison of CA IX Expression in Normal, Benign and Malignant Breast Tissues with ER, C-erbB-2 (HER-2/neu), C-erbB3 and CD44 Expression

MATERIALS AND METHODS

Tissue specimens

Breast tissue specimens were obtained from 111 patients (mean age 25 50.4 years, ranging from 19 to 82) during surgical treatment (KP) at the Department of Obstetrics and Gynaecology II, School of Medicine, Comenius University, Bratislava, in 1998-1999. The patients had not received anti-tumour treatment before surgery. Portions of all tissues were fixed in formaldehyde, embedded in paraffin wax and processed for routine histopathology. The specimens were divided 30 into two overlapping groups, so that the tissues of 36 patients were analysed by IHC only, the tissues of 36 patients were subjected to both IHC and RT-PCR, and the tissues of 39 patients were used for RT-PCR only. IHC was performed using the paraffin-embedded specimens. For RT-PCR, fresh tissues were snap-frozen in liquid nitrogen and stored at -80°C until used for RNA extraction.

Histopathology

Histopathological evaluation of tissues was performed independently. The diagnosis was assessed separately for the sections subjected to IHC and for the specimens corresponding to tissues analysed by RT-PCR. The tissues were 5 classified according to the WHO classification (World Health Organization 1981) and categorized as normal (derived from distant areas of surgical tumour specimens), benign (fibrocystic change, fibroadenoma and other types) and malignant (carcinomas *in situ* and invasive carcinomas).

10 Immunohistochemistry

The tissue sections were immunostained by the biotin-streptavidin complex method using the monoclonal antibody M75 to the N-terminal domain of CA IX and applied in 1:10 dilution for 1 h at room temperature, as described previously [Pastorekova et al. 1997]. Briefly, the procedure was performed as follows: (1) Pre-15 treatment with undiluted cow colostral whey for 40 min and rinsing in phosphate-buffered saline (PBS). (2) Incubation for 1 h with M75 monoclonal antibody in PBS containing 1% bovine serum albumin (BSA). (3) Incubation for 1 h with biotinylated goat anti-mouse IgG (Dakopatts, Copenhagen, Denmark) diluted 1:300 in 1% BSA-PBS. (4) Incubation for 30 min with peroxidase-conjugated streptavidin (Dakopatts) 20 diluted 1:500 in PBS. (5) Visualization for 2 min in diaminobenzidine solution (Fluka, Buchs, Switzerland). The sections were washed three times for 10 min in PBS after steps 2, 3, and 4. All the incubations and washings were carried out at room temperature. The sections were counterstained with haematoxylin, mounted in Permount [Fisher Scientific, Fair Lawn, NJ (USA)], examined and photographed with 25 a Nikon Eclipse E600 (Tokyo, Japan) microscope. The level of staining was scored in a blinded manner, taking into account intensity of signal, pattern and extent of staining under low and high magnification. Sections of normal human intestine were used as positive controls. For the negative control, M75 antibody was substituted with PBS. The staining intensity was scored using a scale of 0-3 as follows: 0, no 30 reaction; 1, weak reaction; 2, moderate reaction; 3, strong reaction. The staining pattern was evaluated as cytoplasmic or membranous and positivity was assigned only to those specimens that showed the plasma membrane staining. The extent of staining was evaluated as focal if occasional single cells or small groups of cells were positive, or diffuse, if continuous or extensive areas were stained.

RNA extraction and reverse transcription of cDNA

Extraction of total RNA from the frozen breast specimens was done by disrupting the tissues in Trizol solution (GIBCO, Life Technologies). RNA was precipitated by ethanol, dissolved in water treated with diethylpyrocarbonate (DEPC, Sigma) and reverse transcribed with SuperScriptII reverse transcriptase (GIBCO, Life Technologies) using oligo(dT)₁₂₋₁₈ (500 µg/ml). 5 µl RNase-free sterile water containing 1 µg of total RNA was added to a reaction mixture composed of dNTPs, each at 0.5 mM concentration (Pharmacia), and reverse transcriptase buffer containing 6 mM MgCl₂, 40 mM KCl, 1 mM DTT, 0.1 mg/ml BSA and 50 mM Tris-HCl, pH 8.3. The mixture in a final volume of 20 µl was heated for 10 min at 70°C, cooled quickly on ice, supplemented with 200 U of reverse transcriptase, incubated for 1 h at 42°C, heated for 15 min at 70°C and stored at - 80°C until used.

15 PCR amplification

PCR reaction was performed with an automatic DNA thermal cycler (BIORAD) using the cDNA-specific primers for CA9 as well as for β_2 -microglobulin (β_2 -m) which served as an internal standard. The nucleotide sequences of the primers, with relevant positions and database accession numbers in parentheses, were as follows:

20 CA9 (X66839): MN1 5' CCGAGCGACGCAGCCTTGA 3' (1188-1207) (SEQ ID NO: 107), MN2 5' TAGTCGACTAGGCTCCAGTCTCGGCTACCT 3' (1443-1414) (SEQ ID NO: 108); β_2 -microglobulin (AF072097): B2M1 5' CATCCAGCGTACTCCAAAGA 3' (860-879) (SEQ ID NO: 109), B2M2 5' GACAAGTCTGAATGCTCCAC 3' (1024-25 1005) (SEQ ID NO: 110).

To compare the expression of CA9 with breast tumour markers *ER*, *c-erbB2*, *c-erbB3* and *CD44*, we used the same templates for parallel semi-quantitative RT-PCR reactions using the following primers:

30 *Oestrogen receptor* (M12674): ER1 5' ACTCGCTACTGTGCAGTGTGCAATG 3' (776-800) (SEQ ID NO: 111), ER2 5' CCTCTTCGGTCTTTCGTATCCCAC 3' (1014-990) (SEQ ID NO: 112); *c-erbB-2* (M11730): EB2-1 5' AGTTTCCAGATGAGGAGGG CGCATGCC 3' (1994-2020) (SEQ ID NO: 113), EB2-2 5' TTCTCCCCATCAGGGAT CCAGATGCC 3' (2384-2358) (SEQ ID NO: 114);

c-erbB-3 (M34309): EB3-1 5' GGTGCTGGGCTTGCTTTCAGCCTGG 3' (222-247) (SEQ ID NO: 115), EB3-2 5' ACCACGCGGAGGTTGGGCAATGGTAG 3' (512-487) (SEQ ID NO: 116); *CD44* (M59040.1): CD44-1 5' GGGTCCCATAACCACTCATGGA TCT 3' (725-748) (SEQ ID NO: 117), CD44-2 5' GGGAAAGGTTGGCGATCAGGAA

5 TA 3' (1444-1421) (SEQ ID NO: 118).

The reaction mixture was composed of 1/40 of cDNA template obtained from 1 μ g of RNA, 15 pmol of each upstream and downstream primers for both the analysed gene and β_2 -m, 0.2 mM of each dNTP (Pharmacia), 1 U of *Taq* DNA polymerase (Boehringer Mannheim) and PCR buffer (10 mM Tris-HCl pH 8.3, 10 mM KCl and 1.5 mM MgCl₂) in a total volume of 25 μ l. Following an initial denaturation at 95°C for 1 min, the amplification program was set as follows: denaturation at 95°C for 20 s, annealing at 65°C for 30 s, and extension at 72°C during 40 s for a total of 30 cycles, and finally 5 min at 72°C. In these conditions, amplified products were obtained in the exponential phase for the two sets of primers, and the yield of PCR products obtained by co-amplification was similar to those obtained by individual amplifications in separate tubes. In addition to tumour samples, negative and positive controls were systematically processed in parallel.

Semi-quantitation of RT-PCR products

20 20 μ l of RT-PCR products were run on a 1.8% agarose gel.

Quantification of PCR products was done using Scion Image software. The amount of CA9-specific PCR product was expressed as a percentage of the internal standard. The specimens were classified as 0 when amount of CA9 product was less than or equal to 10% of internal standard, as 1 for 11-50%, 2 for 51-80% and 3 for 25 more than 80% of β_2 -m. Similar semi-quantitation in relative percentages of gene-specific products was used for the other markers without further categorization of data.

Statistical evaluation

30 Association between expression of CA9 and expression of *ER*, *c-erbB2*, *c-erbB3* and *CD44* in breast tumours was evaluated by chi-square test of independence (or by Fisher's exact test) using data obtained in a parallel RT-PCR analysis of the same specimens. Mann-Whitney rank test applied to positive

specimens was used to compare expression levels of individual markers in CA9-positive versus CA9-negative subgroups of malignant tissues. A significance level of $p \leq 0.05$ was used in both tests.

5 RESULTS

Immunohistochemical analysis of breast tissues

The set of 72 breast specimens subjected to IHC analysis of CA IX expression consisted of 10 normal tissues, 36 benign lesions and 26 malignant tumours (Table 8). The benign lesions included 20 specimens with fibrocystic changes, six fibroadenomas and 10 specimens of other type (two hyperplasias, two adenoses, four fibroses, one adenoma, one benign phylodes tumour). The malignant tumours included five ductal carcinomas *in situ*, two lobular carcinomas *in situ*, 13 invasive ductal carcinomas, two invasive lobular carcinomas, three tubular carcinomas and one mucinous carcinoma.

All 10 normal breast tissues were negative for membrane CA IX, with only few occasional cells with weak cytoplasmic staining found in one specimen of lactating breast. In benign lesions, a positive membrane signal ranging from weak to strong was detected in four of 36 (11%) specimens (Table 8). All positive lesions were classified as fibrocystic changes. Among negative specimens, one fibroadenoma and three lesions with fibrocystic changes showed weak cytoplasmic staining in a few epithelial cells, while other benign lesions did not stain at all.

In sections with fibrocystic changes, the staining signal was mainly confined to abnormal epithelium, mostly in areas of apocrine metaplasia. [E.g., weak diffuse cytoplasmic staining seen in apocrine metaplastic epithelium.] Weak signal of a diffuse cytoplasmic pattern was observed in three specimens. The four moderately to strongly positive specimens showed focal membrane staining. [E.g., strong focal membrane staining of epithelial cells seen in benign hyperplastic epithelium.] In one case with fibrocystic change and sclerosing adenosis, strong CA IX-specific staining was detected in sub-epithelial fibroblasts and endothelium.

Table 8

Summary of the immunohistochemical staining of CA IX in the
normal, benign, and malignant breast tissues

Type of tissue	Total No.	Positive specimens*		Expression Level	
		No.	%	Mean	Range
Normal breast	10	1	10	0.10	0-1
Benign lesions	36	4	11	0.39	0-3
Fibroadenomas	6	0	0	0.17	0-1
Fibrocystic changes	20	4	20	0.65	0-3
Other types	10	0	0	0.00	
Malignant tumours	26	12	46	1.42	0-3
<i>In situ</i>	7	4	57	1.28	1-2
Invasive	19	8	42	1.47	0-3

5

*Positivity was assigned only to specimens with membrane staining

Out of 26 malignant breast tissue specimens, plasma membrane expression of CA IX protein was detectable in 12 carcinomas (46%) (Table 8). The positivity was observed mainly in the abnormal epithelium. The majority of weakly stained specimens showed a focal cytoplasmic pattern, while moderate to strong staining was mainly of focal membrane type. Interestingly, in four invasive ductal carcinomas out of six strongly positive malignant cases, staining was observed in stromal fibroblasts and occasionally also in endothelial cells. Indeed, there were two specimens with strongly positive stroma and negative carcinoma cells. [E.g., strong specific positivity was present in stromal fibroblasts and endothelial cells, but absent in the area of invasive ductal carcinoma in a tumour specimen.] In one specimen of ductal *in situ* carcinoma with sclerosing adenosis, strong positivity was found in adenosis, whereas the *in situ* area was negative. The last strongly positive tumour tissue specimen was classified as mucinous carcinoma and was found to express CA IX focally in membranes of abnormal epithelial cells. On the other hand, both lobular carcinomas *in situ* and one of two invasive lobular carcinomas showed only

weak cytoplasmic staining, while the other lobular carcinoma specimen was completely negative.

Comparison of CA IX expression with basic clinicopathological parameters of the analysed malignant tumors did not reveal any significant relationship with the age, nodal status, tumor size and grade.

Table 9
Summary of the RT-PCR analysis of CA9 gene expression in the normal, benign and malignant breast tissues

10

Type of tissue	Total	Positive specimens		Expression level	
		No.	%	Mean	Range
Normal breast	3	0	0	0.0	
Benign lesions	33	11	33	0.39	0-3
Fibroadenomas	9	5	56	0.56	0-3
Fibrocystic changes	20	6	30	0.40	0-1
Other types	4	0	0	0.00	
Malignant tumours	39	25	64	1.03	0-3
In situ	3	1	33	0.33	1-3
Invasive	36	24	67	1.08	0-3

RT-PCR analysis of breast tissues

The specimens utilized for RT-PCR analysis included three normal tissues, 33 benign lesions and 39 malignant tumours (Table 9). The benign tissue specimens consisted of 20 lesions with fibrocystic changes, nine fibroadenomas and four lesions of other types (one adenosis, one epitheliosis, one intraductal papilloma and one non-specific autoimmune alveolitis). The malignant tissues involved three ductal carcinomas *in situ*, 32 invasive ductal carcinomas, two invasive lobular carcinomas, one tubular carcinoma and one mucinous carcinoma.

All three normal tissue specimens were negative for CA9 transcript, while the specific RT-PCR product was detected in 33% of benign lesions. Nine

benign lesions were evaluated as weakly positive, one lesion showed moderate positivity and only one benign lesion showed strong positivity. On the other hand, 64% of malignant tumours expressed CA9, of which 14 tissues were weakly positive, nine were moderately positive and three were strongly positive (Table 9). [The CA9 5 specific PCR product of 255 bp was detected using β_2 -microglobulin-related PCR product of 165 bp as a standard.] As above, there was no significant association between CA9 expression and any of the clinicopathological parameters.

Concordance of IHC and RT-PCR data

10 Comparison of IHC and RT-PCR data obtained from specimens of 36 patients analysed simultaneously by both methods revealed 69.4 % concordance of the results. There were 19 IHC-negative/RT-PCR-negative, six IHC-positive/RT-PCR-positive, 10 IHC-negative/RT-PCR positive patients, and one IHC-positive/RT-PCR-negative. The discrepancies could partially result from differences in 15 methodology, which accounted for at least some RT-PCR-positive/IHC-negative data. Indeed, weak cytoplasmic staining was observed in six specimens evaluated as negative in IHC, but found to be positive in RT-PCR. In addition, there was an objective problem connected with breast tumour heterogeneity and related to the fact that the two methods were performed using different portions of tissue obtained from 20 the same patient. This problem could be relevant especially in the cases with focal CA IX expression in a small area, present in the first portion of the breast specimen but lacking from the second. In support of this assumption was differential histological evaluation of five paired specimens, in which CA IX negativity was observed in the portion of tissue containing less severe morphological changes such 25 as hyperplasia, while the positivity was associated with the presence of more striking abnormalities such as carcinoma *in situ*.

Relationship of CA9 to breast tumour markers

30 In order to understand the molecular context of CA9 gene expression and to learn more about its possible significance in breast cancer, we have performed simultaneous semi-quantitative RT-PCR analyses of four additional markers. They included the genes encoding: (1) oestrogen receptor (ER), a known predictor of response to endocrine therapy; (2) type 1 receptor tyrosine kinase c-erbB2 (HER-2/neu), associated with lack of endocrine response, aggressive

phenotype and poor prognosis; (3) c-erbB3, a catalytically-inactive ligand-binding c-erbB2 homologue, proposed as a favourable predictor of endocrine response in ER positive tumours; and (4) an adhesion molecule CD44, a promising indicator of metastatic potential [Osborne et al. (1996); Revillion et al. (1998); Knowlden et al.

5 (1998); Kaufmann et al. (1995)].

For the statistical analysis, 39 malignant specimens were divided into two groups. The CA9-negative group contained 14 specimens with expression of CA9 below 10% of internal control and the CA9-positive group consisted of 25 specimens expressing CA9 mRNA at any level above 10%. In both groups, 10 specimens were categorized as either positive or negative for expression of each of the four markers. The cut-off value of 10% of internal control was used for *ER*, *c-erbB3* and *CD44*. The cut-off value of 100% of internal control was estimated for the overexpression of *c-erbB2* as a value corresponding to the mean expression level in *c-erbB2*-positive benign lesions multiplied by two. Using this criterion, 25.6% of 15 malignant breast tissues in our collection were found to overexpress *c-erbB2*, in agreement with the data from literature [Revillion (1998)]. Association between CA9 and each marker was tested by the Chi-square test (or the Fisher's exact test in the case of *c-erbB2*) and concordance in negativity/positivity evaluation was calculated (Figure 7A).

20 Expression of CA9 in malignant breast tissues showed no significant relationship with *ER* ($p=0.86$), *c-erbB3* ($p=0.35$) and *CD44* ($p=0.15$), but there was a positive association between CA9 and *c-erbB2* ($p=0.05$). Nine of 25 (36%) specimens positive for CA9 mRNA overexpressed *c-erbB2*, while only 1/14 (7%) CA9 negative tissues were classified as positive for *c-erbB2* overexpression.

25 To test whether expression levels of the markers differ between CA9-negative tissues and CA9-positive tissues, Mann-Whitney rank test was performed including only the marker-positive specimens. In the group of 14 CA9-negative cases, there were eight *ER*-, one *c-erbB2*-, eight *erbB3*- and eight *CD44*-positive specimens. On the other hand, there were 15 *ER*-, nine *c-erbB2*-, 18 *erbB3*- and 19 *CD44*-positive specimens among 25 CA9-positive cases. The distribution of 30 expression values for individual markers was of similar shape and differed between CA9-positive and -negative tissues. Although three of the markers, namely *ER*, *c-erbB2* and *c-erbB3*, showed a higher median of expression in the CA9-positive group of specimens, a significant difference ($p=0.02$) was found only for *c-erbB2* (Figure

7B). Median expression of *c-erbB2* was 57% higher in the CA9-positive than the CA9-negative group of tissues. This result further supported the association between CA9 and *c-erbB2*.

5 DISCUSSION

Development of breast cancer is driven by accumulation of numerous molecular changes. This process does not follow a linear progression model, but is highly complex and variable [Bergstein, I. (1999)]. Its understanding and

10 identification of relevant components is essential not only for better stratification of patients for treatment, but also to allow for the development of more effective therapeutic strategies targeted to aberrant cellular pathways.

According to Example 11, ectopic activation of a cell surface carbonic anhydrase IX appears to be one of the molecular alterations contributing to breast 15 tumourigenesis. Neither mRNA nor the protein was found in normal breast tissues. CA IX expression was observed in relatively low percentage of benign lesions, while the incidence and level of CA IX in the malignant tumours were considerably higher, as documented by both IHC and RT-PCR analyses performed on two partially independent series of specimens. A similar scenario, with relatively early onset and 20 increased CA IX expression in malignant tissues, was earlier observed in other types of carcinomas derived from the uterine cervix, oesophagus and colon [Liao et al (1994), Turner et al. (1997), Saarnio et al. (1998)]. On the other hand, lack of expression in preneoplastic disease and its association with malignant conversion 25 was demonstrated in renal cell carcinomas and lung carcinomas [McKiernan et al. (1997), Vermulen et al. (1999), Liao et al (1997)]. The cause of a different timing of activation in different tissues is unclear, but it may be connected with regulatory pathways involved in the development of diverse type of tumours. For example, high and homogeneous expression of CA IX in renal cell carcinomas appears to be linked 30 to inactivation of von Hippel Lindau tumour suppressor protein, leading to elimination of its negative control over CA IX [Ivanov et al. (1998)].

Present immunohistochemical analysis revealed that the majority of CA IX-positive breast lesions contained staining signal in abnormal epithelial cells. The expression pattern was very variable, most probably reflecting the heterogeneity of breast tumour cells: the protein was localized in the plasma membrane and/or

cytoplasm, and the stained area varied from focal to diffuse. Noteworthy, there were two cases, in which strong specific positivity was detected also in stromal cells and two cases with strong staining present in stroma but absent from the area of carcinoma. Such a distribution of CA IX has been observed before in malignant 5 colorectal tumours, where desmoplastic connective tissue occasionally showed prominent immunostaining [Saarnio et al. (1998)]. These peculiar findings are difficult to explain but suggest existence of microenvironmental factors influencing CA IX expression. It is well known that mutual cross-talk between epithelium and adjacent stroma plays an important role in modulating the process of neoplastic 10 transformation [Heber et al (1996), Goldyne et al. (1991)]. Activation of CA IX in stroma may therefore represent a consequence of aberrant paracrine communication between abnormal epithelial cells and surrounding fibroblasts. Alternatively, expression of CA IX in the tumour stroma might be connected with 15 genetic aberrations recently observed in stromal cells in mammary carcinoma [Moinfar et al. (2000)].

The expression pattern of CA IX may be also affected by microenvironmental stresses, whose critical contribution to the development of tumour phenotype has become an increasingly accepted phenomenon [Blancher and Harris (1998)]. Indeed, Wykoff et al. 2000 have recently demonstrated an 20 intimate connection between hypoxic stress and induction of CA IX. They have shown that upregulation of CA IX occurs at the level of transcriptional activation via HIF-1 transcriptional complex, the critical mediator of hypoxic responses, and they have proposed that CA IX may be a useful marker for tumour hypoxia.

Hypoxia is one of the major drives to tumour progression [Blancher and 25 Harris (1998)]. It leads to activation of genes involved in the development of tumour metabolic pathways including aerobic glycolysis and neovascularization. CA IX appears to participate in hypoxia-induced oncogenic metabolism via extracellular acidification and maintenance of normal intracellular pH, thus contributing to conditions required for the spread and survival of tumor cells [Wykoff et al. (2000)]. 30 From the clinical point of view, hypoxia is associated with poor prognosis, aggressive phenotype and resistance to anti-cancer therapy [Blancher and Harris (1998)]. This may explain our finding of an association between ectopic expression of CA IX and overexpression of c-erbB2, an oncogene encoding a receptor tyrosine kinase that

serves as a marker of aggressive breast tumours with poor outcome [Revillion et al. (1998)].

Signal transduction mediated by activated oncogenes may induce the expression of a tumour metabolic phenotype independently of hypoxia, or may amplify the hypoxic response [Blancher and Harris (1998)]. It was shown that inactivation of c-erbB2 was associated with decreased expression of an important hypoxic target vascular endothelial growth factor [Petit et al. (1997)]. By analogy, this observation may offer clues to a functional link between c-erbB2 and CA IX. It is possible that some of the features associated with high c-erbB2 expression, such as invasion and metastatic capability, are also mediated by coexpression of CA IX. In fact, a significant proportion of c-erbB2-positive cancers does not respond to treatment by herceptin, a humanized monoclonal antibody against c-erbB2 [Kuter, I. (2001)]. Thus it is conceivable that inhibitors of the associated expression of CA IX could be of further therapeutic value. This assumption is supported by the evidence that inhibition of CA activity reduces invasion of some tumour cells lines [Parkkila et al. (2000)] and that treatment by CA inhibitor may be beneficial as an adjunct to cancer chemotherapy [Teicher et al. (1993)].

In conclusion, this example has shown that expression of CA9 gene is associated with breast cancer in a manner similar to some other types of carcinomas, with respect to both incidence and/or expression pattern. The data shown here highlight the need for further large-scale analyses, specifically directed to a possible prognostic/predictive value of CA9 in breast cancer and a significance of its relationship with c-erbB2. In general, our work adds to accumulating evidence supporting the view that CA9 activation is a common event in carcinogenesis and is a new therapeutic target.

EXAMPLE 12

Accessibility In Vivo of MN Protein Expressed in Tumor Cells and in Stomach

Lewis rats (384g) carrying a BP6 subcutaneous tumor (about 1 cm in diameter) expressing rat MN protein were injected intraperitoneally (i.p.) with ^{125}I -M75 Mab (2.5×10^6 cpm). Five days later, 0.5-1g pieces of the tumor and organs were weighed and their radioactivity was measured by a gamma counter.

Table 10 summarizes the results. The highest radioactivity was present in the tumor. Relatively high radioactivity was found in the liver and kidney,

apparently reflecting the clearance of mouse IgG from the blood. The stomach continued a relatively low level of radioactivity, indicating that the M75 Mab had only limited access to MN protein exposed in the gastric mucosa.

5

TABLE 10Distribution of radioactivity of ^{125}I -M75 in rat organs and in the tumor

10

<u>Organ</u>	<u>cpm/g</u>			
Kidney	2153	2184		
Spleen	653	555		
Liver	1993	1880		
Lung	1183	1025		
Blood	1449			
Heart	568	477		
Stomach	1184	1170		
Testis	812	779		
Tail	647			
Tumor	3646	4058	3333	8653
				3839

Budapest Treaty Deposits

The materials listed below were deposited with the American Type Culture Collection (ATCC) now at 10810 University Blvd., Manassus, Virginia 20110-2209 (USA). The deposits were made under the provisions of the Budapest Treaty on the International Recognition of Deposited Microorganisms for the Purposes of Patent Procedure and Regulations thereunder (Budapest Treaty). Maintenance of a viable culture is assured for thirty years from the date of deposit. The hybridomas and plasmids will be made available by the ATCC under the terms of the Budapest Treaty, and subject to an agreement between the Applicants and the ATCC which assures unrestricted availability of the deposited hybridomas and plasmids to the public upon the granting of patent from the instant application. Availability of the deposited strain is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any Government in accordance with its patent laws.

<u>Hybridoma</u>	<u>Deposit Date</u>	<u>ATCC #</u>
VU-M75	September 17, 1992	HB 11128
MN 12.2.2	June 9, 1994	HB 11647

<u>Plasmid</u>	<u>Deposit Date</u>	<u>ATCC #</u>
A4a	June 6, 1995	97199
XE1	June 6, 1995	97200
XE3	June 6, 1995	97198

Similarly, the hybridoma cell line V/10-VU which produces the V/10 monoclonal antibodies was deposited on February 19, 2003 under the Budapest Treaty at the International Depository Authority (IDA) of the Belgian Coordinated Collections of Microorganisms (BCCM) at the Laboratorium voor Moleculaire

Biologie-Plasmidencollectie (LMBP) at the Universiteit Gent, K.L. Ledeganckstraat 35, B-9000 Gent, Belgium [BCCM/LMBP] under the Accession No. LMBP 6009CB.

The description of the foregoing embodiments of the invention have been presented for purposes of illustration and description. They are not intended to be exhaustive or to limit the invention to the precise form disclosed, and obviously

many modifications and variations are possible in light of the above teachings. The embodiments were chosen and described in order to explain the principles of the invention and its practical application to enable thereby others skilled in the art to utilize the invention in various embodiments and with various modifications as are 5 suited to the particular use contemplated.

All references cited herein are hereby incorporated by reference.

The claims defining the invention are as follows:

1. An isolated soluble form of MN/CA IX antigen, wherein said isolated soluble form of MN/CA IX antigen comprises at least one non-immunodominant epitope of MN/CA IX protein, which is released from precancerous and/or cancerous cells of a vertebrate into a body fluid.

2. The soluble form of the MN/CA IX antigen of claim 1 with a molecular weight of about 50 to 54 kd.

3. The soluble form of the MN/CA IX antigen of claim 1 with a molecular weight of about 20 to 30 kd.

4. The soluble form of the MN/CA IX antigen according to claim 1 that is specifically bound by the M75 monoclonal antibody that is secreted from the hybridoma VU-M75, which was deposited at the American Type Culture Collection under ATCC No. HB 11128.

5. The soluble form of the MN/CA IX antigen according to claim 1 wherein said vertebrate cells are human cells.

6. The soluble form of the MN/CA IX antigen of claim 1 wherein said body fluid is selected from the group consisting of blood, serum, plasma, semen, breast exudate, saliva, tears, sputum, mucous, urine, gastric secretions, fecal suspensions, bile, lymph, cytosols, ascites, pleural effusions, amniotic fluid, bladder washes, bronchioalveolar lavages and cerebrospinal fluid.

7. The soluble form of the MN/CA IX antigen of claim 1 or 2, wherein said soluble form of the MN/CA IX antigen comprises the proteoglycan-like (PG) and carbonic anhydrase (CA) domains of the MN/CA IX antigen.

8. The soluble form of the MN/CA IX antigen of claim 1 or 3, wherein said soluble form of the MN/CA IX antigen comprises the carbonic anhydrase (CA) domain of the MN/CA IX antigen or parts of said CA domain.

9. A method of detecting or detecting and quantifying in a vertebrate body fluid soluble MN/CA IX antigen, wherein said soluble MN/CA IX antigen comprises at least one non-immunodominant epitope of MN/CA IX protein, comprising the steps of:

(a) contacting a sample of said body fluid with one or more MN/CA IX-specific antibodies and/or with one or more MN/CA IX-specific antigen binding antibody fragments, wherein at least one of said MN/CA IX-specific antibodies or antibody fragments, specifically binds to a non-immunodominant epitope of MN/CA IX protein; and

(b) detecting or detecting and quantifying binding of said one or more antibodies and/or said one or more antibody fragments in said sample.

10. The method according to claim 9 wherein one or more of said antibodies and/or antibody fragments are labeled.

5 11. The method according to claim 9 or 10 wherein said method is in a format that is selected from the group consisting of Western blots, enzyme-linked immunosorbent assays, radioimmunoassays, competition immunoassays, dual antibody sandwich assays, immunohistochemical staining assays, agglutination assays, and fluorescent immunoassays.

10 12. The method according to any one of claims 9 to 11, wherein said one or more antibodies and/or said one or more antibody fragments specifically bind to a soluble form of MN/CA IX antigen, which soluble MN/CA IX antigen is released from precancerous and/or cancerous cells of a vertebrate into a body fluid.

15 13. The method according to any one of claims 9 to 12, wherein said one or more antibodies are monoclonal.

14. The method according to claim 13 wherein said one or more monoclonal antibodies are selected from the group consisting of the monoclonal antibodies designated M75, which are secreted by the hybridoma VU-M75, which is deposited at the American Type Culture Collection under Accession No. HB 11128, and monoclonal antibodies that 20 are not directed to the M75 epitope.

15. The method according to any one of claims 9 to 14, which is diagnostic and/or prognostic for precancerous and/or cancerous disease, wherein said disease is associated with abnormal expression of MN/CA IX antigen, selected from the group consisting of mammary, urinary tract, kidney, ovarian, uterine, bladder, cervical, endometrial, vaginal, 25 vulvar, prostate, liver, lung, skin, thyroid, pancreatic, testicular, brain, head and neck, gastrointestinal, colorectal and mesodermal precancerous and cancerous diseases.

16. The method according to any one of claims 9 to 15, which is diagnostic, or diagnostic and prognostic for precancerous and/or cancerous disease selected from the group consisting of renal cell carcinoma, urinary tract precancerous and cancerous 30 diseases, breast cancer, breast precancer, colorectal cancer and colorectal precancer.

17. The method according to any one of claims 9 to 16, wherein a sandwich immunoassay is used to detect, or detect and quantify said soluble MN/CA IX antigen.

18. The method according to claim 17, wherein the antibodies are monoclonal, and wherein one monoclonal antibody of said sandwich is specific for the carbonic 35 anhydrase (CA) domain of the MN/CA IX antigen, and wherein the other monoclonal

said sandwich assay is directed to the proteoglycan-like (PG) domain of the MN/CA IX antigen.

19. The method according to claim 18 wherein the antibody directed to the CA domain is the V/10 monoclonal antibody, which is secreted from the hybridoma cell line 5 V/10-VU, which is deposited under the Budapest Treaty at the International Depository Authority of the Belgian Coordinated Collection of Microorganisms (BCCM) at the Laboratorium voor Moleculaire Biologie-Plasmidencollectie (LMBP) at the Universiteit Gent in Gent, Belgium, under Accession No. LMBP 6009CB, and wherein the antibody directed to the PG domain is the M75 monoclonal antibody, which is secreted from the 10 hybridoma cell line VU-M75, which is deposited under the Budapest Treaty at the American Type Culture Collection under Accession No. HB 11128.

20. The method according to claim 9 wherein the one or more antibodies and/or antibody fragments are selected from the group comprising MN/CA IX- specific monoclonal antibodies generated from MN/CA IX-deficient mice, fragments of MN/CA 15 IX-specific antibodies generated from MN/CA IX-deficient mice, antibodies and antibody fragments specific to the MN/CA IX carbonic anhydrase (CA) domain, antibodies and antibody fragments specific to MN/CA IX non-immunodominant epitopes, and antibodies and antibody fragments specific to the proteoglycan-like (PG) domain of the MN/CA IX antigen.

21. The method according to any one of claims 9 to 20, further comprising using 20 antibodies and/or antibody fragments specific to the HER-2 ectodomain to detect, or to detect and quantify HER-2 ectodomain having a molecular weight of from about 97 to about 115 kilodaltons in said body fluid.

22. The method according to any one of claims 9 to 21, wherein the body fluid is 25 from a cancer patient, whose response to treatment comprising the use of a monoclonal antibody or antibody fragment specific to a HER-2 protein/polypeptide is considered unsatisfactory.

23. The method according to claim 21 wherein the body fluid is from a cancer patient, further comprising basing treatment modalities upon whether both soluble 30 MN/CA IX antigen and HER-2 ectodomain are present in said body fluid.

24. A monoclonal antibody generated from a MN/CA IX-deficient mammal wherein said antibody binds specifically to a non-immunodominant epitope of MN/CA IX antigen.

25. The monoclonal antibody of claim 24, wherein said MN/CA IX- deficient 35 mammal is a mouse that has a null mutation in *Car9*.

26. The monoclonal antibody of claim 24 which specifically binds to a domain of the MN/CA IX antigen, wherein said domain is selected from the group consisting of the carbonic anhydrase (CA) domain, the proteoglycan-like (PG) domain, the transmembrane (TM) domain, and the intracellular (IC) domain.

5 27. The monoclonal antibody of claim 24 which specifically binds to a domain of the MN/CA IX antigen, wherein said domain is selected from the group consisting of the carbonic anhydrase (CA) domain and the proteoglycan-like (PG) domain.

28. The monoclonal antibody of claim 24 which specifically binds the carbonic anhydrase (CA) domain of the MN/CA IX antigen.

10 29. The monoclonal antibody of claim 24, wherein the epitope for said monoclonal antibody is within the amino acid sequence of SEQ ID NO: 9, which has the amino acid sequence from amino acid 135 to amino acid 391 of Figure 1, is within the amino acid sequence of SEQ ID NO: 101, which has the amino acid sequence from amino acid 121 to amino acid 397 of Figure 1, or is within amino acid sequences substantially homologous to the amino acid sequences of SEQ ID NOS: 9 and 101.

15 30. The monoclonal antibody of claim 24, wherein the epitope for said monoclonal antibody is closely associated with the amino acid sequence of SEQ ID NO: 67, which has the amino acid sequence from amino acid 279 to amino acid 291 of Figure 1, or which monoclonal antibody specifically binds to an epitope within SEQ ID NO: 69, which has the amino acid sequence from amino acid 166 to amino acid 397 of Figure 1, 20 or to an epitope within an amino acid sequence substantially homologous to SEQ ID NO: 69.

31. The monoclonal antibody of claim 24 which specifically binds to the proteoglycan-like (PG) domain of the MN/CA IX antigen.

25 32. The monoclonal antibody of claim 24, wherein the epitope for said monoclonal antibody is within an amino acid sequence selected from the group consisting of SEQ ID NO: 8, which has an amino acid sequence from amino acid 53 to amino acid 111 of Figure 1, SEQ ID NO: 98, which has an amino acid sequence from amino acid 52 to amino acid 125 of Figure 1, and amino acid sequences substantially homologous to SEQ ID NO: 8 and SEQ ID NO: 98.

30 33. The monoclonal antibody of claim 24 which specifically binds the transmembrane domain of the MN/CA IX antigen, wherein said transmembrane domain has the amino acid sequence of SEQ ID NO: 6, which has the amino acid sequence from amino acid 415 to amino acid 434 of Figure 1, or has an amino acid sequence 35 substantially homologous to SEQ ID NO: 6.

34. The monoclonal antibody of claim 24 which specifically binds the intracellular domain of MN/CA IX antigen, wherein said intracellular domain has the amino acid sequence of SEQ ID NO: 7, which has the amino acid sequence from amino acid 435 to amino acid 459 of Figure 1, or has an amino acid sequence that is substantially homologous to SEQ ID NO: 7.

35. The monoclonal antibody of claim 34, that binds the epitope represented by SEQ ID NO: 68 which has the amino acid sequence from amino acid 435 to amino acid 450 of Figure 1.

36. The monoclonal antibody of claim 28, which is produced by the hybridoma 10 VU-V10, deposited at BCCMTM/LMBP under Accession No. LMBP 6009CB.

37. The monoclonal antibody of claim 24 which is selected from the group consisting of antigen-binding fragments comprising MN/CA IX antigen binding regions.

38. The monoclonal antibody of claim 37 wherein the said fragments are single chain molecules, comprising peptide-linked V_H and V_L domains.

39. The monoclonal antibody of claim 38, wherein said fragments have been 15 dimerized.

40. The hybridoma VU-V10 which produces the monoclonal antibody V/10 and which has been deposited at BCCMTM/LMBP under Accession No. LMBP 6009CB.

41. A monoclonal antibody or antibody fragment that is specific to MN/CA IX 20 antigen that is not directed to an immunodominant epitope of the MN/CA IX antigen.

42. The monoclonal antibody or antibody fragments of any one of claims 24, 28, 37 and 41 wherein said antibody or antibody fragments is or are humanized.

43. The monoclonal antibody or antibody fragments of any one of claims 24, 28, 37, 41 and 42 wherein said antibody or antibody fragments is or are coupled with a 25 radioisotope, a chemotherapeutic drug, a toxin or a carbonic anhydrase inhibitor.

44. A method of therapy for precancerous and/or cancerous disease, wherein said disease is associated with abnormal expression of MN/CA IX antigen, comprising the use of one or more monoclonal antibodies or antibody fragments according to any one of claims 24, 25, 28, 37, 41, 42 and 43.

45. A method of therapy for precancerous and/or cancerous disease, comprising 30 the use of a monoclonal antibody according to claim 24, administered in conjunction with one or more chemotherapeutic drugs, carbonic anhydrase inhibitors, cytokines, antibodies directed to immunodominant epitopes of MN/CA IX antigen, antibodies to cancer-related antigens other than MN/CA IX antigen, and/or radiotherapy.

46. A method of therapy for a cancer patient of claim 23, whose body fluids contain both detectable soluble MN/CA IX antigen and HER-2 ectodomain, comprising the use of a monoclonal antibody, wherein said antibody binds specifically to MN/CA IX antigen.

5 47. A method of therapy for a cancer patient of claim 23, whose body fluids contain both detectable soluble MN/CA IX antigen and HER-2 ectodomain, comprising the use of a carbonic anhydrase inhibitor.

10 48. A method of gene therapy for a precancerous and/or cancerous disease, wherein said disease is associated with abnormal expression of MN/CA IX antigen, comprising the use of the antibody of claim 28, coupled to a plasmid/vector for targeted delivery to a cell expressing MN/CA IX antigen.

49. An anti-idiotype antibody to an idioype of the monoclonal antibody of claims 24 and 41.

15 50. A method of therapy for precancerous and/or cancerous disease, comprising the administration of the anti-idiotype antibody of claim 49 as a vaccine.

51. A method of detecting deletion variants of MN/CA IX antigen, comprising the use of a monoclonal antibody or monoclonal antibodies according to claims 24 and 41, and optionally a monoclonal antibody or monoclonal antibodies directed to an immunodominant epitope of MN/CA IX antigen.

20 52. A hybridoma that secretes a monoclonal antibody according to any one of claims -24, 35, 37, 39, 41 and 42.

25 53. Use of one or more MN/CA IX-specific antibodies and/or one or more MN/CA IX-specific antigen binding antibody fragments in the preparation of a diagnostic or medicament for use in the diagnosis and/or prognosis for precancerous and/or cancerous disease associated with abnormal expression of MN/CA IX antigen, wherein at least one of said MN/CA IX-specific antibodies or antibody fragments specifically binds to a non-immunodominant epitope of MN/CA IX protein.

54. The use of claim 53, wherein the disease is selected from the group consisting of mammary, urinary tract, kidney, ovarian, uterine, bladder, cervical, endometrial, vaginal, vulvar, prostate, liver, lung, skin, thyroid, pancreatic, testicular, brain, head and neck, gastrointestinal, colorectal and mesodermal precancerous and cancerous diseases.

30 55. Use of a monoclonal antibody generated from a MN/CA IX-deficient mammal in the preparation of a medicament for use in the treatment of precancerous and/or cancerous diseases associated with abnormal expression of MN/CA IX antigen,

wherein said MN/CA IX-specific antibody specifically binds to a non-immunodominant epitope of MN/CA IX protein.

5. 56. The use of claim 55, wherein the monoclonal antibody specifically binds the carbonic anhydrase (CA) domain of MN/CA IX.

5. 57. Use of a monoclonal antibody generated from a MN/CA IX-deficient mammal which specifically binds to a non-immunodominant epitope of the carbonic anhydrase (CA) domain of MN/CA IX protein, coupled to a plasmid/vector in the preparation of a medicament for targeted delivery of gene therapy for a precancerous and/or cancerous disease associated with abnormal expression of MN/CA IX antigen.

10. 58. Use of an anti-idiotype antibody directed to an idiotype of an antibody which specifically binds to a non-immunodominant epitope of MN/CA IX protein in the preparation of a vaccine for the therapy of a precancerous and/or cancerous disease associated with the expression of MN/CA IX antigen.

15. 59. An isolated soluble form of MN/CA IX antigen according to claim 1, substantially as herein described with reference to any one of the Examples.

60. A method according to claim 9, substantially as herein described with reference to any one of the Examples.

61. A monoclonal antibody according to claim 24, substantially as herein described with reference to any one of the Examples.

20. 62. A monoclonal antibody or antibody fragment according to claim 41, substantially as herein described with reference to any one of the Examples.

63. A use according to any one of claims 53, 55, 57 or 58, substantially as herein described with reference to any one of the Examples.

Dated 10 January 2008

Institute of Virology

Patent Attorneys for the Applicant/Nominated Person

SPRUSON & FERGUSON

1	M	A	P	L	C	P	S	P	W	L	P	L	12				
1	ACA	GTC	AGC	CGC	ATG	GCT	CCC	CTG	TGC	CCC	AGC	CCC	TGG	CTC	CCT	CTG	48
13	L	I	P	A	P	A	P	G	L	T	V	Q	L	L	L	S	28
49	TTG	ATC	CCG	GCC	CCT	GCT	CCA	GGC	CTC	ACT	GTG	CAA	CTG	CTG	CTG	TCA	96
29	L	L	L	L	M	P	V	H	P	Q	R	L	P	R	M	Q	44
97	CTG	CTG	CTT	CTG	ATG	CCT	GTC	CAT	CCC	CAG	AGG	TTG	CCC	CGG	ATG	CAG	144
45	E	D	S	P	L	G	G	G	S	S	G	E	D	D	P	L	60
145	GAG	GAT	TCC	CCC	TTG	GGA	GGA	GGC	TCT	TCT	GGG	GAA	GAT	GAC	CCA	CTG	192
61	G	E	E	D	L	P	S	E	E	D	S	P	R	E	E	D	76
193	GGC	GAG	GAG	GAT	CTG	CCC	AGT	GAA	GAG	GAT	TCA	CCC	AGA	GAG	GAG	GAT	240
77	P	P	G	E	E	D	L	P	G	E	E	D	L	P	G	E	92
241	CCA	CCC	GGA	GAG	GAG	GAT	CTA	CCT	GGA	GAG	GAG	GAT	CTA	CCT	GGA	GAG	288
93	E	D	L	P	E	V	K	P	K	S	E	E	E	G	S	L	108
289	GAG	GAT	CTA	CCT	GAA	GTT	AAG	CCT	AAA	TCA	GAA	GAA	GAG	GGC	TCC	CTG	336
109	K	L	E	D	L	P	T	V	E	A	P	G	D	P	Q	E	124
337	AAG	TTA	GAG	GAT	CTA	CCT	ACT	GTT	GAG	GCT	CCT	GGA	GAT	CCT	CAA	GAA	384
125	P	Q	N	N	A	H	R	D	K	E	G	D	D	Q	S	H	140
385	CCC	CAG	AAT	AAT	GCC	CAC	AGG	GAC	AAA	GAA	GGG	GAT	GAC	CAG	AGT	CAT	432
141	W	R	Y	G	G	D	P	P	W	P	R	V	S	P	A	C	156
433	TGG	CGC	TAT	GGA	GGC	GAC	CCG	CCC	TGG	CCC	CGG	GTG	TCC	CCA	GCC	TGC	480
157	A	G	R	F	Q	S	P	V	D	I	R	P	Q	L	A	A	172
481	GCG	GGC	CGC	TTC	CAG	TCC	CCG	GTG	GAT	ATC	CGC	CCC	CAG	CTC	GCC	GCC	528

WO 03/100029

1 / 20

PCT/US03/05136

FIG._1A

173	F	C	P	A	L	R	P	L	E	L	L	G	F	Q	L	P	188
529	TTC	TGC	CCG	GCC	CTG	CGC	CCC	CTG	GAA	CTC	CTG	GGC	TTC	CAG	CTC	CCG	576
189	P	L	P	E	L	R	L	R	N	N	G	H	S	V	Q	L	204
577	CCG	CTC	CCA	GAA	CTG	CGC	CTG	CGC	AAC	AAT	GGC	CAC	AGT	GTG	CAA	CTG	624
205	T	L	P	P	G	L	E	M	A	L	G	P	G	R	E	Y	220
625	ACC	CTG	CCT	CCT	GGG	CTA	GAG	ATG	GCT	CTG	GGT	CCC	GGG	CGG	GAG	TAC	672
221	R	A	L	Q	L	H	L	H	W	G	A	A	G	R	P	G	236
673	CGG	GCT	CTG	CAG	CTG	CAT	CTG	CAC	TGG	GGG	GCT	GCA	GGT	CGT	CCG	GGC	720
237	S	E	H	T	V	E	G	H	R	F	P	A	E	I	H	V	252
721	TCG	GAG	CAC	ACT	GTG	GAA	GGC	CAC	CGT	TTC	CCT	GCC	GAG	ATC	CAC	GTG	768
253	V	H	L	S	T	A	F	A	R	V	D	E	A	L	G	R	268
769	GTT	CAC	CTC	AGC	ACC	GCC	TTT	GCC	AGA	GTT	GAC	GAG	GCC	TTG	GGG	CGC	816
269	P	G	G	L	A	V	L	A	A	F	L	E	E	G	P	E	284
817	CCG	GGA	GGC	CTG	GCC	GTG	TTG	GCC	GCC	TTT	CTG	GAG	GAG	GGC	CCG	GAA	864
285	E	N	S	A	Y	E	Q	L	L	S	R	L	E	E	I	A	300
865	GAA	AAC	AGT	GCC	TAT	GAG	CAG	TTG	CTG	TCT	CGC	TTG	GAA	GAA	ATC	GCT	912
301	E	E	G	S	E	T	Q	V	P	G	L	D	I	S	A	L	316
913	GAG	GAA	GGC	TCA	GAG	ACT	CAG	GTC	CCA	GGA	CTG	GAC	ATA	TCT	GCA	CTC	960
317	L	P	S	D	F	S	R	Y	F	Q	Y	E	G	S	L	T	332
961	CTG	CCC	TCT	GAC	TTC	AGC	CGC	TAC	TTC	CAA	TAT	GAG	GGG	TCT	CTG	ACT	1008
333	T	P	P	C	A	Q	G	V	I	W	T	V	F	N	Q	T	348
1009	ACA	CCG	CCC	TGT	GCC	CAG	GGT	GTC	ATC	TGG	ACT	GTG	TTT	AAC	CAG	ACA	1056

FIG._1B

349	V	M	L	S	A	K	Q	L	H	T	L	S	D	T	L	W	364
1057	GTG	ATG	CTG	AGT	GCT	AAG	CAG	CTC	CAC	ACC	CTC	TCT	GAC	ACC	CTG	TGG	1104
365	G	P	G	D	S	R	L	Q	L	N	F	R	A	T	Q	P	380
1105	GGA	CCT	GGT	GAC	TCT	CGG	CTA	CAG	CTG	AAC	TTC	CGA	GCG	ACG	CAG	CCT	1152
381	L	N	G	R	V	I	E	A	S	F	P	A	G	V	D	S	396
1153	TTG	AAT	GGG	CGA	GTG	ATT	GAG	GCC	TCC	TTC	CCT	GCT	GGA	GTG	GAC	AGC	1200
397	S	P	R	A	A	E	P	V	Q	L	N	S	C	L	A	A	412
1201	AGT	CCT	CGG	GCT	GCT	GAG	CCA	GTC	CAG	CTG	AAT	TCC	TGC	CTG	GCT	GCT	1248
413	G	D	I	L	A	L	V	F	G	L	L	F	A	V	T	S	428
1249	GGT	GAC	ATC	CTA	GCC	CTG	GTT	TTT	GGC	CTC	CTT	TTT	GCT	GTC	ACC	AGC	1296
429	V	A	F	L	V	Q	M	R	R	Q	H	R	R	G	T	K	444
1297	GTC	GCG	TTC	CTT	GTG	CAG	ATG	AGA	AGG	CAG	CAC	AGA	AGG	GGA	ACC	AAA	1344
445	G	G	V	S	Y	R	P	A	E	V	A	E	T	G	A	*	460
1345	GGG	GGT	GTG	AGC	TAC	CGC	CCA	GCA	GAG	GTA	GCC	GAG	ACT	GGA	GCC	TAG	1392
1393	AGG	CTG	GAT	CTT	GGA	GAA	TGT	GAG	AAG	CCA	GCC	AGA	GGC	ATC	TGA	GGG	1440
1441	GGA	GCC	GGT	AAC	TGT	CCT	GTC	CTG	CTC	ATT	ATG	CCA	CTT	CCT	TTT	AAC	1488
1489	TGC	CAA	GAA	ATT	TTT	TAAT	AAT	AAA	TAT	TTA	TAAT	T					1522

FIG._1C**FIG._1****FIG._1A****FIG._1B****FIG._1C**

1 ggatcctgtt gactcgtgac cttaccccca accctgtgct ctctgaaaca tgagctgtgt
 61 ccactcaggg ttaaatggat taagggcggt gcaagatgtg ctttgttaaa cagatgcttgc
 121 aaggcagcat gctcgtaag agtcatcacc aatccctaattt ctcagaat cagggacaca
 181 aacactgcgg aaggccgcag ggtcctctgc ctaggaaaaac cagagacctt tggacttgc
 241 tttatctgac cttccctcca ctattgtcca tgaccctgccc aaatccccctt ctgtgagaaa
 301 cacccaagaa ttatcaataa aaaaataaaat taaaaaaaaaaa aataaaaaaaa aaaaaaaaaaaa
 361 aaaaaaaaaaa gacttacgaa tagttattga taaatgaata gctattggta aagccaagta
 421 aatgatcata ttcaaaaacca gacggccatc atcacagctc aagtctacccctt gattgtatct
 481 ctttatcatt gtcattcttt ggattcaacta gattagtcat catccctcaaa attctcccccc
 541 aagttctaat tacgttccaa acatttaggg gttacatgaa gcttgaacccctt actaccttct
 601 ttgcgtttga gccatgagtt gtaggaatga tgagtttaca cttacatgc tggggattaa
 661 tttaaactttt acctctaagt cagttggta gcctttggct tattttgtt gctaatttttgc
 721 tagttaatgg atgcactgtg aatcttgcta tgatagttt cttccacact ttgccactag
 781 gggtaggtag gtactcagtt ttcagtaatt gcttacctaa gaccctaagc cctatttctc
 841 ttgtactggc ctttatctgt aatatggca tatttaatac aatataattt ttggagttt
 901 tttgtttgtt tttttttttt tttttttttag acggagtctt gcatctgtca tgccaggct
 961 ggagtagcag tgggccatc tcggctcaact gcaagctcca cctcccgagt tcacgcccatt
 1021 ttcctgcctc agcctccca gtagctggaa ctacaggcgc cggccaccat gcccggctaa
 1081 tttttgtat ttttggtaga gacggggttt caccgttta gccagaatgg tctcgatctc
 1141 ctgacttcgt gatccaccccg cctcgccctc ccaaagttt gggattacag gtgtgagcca
 1201 ccgcacctgg ccaattttt gagtctttt aagttttt atgttttta agctggtaac
 1261 tatggtacat ttccttttat taatgtggtg ctgacggtca tataggttt tttgagttt
 1321 gcatgcataat gctactttt gcagtcctt cattacattt ttctctcttc atttgaagag
 1381 catgttatat ctttagctt cactggctt aaaaggttt ctcattagcc taacacagtg
 1441 tcattgttgg taccacttgg atcataagtg gaaaaacagt caagaaattt cacagtaata
 1501 cttgtttgtt agagggatga ttcaggtgaa tctgacacta agaaaactccc ctacctgagg
 1561 tctgagattc ctctgacatt gctgtatata ggcttttctt ttgacagcct gtgactgcgg
 1621 actattttc ttaagcaaga tatgctaaag ttttggatcatcattggc cttttccag agagaggct
 1681 catatctgca tcaagtgaga acatataatg tctgcatgtt tccatatttc aggaatgtt
 1741 gcttgtgttt tatgcttttata tatacagg gaaacttgg cctcagtgac cccaaagagg
 1801 tggaaattgt tattggatcatcattggc ccacgcttgc tgaccttggaa aacaattaag
 1861 ggttcataat ctcaattctg tcagaattgg tacaagaat agctgctatg tttcttgaca
 1921 ttccacttgg taggaaataa gaatgtgaaa ctcttcagg ggtgtgtgtc cct?gtttt

FIG._2A

1981 ttgcaattc cttcttactg tgtaaaaaaa aagtatgatc ttgctctgag aggtgaggca
 2041 ttcttaatca tgatcttaa agatcaataa tataatcctt tcaaggatta tgtctttatt
 2101 ataataaaaga taatttgtct ttaacagaat caataatata atcccttaaa ggattatatc
 2161 tttgctggc gcagtggctc acacctgtaa tcccagcact ttgggtggcc aaggtggaag
 2221 gatcaaattt gcctacttct atattatctt ctaaagcaga attcatctct cttccctcaa
 2281 tatgatgata ttgacagggt ttgcctcac tcactagatt gtgagctcct gctcagggca
 2341 ggttagcgttt ttgtttttg ttttgtttt tcttttttga gacagggtct tgctctgtca
 2401 cccaggccag agtcaatgg tacagtctca gctcaactgca gcctcaaccg cctcggctca
 2461 aaccatcatc ccatttcagc ctcctgagta gctgggacta caggcacatg ccattacacc
 2521 tgcttaattt ttttgttattt cttagtagaga cagggtttgg ccatgttgcc cgggctggtc
 2581 tcgaactcct ggactcaagc aatccaccca cctcagcctc ccaaaatgag ggaccgtgtc
 2641 ttattcattt ccatgtccct agtccatagc ccagtgtctt acctatggta gtactaaata
 2701 aatatttggta gaatgcaata gtaaatagca tttcaggggag caagaactag attaacaag
 2761 gtggtaaaag gtttggagaa aaaaataata gtttaatttgc tagagtat gaggagagt
 2821 agtaggagac aagatggaaa ggtcttttgg gcaagggtttt gaaggaagtt ggaagtcaga
 2881 agtacacaat gtgcataatcg tggcaggcag tggggagcca atgaaggctt ttgagcagga
 2941 gagtaatgtg ttgaaaaata aatataaggaa aacctatca gagccctct gacacataca
 3001 cttgcttttca attcaagctc aagtttgc tccacatacc cattacttaa ctcaccctcg
 3061 ggctccccta gcagcctgcc ctacctctt acctgcttcc tgggtggagtc agggatgtat
 3121 acatgagctg cttccctct cagccagagg acatgggggg cccagctcc cctgccttcc
 3181 cccttctgtg cttggagctg ggaagcaggc cagggttagc tgaggctggc tggcaagcag
 3241 ctgggtggtg ccagggagag cctgcatagt gccaggtggt gccttgggtt ccaagctagt
 3301 ccatggcccc gataaccttc tgcctgtca cacacgtcc ctcactcca ccccatcct
 3361 agctttggta tgggggagag ggcacaggc cagacaaacc tgtgagactt tggctccatc
 3421 tctgcaaaag ggcgtctgt gagtcaagcct gtcctccaggcttgccttcc cttccccacc
 3481 cagctctcgat ttccaatgca cgtacagccc gtacacaccg tgtgctggaa caccggACAG
 3541 TCAGCCGCAT GGCTCCCCCTG TGCCCCAGCC CCTGGCTCCC TCTGTTGATC CCGGGCCCCCTG
 3601 CTCCAGGCCT CACTGTGCAA CTGCTGCTGT CACTGCTGCT TCTGGTGCCT GTCCATCCCC
 3661 AGAGGTTGCC CCGGATGCAG GAGGATTCCC CCTTGGGAGG AGGCTCTTCT GGGGAAGATG
 3721 ACCCACTGGG CGAGGAGGAT CTGCCCAGTG AAGAGGATTC ACCCAGAGAG GAGGATCCAC
 3781 CCGGAGAGGA GGATCTACCT GGAGAGGAGG ATCTACCTGG AGAGGAGGAT CTACCTGAAG
 3841 TTAAGCCTAA ATCAGAAGAA GAGGGCTCCC TGAAGTTAGA GGATCTACCT ACTGTTGAGG
 3901 CTCCCTGGAGA TCCTCAAGAA CCCCAGAATA ATGCCACAG GGACAAAGAA Ggttaagtgg

FIG._2B

3961 catcaatctc caaatccagg ttccaggagg ttcatgactc ccctcccata ccccagccta
 4021 ggctctgttc actcagggaa ggaggggaga ctgtactccc cacagaagcc cttccagagg
 4081 tcccatacca atatccccat ccccactctc ggaggtagaa agggacagat gtggagagaa
 4141 aataaaaaagg gtgcaaaagg agagagggtga gctggatgag atgggagaga agggggaggc
 4201 tggagaagag aaagggatga gaactgcaga ttagagaaaa aatgtgcaga cagagaaaa
 4261 aaataggtgg agaaggagag tcagagagtt tgaggggaag agaaaaggaa agcttgggag
 4321 gtgaagtggg taccagagac aagcaagaag agctggtaga agtcatctca tcttaggcta
 4381 caatgagggaa ttgagaccta ggaagaaggg acacagcagg tagagaaacg tggcttctg
 4441 actcccaagc caggaatttgg gggaaagggg ttggagacca tacaaggcag agggatgagt
 4501 ggggagaaga aagaagggag aaaggaaaga tggtgtactc actcatttgg gactcaggac
 4561 tgaagtggcc actcacttttttttttttggagac aaactttcac ttttgttgc
 4621 caggctggag tgcaatggcg cgatctggc tcactgcaac ctccacctcc cgggttcaag
 4681 tgattctcct gcctcagcct ctagccaatg agctgcgtt acaggcatgc gccaccacgc
 4741 ccggctaatt ttgttatttt tagtagagac ggggttgc catgttggtc aggctggtct
 4801 cgaactcctg attcaggtg atccaaccac cttggcctcc caaagtctg ggattatagg
 4861 cgtgagccac agcgcctggc ctgaagcagc cactcacttt tacagaccct aagacaatga
 4921 ttgcaagctg gttaggattgc tggttggccc acccagctgc ggtgttgagt ttgggtgcgg
 4981 ttcctgtgc ttgcacctg gcccgtttaa ggcatttgc acccgtaatg ctccctgttaag
 5041 gcatctgcgt ttgtgacatc gtttggtcg ccaggaaggg attggggctc taagcttgag
 5101 cggttcatcc ttttcattta tacagGGGAT GACCAGAGTC ATTGGCGCTA TGGAGgtgag
 5161 acacccaccc gctgcacaga cccaatctgg gaacccagct ctgtggatct cccctacagc
 5221 cgtccctgaa cactggtccc gggcgccca cccgcccggcc accgtcccac cccctcacct
 5281 ttctaccccg gttcccttaa gttcctgacc taggcgtcag acttcctcac tataactctcc
 5341 caccccaagGC GACCCGCCCT GGCCCCGGGT GTCCCCAGCC TGCGCGGGCC GCTTCCAGTC
 5401 CCCGGTGGAT ATCCGCCCTT AGCTCGCCGC CTTCTGCCCG GCCCTGCGCC CCCTGGAACT
 5461 CCTGGGCTTC CAGCTCCCAGC CGCTCCCAGA ACTGCGCCTG CGAACAAATG GCCACAGTG
 5521 tgagggggtc tccccgccga gacttggga tggggcgggg cgcaaggaaag ggaaccgtcg
 5581 cgcaactgcgtt gcccgggggt tgggctggcc ctaccgggccc gggccggctc acttgcctct
 5641 ccctacgcag TGCAACTGAC CCTGCCTCCT GGGCTAGAGA TGGCTCTGGG TCCCGGGCGGG
 5701 GAGTACCGGG CTCTGCAGCT GCATCTGCAC TGGGGGGCTG CAGGTCGTCC GGGCTCGGAG
 5761 CACACTGTGG AAGGCCACCG TTTCCCTGCC GAGgtgagcg cggactggcc gagaagggc
 5821 aaaggagccgg ggcggacggg ggccagagac gtggccctct cctaccctcg tgccttttc
 5881 agATCCACGT GGTTCACCTC AGCACCGCCCT TTGCCAGAGT TGACGAGGCC TTGGGGCGCC

FIG. 2C

5941 CGGGAGGCCT GGCCGTGTTG GCCGCCCTTC TGGAGgtacc agatcctgga cacccccac
 6001 tccccgctt cccatccat gtcctcccg gactctatcg tggagccaga gaccccatcc
 6061 cagcaagctc actcaggccc ctggctgaca aactcattca cgcactgtt gttcattaa
 6121 caccactgt gaaccaggca ccagccccca acaaggattc tgaagctgta ggtccttgcc
 6181 tctaaggagc ccacagccag tggggaggc tgacatgaca gacacatagg aaggacatag
 6241 taaagatggt ggtcacagag gaggtgacac ttaaaggcctt cactggtaga aaagaaaaagg
 6301 aggtgttcat tgcagaggaa acagaatgtg caaagactca gaatatggcc tatttaggaa
 6361 atggctacat acaccatgat tagaggaggc ccagtaaagg gaagggatgg tgagatgcct
 6421 gctaggttca ctcactcact tttattttt tatttatttt tttgacagtc tctctgtcgc
 6481 ccaggctgga gtgcagtggt gtgatcttgg gtcactgcaa cttccgcctc ccgggttcaa
 6541 gggattctcc tgcctcagct tcctgagtag ctggggttac aggtgtgtgc caccatgccc
 6601 agctaatttt tttttgtatt ttttagtagac agggttcac catgttggtc aggctggct
 6661 caaactcctg gcctcaagtg atccgcctga ctcagcctac caaagtgtcg attacaagt
 6721 tgagccaccg tgcccagcca cactcactga ttctttaatg ccagccacac agcacaaagt
 6781 tcagagaaat gcctccatca tagcatgtca atatgttcat actcttaggt tcatgatgtt
 6841 cttaacatta gttcataag caaaataaga aaaaagaata ataaataaaa gaagtggcat
 6901 gtcaggacct cacctaaaaa gccaaacaca gaatcatgaa ggtaatgca gaggtgacac
 6961 caacacaaaag gtgtatatat gtttctgt gggagtagt tacggaggca gcagttagt
 7021 agactgcaaa cgtcagaagg gcacgggtca ctgagagcct agtacccat taaagtggc
 7081 tctctccctc tctctccagc ttgtcattga aaaccagtcc accaagctt gttgttcgca
 7141 cagcaagagt acatagagtt taaaataata cataggattt taagagggag acactgtc
 7201 taaaaaaaaa aacaacagca acaaaaaaaaaa gcaacaacca ttacaatttt atgttccctc
 7261 agcattctca gagctgagga atgggagagg actatggaa ccccttcattt gttccggcct
 7321 tcagccatgg ccctggatac atgcactcat ctgtcttaca atgtcattcc cccagGAGGG
 7381 CCCGGAAGAA AACAGTGCCT ATGAGCAGTT GCTGTCTCGC TTGGAAAGAAA TCGCTGAGGA
 7441 AGgtcagttt gttggctgg ccactaatct ctgtggccta gttcataaaag aatcacccctt
 7501 tggagcttca ggtctgaggc tggagatggg ctccctccag tgcaggaggg attgaagcat
 7561 gagccagcgc tcatcttgat aataaccatg aagctgacag acacagttac ccgcaaacgg
 7621 ctgcctacag attaaaaacc aagaaaaac cggccggcactt ggtggctcac gcctgtatc
 7681 ccagcacttt gggaggccaa ggcagggtgga tcacgaggc aagagatcaa gaccatccctg
 7741 gccaacatgg taaaacccca tctctactaa aaatacgaaa aaatagccag gcgtggtggc
 7801 gggtgctgt aatcccagct actcgggagg ctgaggcagg agaatggcat gaacccggga
 7861 ggcagaagtt gcagtgagcc gagatcgtgc cactgcactc cagcctggc aacagagcga

FIG._2D

7921 gactcttgc tcaaaaaaaaaaaaaaaa aaaaaaaaaaaa gaaaaccaag caaaaaccaa aatgagacaa
 7981 aaaaaacaag accaaaaaaaaat ggtgtttgga aattgtcaag gtcaagtctg gagagctaaa
 8041 cttttctga gaactgtta tcttaataa gcatcaaata ttttaacttt gtaaaatactt
 8101 ttgttggaaa tcgttctt cttagtcact cttgggtcat tttaaatctc acttactcta
 8161 ctagacctt taggttctg ctagactagg tagaactctg ctttgcatt tcttgtgtct
 8221 gtttgtata gttatcaata ttcatattta ttacaagtt attcagatca tttttctt
 8281 tctttttttt tttttttttt ttttttacat ctttagtaga gacagggtt caccatattg
 8341 gccaggctgc tctcaaactc ctgaccttgc gatccaccag ctcggccctc ccaaagtgc
 8401 gggattcatt ttttctttt aatttgctct gggcttaaac ttgtggccca gcactttatg
 8461 atggtacaca gagttaaagag ttagactca gacggtctt cttctttctt tctcttcctt
 8521 cctcccttcc ctcccacccctt cccttctctc cttcctttctt ttcttcctctt cttgcttcct
 8581 caggcctctt ccagttgttc caaagccctg tactttttt tgagttaaacg tcttatggaa
 8641 agggcctgca cttagtgaag aagtggctc agagttgagt taccttgct tctgggaggt
 8701 gaaactgtat ccctataaccc tgaagctta aggggggtca atgttagatga gaccccaaca
 8761 tagatcctct tcacagGCTC AGAGACTCAG GTCCCAGGAC TGGACATATC TGCACCTCTG
 8821 CCCTCTGACT TCAGCCGCTA CTTCCAATAT GAGGGGTCTC TGACTACACC GCCCTGTGCC
 8881 CAGGGTGTCA TCTGGACTGT GTTTAACAG ACAGTGATGC TGAGTGCTAA GCAGgtggc
 8941 ctgggggtgtg tgtggacaca gtgggggtcggtt gggaaagagg atgttagatg agatgagaaa
 9001 caggagaaga aagaaatcaa ggctgggttc tgtggcttac gcctataatc ccaccacgtt
 9061 gggaggctga ggtggggagaa tgggttggc ccaggagttc aagacaaggc gggcaacat
 9121 agtgtgaccc catctcttacc aaaaaaaaaacc caacaaaacc aaaaatagcc gggcatggtg
 9181 gtatgcggcc tagtcccagc tactcaagga ggctgaggtg ggaagatcgc ttgattccag
 9241 gagtttgaga ctgcagtggatctatgatcccc accactggctt accatcttta ggatacattt
 9301 atttattttt aaaaagaatc aagaggctgg atggggataa caggagctgg aggggtggagc
 9361 cctgaggtgc tgggtgttag ctggccttggg acccttggg cctgtcatgc catgaaccca
 9421 cccacactgt ccactgaccc cttagCTCC ACACCCCTCTC TGACACCCTG TGGGGACCTG
 9481 GTGACTCTCG GCTACAGCTG AACTTCCGAG CGACGCAGCC TTTGAATGGG CGAGTGATTG
 9541 AGGCCTCCTT CCCTGCTGGA GTGGACAGCA GTCCTCGGGC TGCTGAGCCA Ggtacagctt
 9601 tgtctggttt ccccccagcc agtagtccct tattcctccca tgtgtgtgcc agtgtctgtc
 9661 attgggtgtc acagccccc tctcacatct ctttttctc tccagTCCAG CTGAATTCT
 9721 GCCTGGCTGC TGgtgagttt gcccctcctc ttgggtcctga tgccaggaga ctcctcagca
 9781 ccattcagcc ccagggctgc tcaggacccgc ctctgctccc tctcctttc tgcagaacag
 9841 accccaaccc caatattaga gaggcagatc atgggtgggaa ttccccatt gtccccagag

FIG._2E

9901 gctaattgat tagaatgaag cttgagaaat ctcccagcat ccctctcgca aaagaatccc
 9961 cccccctttt tttaaagata gggctcact ctgtttgcc caggctgggg tttgtggca
 10021 cgatcatagc tcactgcagc ctcgaactcc taggctcagg caatccttc accttagctt
 10081 ctcaaagcac tggactgta ggcattgagcc actgtgcctg gccccaaacg gccctttac
 10141 ttggcttta ggaagcaaaa acggtgctt tcttaccct tctcgtgtat ccaccctcat
 10201 cccttggctg gcctcttctg gagactgagg cactatgggg ctgcctgaga actcggggca
 10261 ggggtgggtgg agtgcactga ggcagggttt gaggaactct gcagaccctt cttccttccc
 10321 aaagcagccc tctctgctct ccatcgca g TGACATCCTA GCCCTGGTTT TTGGCCTCCT
 10381 TTTTGCTGTC ACCAGCGTCG CGTTCCCTGT GCAGATGAGA AGGCAGCAC A Gtattacac
 10441 tgacccttcc ttcaaggcaca agttcccccc acccttgggg agtcaacttca tgcaaagcgc
 10501 atgcaaatga gctgctcctg ggccagttt ctgattagcc tttcctgttg tgtacacaca
 10561 gAAGGGGAAAC CAAAGGGGGT GTGAGCTACC GCCCAGCAGA GGTAGCCGAG ACTGGAGCCT
 10621 AGAGGGCTGGA TCTTGGAGAA TGTGAGAAAGC CAGCCAGAGGG CATCTGAGGG GGAGCCGGTA
 10681 ACTGTCCCTGT CCTGCTCATT ATGCCACTTC CTTTTAACTG CCAAGAAATT TTTTAAAATA
 10741 AATATTTATA ATaaaatatg tgtagtcac ctttggccc caaatcagaa ggaggtat
 10801 gaatttccta ttactgttat tagcaccaat ttagtggtaa tgcatttatt ctattacat
 10861 tcggcctcct tccacacatc actccaaatgt gttgctcc

FIG._2F

FIG._2A

FIG._2B


FIG._2C

FIG._2D

FIG._2E

FIG._2F

FIG._2

**FIG. 3**

11 / 20




FIG. 4

2003217606 20 Sep 2004

WO 03/100029

PCT/US03/05136

12 / 20

HCA	IX	1	10	20	30	40	50	59
MCA	IX	MAPLCPSPWPLLIPAPAPGLTVQLLLSLLLMPVHPQRLPRMQ	-EDS	PLGGGSSGEEDP				
		MASLGSPWAPLSTPAP	--	-TAQLLLFLLLQVSAQPQGLSGMQGEPS	-LGDSSSGEDE-			
HCA	IX	61	70	80	90	100	110	
MCA	IX	LGEED-LPSEEDSPREE-DPPGE	EDLPGEED	LPGEEDLP	EVKPKSE	--EEGSLKLEDLP		
		LGV-DVLPSEEDAP	--EEADPP	--D-	GE-D-P	--PEVN--SEDRMEE-SLGLEDLS		
HCA	IX	120	130	140	150	160	170	
MCA	IX	TVEAPGDPQE	P-QNNAHARD	-KEGDDQS	HWRYYGGDP	PPPRVSPACAGRF	QSPVDIRPQLA-	
		TPEAP	--EHSQGS	-HGD	EKGHH-S	HWSYGGTL	LWPQVSPACAGRF	QSPVDIR--LER
HCA	IX	180	190	200	210	220	230	
MCA	IX	-AFCPA	LRPL	ELLGFQLPPLPEL	RLLRNNGHS	VQLTLPPGL	EMALGPGR	EYRALQLHLHWG
		TAFCRT	LQPL	ELLGYELQPLPEL	SLSNNGHTV	QVQLTLPPGL	KMALGPGQ	EYRALQLHLHWG
HCA	IX	240	250	260	270	280	290	
MCA	IX	AAGRPG	SEHT	VEGHRFP	AEIHV	VHLSTAFAR	VDEALGRPG	GLAVLAAF
		SDHPG	SEHT	VNGHRFP	AEIHV	VHLSTAFSEL	HEALGRPG	GLAVLAAF
hCA	IX	300	310	320	330	340	348	
MCA	IX	QLLSRL	EEIA	EEGS	--ETQVPG	LDISA	LLPSDFS	RYFQYEGSLTT
		QLLSHL	EEIS	EEGSKIE	--IPGL	DVSA	LLPSDFS	RYYRYEGSLTT
HCA	IX	360	370	380	390	400	408	
MCA	IX	VMLS	SAKQLHT	LSDTLWGP	GDSRLQLNFRATQ	PLNGRVIEA	SFPAGVDS	SPRAAEPVQLNS
		VK	LSAKQLHT	LSVSLWGP	PRDSRLQLNFRATQ	PLNGRTIEA	SFPAAEDS	SP---EPVHVNS
HCA	IX	420	430	440	450	459		
HCA	IX	CLAAGD	ILALVFG	LLFAVT	SVAFLVQM	RRQHRR	--G	
		CFTAGD	ILALVFG	LLFAVT	SIAFLLQL	RRQHRRHSGTKDRVSYS	PAEMTETGA	

Fig. 5A

13 / 20




Fig._5B




Fig. 6

15 / 20




Fig. 7A

16 / 20










Fig. 7B


17 / 20

**FIG. 8A****FIG. 8B**

**FIG. 9A****FIG. 9B****FIG. 9C**

**FIG._9D**

20 / 20

**FIG. 10**

19 Nov 2004

2003217606

1/50

SEQUENCE LISTING

<110> Bayer Corporation
Bayer HealthCare
Institute of Virology of the Slovak Academy of Sciences
Pastorek, Jaromir
Zavada, Jan
Ortova Gut, Marta
Zatovicova, Miriam
Pastorekova, Silvia

<120> MN/CA IX-SPECIFIC MONOCLONAL ANTIBODIES GENERATED FROM MN/CA IX-DEFICIENT MICE AND METHODS OF USE

<130> MST-2363 PCT

<140> PCT/US03/05136
<141> 2003-02-21

<150> 60/358,824
<151> 2002-02-21

<150> 60/383,068
<151> 2002-05-23

<150> 60/431,499
<151> 2002-12-05

<160> 118

<170> PatentIn version 3.2

<210> 1
<211> 1522
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (13)..(1389)

<220>
<221> mat_peptide
<222> (124)..(1389)

<400> 1
acagtcagcc gc atg gct ccc ctg tgc ccc agc ccc tgg ctc cct ctg ttg 51
Met Ala Pro Leu Cys Pro Ser Pro Trp Leu Pro Leu Leu
-35 -30 -25

atc ccg gcc cct gct cca ggc ctc act gtg caa ctg ctg ctg tca ctg 99
Ile Pro Ala Pro Ala Pro Gly Leu Thr Val Gln Leu Leu Ser Leu
-20 -15 -10

ctg ctt ctg atg cct gtc cat ccc cag agg ttg ccc cgg atg cag gag 147
Leu Leu Leu Met Pro Val His Pro Gln Arg Leu Pro Arg Met Gln Glu
-5 -1 1 5

gat tcc ccc ttg gga gga ggc tct tct ggg gaa gat gac cca ctg ggc 195
Asp Ser Pro Leu Gly Gly Ser Ser Gly Glu Asp Asp Pro Leu Gly
10 15 20

gag gag gat ctg ccc agt gaa gag gat tca ccc aga gag gag gat cca 243
Glu Glu Asp Leu Pro Ser Glu Glu Asp Ser Pro Arg Glu Glu Asp Pro
25 30 35 40

ccc gga gag gag gat cta cct gga gag gag gat cta cct gga gag gag 291

2003217606 19 Nov 2004

2/50

Pro	Gly	Glu	Glu	Asp	Leu	Pro	Gly	Glu	Glu	Asp	Leu	Pro	Gly	Glu	Glu	
						45					50					55
gat	cta	cct	gaa	gtt	aag	cct	aaa	tca	gaa	gaa	gag	ggc	tcc	ctg	aag	
Asp	Leu	Pro	Glu	Val	Lys	Pro	Lys	Ser	Glu	Glu	Glu	Gly	Ser	Leu	Lys	
					60				65				70			
tta	gag	gat	cta	cct	act	gtt	gag	gct	cct	gga	gat	cct	caa	gaa	ccc	
Leu	Glu	Asp	Leu	Pro	Thr	Val	Glu	Ala	Pro	Gly	Asp	Pro	Gln	Glu	Pro	
					75				80				85			
cag	aat	aat	gcc	cac	agg	gac	aaa	gaa	ggg	gat	gac	cag	agt	cat	tgg	
Gln	Asn	Asn	Ala	His	Arg	Asp	Lys	Glu	Gly	Asp	Asp	Gln	Ser	His	Trp	
					90				95				100			
cgc	tat	gga	ggc	gac	ccg	ccc	tgg	ccc	cg	gtg	tcc	cca	gcc	tgc	g	
Arg	Tyr	Gly	Gly	Asp	Pro	Pro	Trp	Pro	Arg	Val	Ser	Pro	Ala	Cys	Ala	
					105				110				115		120	
ggc	cgc	ttc	cag	tcc	ccg	gtg	gat	atc	cgc	ccc	cag	ctc	gcc	gcc	ttc	
Gly	Arg	Phe	Gln	Ser	Pro	Val	Asp	Ile	Arg	Pro	Gln	Leu	Ala	Ala	Phe	
					125				130				135			
tgc	ccg	gcc	ctg	cgc	ccc	ctg	gaa	ctc	ctg	ggc	ttc	cag	ctc	ccg	ccg	
Cys	Pro	Ala	Leu	Arg	Pro	Leu	Glu	Leu	Leu	Gly	Phe	Gln	Leu	Pro	Pro	
					140				145				150			
ctc	cca	gaa	ctg	cgc	ctg	cgc	aac	aat	ggc	cac	agt	gtg	caa	ctg	acc	
Leu	Pro	Glu	Leu	Arg	Leu	Arg	Asn	Asn	Gly	His	Ser	Val	Gln	Leu	Thr	
					155				160				165			
ctg	cct	cct	ggg	cta	gag	atg	gct	ctg	gg	ccc	ggg	cg	gag	tac	cg	
Leu	Pro	Pro	Gly	Leu	Glu	Met	Ala	Leu	Gly	Pro	Gly	Arg	Glu	Tyr	Arg	
					170				175				180			
gct	ctg	cag	ctg	cat	ctg	cac	tgg	ggg	gct	gca	ggt	cgt	ccg	ggc	tcg	
Ala	Leu	Gln	Leu	His	Leu	His	Trp	Gly	Ala	Ala	Gly	Arg	Pro	Gly	Ser	
					185				190				195		200	
gag	cac	act	gtg	gaa	ggc	cac	cgt	tcc	cct	gcc	gag	atc	cac	gtg	gtt	
Glu	His	Thr	Val	Glu	Gly	His	Arg	Phe	Pro	Ala	Glu	Ile	His	Val	Val	
					205				210				215			
cac	ctc	agc	acc	gcc	ttt	gcc	aga	gtt	gac	gag	gcc	ttg	ggg	cg	ccg	
His	Leu	Ser	Thr	Ala	Phe	Ala	Arg	Val	Asp	Glu	Ala	Leu	Gly	Arg	Pro	
					220				225				230			
gga	ggc	ctg	gcc	gtg	ttg	gcc	gcc	ttt	ctg	gag	gag	ggc	ccg	gaa	gaa	
Gly	Gly	Leu	Ala	Val	Leu	Ala	Ala	Phe	Leu	Glu	Glu	Gly	Pro	Glu	Glu	
					235				240				245			
aac	agt	gcc	tat	gag	cag	ttg	ctg	tct	cgc	ttg	gaa	gaa	atc	gct	gag	
Asn	Ser	Ala	Tyr	Glu	Gln	Leu	Leu	Ser	Arg	Leu	Glu	Glu	Ile	Ala	Glu	
					250				255				260			
gaa	ggc	tca	gag	act	cag	gtc	cca	gga	ctg	gac	ata	tct	gca	ctc	ctg	
Glu	Gly	Ser	Glu	Thr	Gln	Val	Pro	Gly	Leu	Asp	Ile	Ser	Ala	Leu	Leu	
					265				270				275		280	
ccc	tct	gac	ttc	agc	cgc	tac	ttc	caa	tat	gag	ggg	tct	ctg	act	aca	
Pro	Ser	Asp	Phe	Ser	Arg	Tyr	Phe	Gln	Tyr	Glu	Gly	Ser	Leu	Thr	Thr	
					285				290				295			
ccg	ccc	tgt	gcc	cag	gg	gtc	atc	tgg	act	gtg	ttt	aac	cag	aca	gtg	
Pro	Pro	Cys	Ala	Gln	Gly	Val	Ile	Trp	Thr	Val	Phe	Asn	Gln	Thr	Val	
					300				305				310			
atg	ctg	agt	gct	aag	cag	ctc	cac	acc	ctc	tct	gac	acc	ctg	tgg	gga	

2003217606 19 Nov 2004

3/50

Met Leu Ser Ala Lys Gln Leu His Thr Leu Ser Asp Thr Leu Trp Gly			
315	320	325	
cct ggt gac tct cgg cta cag ctg aac ttc cga gcg acg cag cct ttg			1155
Pro Gly Asp Ser Arg Leu Gln Leu Asn Phe Arg Ala Thr Gln Pro Leu			
330	335	340	
aat ggg cga gtg att gag gcc tcc ttc cct gct gga gtg gac agc agt			1203
Asn Gly Arg Val Ile Glu Ala Ser Phe Pro Ala Gly Val Asp Ser Ser			
345	350	355	360
cct cgg gct gct gag cca gtc cag ctg aat tcc tgc ctg gct gct ggt			1251
Pro Arg Ala Ala Glu Pro Val Gln Leu Asn Ser Cys Leu Ala Ala Gly			
365	370	375	
gac atc cta gcc ctg gtt ttt ggc ctc ctt ttt gct gtc acc agc gtc			1299
Asp Ile Leu Ala Leu Val Phe Gly Leu Leu Phe Ala Val Thr Ser Val			
380	385	390	
gcg ttc ctt gtg cag atg aga agg cag cac aga agg gga acc aaa ggg			1347
Ala Phe Leu Val Gln Met Arg Arg Gln His Arg Arg Gly Thr Lys Gly			
395	400	405	
ggt gtg agc tac cgc cca gca gag gta gcc gag act gga gcc			1389
Gly Val Ser Tyr Arg Pro Ala Glu Val Ala Glu Thr Gly Ala			
410	415	420	
tagaggctgg atcttgaga atgtgagaag ccagccagag gcacatctgagg gggagccggt			1449
aactgtcctg tcctgctcat tatgccactt ccttttaact gccaagaaat tttttaaaat			1509
aaatatttat aat			1522

<210> 2
<211> 459
<212> PRT
<213> Homo sapiens

<400> 2

Met Ala Pro Leu Cys Pro Ser Pro Trp Leu Pro Leu Leu Ile Pro Ala
-35 -30 -25

Pro Ala Pro Gly Leu Thr Val Gln Leu Leu Leu Ser Leu Leu Leu Leu
-20 -15 -10

Met Pro Val His Pro Gln Arg Leu Pro Arg Met Gln Glu Asp Ser Pro
-5 -1 1 5 10

Leu Gly Gly Ser Ser Gly Glu Asp Asp Pro Leu Gly Glu Glu Asp
15 20 25

Leu Pro Ser Glu Glu Asp Ser Pro Arg Glu Glu Asp Pro Pro Gly Glu
30 35 40

Glu Asp Leu Pro Gly Glu Glu Asp Leu Pro Gly Glu Glu Asp Leu Pro
45 50 55

Glu Val Lys Pro Lys Ser Glu Glu Glu Gly Ser Leu Lys Leu Glu Asp
60 65 70 75

2003217606 19 Nov 2004

4/50

Leu Pro Thr Val Glu Ala Pro Gly Asp Pro Gln Glu Pro Gln Asn Asn
80 85 90

Ala His Arg Asp Lys Glu Gly Asp Asp Gln Ser His Trp Arg Tyr Gly
95 100 105

Gly Asp Pro Pro Trp Pro Arg Val Ser Pro Ala Cys Ala Gly Arg Phe
110 115 120

Gln Ser Pro Val Asp Ile Arg Pro Gln Leu Ala Ala Phe Cys Pro Ala
125 130 135

Leu Arg Pro Leu Glu Leu Leu Gly Phe Gln Leu Pro Pro Leu Pro Glu
140 145 150 155

Leu Arg Leu Arg Asn Asn Gly His Ser Val Gln Leu Thr Leu Pro Pro
160 165 170

Gly Leu Glu Met Ala Leu Gly Pro Gly Arg Glu Tyr Arg Ala Leu Gln
175 180 185

Leu His Leu His Trp Gly Ala Ala Gly Arg Pro Gly Ser Glu His Thr
190 195 200

Val Glu Gly His Arg Phe Pro Ala Glu Ile His Val Val His Leu Ser
205 210 215

Thr Ala Phe Ala Arg Val Asp Glu Ala Leu Gly Arg Pro Gly Gly Leu
220 225 230 235

Ala Val Leu Ala Ala Phe Leu Glu Glu Gly Pro Glu Glu Asn Ser Ala
240 245 250

Tyr Glu Gln Leu Leu Ser Arg Leu Glu Glu Ile Ala Glu Glu Gly Ser
255 260 265

Glu Thr Gln Val Pro Gly Leu Asp Ile Ser Ala Leu Leu Pro Ser Asp
270 275 280

Phe Ser Arg Tyr Phe Gln Tyr Glu Gly Ser Leu Thr Thr Pro Pro Cys
285 290 295

Ala Gln Gly Val Ile Trp Thr Val Phe Asn Gln Thr Val Met Leu Ser
300 305 310 315

Ala Lys Gln Leu His Thr Leu Ser Asp Thr Leu Trp Gly Pro Gly Asp
320 325 330

Ser Arg Leu Gln Leu Asn Phe Arg Ala Thr Gln Pro Leu Asn Gly Arg
335 340 345

Val Ile Glu Ala Ser Phe Pro Ala Gly Val Asp Ser Ser Pro Arg Ala
350 355 360

Ala Glu Pro Val Gln Leu Asn Ser Cys Leu Ala Ala Gly Asp Ile Leu
365 370 375

Ala Leu Val Phe Gly Leu Leu Phe Ala Val Thr Ser Val Ala Phe Leu
380 385 390 395

Val Gln Met Arg Arg Gln His Arg Arg Gly Thr Lys Gly Gly Val Ser
400 405 410

Tyr Arg Pro Ala Glu Val Ala Glu Thr Gly Ala
415 420

<210> 3
<211> 10898
<212> DNA
<213> Homo sapiens

<220>
<221> gene
<222> (1)..(10898)

<220>
<221> misc_feature
<222> (1974)..(1974)
<223> n is a, c, g, or t

<400> 3
ggatcctgtt gactcgtgac cttaccccca accctgtgct ctctgaaaca tgagctgtgt 60
ccactcaggg ttaaatggat taagggcggt gcaagatgtg ctttgttaaa cagatgcttg
aaggcagcat gctcgtaag agtcatcacc aatccctaatt ctcaggtaat cagggacaca 120
aacactgcgg aaggccgcag ggtccctctgc ctaggaaaac cagagacctt tgttcacttg
tttatctgac cttccctcca ctattgtcca tgaccctgcc aaatccccct ctgtgagaaa 180
caccaagaa ttatcaataa aaaaataaat ttaaaaaaaaaa aataaaaaaaaaa aaaaaaaaaa 240
aaaaaaaaaa gacttacgaa tagttattga taaatgaata gctattggta aagccaagta 300
aatgatcata ttcaaaacca gacggccatc atcacagctc aagtctacct gatttgatct
ctttatcatt gtcattctt ggattcacta gattagtcat catcctcaaa attctcccc 360
aagttctaat tacgttccaa acattttaggg gttacatgaa gcttgaacct actaccttct
ttgctttga gccatgagtt gtaggaatga tgagttaca cttacatgc tggggattaa 420
tttaaacttt acctctaatcgttggta gcctttggct tattttgtt gctaatttt
tagttaatgg atgcactgtg aatcttgcta tgatagttt cttccacact ttgccactag
ggtaggttag gtactcagtt ttcagtaatt gcttacctaa gaccctaagc cctatttctc
ttgtactggc ctttatctgt aatatggca tatttaatac aatataattt ttggagttt 480
tttggttgtt tgtttggttt gtttttgag acggagtc tt gcatctgtca tgcccaggct 540
600
660
720
780
840
900
960

ggagtagcag	tggtgccatc	tcggctca	gcaagctcca	cctcccgagt	tcacgcccatt	1020
ttccctgcctc	agcctccga	gtagctggga	ctacaggcgc	ccgccaccat	gcccggtctaa	1080
ttttttgtat	ttttggtaga	gacggggttt	caccgtgtta	gccagaatgg	tctcgatctc	1140
ctgacttcgt	gatccacccg	cctcgccctc	ccaaagttct	gggattacag	gtgtgagcca	1200
ccgcacctgg	ccaattttt	gagtctttta	aagtaaaaat	atgtcttgta	agctggtaac	1260
tatggtacat	ttccttttat	taatgtggtg	ctgacggtca	tataggttct	tttgagtttg	1320
gcatgcatat	gctacttttt	gcagtccttt	cattacattt	ttctctcttc	atttgaagag	1380
catgttatat	cttttagctt	cactggctt	aaaaggttct	ctcattagcc	taacacagt	1440
tcattgttgg	taccacttgg	atcataagt	gaaaaacagt	caagaaattt	cacagtaata	1500
cttggggta	agagggatga	ttcaggtgaa	tctgacacta	agaaactccc	ctacctgagg	1560
tctgagattc	ctctgacatt	gctgtatata	ggctttcct	ttgacagcct	gtgactgcgg	1620
actatttttc	ttaagcaaga	tatgctaaag	ttttgtgagc	ctttttccag	agagaggct	1680
catatctgca	tcaagtgaga	acatataatg	tctgcatgtt	tccatatttc	aggaatgtt	1740
gcttgtttt	tatgctttt	tatagacagg	gaaacttgtt	cctcagtgac	ccaaaagagg	1800
tgggaattgt	tattggatat	catcattggc	ccacgcttcc	tgaccttgga	aacaattaag	1860
ggttcataat	ctcaattctg	tcagaattgg	tacaagaaat	agctgctatg	tttcttgaca	1920
ttccacttgg	taggaataaa	gaatgtgaaa	ctcttcagtt	ggtgtgtgtc	cctngtttt	1980
ttgcaatttc	cttcttactg	tgtaaaaaaaaa	aagtatgatc	ttgctctgag	aggtgaggca	2040
ttcttaatca	tgatctttaa	agatcaataa	tataatcctt	tcaaggatta	tgtctttatt	2100
ataataaaga	taatttgcct	ttaacagaat	caataatata	atcccttaaa	ggattatatc	2160
tttgctgggc	gcagtggctc	acacctgtaa	tcccagca	ttgggtggcc	aaggtggaag	2220
gatcaaattt	gcctacttct	atattatctt	ctaaagcaga	attcatctct	cttccctcaa	2280
tatgatgata	ttgacagggt	ttgccctcac	tcactagatt	gtgagctcct	gctcaggggca	2340
ggtagcgttt	tttgggggg	ttttgtttt	tcttttttga	gacagggct	tgctctgtca	2400
cccaggccag	agtgcataatgg	tacagtctca	gctca	gcctcaaccg	cctcggtctca	2460
aaccatcatc	ccatccagc	ctcctgagta	gctgggacta	caggcacatg	ccattacacc	2520
tggctaattt	ttttgtattt	ctagtagaga	cagggttgg	ccatgttgcc	cgggctggc	2580
tcgaactcct	ggactcaagc	aatccaccca	cctcagccctc	ccaaaatgag	ggaccgtgtc	2640
ttattcattt	ccatgtccct	agtccatagc	ccagtgtgg	acctatggta	gtactaaata	2700
aatatttgcct	aatgcataa	gtaaatagca	tttcagggag	caagaactag	attaacaaag	2760
gtggtaaaag	gtttggagaa	aaaaataata	gtttaatttgc	gctagagtat	gagggagagt	2820
agtaggagac	aagatggaaa	ggtcttttgg	gcaagggtttt	gaaggaagtt	ggaagtcaga	2880
agtacacaat	gtgcataatcg	tggcaggcag	tggggagcca	atgaaggctt	ttgagcagga	2940
gagtaatgtg	ttgaaaaata	aatatagttt	aaacctatca	gagccctct	gacacataca	3000

2003217606 19 Nov 2004

7/50

cttgctttc attcaagctc aagtttgct cccacatacc cattactaa ctcaccctcg	3060
ggctcccta gcagcctgcc ctacctctt acctgctcc tggtgagtc agggatgtat	3120
acatgagctg cttccctct cagccagagg acatgggggg ccccagctcc cctgccttc	3180
cccttctgtg cctggagctg ggaagcaggc cagggtagc tgaggctggc tggcaagcag	3240
ctgggtggtg ccagggagag cctgcatagt gccaggtggt gccttgggtt ccaagctagt	3300
ccatggcccc gataaccttc tgcctgtca cacacctgcc cctcaactcca ccccccac	3360
agctttggta tggggagag ggcacaggc cagacaaacc tgtgagactt tggctccatc	3420
tctgcaaaag ggcgctctgt gagtcagcct gctccctcc aggcttgctc ctccccacc	3480
cagctctcgt ttccaatgca cgtacagccc gtacacaccc tggtctggga caccacac	3540
tcagccgcat ggctccctg tgccccagcc cctggctccc tctgttgatc cggccccc	3600
ctccaggcct cactgtgcaa ctgctgtgt cactgctgct tctggtgccct gtccatcccc	3660
agagggttgcc ccggatgcag gaggattccc cttggaggagg aggctttct gggaaagatg	3720
acccactggg cgaggaggat ctgcccagtg aagaggattc acccagagag gaggatccac	3780
ccggagagga gnatctacct ggagaggagg atctacacctt agaggaggat ctacctaag	3840
ttaagcctaa atcagaagaa gagggctccc tgaagtttga ggatctacctt actgttgagg	3900
ctccctggaga tcctcaagaa cccagaata atgcccacag ggacaaagaa ggtaagtgg	3960
catcaatctc caaatccagg ttccaggagg ttcatgactc ccctcccata cccagccta	4020
ggctctgttc actcaggaa ggaggggaga ctgtactccc cacagaagcc cttccagagg	4080
tcccatacca atatccccat cccactctc ggaggttagaa agggacagat gtggagagaa	4140
aataaaaagg gtcaaaagg agagaggtga gctggatgag atggagaga agggggaggc	4200
tggagaagag aaagggatga gaactgcaga tgagagaaaa aatgtgcaga cagagaaaa	4260
aaataggtgg agaaggagag tcagagagtt tgaggggaag agaaaaggaa agcttggag	4320
gtgaagtggg taccagagac aagcaagaag agctggtaga agtcatctca tcttaggcta	4380
caatgaggaa ttgagaccta ggaagaaggg acacagcagg tagagaaacg tggcttctt	4440
actcccaagc caggaatttg gggaaagggg ttggagacca tacaaggcag agggatgagt	4500
ggggagaaga aagaagggag aaagggaaaga tggtgactc actcatttgg gactcaggac	4560
tgaagtggccc actcaacttt ttttttttt ttttgagac aaactttcac ttttgtgcc	4620
caggctggag tgcaatggcg cgatctcgcc tcactgcaac ctccacctcc cgggttcaag	4680
tgattctcct gcctcagcct ctagccaagt agctgcgatt acaggcatgc gccaccacgc	4740
ccggctaatt tttgtatattt tagtagagac ggggtttcgc catgtggtc aggctggct	4800
cgaactcctg atctcagggt atccaaccac cctggccctcc caaagtgcgt ggattatagg	4860
cgtgagccac agcgcctggc ctgaagcagc cactcaactt tacagaccct aagacaatga	4920
ttgcaagctg gtaggattgc tggggccccc acccagctgc ggtgttgagt ttgggtgcgg	4980
tctcctgtgc tttgcacctg gcccgtttaa ggcatttgtt acccgtaatg ctccgtaa	5040

2003217606 19 Nov 2004

8/50

gcatctgcgt ttgtgacatc gttttggctcg ccaggaaggg attggggctc taagctttag	5100
cggttcatcc ttttcattta tacagggat gaccagagtc attggcgcta tggaggttag	5160
acacccaccc gctgcacaga cccaatctgg gaacccagct ctgtggatct cccctacagc	5220
cgtccctgaa cactggtccc gggcgccca cccgccc accgtcccac cccctcacct	5280
tttctacccg gttccctaa gttcctgacc taggcgtcag acttcctcac tatactctcc	5340
caccccaggc gacccgccc ggccccgggt gtccccagcc tgcgcgggccc gcttccagtc	5400
cccggtggat atccgcggcc agctcgccgc cttctgccc gccctgcgcc ccctggaaact	5460
cctgggcttc cagctccgcg cgctccaga actgcgcctg cgcaacaatg gccacagtgg	5520
tgagggggtc tccccgccga gacttggga tggggcgggg cgcaggaaag ggaaccgtcg	5580
cgcagtgcct gcccgggggt tgggctggcc ctaccggcg gggccggctc acttgcctct	5640
ccctacgcag tgcaactgac cctgcctcct gggctagaga tggctctggg tcccggcg	5700
gagtaccggg ctctgcagct gcatctgcac tggggggctg caggtcggtcc gggctcgag	5760
cacactgtgg aaggccaccg tttccctgcc gaggtagcg cgactggcc gagaagggc	5820
aaaggagcgg ggcggacggg ggccagagac gtggccctct cctaccctcg tgtcctttc	5880
agatccacgt ggttcacctc agcaccgcct ttgcagagt tgacgaggcc ttggggcgcc	5940
cgggaggcct ggccgtgttgc gccccttcc tggaggtacc agatcctgga cacccttac	6000
tccccgttt cccatccat gctcctcccg gactctatcg tggagccaga gacccatcc	6060
cagcaagctc actcaggccc ctggctgaca aactcattca cgcaactgtt gttcattaa	6120
cacccactgt gaaccaggca ccagccccc acaaggattc tgaagctgta ggtccttgcc	6180
tctaaggagc ccacagccag tgggggaggc tgacatgaca gacacatagg aaggacatag	6240
taaagatggt ggtcacagag gaggtgacac ttaaagcctt cactggtaga aaagaaaagg	6300
aggtgttcat tgcagagaa acagaatgtg caaagactca gaatatggcc tatttaggaa	6360
atggctacat acaccatgat tagaggaggc ccagtaaagg gaaggatgg tgagatgcct	6420
gctaggttca ctcactcact ttttatttatt tattttttt tttgacagtc tctctgtcgc	6480
ccaggctgga gtgcagtggt gtgatcttgg gtcactgcaa cttccgcctc ccgggttcaa	6540
gggattctcc tgcctcagct tcctgagtag ctggggttac aggtgtgtgc caccatgccc	6600
agctaatttt tttttgtatt ttttagtagac agggtttac catgtggtc aggctggct	6660
caaactcctg gcctcaagtg atccgcctga ctcagcctac caaagtgctg attacaagt	6720
tgagccaccg tgcccagcca cactcactga ttctttaatg ccagccacac agcacaaagt	6780
tcagagaaat gcctccatca tagcatgtca atatgttcat actcttaggt tcatgatgtt	6840
cttaacatta ggttcataag caaaaataaga aaaaagaata ataaataaaa gaagtggcat	6900
gtcaggaccc cacctgaaaa gccaaacaca gaatcatgaa ggtgaatgca gaggtgacac	6960
caacacaaag gtgtatataat ggtttcctgt ggggagtagtacggaggca gcagttagtg	7020
agactgcaaa cgtcagaagg gcacgggtca ctgagagcct agtacccatg taaagtggc	7080

2003217606 19 Nov 2004

9/50

tctctccctc tctctccagc ttgtcattga aaaccagtcc accaagctt gtttcgca 7140
cagcaagagt acatagagtt taaaataata cataggattt taagagggag acactgtctc 7200
aaaaaaaaa aacaacagca acaacaaaaa gcaacaacca ttacaatttt atgtccctc 7260
agcattctca gagctgagga atggagagg actatggaa ccccttcat gttccggcct 7320
tcagccatgg ccctggatac atgcactcat ctgtcttaca atgtcattcc cccaggaggg 7380
cccggaaagaa aacagtgcct atgagcagtt gctgtctgc ttgaaagaaa tcgctgagga 7440
aggtcagttt gttggctgg ccactaatct ctgtggccta gttcataaag aatcaccctt 7500
tggagcttca ggtctgaggc tggagatggg ctccctccag tgcaggaggg attgaagcat 7560
gagccagcgc tcatcttgc aataaccatg aagctgacag acacagttac ccgcaaacgg 7620
ctgcctacag attgaaaacc aagcaaaaac cgccggcac ggtggctcac gcctgttaatc 7680
ccagcacttt gggaggccaa ggcaggtgga tcacgaggtc aagagatcaa gaccatcctg 7740
gccaacatgg tgaaacccca tctctactaa aaatacgaaa aaatagccag gcgtggtggc 7800
gggtgcctgt aatcccagct actcgggagg ctgaggcagg agaatggcat gaacccggga 7860
ggcagaagtt gcagtgagcc gagatcgtgc cactgcactc cagcctggc aacagagcga 7920
gactcttgc tcaaaaaaaaaaaaaaaa gaaaaccaag caaaaaccaa aatgagacaa 7980
aaaaaacaag accaaaaaat ggtgtttgga aattgtcaag gtcaagtctg gagagctaaa 8040
cttttctga gaactgttta tctttaataa gcatcaaata ttttaacttt gtaaatactt 8100
ttgttggaaa tcgttctctt cttagtcact cttgggtcat tttaaatctc acttactcta 8160
ctagaccttt taggttctg ctagactagg tagaactctg ctttgcatt tcttgtgtct 8220
gttttgtata gttatcaata ttcatattta ttacaagtt attcagatca tttttcttt 8280
tctttttttt tttttttttt tttttacat ctttagtaga gacagggttt caccatattg 8340
gccaggctgc tctcaaactc ctgaccttgc gatccaccag cctcggcctc ccaaagtgt 8400
gggattcatt tttttttttt aatttgctct gggctaaac ttgtggccca gcactttatg 8460
atggtacaca gagtaagag tgtagactca gacggtctt cttttttct tctttccctt 8520
cctcccttcc ctcccacctt ccctctctc cttcccttct ttcttcctct cttgcttcct 8580
caggcctctt ccagttgctc caagccctg tactttttt tgagttaacg tcttatggga 8640
agggcctgca cttagtgaag aagtggctc agagttgagt tacctggct tctggaggt 8700
gaaactgtat ccctataccc tgaagcttta agggggtgca atgttagatga gacccaaaca 8760
tagatcctct tcacaggctc agagactcag gtcccaggac tggacatatac tgcactcctg 8820
ccctctgact tcagccgcta cttccaatat gaggggtctc tgactacacc gccctgtgcc 8880
cagggtgtca tctggactgt gtttaaccag acagtgtatgc tgagtgtctaa gcagggtggc 8940
ctgggggtgtg tgtggacaca gtgggtgcgg gggaaagagg atgttagatg agatgagaaa 9000
caggagaaga aagaaatcaa ggctggcctc tgtggcttac gcctataatc ccaccacgtt 9060
gggaggctga ggtggagaa tggtttgagc ccaggagttc aagacaaggc gggcaacat 9120

2003217606 19 Nov 2004

10/50

agtgtgaccc	catctctacc	aaaaaaaaccc	caacaaaacc	aaaaatagcc	gggcatggtg	9180
gtatgcggcc	tagtcccagc	tactcaagga	ggctgaggtg	ggaagatcgc	ttgattccag	9240
gagtttggaga	ctgcagttag	ctatgatccc	accactgcct	accatctta	ggatacattt	9300
atttatattat	aaaagaaatc	aagaggctgg	atggggata	caggagctgg	agggtggagc	9360
cctgaggtgc	tggttgttag	ctggcctggg	acccttgttt	cctgtcatgc	catgaaccca	9420
cccacactgt	ccactgaccc	ccctagctcc	acaccctctc	tgacaccctg	tggggacctg	9480
gtgactctcg	gctacagctg	aacttccgag	cgacgcagcc	tttgaatggg	cgagtgattg	9540
aggcctcctt	ccctgctgga	gtggacagca	gtcctcgggc	tgctgagcca	ggtacagctt	9600
tgtctggttt	ccccccagcc	agtagtccct	tatcctccca	tgtgtgtgcc	agtgtctgtc	9660
attggtggtc	acagcccgcc	tctcacatct	ccttttctc	tccagtcag	ctgaattcct	9720
gcctggctgc	tggtgagtct	gcccccctc	ttggtcctga	tgccaggaga	ctcctcagca	9780
ccattcagcc	ccagggctgc	tcaggaccgc	ctctgctccc	tctccttttc	tgcagaacag	9840
accccaaccc	caatattaga	gaggcagatc	atggtgggga	ttcccccatt	gtccccagag	9900
gctaattgtat	tagaatgaag	cttgagaaat	ctcccagcat	ccctctcgca	aaagaatccc	9960
ccccctttt	tttaaagata	gggtctca	ctgtttgccc	caggctgggg	tgttgtggca	10020
cgatcatagc	tcactgcagc	ctcgaactcc	taggctcagg	caatccttcc	accttagctt	10080
ctcaaagcac	tgggactgta	ggcatgagcc	actgtgcctg	gccccaaacg	gccctttac	10140
ttggctttta	ggaagcaaaa	acggtgctta	tcttaccctt	tctcgtgtat	ccaccctcat	10200
cccttggctg	gcctttctg	gagactgagg	cactatgggg	ctgcctgaga	actcggggca	10260
ggggtgtgg	agtgcactga	ggcaggtgtt	gaggaactct	gcagacccct	tttccttccc	10320
aaagcagccc	tctctgctt	ccatcgagg	tgacatccta	gccctggttt	ttggcctcct	10380
ttttgctgtc	accagcgctg	cgttccttgt	gcagatgaga	aggcagcaca	ggtattacac	10440
tgaccctttc	ttcaggcaca	agctcccccc	acccttgg	agtcacttca	tgcaaagcgc	10500
atgcaaatga	gctgctcctg	ggccagtttt	ctgattagcc	tttcctgttg	tgtacacaca	10560
gaaggggaac	caaagggggt	gtgagctacc	gcccagcaga	gtagccgag	actggagcct	10620
agaggctgga	tcttggagaa	tgtgagaagc	cagccagagg	catctgaggg	ggagccggta	10680
actgtcctgt	cctgctcatt	atgccacttc	cttttaactg	ccaagaaatt	ttttaaaata	10740
aatatttata	ataaaatatg	tgttagtcac	ctttgttccc	caaatcagaa	ggaggtattt	10800
gaatttccta	ttactgttat	tagcaccaat	ttagtgtaa	tgcattttatt	ctattacagt	10860
tcggcctcct	tccacacatc	actccaaatgt	gttgctcc			10898

<210> 4
<211> 37
<212> PRT
<213> Homo sapiens
<400> 4

2003217606 19 Nov 2004

11/50

Met Ala Pro Leu Cys Pro Ser Pro Trp Leu Pro Leu Leu Ile Pro Ala
1 5 10 15

Pro Ala Pro Gly Leu Thr Val Gln Leu Leu Leu Ser Leu Leu Leu
20 25 30

Met Pro Val His Pro
35

<210> 5
<211> 377
<212> PRT
<213> Homo sapiens

<400> 5

Gln Arg Leu Pro Arg Met Gln Glu Asp Ser Pro Leu Gly Gly Ser
1 5 10 15

Ser Gly Glu Asp Asp Pro Leu Gly Glu Glu Asp Leu Pro Ser Glu Glu
20 25 30

Asp Ser Pro Arg Glu Glu Asp Pro Pro Gly Glu Glu Asp Leu Pro Gly
35 40 45

Glu Glu Asp Leu Pro Gly Glu Glu Asp Leu Pro Glu Val Lys Pro Lys
50 55 60

Ser Glu Glu Glu Gly Ser Leu Lys Leu Glu Asp Leu Pro Thr Val Glu
65 70 75 80

Ala Pro Gly Asp Pro Gln Glu Pro Gln Asn Asn Ala His Arg Asp Lys
85 90 95

Glu Gly Asp Asp Gln Ser His Trp Arg Tyr Gly Asp Pro Pro Trp
100 105 110

Pro Arg Val Ser Pro Ala Cys Ala Gly Arg Phe Gln Ser Pro Val Asp
115 120 125

Ile Arg Pro Gln Leu Ala Ala Phe Cys Pro Ala Leu Arg Pro Leu Glu
130 135 140

Leu Leu Gly Phe Gln Leu Pro Pro Leu Pro Glu Leu Arg Leu Arg Asn
145 150 155 160

Asn Gly His Ser Val Gln Leu Thr Leu Pro Pro Gly Leu Glu Met Ala
165 170 175

Leu Gly Pro Gly Arg Glu Tyr Arg Ala Leu Gln Leu His Leu His Trp
180 185 190

2003217606 19 Nov 2004

12/50

Gly Ala Ala Gly Arg Pro Gly Ser Glu His Thr Val Glu Gly His Arg
195 200 205

Phe Pro Ala Glu Ile His Val Val His Leu Ser Thr Ala Phe Ala Arg
210 215 220

Val Asp Glu Ala Leu Gly Arg Pro Gly Gly Leu Ala Val Leu Ala Ala
225 230 235 240

Phe Leu Glu Glu Gly Pro Glu Glu Asn Ser Ala Tyr Glu Gln Leu Leu
245 250 255

Ser Arg Leu Glu Glu Ile Ala Glu Glu Gly Ser Glu Thr Gln Val Pro
260 265 270

Gly Leu Asp Ile Ser Ala Leu Leu Pro Ser Asp Phe Ser Arg Tyr Phe
275 280 285

Gln Tyr Glu Gly Ser Leu Thr Thr Pro Pro Cys Ala Gln Gly Val Ile
290 295 300

Trp Thr Val Phe Asn Gln Thr Val Met Leu Ser Ala Lys Gln Leu His
305 310 315 320

Thr Leu Ser Asp Thr Leu Trp Gly Pro Gly Asp Ser Arg Leu Gln Leu
325 330 335

Asn Phe Arg Ala Thr Gln Pro Leu Asn Gly Arg Val Ile Glu Ala Ser
340 345 350

Phe Pro Ala Gly Val Asp Ser Ser Pro Arg Ala Ala Glu Pro Val Gln
355 360 365

Leu Asn Ser Cys Leu Ala Ala Gly Asp
370 375

<210> 6

<211> 20

<212> PRT

<213> Homo sapiens

<400> 6

Ile Leu Ala Leu Val Phe Gly Leu Leu Phe Ala Val Thr Ser Val Ala
1 5 10 15

Phe Leu Val Gln
20

<210> 7

<211> 25

<212> PRT

<213> Homo sapiens

19 Nov 2004

2003217606

13/50

<400> 7

Met Arg Arg Gln His Arg Arg Gly Thr Lys Gly Gly Val Ser Tyr Arg
1 5 10 15

Pro Ala Glu Val Ala Glu Thr Gly Ala
20 25

<210> 8

<211> 59

<212> PRT

<213> Homo sapiens

<400> 8

Ser Ser Gly Glu Asp Asp Pro Leu Gly Glu Glu Asp Leu Pro Ser Glu
1 5 10 15

Glu Asp Ser Pro Arg Glu Glu Asp Pro Pro Gly Glu Glu Asp Leu Pro
20 25 30

Gly Glu Glu Asp Leu Pro Gly Glu Glu Asp Leu Pro Glu Val Lys Pro
35 40 45

Lys Ser Glu Glu Glu Gly Ser Leu Lys Leu Glu
50 55

<210> 9

<211> 257

<212> PRT

<213> Homo sapiens

<400> 9

Gly Asp Asp Gln Ser His Trp Arg Tyr Gly Gly Asp Pro Pro Trp Pro
1 5 10 15

Arg Val Ser Pro Ala Cys Ala Gly Arg Phe Gln Ser Pro Val Asp Ile
20 25 30

Arg Pro Gln Leu Ala Ala Phe Cys Pro Ala Leu Arg Pro Leu Glu Leu
35 40 45

Leu Gly Phe Gln Leu Pro Pro Leu Pro Glu Leu Arg Leu Arg Asn Asn
50 55 60

Gly His Ser Val Gln Leu Thr Leu Pro Pro Gly Leu Glu Met Ala Leu
65 70 75 80

Gly Pro Gly Arg Glu Tyr Arg Ala Leu Gln Leu His Leu His Trp Gly
85 90 95

Ala Ala Gly Arg Pro Gly Ser Glu His Thr Val Glu Gly His Arg Phe
100 105 110

2003217606 19 Nov 2004

14/50

Pro Ala Glu Ile His Val Val His Leu Ser Thr Ala Phe Ala Arg Val
115 120 125

Asp Glu Ala Leu Gly Arg Pro Gly Gly Leu Ala Val Leu Ala Ala Phe
130 135 140

Leu Glu Glu Gly Pro Glu Glu Asn Ser Ala Tyr Glu Gln Leu Leu Ser
145 150 155 160

Arg Leu Glu Glu Ile Ala Glu Glu Gly Ser Glu Thr Gln Val Pro Gly
165 170 175

Leu Asp Ile Ser Ala Leu Leu Pro Ser Asp Phe Ser Arg Tyr Phe Gln
180 185 190

Tyr Glu Gly Ser Leu Thr Thr Pro Pro Cys Ala Gln Gly Val Ile Trp
195 200 205

Thr Val Phe Asn Gln Thr Val Met Leu Ser Ala Lys Gln Leu His Thr
210 215 220

Leu Ser Asp Thr Leu Trp Gly Pro Gly Asp Ser Arg Leu Gln Leu Asn
225 230 235 240

Phe Arg Ala Thr Gln Pro Leu Asn Gly Arg Val Ile Glu Ala Ser Phe
245 250 255

Pro

<210> 10
<211> 59
<212> PRT
<213> Homo sapiens

<400> 10

Ser Ala Ser Glu Glu Pro Ser Pro Ser Glu Val Pro Phe Pro Ser Glu
1 5 10 15

Glu Pro Ser Pro Ser Glu Glu Pro Phe Pro Ser Val Arg Pro Phe Pro
20 25 30

Ser Val Val Leu Phe Pro Ser Glu Glu Pro Phe Pro Ser Lys Glu Pro
35 40 45

Ser Pro Ser Glu Glu Pro Ser Ala Ser Glu Glu
50 55

<210> 11
<211> 7
<212> PRT
<213> Homo sapiens

2003217606 19 Nov 2004

15/50

<400> 11

Pro Gly Glu Glu Asp Leu Pro
1 5

<210> 12

<211> 36

<212> PRT

<213> Homo sapiens

<400> 12

Gly Glu Glu Asp Leu Pro Ser Glu Glu Asp Ser Pro Arg Glu Glu Asp
1 5 10 15

Pro Pro Gly Glu Glu Asp Leu Pro Gly Glu Glu Asp Leu Pro Gly Glu
20 25 30

Glu Asp Leu Pro
35

<210> 13

<211> 6

<212> PRT

<213> Homo sapiens

<400> 13

Gly Glu Glu Asp Leu Pro
1 5

<210> 14

<211> 4

<212> PRT

<213> Homo sapiens

<400> 14

Glu Glu Asp Leu
1

<210> 15

<211> 5

<212> PRT

<213> Homo sapiens

<400> 15

Glu Glu Asp Leu Pro
1 5

<210> 16

<211> 6

<212> PRT

<213> Homo sapiens

<400> 16

Glu Asp Leu Pro Ser Glu
1 5

2003217606 19 Nov 2004

16/50

<210> 17
<211> 7
<212> PRT
<213> Homo sapiens

<400> 17

Glu Glu Asp Leu Pro Ser Glu
1 5

<210> 18
<211> 6
<212> PRT
<213> Homo sapiens

<400> 18

Asp Leu Pro Gly Glu Glu
1 5

<210> 19
<211> 6
<212> PRT
<213> Homo sapiens

<400> 19

Glu Glu Asp Leu Pro Ser
1 5

<210> 20
<211> 6
<212> PRT
<213> Homo sapiens

<400> 20

Gly Glu Asp Asp Pro Leu
1 5

<210> 21
<211> 16
<212> PRT
<213> Homo sapiens

<400> 21

His Pro Gln Arg Leu Pro Arg Met Gln Glu Asp Ser Pro Leu Gly Gly
1 5 10 15

<210> 22
<211> 24
<212> PRT
<213> Homo sapiens

<400> 22

Glu Glu Asp Ser Pro Arg Glu Glu Asp Pro Pro Gly Glu Glu Asp Leu
1 5 10 15

Pro Gly Glu Glu Asp Leu Pro Gly

2003217606 19 Nov 2004

17/50

20

<210> 23
<211> 21
<212> PRT
<213> Homo sapiens
<400> 23

Asn Asn Ala His Arg Asp Lys Glu Gly Asp Asp Gln Ser His Trp Arg
1 5 10 15

Tyr Gly Gly Asp Pro
20

<210> 24
<211> 540
<212> DNA
<213> Homo sapiens

<220>
<221> promoter
<222> (1)..(540)

<400> 24

cttgcttttc	attcaagctc	aagtttgtct	cccacataacc	cattacttaa	ctcaccctcg	60
ggctccctta	gcagcctgcc	ctacctcttt	acctgcttcc	tggtgagtc	aggatgtat	120
acatgagctg	ctttccctct	cagccagagg	acatgggggg	ccccagctcc	cctgccttcc	180
cccttctgtg	cctggagctg	ggaagcaggc	cagggttagc	tgaggctggc	tggcaagcag	240
ctgggtggtg	ccagggagag	cctgcatagt	gccaggtgg	gccttgggtt	ccaagctagt	300
ccatggccccc	gataaccttc	tgcctgtgca	cacacctgcc	cctcaactcca	ccccatcct	360
agctttggta	tgggggagag	ggcacagggc	cagacaaacc	tgtgagactt	tggctccatc	420
tctgcaaaag	ggcgctctgt	gagtcagcct	gctccctcc	aggcttgctc	ctccccacc	480
cagctctcg	ttccaatgca	cgtacagccc	gtacacaccg	tgtgctggga	cacccacag	540

<210> 25
<211> 445
<212> DNA
<213> Homo sapiens

<400> 25

gccccgtacac	accgtgtgct	gggacacccc	acagtcagcc	gcatggctcc	cctgtgcccc	60
agccccctggc	tccctctgtt	gatccggcc	cctgctccag	gcctcaactgt	gcaactgctg	120
ctgtcaactgc	tgcttctggt	gcctgtccat	ccccagaggt	tgccccggat	gcaggaggat	180
tcccccttgg	gaggaggctc	ttctgggaa	gatgaccac	tggcgagga	ggatctgccc	240
agtgaagagg	attcacccag	agaggaggat	ccacccggag	aggaggatct	acctggagag	300
gaggatctac	ctggagagga	ggatctacct	gaagttaagc	ctaaatcaga	agaagagggc	360
tccctgaagt	tagaggatct	acctactgtt	gaggctcctg	gagatcctca	agaacccag	420

2003217606 19 Nov 2004

18/50

445

aataatgccc acagggacaa agaag

<210> 26
<211> 30
<212> DNA
<213> Homo sapiens

<400> 26
gggatgacca gagtcattgg cgctatggag

30

<210> 27
<211> 171
<212> DNA
<213> Homo sapiens

<400> 27
gcgacccgccc ctggccccgg gtgtccccag cctgcgcggg ccgccttccag tccccgggtgg 60
atatccgccc ccagctcgcc gccttctgcc cggccctgcg ccccccggaa ctccctggct 120
tccagctccc gccgctccca gaactgcgcc tgcgcaacaa tggccacagt g 171

<210> 28
<211> 143
<212> DNA
<213> Homo sapiens

<400> 28
tgcaactgac cctgcctcct gggctagaga tggctctggg tcccgccggg gagtaccggg 60
ctctgcagct gcatctgcac tggggggctg caggtcgtcc gggctcgag cacactgtgg 120
aaggccacccg tttccctgcc gag 143

<210> 29
<211> 93
<212> DNA
<213> Homo sapiens

<400> 29
atccacgtgg ttcacctcag caccgcctt gccagagttg acgaggcctt ggggcggccg 60
ggaggcctgg ccgtgttggc cgccttctg gag 93

<210> 30
<211> 67
<212> DNA
<213> Homo sapiens

<400> 30
gagggcccg aagaaaacag tgcctatgag cagttgtgt ctcgcttggaa agaaaatcgct 60
gaggaag 67

<210> 31
<211> 158
<212> DNA
<213> Homo sapiens

<400> 31
gctcagagac tcaggtccca ggactggaca tatctgcact cctgcctct gacttcagcc 60

2003217606 19 Nov 2004

gctacttcca atatgagggg tctctgacta caccgcctg tgcccagggt gtcatctgga	120
ctgtgttaa ccagacagtg atgctgagtg ctaagcag	158
<210> 32	
<211> 145	
<212> DNA	
<213> Homo sapiens	
<400> 32	
ctccacaccc tctctgacac cctgtggga cctggtaact ctggctaca gctgaacttc	60
cgagcgacgc agccttgaa tggcgagtg attgaggcct cttccctgc tggagtggac	120
agcagtcctc gggctgctga gccag	145
<210> 33	
<211> 27	
<212> DNA	
<213> Homo sapiens	
<400> 33	
tccagctgaa ttcctgcctg gctgctg	27
<210> 34	
<211> 82	
<212> DNA	
<213> Homo sapiens	
<400> 34	
gtgacatcct agccctggtt tttggcctcc ttttgctgt caccagcgtc gcgttccttg	60
tgcagatgag aaggcagcac ag	82
<210> 35	
<211> 191	
<212> DNA	
<213> Homo sapiens	
<400> 35	
aaggggaaacc aaagggggtg tgagctaccg cccagcagag gtagccgaga ctggagccct	60
gaggctggat cttggagaat gtgagaagcc agccagaggc atctgagggg gagccggtaa	120
ctgtcctgtc ctgctcatta tgccacttcc ttttaactgc caagaaattt tttaaaataa	180
atatttataa t	191
<210> 36	
<211> 1174	
<212> DNA	
<213> Homo sapiens	
<400> 36	
gtaagtggtc atcaatctcc aaatccaggt tccaggaggt tcatgactcc cttccatcc	60
cccagcctag gctctgttca ctcagggaaag gaggggagac tgtactcccc acagaagccc	120
ttccagaggt cccataccaa tatccccatc cccactctcg gaggtagaaa gggacagatg	180
tggagagaaa ataaaaaggg tgcaaaagga gagaggtgag ctggatgaga tggagagaaa	240
gggggaggct ggagaagaga aaggatgag aactgcagat gagagaaaaa atgtgcagac	300

2003217606 19 Nov 2004

20/50

agagaaaaaa aatagggtgga gaaggagagt cagagagttt gaggggaaga gaaaaggaaa	360
gcttgggagg tgaagtgggt accagagaca agcaagaaga gctggtagaa gtcatctcat	420
cttaggctac aatgaggaat tgagacctag gaagaaggga cacagcaggt agagaaacgt	480
ggcttcttga ctcccaagcc aggaatttgg ggaaagggtt tggagaccat acaaggcaga	540
gggatgagtg gggagaagaa agaaggaga aaggaaagat ggtgtactca ctcatttggg	600
actcaggact gaagtgccca ctcactttt tttttttt ttttgagaca aactttcact	660
tttggcggcc aggctggagt gcaatggcgc gatctcgct cactgcaacc tccacccccc	720
gggttcaagt gattctcctg cctcagcctc tagccaagta gctgcgatta caggcatgcg	780
ccaccacgccc cggctaattt ttgtattttt agtagagacg gggtttcgccc atgttggtca	840
ggctggtctc gaactcctga tctcaggtga tccaccacc ctggcctccc aaagtgctgg	900
gattataggc gtgagccaca gcgcctggcc tgaagcagcc actcactttt acagacccta	960
agacaatgat tgcaagctgg taggattgct gtttggccca cccagctgcg gtgttggatt	1020
tgggtgcgggt ctccctgtgct ttgcacctgg cccgcttaag gcatttggta cccgtaatgc	1080
tcctgttaagg catctgcgtt tgtgacatcg ttttggtcgc caggaaggga ttggggctct	1140
aagcttgagc gtttcatcct tttcattttt acag	1174

<210> 37
<211> 193
<212> DNA
<213> Homo sapiens

<400> 37 gtgagacacc cacccgctgc acagacccaa tctggaaacc cagctctgtg gatctccct	60
acagccgtcc ctgaacactg gtcccgccg tcccaccgc cgcccaccgt cccacccct	120
cacctttctt acccggttc cctaagttcc tgacctaggc gtcagacttc ctcactatac	180
tctccacccc cag	193

<210> 38
<211> 131
<212> DNA
<213> Homo sapiens

<400> 38 gtgaggggggt ctccccgcgg agacttgggg atggggccgg ggcgcaggaa gggacccgtc	60
gcccgcgtgcc tgcccgcccc ttgggctggc cctaccggc gggccggct cactgcctc	120
tccctacgca g	131

<210> 39
<211> 89
<212> DNA
<213> Homo sapiens

<400> 39 gtgagcgcgg actggccgag aaggggcaaa ggagcggggc ggacggggc cagagacgtg	60
--	----

2003217606 19 Nov 2004

21/50

gcccttcctt accctcggt cctttcag	89
<210> 40	
<211> 1400	
<212> DNA	
<213> Homo sapiens	
<400> 40	
gtaccagatc ctggacaccc cctactcccc gctttccat cccatgctcc tcccgactc	60
tatcgtaggag ccagagaccc catccagca agctcactca ggcccctggc tgacaaactc	120
attcacgcac tgtttgttca tttaacaccc actgtgaacc aggaccagc ccccaacaag	180
gattctgaag ctgttaggtcc ttgcctctaa ggagccaca gccagtgggg gaggctgaca	240
tgacagacac ataggaagga catagtaaag atggtggtca cagaggaggt gacacttaaa	300
gccttcactg gttagaaaaga aaaggaggtg ttcattgcag agggaaacaga atgtgcaaag	360
actcagaata tggcctattt agggaatggc tacatacacc atgatttagag gaggcccagt	420
aaagggaaagg gatggtgaga tgccctgtag gttcactcac tcacttttat ttatttat	480
attttttga cagtctctct gtcgcccagg ctggagtgca gtgggtgtat cttgggtcac	540
tgcaacttcc gcctcccggg ttcaagggat tctcctgcct cagcttcctg agtagctggg	600
gttacaggtg tgtgccacca tgcccagcta atttttttt gtattttag tagacagggt	660
ttcaccatgt tggtcaggct ggtctcaaac tcctggcctc aagtgtatccg cctgactcag	720
cctaccaaag tgctgattac aagtgtgagc caccgtgccc agccacactc actgattctt	780
taatgccagc cacacagcac aaagttcaga gaaatgcctc catcatagca tgtcaatatg	840
ttcatactct taggttcatg atgttcttaa cattaggttc ataagcaaaa taagaaaaaa	900
gaataataaa taaaagaagt ggcatgtcag gacctcacct gaaaagccaa acacagaatc	960
atgaaggtga atgcagaggt gacaccaaca caaaggtgta tatatggttt cctgtggga	1020
gtatgtacgg aggcagcagt gagtgagact gcaaacgtca gaagggcacg ggtcactgag	1080
agcctagtat cctagtaaag tgggctctct ccctctctccagcttgc attgaaaacc	1140
agtccaccaa gcttgggt tcgcacagca agagtacata gagttgaaa taatacatag	1200
gattttaga gggagacact gtctctaaaa aaaaaaacaac cagcaacaac aaaaagcaac	1260
aaccattaca attttatgtt ccctcagcat tctcagagct gaggaatggg agaggactat	1320
ggaaaccccc ttcatgttcc ggccttcagc catggccctg gatacatgca ctcatctg	1380
ttacaatgtc attccccca	1400
<210> 41	
<211> 1334	
<212> DNA	
<213> Homo sapiens	
<400> 41	
gtcagtttgt tggctggcc actaatctct gtggcctagt tcataaagaa tcacccttg	60
gagcttcagg tctgaggctg gagatggct ccctccagtg caggaggat tgaagcatga	120

2003217606 19 Nov 2004

22/50

gccagcgctc atcttgataa taaccatgaa gctgacagac acagttaccc gcaaacggct	180
gcctacagat tgaaaaccaa gcaaaaacccg ccgggcacgg tggctcacgc ctgtaatccc	240
agcactttgg gaggccaagg caggtggatc acgaggtcaa gagatcaaga ccatcctggc	300
caacatggtg aaaccccatc tctactaaaa atacgaaaaa atagccaggc gtggtggcgg	360
gtgcctgtaa tcccagctac tcgggaggct gaggcaggag aatggcatga acccgggagg	420
cagaagttgc agtgagccga gatcgtgcca ctgcactcca gcctggcaa cagagcgaga	480
ctcttgtctc aaaaaaaaaa aaaaaaaaaga aaaccaagca aaaaccaaaa tgagacaaaa	540
aaaacaagac caaaaaatgg tgtttggaaa ttgtcaaggt caagtctgga gagctaaact	600
ttttctgaga actgtttatc ttaataagc atcaaataatt ttaactttgt aaatactttt	660
gttggaaatc gttctttct tagtcaactt tgggtcattt taaatctcac ttactctact	720
agacctttta gttttctgct agacttagta gaactctgcc tttgcatttc ttgtgtctgt	780
tttgtatagt tatcaatatt catatttatt tacaagttat tcagatcatt ttttctttc	840
ttttttttt tttttttttt ttttacatct ttagtagaga cagggtttca ccatattggc	900
caggctgctc tcaaactcct gaccttgtga tccaccagcc tcggcctccc aaagtgcgg	960
gattcatttt ttcttttaa tttgctctgg gcttaaactt gtggcccagc actttatgat	1020
ggtacacaga gttaagagtg tagactcaga cggtcttct tcttccttc tcttccttc	1080
tccctccct cccacccccc cttctctcct tcctttctt cttcctctc tgcctcctca	1140
ggcctttcc agttgctcca aagccctgta ctttttttg agttaacgtc ttatggaaag	1200
ggcctgcact tagtgaagaa gtggctcag agttgagtt ccttggcttc tgggagggtga	1260
aactgtatcc ctataccctg aagcttaag ggggtgcaat gtagatgaga ccccaacata	1320
gatcctcttc acag	1334

<210> 42
<211> 512
<212> DNA
<213> Homo sapiens

<400> 42 gtggccctgg ggtgtgtgtg gacacagtgg gtgcggggga aagaggatgt aagatgagat	60
gagaaacagg agaagaaaga aatcaaggct gggctctgtg gcttacgcct ataatccac	120
cacgttggga ggctgaggtg ggagaatggt ttgagcccag gagttcaaga caaggcgggg	180
caacatagtg tgacccatc tctacaaaaa aaaccccaac aaaaccaaaa atagccgggc	240
atgggttat gcggcctagt cccagctact caaggaggtc gaggtggaa gatcgcttga	300
ttccaggagt ttgagactgc agttagctat gatcccacca ctgcctacca tctttaggat	360
acatttattt atttataaaa gaaatcaaga ggctggatgg ggaatacagg agctggaggg	420
tggagccctg aggtgctgg ttttgcgtgg cctggaccc ttgtttcctg tcatgccatg	480
aacccaccca cactgtccac tgacctccct ag	512

19 Nov 2004

2003217606

<210> 43						
<211> 114						
<212> DNA						
<213> Homo sapiens						
<400> 43						
gtacagctt	gtctggttc	ccccagcca	gtagtccctt	atcctccat	gtgtgtgcca	60
gtgtctgtca	ttggtggtca	cagccgcct	ctcacatctc	cttttctct	ccag	114
<210> 44						
<211> 617						
<212> DNA						
<213> Homo sapiens						
<400> 44						
gtgagtcgc	ccctcctctt	ggtcctgatg	ccaggagact	cctcagcacc	attcagcccc	60
agggctgctc	aggaccgcct	ctgctccctc	tcctttctg	cagaacagac	ccaaacccca	120
atattagaga	ggcagatcat	ggtggggatt	ccccattgt	ccccagaggc	taattgatta	180
gaatgaagct	tgagaaatct	cccagcatcc	ctctcgcaaa	agaatcccc	cccccccc	240
taaagatagg	gtctcactct	gtttgcccc	ggctgggtg	ttgtggcacg	atcatagctc	300
actgcagcct	cgaactccta	ggctcaggca	atccittcac	cttagcttct	caaagcactg	360
ggactgttagg	catgagccac	tgtgcctggc	cccaaacggc	cctttactt	ggcttttagg	420
aagcaaaaac	ggtgcttatac	ttacccttcc	tcgtgtatcc	accctcatcc	cttggctggc	480
ctcttctgga	gactgaggca	ctatggggct	gcctgagaac	tcggggcagg	ggtggtggag	540
tgcactgagg	caggtgttga	ggaactctgc	agaccctct	tccttcccaa	agcagccctc	600
tctgctctcc	atcgacag					617
<210> 45						
<211> 130						
<212> DNA						
<213> Homo sapiens						
<400> 45						
gtattacact	gaccctttct	tcaggcacaa	gcttccccca	cccttgtgga	gtcacttcat	60
gcaaagcgca	tgcaaatgag	ctgctcctgg	gccagtttc	tgattagcct	ttcctgttgt	120
gtacacacag						130
<210> 46						
<211> 11						
<212> DNA						
<213> Homo sapiens						
<400> 46						
agaaggtaag	t					11
<210> 47						
<211> 11						
<212> DNA						
<213> Homo sapiens						
<400> 47						

2003217606 19 Nov 2004

24/50

11

tggaggtgag a

<210> 48
<211> 11
<212> DNA
<213> Homo sapiens

<400> 48
cagtcgtgag g

11

<210> 49
<211> 11
<212> DNA
<213> Homo sapiens

<400> 49
ccgaggtgag c

11

<210> 50
<211> 11
<212> DNA
<213> Homo sapiens

<400> 50
tggaggtacc a

11

<210> 51
<211> 11
<212> DNA
<213> Homo sapiens

<400> 51
ggaaggtag t

11

<210> 52
<211> 11
<212> DNA
<213> Homo sapiens

<400> 52
agcaggtggg c

11

<210> 53
<211> 11
<212> DNA
<213> Homo sapiens

<400> 53
gccaggtaca g

11

<210> 54
<211> 11
<212> DNA
<213> Homo sapiens

<400> 54
tgctggtag t

11

<210> 55
<211> 11

2003217606 19 Nov 2004

25/50

<212> DNA		
<213> Homo sapiens		
<400> 55		
cacaggtatt a		11
<210> 56		
<211> 11		
<212> DNA		
<213> Homo sapiens		
<400> 56		
atacagggga t		11
<210> 57		
<211> 11		
<212> DNA		
<213> Homo sapiens		
<400> 57		
ccccagggcga c		11
<210> 58		
<211> 11		
<212> DNA		
<213> Homo sapiens		
<400> 58		
acgcagtgc a		11
<210> 59		
<211> 11		
<212> DNA		
<213> Homo sapiens		
<400> 59		
tttcagatcc a		11
<210> 60		
<211> 11		
<212> DNA		
<213> Homo sapiens		
<400> 60		
ccccaggagg g		11
<210> 61		
<211> 11		
<212> DNA		
<213> Homo sapiens		
<400> 61		
tcacaggctc a		11
<210> 62		
<211> 11		
<212> DNA		
<213> Homo sapiens		
<400> 62		
ccctagctcc a		11

2003217606 19 Nov 2004

26/50

<210> 63	
<211> 11	
<212> DNA	
<213> Homo sapiens	
<400> 63	
ctccagtcga g	11
<210> 64	
<211> 12	
<212> DNA	
<213> Homo sapiens	
<400> 64	
tcgcaggtga ca	12
<210> 65	
<211> 11	
<212> DNA	
<213> Homo sapiens	
<400> 65	
acacagaagg g	11
<210> 66	
<211> 470	
<212> RNA	
<213> Homo sapiens	
<400> 66	
cauggcccg auaacuuucu gccugugcac acaccugccc cucacuccac ccccauccua	60
gcuuugguaau gggggagagg gcacagggcc agacaaaccu gugagacuuu ggcuccaucu	120
cugcaaaagg ggcgcucugug agucagccug cuccccucca ggcuugcucc ucccccaccc	180
agcucucguu uccaaugcac guacagcccg uacacaccgu gugcugggac accccacagu	240
cagccgcaug gcuccccugu gccccagccc cuggcuuccu cuguugaucc cggccccugc	300
uccaggccuc acugugcaac ugcugcuguc acugcugcuu cuggugccug uccaucccc	360
gaggugccc cggaugcagg aggauucccc cuugggagga ggcucuucug ggaaagauga	420
cccacugggc gaggaggauc ugcccaguga agaggauca cccagagagg	470
<210> 67	
<211> 13	
<212> PRT	
<213> Homo sapiens	
<400> 67	
Leu Glu Glu Gly Pro Glu Glu Asn Ser Ala Tyr Glu Gln	
1 5 10	
<210> 68	
<211> 16	
<212> PRT	
<213> Homo sapiens	

2003217606 19 Nov 2004

27/50

<400> 68

Met Arg Arg Gln His Arg Arg Gly Thr Lys Gly Gly Val Ser Tyr Arg
1 5 10 15

<210> 69

<211> 232

<212> PRT

<213> Homo sapiens

<400> 69

Ile Arg Pro Gln Leu Ala Ala Phe Cys Pro Ala Leu Arg Pro Leu Glu
1 5 10 15

Leu Leu Gly Phe Gln Leu Pro Pro Leu Pro Glu Leu Arg Leu Arg Asn
20 25 30

Asn Gly His Ser Val Gln Leu Thr Leu Pro Pro Gly Leu Glu Met Ala
35 40 45

Leu Gly Pro Gly Arg Glu Tyr Arg Ala Leu Gln Leu His Leu His Trp
50 55 60

Gly Ala Ala Gly Arg Pro Gly Ser Glu His Thr Val Glu Gly His Arg
65 70 75 80

Phe Pro Ala Glu Ile His Val Val His Leu Ser Thr Ala Phe Ala Arg
85 90 95

Val Asp Glu Ala Leu Gly Arg Pro Gly Gly Leu Ala Val Leu Ala Ala
100 105 110

Phe Leu Glu Glu Gly Pro Glu Glu Asn Ser Ala Tyr Glu Gln Leu Leu
115 120 125

Ser Arg Leu Glu Glu Ile Ala Glu Glu Gly Ser Glu Thr Gln Val Pro
130 135 140

Gly Leu Asp Ile Ser Ala Leu Leu Pro Ser Asp Phe Ser Arg Tyr Phe
145 150 155 160

Gln Tyr Glu Gly Ser Leu Thr Thr Pro Pro Cys Ala Gln Gly Val Ile
165 170 175

Trp Thr Val Phe Asn Gln Thr Val Met Leu Ser Ala Lys Gln Leu His
180 185 190

Thr Leu Ser Asp Thr Leu Trp Gly Pro Gly Asp Ser Arg Leu Gln Leu
195 200 205

Asn Phe Arg Ala Thr Gln Pro Leu Asn Gly Arg Val Ile Glu Ala Ser
210 215 220

2003217606 19 Nov 2004

28/50

Phe Pro Ala Gly Val Asp Ser Ser
225 230

<210> 70
<211> 1552
<212> DNA
<213> Homo sapiens

<300>
<308> EMBL Accession No. X66839
<309> 1995-10-10
<313> (1)..(1552)

<400> 70	gccccgtacac accgtgtgct gggacaccccc acagtcagcc gcatggctcc cctgtgcccc	60
	agccccctggc tccctctgtt gatcccggcc cctgctccag gcctcactgt gcaactgctg	120
	ctgtcactgc tgcttctgtat gcctgtccat ccccaagaggt tgcccccggat gcaggaggat	180
	tcccccttgg gaggaggctc ttctggggaa gatgaccac tggcgagga gatatctgccc	240
	agtgaagagg attcacccag agaggaggat ccacccggag aggaggatct acctggagag	300
	gaggatctac ctggagagga gatatctacct gaagttaagc ctaaatcaga agaagagggc	360
	tccctgaagt tagaggatct acctactgtt gaggctcctg gagatcctca agaacccag	420
	aataatgccc acagggacaa agaagggat gaccagagtc attggcgcta tggaggcgac	480
	ccgccccctggc cccgggtgtc cccagcctgc gcggggccgct tccagtcccc ggtggatatc	540
	cgccccccagc tcgcccgcctt ctgccccggcc ctgcgccttgg tggaaactcct gggcttccag	600
	ctccccccgc tcccagaact gcgcctgcgc aacaatggcc acagtgtgca actgaccctg	660
	cctcctggc tagagatggc tctgggtccc gggcgggagt accggctct gcagctgcat	720
	ctgcactggg gggctgcagg tcgtccgggc tcggagcaca ctgtggaagg ccaccgtttc	780
	cctgcccaga tccacgtggt tcacccctcgc accgcctttg ccagagttga cgaggccttg	840
	gggcgcccgg gaggcctggc cgtttggcc gcctttctgg aggagggccc ggaagaaaac	900
	agtgcctatg agcagttgt gtctcgcttgc gaagaaatcg ctgaggaagg ctcagagact	960
	caggtcccag gactggacat atctgcactc ctgcctctg acttcagccg ctacttccaa	1020
	tatgaggggt ctctgactac accgcctgt gcccagggtg tcacccctgac tgtgtttaac	1080
	cagacagtga tgctgagtgc taagcagctc cacaccctct ctgacaccct gtggggacct	1140
	ggtgactctc ggctacagct gaacttccga ggcacgcagc ctttgaatgg ggcagtgatt	1200
	gaggcctcct tccctgctgg agtggacagc agtcctcggt ctgctgagcc agtccagctg	1260
	aattccgtcc tggctgctgg tgacatccta gcccgggtt ttggcctcct ttttgcgtc	1320
	accaggcgtcg cttcccttgtt gcagatgaga aggcagcaca gaagggaaac caaagggggt	1380
	gtgagctacc gcccagcaga ggtagccgag actggagcct agaggctgga tcttggagaa	1440
	tgtgagaagc cagccagagg catctgaggg ggagccggta actgtcctgt cctgctcatt	1500
	atgccacttc ctttaactg ccaagaaatt ttttaaaata aatatttata at	1552

19 Nov 2004

29/50

2003217606

<210> 71
<211> 20
<212> DNA
<213> Homo sapiens

<400> 71
atccacgtgg ttcacacctag

20

<210> 72
<211> 20
<212> DNA
<213> Homo sapiens

<400> 72
ctttggttcc ctttctgtgc

20

<210> 73
<211> 586
<212> DNA
<213> Homo sapiens

<400> 73
atccacgtgg ttcacacctag caccgccttt gccagagttg acgaggcctt ggggcgccccg 60
ggaggcctgg cctgtttggc cgcctttctg gaggagggcc cgaaagaaaaa cagtgcctat 120
gagcagttgc tgtctcgctt ggaagaaaatc gctgaggaag gctcagagac tcaggtccca 180
ggactggaca tatctgcact cctgcctct gacttcagcc gctacttcca atatgagggg 240
tctctgacta caccgcctg tgcccagggt gtcatctgga ctgtgtttaa ccagacagtg 300
atgctgagtg ctaaggcagct ccacaccctc tctgacacccc tgtggggacc tggtgactct 360
cggttacagc tgaacttccg agcgacgcag ccttgaatg ggcgagtgtat tgaggcctcc 420
ttccctgctg gagtggacag cagtcctcgg gctgctgagc cagtccagct gaattcctgc 480
ctggctgctg gtgacatcct agccctgggtt tttggcctcc ttttgctgt caccagcgtc 540
gcgttccttg tgcagatgag aaggcagcac agaaggggaa ccaaag 586

<210> 74
<211> 20
<212> DNA
<213> Homo sapiens

<400> 74
caggagagcc cagaagaaaa

20

<210> 75
<211> 20
<212> DNA
<213> Homo sapiens

<400> 75
tgaagggtct ctgaccacac

20

<210> 76
<211> 20
<212> DNA
<213> Homo sapiens

2003217606 19 Nov 2004

		30/50	
<400> 76	agctgttagga ggaaggcgt		20
<210> 77			
<211> 20			
<212> DNA			
<213> Homo sapiens			
<400> 77	tgacagcaaa gagaaggcca		20
<210> 78			
<211> 20			
<212> DNA			
<213> Homo sapiens			
<400> 78	cagggaaagga agcctcaatc		20
<210> 79			
<211> 1965			
<212> DNA			
<213> Mus musculus			
<400> 79	acagtgtgtc ctgggacacc ccagtcagct gcatggcctc cctgggcccc agcccctgg	60	
	ccccctttgtc gaccccagcc cctactgcac agctgctgct gttcctgctg ctccaagtgt	120	
	ctgctcagcc ccagggcctg tccgggatgc agggggagcc ctccctggga gacagttcat	180	
	ctggggagga ttagctggc gtggatgttc tgcccagtga agaggatgca cctgaagagg	240	
	cggatccacc cgatggggag gatccacctg aagttaattc tgaagacagg atggaggagt	300	
	cccttgggtt agaggatcta tcgactcccg aggctcctga gcacagtcaa gttcccacg	360	
	gggatgaaaa agggggtggc cacagtcatt ggagctatgg aggccaccta ctctggcccc	420	
	aggtgtcccc agcctgtgct ggccgcttgc agtccccggg agacatccgc ctggagcgc	480	
	ccgcattctg ccgcactctg caacccctgg aacttctggg ttatgagctc cagcctctcc	540	
	cggaaactgag cctatccaaac aatggccaca cggtacagct gactctgccg ccggggctga	600	
	agatggctct gggacctggg caggaatacc gggccttgca gttgcatcta cactggggaa	660	
	cttcagatca cccaggctca gaacacacag tcaatggtca ccgtttccct gctgagatcc	720	
	acgtggtgca cctcagttact gctttctccg aacttcatga agccttggc cgcccaggag	780	
	gcctggcagt tttggctgcc tttctgcagg agagcccaga agaaaacagt gcttacgaac	840	
	agttgtgtc ccattttggaa gaaatctgg aggaaggctc caagatttag atcccaggtt	900	
	tggatgtatc tgcactgttg ccctcgacc tcagccgcta ctaccgatat gaagggtctc	960	
	tgaccacacc tccctgcagc cagggggtca tctggactgt gttcaatgag acagtgaaac	1020	
	tgagcgctaa gcagctccat actctctccg tttccttggt gggacctcggt gattctcgcc	1080	
	tacaactgaa cttccgagcc acgcaaccct tgaatggcg aacgatttag gttcccttcc	1140	
	ctgctgcaga ggatagcagc cctgagccag tccatgtgaa ttcctgcttc actgctggtg	1200	

2003217606 19 Nov 2004

31/50

acatccttagc	cttgggtgttt	ggccttctct	ttgctgtcac	cagcatcgcc	ttcctcctac	1260
agctgaggag	gcagcacagg	cacagaagtg	ggaccaaaga	tagagttagc	tacagtccgg	1320
cagagatgac	agaaaactgga	gcctaataag	gagaaaccag	ctaaaggaat	ctggaaacct	1380
tgtcctgtcc	tgcctgttat	acagcctcct	tttaaccac	tacgaaatca	tttccatctt	1440
tttaacttgc	ttctttcctt	aaagtactgt	gataggagct	aaccgtgaaa	aaacaagatt	1500
gggctcaatt	cttgcgtgggt	tttgcgtgtt	ttgaagacag	ggtttctctg	tgtagccctg	1560
gctgtcctgg	gactcactct	gtagcctagg	ctggccttga	actcagagat	ccgattgcct	1620
ctgccttcctt	agtgcgcaggaa	ctgagggtat	gtaccactac	caccgcacc	ccgcaattct	1680
tgcttttatt	ctgcagtcaa	atgctccacc	actgagctac	acacccctcc	atcttactat	1740
gcaggcagac	tggccttgca	ttgtgtatgt	atggtgatgg	agtttgaagc	cagggtctta	1800
cctactaggc	aagcgttcta	tcactgacct	aagcctctct	agtcccttct	cttgaaccct	1860
ctatttcctt	gtcccagcct	cttgaatgct	gggattacag	aatgcacca	tcatgcttgg	1920
tcatcccaat	tataaaaaa	aaatataaa	atcttcctag	taaaa		1965

<210> 80
<211> 8725
<212> DNA
<213> *Mus musculus*

<300>
<308> EMBL Accession No. AY049077
<309> 2002-12-19
<313> (1)..(8725)

<220>
<221> misc_feature
<222> (1434)..(1434)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (1470)..(1470)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (1482)..(1482)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (1634)..(1634)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (1655)..(1655)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (1734)..(1734)
<223> n is a, c, g, or t

2003217606 19 Nov 2004

32/50

```
<220>
<221> misc_feature
<222> (1752)..(1752)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (3057)..(3057)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (3499)..(3499)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (3781)..(3781)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (4535)..(4535)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (6708)..(6708)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (6923)..(6923)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (7020)..(7020)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (7087)..(7087)
<223> n is a, c, g, or t

<400> 80
aaatataatg caggcaaaac agcaatgcac atgaaataaa aataaccaag tttaaacctg      60
gttaggtccc tcaaataaag ttccctggac ccttctgtat agatactacc ttttatttag      120
atcaggaatc atctagaagg ctctcaaaga gaagatggga tagcagggtt acctagagcc      180
atggatgta gctgtatgtc tccaggaata aaaataactc aatgcattca attaacctag      240
acaccacac tggatggatgc tcgttgcattc attttagata cctggatgaa acgaccttat      300
tctttatag ttgctgaggc tatggaaatc tcctggaaat gggagctgca gagcttaagg      360
ctgtctgcta ttctgtgctg cgtgcctgga gacaccagca gagtcaagga cactgggaga      420
ggcttggtagt atggtcacta gatggacaga ttgggagctc catccgttct cactctgtcc      480
tgattcataa agaatcaggc tgcctgtgaa atccacactc atagttgtct tccacatggc      540
ctgatgtaaatg aactggtctc tgtcacgctc ttcaaaagac tttatattac atctatttgg      600
tgtatgtgtg tgtgtgtgca catgcatgtg ccatggcaca cacagggggc agagggcaac      660
```

2003217606 19 Nov 2004

33/50

ttgttagtaca gtttctctct ttccaccatg tcgattttgg gttccacct cagatcatca 720
gattcggtgg caagtgtctt taccactaa gcctctgacc agtctctatt caaaatggtc 780
catgtctctt ctttgcctcag aattccaatc tctttactgt gattattaac caacccctcc 840
ccgtgggct tctacctctg cttcaaagat gggAACAGAT tttacccaca tccatagttc 900
cttgaggcag aattatgaca tctgtcctca ctcgctggag cgagagcttc tcagatagga 960
gccttcgttt tcatttccgc atccctagtc cacagcccag tgcctaaacat accgttagta 1020
ttaaacaat acggcgtgca aacatgaatg gcattctggg caacaagacg gagattcaca 1080
aaggcagtgc agagtttggg gagacgaatg aatagtttag ctctgggagc aaagctcaag 1140
tgaaagaatg cttgcattggc acccatggcc ccctggaaatc agtctccagc actgaaaaag 1200
aaacaaacaa acaaagcaa aaatgcattgc gcgcaggagc acacacacac aaattatctg 1260
accagaacat taggtggaaag agcaagagac aagactggtt tcttgggtga gttttgaag 1320
acctggaagt cggaaataa aatgatcaga ctttggcagg cagtgggggg gggggggtaa 1380
ccattagagt ctcataatgta gattcaaata atcatgctca aatttgcctt ttanttagct 1440
gtgagccccct ccacctattc acccctaggn tcctccaggg tnttaacctg ccccttacc 1500
caagacctga ctgggccagg atacatgcat ggatttcttgc ctcctcagc ccaactccac 1560
ggggggccag cttctttctt tccctgccc tgccagggcc gggaaagcagg ccaggcttag 1620
cagaggccag gagntgggtg gtgccaggga gaacntatac agtgcagggt ggtgccttgg 1680
gttccaagct gagctggtga tcctgataac cttctttcttgc cctatgaaca cacntgcccc 1740
tcaccccaac ctttacccatt accgcaccaa tgtccaggct ttgatatcg ggagggggca 1800
tagggccaga cagaacctgt gggactttgg ctccatcttca acaaagggc actgtgagtc 1860
agcctgctcc cctcaaggct tgctccccc ctacccagct cctatcccg atgcacgtac 1920
agcccggtcca cagtgtgtcc tggcacaccc cagtcagctg catggcctcc ctggggccca 1980
gccccctggc ccctttgtcg accccagccc ctactgcaca gctgctgctg ttcctgctgc 2040
tccaagtgtc tgctcagccc cagggctgt ccggatgca gggggagccc tccttggag 2100
acagttcatc tggggaggat gagctggcg tggatgtct gcccaggtaa gaggatgcac 2160
ctgaagaggc ggatccaccc gatggggagg atccacctga agttaattct gaagacagga 2220
tggaggagtc ctttgggtta gaggatctat cgactcccgaa ggctcctgag cacagtcaag 2280
gttcccacgg ggtgaaaaaa ggttaagtggt cattaacttc caaatcttgg ctcaggtaag 2340
tttatgcctt gtcctccccc actccctctt cttcccccggaa atgcttagctg agagcattcg 2400
gcaattatac tctaataaggat agtctttccc ccctaaaagg agagaagaaa aaaaaagccg 2460
agaatagggg gaaattaaag aggaaataga actgggaatg gacagagggg gaaaataagt 2520
gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gaagagaggg aggttagagag aatgagagac 2580
agacagacag agacagacac agagagacag agacagagag atgaaaaggg aagagaaggg 2640
ggctcctgga agacacacaa ggagctcaca gccgttactc acctatgatt tgcgggtgtgg 2700

2003217606 19 Nov 2004

34/50

gaaaagacag	gtggaggaac	tttggtttgc	tctggggcg	gaggatgaga	taaggtctta	2760
ttgttagat	cggattggcc	ttgaactagt	tctgccctt	accttcttct	tcctccgagt	2820
tctggattt	caggtgtgt	cgccaccgtg	cttggctcta	agccaggaac	tttagacagg	2880
aaagagagat	gagtggaaag	gtgggtgagt	aaggaaaaaa	gaacgatgat	ttggatctca	2940
aactgaagcc	gtgcctacag	accctagttt	gcaaactatc	ggtagggcta	ctgatggctc	3000
ctgcagtgt	gttgcgggt	ggcggaaattc	ccagctggtg	gttaatccac	tttgcntca	3060
caccaaccct	ggctacattc	ccttctatt	acgtcaaca	ctcttctaag	acatccgggg	3120
ctgtgaggcc	ccctgccaga	gcgggaggga	atattttttt	attctggca	ctgggaaggg	3180
actgggctgt	aagagtgggc	ttattaattc	ttctcattha	tgcagggggt	ggccacagtc	3240
attggagcta	tggaggttaag	acacggccgg	ctacacagac	ccaatctggg	agcccagccc	3300
tggtgatctg	ccgcaccaac	attcccagta	gtagccctag	actggaccca	ggtcctactc	3360
tatggccccc	ctcccgcccc	ccgcaactccc	ccacgcccagt	ccctggagcg	cccccccttc	3420
ctcccaaccc	caagcgtcct	gattccaacc	cttcatttat	cctaacgggtt	cttgtccaaa	3480
tcgctagatt	tcttgcacnt	tttctttca	tcccaggcac	cctactctgg	ccccaggtgt	3540
ccccagcctg	tgctggccgc	tttcagtcctt	cggtagacat	ccgcctggag	cgcaccgcat	3600
tctgccgcac	tctgcaaccc	ctgaaacttc	tggtttatga	gctccagcct	ctcccgaaac	3660
tgagcctatc	caacaatggc	cacacgggtg	agggtctgg	ggcgggacct	atggagggga	3720
gtggcaatca	acgtgtcac	ttaggagttc	tgctgggtct	cacgctcacg	tgtgggtaga	3780
nttctcaatt	gccactcccc	acgcagtaca	gctgactctg	ccgcgggggc	tgaagatggc	3840
tctgggacct	gggcaggaat	accgggcctt	gcagttgcat	ctacactggg	gaacttcaga	3900
tcacccaggc	tcagaacaca	cagtcaatgg	tcaccgttcc	cctgctgagg	tgggactgg	3960
gctgtcccaa	gaagaagcaa	gagggtatga	tcagaggtct	ggccactatc	tgatccttcc	4020
atcctctcta	gatccacgtg	gtgcaccta	gtactgcttt	ctccgaactt	catgaagcct	4080
tggccgcccc	aggaggcctg	gcagttttgg	ctgcctttct	gcaggtaccc	tatttgacat	4140
tcacgtcctg	tgggttcatg	catctggcta	gcagagacac	cattccaagc	acaagccaa	4200
gctggtaat	tagctctag	ccccattcac	tcctttgttc	attcactcag	caccagcagg	4260
gaaccaggag	cagactaaca	caaggcttcc	tttaggagga	aggctgtctt	gacagtata	4320
agtacgtac	acggaaaaaa	taatggccac	agaggaggcg	aaacttaaat	ctttcactga	4380
tgggaaacca	aggaggaata	ctgcacagag	agaggtcagc	gtgagcaagg	ctggagtatg	4440
gaccagttag	ggagtgccac	agcaacaagc	attgccctgg	gaagagccat	ttctctgctg	4500
cttctgtggc	ccctcaacttc	cccttcatga	agtanaagta	ttcaagtgac	ctctttgtac	4560
ctgtataata	caagaacgta	cactccaagg	tgggaggaag	ccaggaagtg	aggacgccta	4620
tgagacttac	cagtgtgaca	ttcacagcac	aaagttcagg	gaagttcctc	aggagcaggc	4680
ggcaggcgt	agttattaaa	gtgaacgcaa	aggcagtaca	agtataacat	acatgatggt	4740

2003217606 19 Nov 2004

35/50

tttttcagg aaaccacggc	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gcgagagaga	4800
gagagagaga	gagagagaga	gagagagaga	gagagagaga	gagagtgtaa	4860
gtgaaacgt	ggacctagat	cttggggcc	aggcagcctg	ggaaacttgc	4920
tttgcatttgc	cttgcatttgc	tgcaagca	gagtaataga	acttgaataa	4980
tccccagcat	ccttagaggt	gaggaacggg	gaaagactat	ggaaacccca	5040
aggctccag	ctgttagtcct	agaaatgggt	atcaattggc	cttgtactat	5100
cacccctgca	ggagagccca	gaagaaaaca	gtgcttacga	acagttgctg	5160
aagaatctc	ggaggaaggt	tggggcttg	cccagtgaac	aatgaacata	5220
gctgagggtg	aactggctct	gactggtgat	agctaaactg	atgagaaaca	5280
ggaaactact	gtccacagggc	ttgacaatta	gaatcaaagc	caaacagaaa	5340
agaaaacaag	caaagctgag	tctggccgtg	gtggcctccc	tggtctatag	5400
aggccggta	gggttacaca	gtaagacctg	gcctcaaaca	caaacaaaac	5460
atagagaaaa	caagccaaag	aaaatgttta	aaatttataa	gactgagtat	5520
acttttttg	tttggaaact	gtctatcatt	tatacatatc	aaatatttat	5580
ttattttgt	tttgcagac	agggttttc	tgtgtagccc	tggctggcct	5640
ctgttagtcca	ggctggcctc	gaactcagaa	atccgcctgc	ctctgcctcc	5700
gattaaaggc	gtggccacca	cgcccagctg	atgaatgatt	ttgagcaggt	5760
catgctgata	ataccaaacgt	ttgggagggtt	ggctactcac	caagccagcc	5820
gaaatcataa	agactagggc	tagggctgaa	gagagaaggc	tcaggggtta	5880
ctgctctccc	agaggtccaa	agtttaattc	ccaaccacat	ggtggctcac	5940
aatgagacct	gatgccctct	tctgggtgt	ccgaagacag	ctacagtgt	6000
ttaaatagat	agtatttgg	agaaaaaaaaa	aaaaaggcta	gggctatagc	6060
gcaagaacat	agcatgcatg	aagccttagg	tccagagctg	caaaaacact	6120
agcttggcc	cttccatgac	tgagccattt	taaacctcac	tctactagac	6180
ttttgataaa	ctggaaactca	tagaactttt	gtgtctgtt	cttacatgtt	6240
atgtatttac	aagttattct	acttgtctat	ctgtgtatcc	acggaaatgt	6300
tagaataacc	ccccacccccc	ccaccccccag	tacccctcct	ccccgagcta	6360
ccgctttatt	ccagtctggg	gttaaccgcg	gtccccccct	tccccacccccc	6420
cctccccgag	ctacattcca	attccgcctt	attccagttct	ggggtaagt	6480
gtattcagat	gattgaaggt	accacaggag	ggcttatgag	cttttggctt	6540
agatggctca	gcagtacaag	gcctcctcta	actgcccggaa	gccctttact	6600
ttatccacac	atagtaagaa	gcattgaaac	tatgcttgtc	ccgaaagctt	6660
gcagtggggg	gggggggggg	ggaacggggcc	cgaggaggca	gggtgatnta	6720
cacacaatcc	caatccgtag	gctccaagat	tgagatccca	ggtttggatg	6780

gttgcctcg gacctcagcc gctactaccg atatgaaggg tctctgacca cacccctcg 6840
cagccagggg gtcatctgga ctgtgttcaa tgagacagtg aaactgagcg ctaagcaggt 6900
tagaatgggg cgtggtattg acntgggtg ttggaaaatg ggaatgtggg aaaaaaggag 6960
gaagggtca tgcagtaaag atagacagag gttgggttc ccctgttcc ttttgcctn 7020
gagcctgtac tatccatcga cccccacttc cccagctcca tactctctcc gttccctgt 7080
ggggacntcg tgattctcg ctacaactga acttccgagc cacgcaaccc ttgaatggc 7140
gaacgattga ggcttccttc cctgctgcag aggatgcag ccctgagcca ggtgcccagt 7200
tatctgatag cccacgttga catatccccaa gtcaggggtc ctgcctcttc ctgtgtctc 7260
atttgtacca gcctgtccca ggtactcatg ggccctgggtt ctaatgtctc ctttatctc 7320
ttcagtccat gtgaattcct gtttactgc tggtgagtct gggcccttg ttccctggc 7380
cagtggcggg agggggccac acccttttag tatttcagcc caggagctag tctttacttt 7440
ttctgttagaa taaacttgat ccccaaatcg atgtgatcgg tcaagtaaga gacctgtacc 7500
tctggcttag ttgtctgaat gaggctccag aaatctcctg tgagaccccc tcccccaagg 7560
caccttcac ctagctgctg gaaggagaa gagtgctta cccttcac tatctgcctc 7620
cattctccag atggcctgtt ctgccgaccg aggccctggg ggctgcctga acactcactg 7680
gggaaagggt caggcaggag tatggaaagc cagttgcag ggaatcccc ggcacccca 7740
gaagcagctg cctctccct tccaggtgac atcctagcct tggtgttgg cttctcttt 7800
gctgtcacca gcatgcctt cttctacag ctgaggagc agcacaggta tctatgaccc 7860
tccttggcat agcattctt tataacccag aattcccgaa ctgcaaatga gctctcatgc 7920
ggagtcggct ttctgattct cgttcttgc tctataggca cagaagtggg accaaagata 7980
gagttagcta cagtccggca gagatgacag aaactggagc ctaataagga gaaaccagct 8040
aaaggaatct ggaaaccttg tcctgtcctg cctgttatac agccctttt ttaaccacta 8100
cgaaatcatt tccatcttt taactttctt ctttccttaa agtactgtga taggagctaa 8160
ccgtgaaaaa acaagattgg gctcaattct tgctgggtt tgatggttt gaagacaggg 8220
tttctctgtg tagccctggc tgtccctggaa ctcactctgt agcctaggct ggccttgcac 8280
tcagagatcc gattgcctct gccttcttag tgccaggact gagggatgtt accactacca 8340
ccgcccccc gcaattctt ctttattct gcagtcaa at gctccaccac tgagctacac 8400
accctccat cttactatgc aggcaactg gccttgcatt gtgtatgtt ggtatggag 8460
tttgaagcca gggcttacc tactaggcaa gcgttctatc actgaccaa gcctcttag 8520
tccctctct tgaaccctct attctctgtt cccagcctct tgaatgctgg gattacagga 8580
atgcaccatc atgcttggc atcccaatta tttaaaaaaa atatataat cttcttagta 8640
aaactcgtgt atttgcctt attcctcaca tcaaaggat attatattaa tttctttagt 8700
ttgccccggaa aacaaagcaa cttcc 8725

2003217606 19 Nov 2004

37/50

<210> 81
<211> 25
<212> DNA
<213> *Mus musculus*

<400> 81
gatacatcca aacctggat ctcaa 25

<210> 82
<211> 25
<212> DNA
<213> *Mus musculus*

<400> 82
tcctgcagaa aggagccaa aactg 25

<210> 83
<211> 25
<212> DNA
<213> *Mus musculus*

<400> 83
caggaaacg gtgaccattg actgt 25

<210> 84
<211> 25
<212> DNA
<213> *Mus musculus*

<400> 84
gacaccccaag tcagctgcat ggcct 25

<210> 85
<211> 26
<212> DNA
<213> *Mus musculus*

<400> 85
cattctcagt attgtttgc caagtt 26

<210> 86
<211> 25
<212> DNA
<213> *Mus musculus*

<400> 86
cgaaggagca aagctgctat tggcc 25

<210> 87
<211> 25
<212> DNA
<213> *Mus musculus*

<400> 87
tgtgctcagg agcctcgaaa gtcga 25

<210> 88
<211> 24
<212> DNA
<213> *Mus musculus*

2003217606 19 Nov 2004

38/50

24

<400> 88
agtcaagggtt cccacgggga tgaa

<210> 89
<211> 25
<212> DNA
<213> Mus musculus

<400> 89
aaggaggctg tataacaggc aggac

25

<210> 90
<211> 437
<212> PRT
<213> Mus musculus

<300>
<308> EMBL Accession Nos. AJ245857; CAC80975.1
<309> 2003-02-01
<313> (1)..(437)

<400> 90

Met Ala Ser Leu Gly Pro Ser Pro Trp Ala Pro Leu Ser Thr Pro Ala
1 5 10 15

Pro Thr Ala Gln Leu Leu Leu Phe Leu Leu Leu Gln Val Ser Ala Gln
20 25 30

Pro Gln Gly Leu Ser Gly Met Gln Gly Glu Pro Ser Leu Gly Asp Ser
35 40 45

Ser Ser Gly Glu Asp Glu Leu Gly Val Asp Val Leu Pro Ser Glu Glu
50 55 60

Asp Ala Pro Glu Glu Ala Asp Pro Pro Asp Gly Glu Asp Pro Pro Glu
65 70 75 80

Val Asn Ser Glu Asp Arg Met Glu Glu Ser Leu Gly Leu Glu Asp Leu
85 90 95

Ser Thr Pro Glu Ala Pro Glu His Ser Gln Gly Ser His Gly Asp Glu
100 105 110

Lys Gly Gly His Ser His Trp Ser Tyr Gly Gly Thr Leu Leu Trp
115 120 125

Pro Gln Val Ser Pro Ala Cys Ala Gly Arg Phe Gln Ser Pro Val Asp
130 135 140

Ile Arg Leu Glu Arg Thr Ala Phe Cys Arg Thr Leu Gln Pro Leu Glu
145 150 155 160

Leu Leu Gly Tyr Glu Leu Gln Pro Leu Pro Glu Leu Ser Leu Ser Asn
165 170 175

2003217606 19 Nov 2004

39/50

Asn Gly His Thr Val Gln Leu Thr Leu Pro Pro Gly Leu Lys Met Ala
180 185 190

Leu Gly Pro Gly Gln Glu Tyr Arg Ala Leu Gln Leu His Leu His Trp
195 200 205

Gly Thr Ser Asp His Pro Gly Ser Glu His Thr Val Asn Gly His Arg
210 215 220

Phe Pro Ala Glu Ile His Val Val His Leu Ser Thr Ala Phe Ser Glu
225 230 235 240

Leu His Glu Ala Leu Gly Arg Pro Gly Gly Leu Ala Val Leu Ala Ala
245 250 255

Phe Leu Gln Glu Ser Pro Glu Glu Asn Ser Ala Tyr Glu Gln Leu Leu
260 265 270

Ser His Leu Glu Glu Ile Ser Glu Glu Gly Ser Lys Ile Glu Ile Pro
275 280 285

Gly Leu Asp Val Ser Ala Leu Leu Pro Ser Asp Leu Ser Arg Tyr Tyr
290 295 300

Arg Tyr Glu Gly Ser Leu Thr Thr Pro Pro Cys Ser Gln Gly Val Ile
305 310 315 320

Trp Thr Val Phe Asn Glu Thr Val Lys Leu Ser Ala Lys Gln Leu His
325 330 335

Thr Leu Ser Val Ser Leu Trp Gly Pro Arg Asp Ser Arg Leu Gln Leu
340 345 350

Asn Phe Arg Ala Thr Gln Pro Leu Asn Gly Arg Thr Ile Glu Ala Ser
355 360 365

Phe Pro Ala Ala Glu Asp Ser Ser Pro Glu Pro Val His Val Asn Ser
370 375 380

Cys Phe Thr Ala Gly Asp Ile Leu Ala Leu Val Phe Gly Leu Leu Phe
385 390 395 400

Ala Val Thr Ser Ile Ala Phe Leu Leu Gln Leu Arg Arg Gln His Arg
405 410 415

His Arg Ser Gly Thr Lys Asp Arg Val Ser Tyr Ser Pro Ala Glu Met
420 425 430

Thr Glu Thr Gly Ala
435

2003217606 19 Nov 2004

40/50

<210> 91
<211> 31
<212> PRT
<213> Mus musculus

<400> 91

Met Ala Ser Leu Gly Pro Ser Pro Trp Ala Pro Leu Ser Thr Pro Ala
1 5 10 15

Pro Thr Ala Gln Leu Leu Leu Phe Leu Leu Leu Gln Val Ser Ala
20 25 30

<210> 92
<211> 358
<212> PRT
<213> Mus musculus

<400> 92

Gln Pro Gln Gly Leu Ser Gly Met Gln Gly Glu Pro Ser Leu Gly Asp
1 5 10 15

Ser Ser Ser Gly Glu Asp Glu Leu Gly Val Asp Val Leu Pro Ser Glu
20 25 30

Glu Asp Ala Pro Glu Glu Ala Asp Pro Pro Asp Gly Glu Asp Pro Pro
35 40 45

Glu Val Asn Ser Glu Asp Arg Met Glu Glu Ser Leu Gly Leu Glu Asp
50 55 60

Leu Ser Thr Pro Glu Ala Pro Glu His Ser Gln Gly Ser His Gly Asp
65 70 75 80

Glu Lys Gly Gly His Ser His Trp Ser Tyr Gly Gly Thr Leu Leu
85 90 95

Trp Pro Gln Val Ser Pro Ala Cys Ala Gly Arg Phe Gln Ser Pro Val
100 105 110

Asp Ile Arg Leu Glu Arg Thr Ala Phe Cys Arg Thr Leu Gln Pro Leu
115 120 125

Glu Leu Leu Gly Tyr Glu Leu Gln Pro Leu Pro Glu Leu Ser Leu Ser
130 135 140

Asn Asn Gly His Thr Val Gln Leu Thr Leu Pro Pro Gly Leu Lys Met
145 150 155 160

Ala Leu Gly Pro Gly Gln Glu Tyr Arg Ala Leu Gln Leu His Leu His
165 170 175

Trp Gly Thr Ser Asp His Pro Gly Ser Glu His Thr Val Asn Gly His

2003217606 19 Nov 2004

41/50

180

185

190

Arg Phe Pro Ala Glu Ile His Val Val His Leu Ser Thr Ala Phe Ser
195 200 205

Glu Leu His Glu Ala Leu Gly Arg Pro Gly Gly Leu Ala Val Leu Ala
210 215 220

Ala Phe Leu Gln Glu Ser Pro Glu Glu Asn Ser Ala Tyr Glu Gln Leu
225 230 235 240

Leu Ser His Leu Glu Glu Ile Ser Glu Glu Gly Ser Lys Ile Glu Ile
245 250 255

Pro Gly Leu Asp Val Ser Ala Leu Leu Pro Ser Asp Leu Ser Arg Tyr
260 265 270

Tyr Arg Tyr Glu Gly Ser Leu Thr Thr Pro Pro Cys Ser Gln Gly Val
275 280 285

Ile Trp Thr Val Phe Asn Glu Thr Val Lys Leu Ser Ala Lys Gln Leu
290 295 300

His Thr Leu Ser Val Ser Leu Trp Gly Pro Arg Asp Ser Arg Leu Gln
305 310 315 320

Leu Asn Phe Arg Ala Thr Gln Pro Leu Asn Gly Arg Thr Ile Glu Ala
325 330 335

Ser Phe Pro Ala Ala Glu Asp Ser Ser Pro Glu Pro Val His Val Asn
340 345 350

Ser Cys Phe Thr Ala Gly
355

<210> 93

<211> 60

<212> PRT

<213> Mus musculus

<400> 93

Ser Ser Ser Gly Glu Asp Glu Leu Gly Val Asp Val Leu Pro Ser Glu
1 5 10 15

Glu Asp Ala Pro Glu Glu Ala Asp Pro Pro Asp Gly Glu Asp Pro Pro
20 25 30

Glu Val Asn Ser Glu Asp Arg Met Glu Glu Ser Leu Gly Leu Glu Asp
35 40 45

Leu Ser Thr Pro Glu Ala Pro Glu His Ser Gln Gly
50 55 60

<210> 94
<211> 258
<212> PRT
<213> Mus musculus
<400> 94

Glu Lys Gly Gly Gly His Ser His Trp Ser Tyr Gly Gly Thr Leu Leu
1 5 10 15

Trp Pro Gln Val Ser Pro Ala Cys Ala Gly Arg Phe Gln Ser Pro Val
20 25 30

Asp Ile Arg Leu Glu Arg Thr Ala Phe Cys Arg Thr Leu Gln Pro Leu
35 40 45

Glu Leu Leu Gly Tyr Glu Leu Gln Pro Leu Pro Glu Leu Ser Leu Ser
50 55 60

Asn Asn Gly His Thr Val Gln Leu Thr Leu Pro Pro Gly Leu Lys Met
65 70 75 80

Ala Leu Gly Pro Gly Gln Glu Tyr Arg Ala Leu Gln Leu His Leu His
85 90 95

Trp Gly Thr Ser Asp His Pro Gly Ser Glu His Thr Val Asn Gly His
100 105 110

Arg Phe Pro Ala Glu Ile His Val Val His Leu Ser Thr Ala Phe Ser
115 120 125

Glu Leu His Glu Ala Leu Gly Arg Pro Gly Gly Leu Ala Val Leu Ala
130 135 140

Ala Phe Leu Gln Glu Ser Pro Glu Glu Asn Ser Ala Tyr Glu Gln Leu
145 150 155 160

Leu Ser His Leu Glu Glu Ile Ser Glu Glu Gly Ser Lys Ile Glu Ile
165 170 175

Pro Gly Leu Asp Val Ser Ala Leu Leu Pro Ser Asp Leu Ser Arg Tyr
180 185 190

Tyr Arg Tyr Glu Gly Ser Leu Thr Thr Pro Pro Cys Ser Gln Gly Val
195 200 205

Ile Trp Thr Val Phe Asn Glu Thr Val Lys Leu Ser Ala Lys Gln Leu
210 215 220

His Thr Leu Ser Val Ser Leu Trp Gly Pro Arg Asp Ser Arg Leu Gln
225 230 235 240

2003217606 19 Nov 2004

43/50

Leu Asn Phe Arg Ala Thr Gln Pro Leu Asn Gly Arg Thr Ile Glu Ala
245 250 255

Ser Phe

<210> 95
<211> 48
<212> PRT
<213> Mus musculus

<400> 95

Asp Ile Leu Ala Leu Val Phe Gly Leu Leu Phe Ala Val Thr Ser Ile
1 5 10 15

Ala Phe Leu Leu Gln Leu Arg Arg Gln His Arg His Arg Ser Gly Thr
20 25 30

Lys Asp Arg Val Ser Tyr Ser Pro Ala Glu Met Thr Glu Thr Gly Ala
35 40 45

<210> 96
<211> 22
<212> PRT
<213> Mus musculus

<400> 96

Asp Ile Leu Ala Leu Val Phe Gly Leu Leu Phe Ala Val Thr Ser Ile
1 5 10 15

Ala Phe Leu Leu Gln Leu
20

<210> 97
<211> 26
<212> PRT
<213> Mus musculus

<400> 97

Arg Arg Gln His Arg His Arg Ser Gly Thr Lys Asp Arg Val Ser Tyr
1 5 10 15

Ser Pro Ala Glu Met Thr Glu Thr Gly Ala
20 25

<210> 98
<211> 74
<212> PRT
<213> Homo sapiens

<400> 98

Gly Ser Ser Gly Glu Asp Asp Pro Leu Gly Glu Glu Asp Leu Pro Ser
1 5 10 15

2003217606 19 Nov 2004

44/50

Glu Glu Asp Ser Pro Arg Glu Glu Asp Pro Pro Gly Glu Glu Asp Leu
20 25 30

Pro Gly Glu Glu Asp Leu Pro Gly Glu Glu Asp Leu Pro Glu Val Lys
35 40 45

Pro Lys Ser Glu Glu Glu Gly Ser Leu Lys Leu Glu Asp Leu Pro Thr
50 55 60

Val Glu Ala Pro Gly Asp Pro Gln Glu Pro
65 70

<210> 99
<211> 26
<212> DNA
<213> Homo sapiens

<400> 99
tagaattcgg ctcttctggg gaagat

26

<210> 100
<211> 27
<212> DNA
<213> Homo sapiens

<400> 100
atactcgagg ggttcttgag gatctcc

27

<210> 101
<211> 277
<212> PRT
<213> Homo sapiens

<400> 101

Asp Pro Gln Glu Pro Gln Asn Asn Ala His Arg Asp Lys Glu Gly Asp
1 5 10 15

Asp Gln Ser His Trp Arg Tyr Gly Gly Asp Pro Pro Trp Pro Arg Val
20 25 30

Ser Pro Ala Cys Ala Gly Arg Phe Gln Ser Pro Val Asp Ile Arg Pro
35 40 45

Gln Leu Ala Ala Phe Cys Pro Ala Leu Arg Pro Leu Glu Leu Leu Gly
50 55 60

Phe Gln Leu Pro Pro Leu Pro Glu Leu Arg Leu Arg Asn Asn Gly His
65 70 75 80

Ser Val Gln Leu Thr Leu Pro Pro Gly Leu Glu Met Ala Leu Gly Pro
85 90 95

Gly Arg Glu Tyr Arg Ala Leu Gln Leu His Leu His Trp Gly Ala Ala
100 105 110

2003217606 19 Nov 2004

45/50

Gly Arg Pro Gly Ser Glu His Thr Val Glu Gly His Arg Phe Pro Ala
115 120 125

Glu Ile His Val Val His Leu Ser Thr Ala Phe Ala Arg Val Asp Glu
130 135 140

Ala Leu Gly Arg Pro Gly Gly Leu Ala Val Leu Ala Ala Phe Leu Glu
145 150 155 160

Glu Gly Pro Glu Glu Asn Ser Ala Tyr Glu Gln Leu Leu Ser Arg Leu
165 170 175

Glu Glu Ile Ala Glu Glu Gly Ser Glu Thr Gln Val Pro Gly Leu Asp
180 185 190

Ile Ser Ala Leu Leu Pro Ser Asp Phe Ser Arg Tyr Phe Gln Tyr Glu
195 200 205

Gly Ser Leu Thr Thr Pro Pro Cys Ala Gln Gly Val Ile Trp Thr Val
210 215 220

Phe Asn Gln Thr Val Met Leu Ser Ala Lys Gln Leu His Thr Leu Ser
225 230 235 240

Asp Thr Leu Trp Gly Pro Gly Asp Ser Arg Leu Gln Leu Asn Phe Arg
245 250 255

Ala Thr Gln Pro Leu Asn Gly Arg Val Ile Glu Ala Ser Phe Pro Ala
260 265 270

Gly Val Asp Ser Ser
275

<210> 102
<211> 26
<212> DNA
<213> Homo sapiens

<400> 102
tagaattcga tcctcaagaa ccccaag

26

<210> 103
<211> 27
<212> DNA
<213> Homo sapiens

<400> 103
aatctcgaga ctgctgtcca ctccagc

27

<210> 104
<211> 346
<212> PRT
<213> Homo sapiens

2003217606 19 Nov 2004

46/50

<400> 104

Gly Ser Ser Gly Glu Asp Asp Pro Leu Gly Glu Glu Asp Leu Pro Ser
1 5 10 15

Glu Glu Asp Ser Pro Arg Glu Glu Asp Pro Pro Gly Glu Glu Asp Leu
20 25 30

Pro Gly Glu Glu Asp Leu Pro Gly Glu Glu Asp Leu Pro Glu Val Lys
35 40 45

Pro Lys Ser Glu Glu Glu Gly Ser Leu Lys Leu Glu Asp Leu Pro Thr
50 55 60

Val Glu Ala Pro Gly Asp Pro Gln Glu Pro Gln Asn Asn Ala His Arg
65 70 75 80

Asp Lys Glu Gly Asp Asp Gln Ser His Trp Arg Tyr Gly Gly Asp Pro
85 90 95

Pro Trp Pro Arg Val Ser Pro Ala Cys Ala Gly Arg Phe Gln Ser Pro
100 105 110

Val Asp Ile Arg Pro Gln Leu Ala Ala Phe Cys Pro Ala Leu Arg Pro
115 120 125

Leu Glu Leu Leu Gly Phe Gln Leu Pro Pro Leu Pro Glu Leu Arg Leu
130 135 140

Arg Asn Asn Gly His Ser Val Gln Leu Thr Leu Pro Pro Gly Leu Glu
145 150 155 160

Met Ala Leu Gly Pro Gly Arg Glu Tyr Arg Ala Leu Gln Leu His Leu
165 170 175

His Trp Gly Ala Ala Gly Arg Pro Gly Ser Glu His Thr Val Glu Gly
180 185 190

His Arg Phe Pro Ala Glu Ile His Val Val His Leu Ser Thr Ala Phe
195 200 205

Ala Arg Val Asp Glu Ala Leu Gly Arg Pro Gly Gly Leu Ala Val Leu
210 215 220

Ala Ala Phe Leu Glu Glu Gly Pro Glu Glu Asn Ser Ala Tyr Glu Gln
225 230 235 240

Leu Leu Ser Arg Leu Glu Glu Ile Ala Glu Glu Gly Ser Glu Thr Gln
245 250 255

Val Pro Gly Leu Asp Ile Ser Ala Leu Leu Pro Ser Asp Phe Ser Arg

2003217606 19 Nov 2004

47/50

260

265

270

Tyr Phe Gln Tyr Glu Gly Ser Leu Thr Thr Pro Pro Cys Ala Gln Gly
275 280 285

Val Ile Trp Thr Val Phe Asn Gln Thr Val Met Leu Ser Ala Lys Gln
290 295 300

Leu His Thr Leu Ser Asp Thr Leu Trp Gly Pro Gly Asp Ser Arg Leu
305 310 315 320

Gln Leu Asn Phe Arg Ala Thr Gln Pro Leu Asn Gly Arg Val Ile Glu
325 330 335

Ala Ser Phe Pro Ala Gly Val Asp Ser Ser
340 345

<210> 105

<211> 232

<212> PRT

<213> Homo sapiens

<400> 105

Ile Arg Pro Gln Leu Ala Ala Phe Cys Pro Ala Leu Arg Pro Leu Glu
1 5 10 15

Leu Leu Gly Phe Gln Leu Pro Pro Leu Pro Glu Leu Arg Leu Arg Asn
20 25 30

Asn Gly His Ser Val Gln Leu Thr Leu Pro Pro Gly Leu Glu Met Ala
35 40 45

Leu Gly Pro Gly Arg Glu Tyr Arg Ala Leu Gln Leu His Leu His Trp
50 55 60

Gly Ala Ala Gly Arg Pro Gly Ser Glu His Thr Val Glu Gly His Arg
65 70 75 80

Phe Pro Ala Glu Ile His Val Val His Leu Ser Thr Ala Phe Ala Arg
85 90 95

Val Asp Glu Ala Leu Gly Arg Pro Gly Gly Leu Ala Val Leu Ala Ala
100 105 110

Phe Leu Glu Glu Gly Pro Glu Glu Asn Ser Ala Tyr Glu Gln Leu Leu
115 120 125

Ser Arg Leu Glu Glu Ile Ala Glu Glu Gly Ser Glu Thr Gln Val Pro
130 135 140

Gly Leu Asp Ile Ser Ala Leu Leu Pro Ser Asp Phe Ser Arg Tyr Phe
145 150 155 160

2003217606 19 Nov 2004

48/50

Gln Tyr Glu Gly Ser Leu Thr Thr Pro Pro Cys Ala Gln Gly Val Ile
165 170 175

Trp Thr Val Phe Asn Gln Thr Val Met Leu Ser Ala Lys Gln Leu His
180 185 190

Thr Leu Ser Asp Thr Leu Trp Gly Pro Gly Asp Ser Arg Leu Gln Leu
195 200 205

Asn Phe Arg Ala Thr Gln Pro Leu Asn Gly Arg Val Ile Glu Ala Ser
210 215 220

Phe Pro Ala Gly Val Asp Ser Ser
225 230

<210> 106

<211> 32

<212> PRT

<213> Homo sapiens

<400> 106

Gly Asp Asp Gln Ser His Trp Arg Tyr Gly Gly Asp Pro Pro Trp Pro
1 5 10 15

Arg Val Ser Pro Ala Cys Ala Gly Arg Phe Gln Ser Pro Val Asp Ile
20 25 30

<210> 107

<211> 20

<212> DNA

<213> Homo sapiens

<400> 107

ccgagcgacg cagcctttga

20

<210> 108

<211> 30

<212> DNA

<213> Homo sapiens

<400> 108

tagtcgacta ggctccagtc tcggctacct

30

<210> 109

<211> 20

<212> DNA

<213> Homo sapiens

<400> 109

catccagcgt actccaaaga

20

<210> 110

<211> 20

<212> DNA

<213> Homo sapiens

2003217606 19 Nov 2004

49/50

<400> 110
gacaagtctg aatgctccac 20

<210> 111
<211> 25
<212> DNA
<213> Homo sapiens

<400> 111
actcgctact gtgcagtgtg caatg 25

<210> 112
<211> 25
<212> DNA
<213> Homo sapiens

<400> 112
cctcttcgtt ctttcgtat cccac 25

<210> 113
<211> 27
<212> DNA
<213> Homo sapiens

<400> 113
agtttccaga tgaggagggc gcatgcc 27

<210> 114
<211> 27
<212> DNA
<213> Homo sapiens

<400> 114
ttctccccat cagggatcca gatgcc 27

<210> 115
<211> 26
<212> DNA
<213> Homo sapiens

<300>
<308> M34309
<309> 1999-07-02
<313> (222)..(247)

<400> 115
ggtgctgggc ttgctttca gcctgg 26

<210> 116
<211> 26
<212> DNA
<213> Homo sapiens

<400> 116
accacgcgga gttgggcaa tggtag 26

<210> 117
<211> 24
<212> DNA
<213> Homo sapiens

2003217606 19 Nov 2004

50/50

<400> 117
gggtccata ccactcatgg atct

24

<210> 118
<211> 24
<212> DNA
<213> Homo sapiens

<400> 118
gggaaagggtt ggcgatcagg aata

24